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Summary
Abnormalities in the cellular senescence programme may contribute to 
premature ageing and cancer predisposition. Primary human cells have a limited 
proliferative capacity, entering a state of irreversible growth arrest/senescence 
arising from telomere attrition (replicative senescence). Stress-induced premature 
senescence (SIPS) can additionally limit cellular lifespan and there are several 
human genomic instability (Gl) disorders - cancer-prone/premature ageing 
syndromes - in which SIPS may prematurely limit cellular lifespan. The hypothesis 
is that increased Gl is a critical factor in limiting the lifespan of somatic cells by 
activating common pathways leading to SIPS. This study examines the extent to 
which Gl cells present restraints on cellular proliferation with a focus on the degree 
to which they share similar properties -  not least a common dependence on the 
p38 mitogen-activated protein kinase (MAPK) mediated stress response pathway. 
The study utilised a panel of normal (N) and a Gl panel of fibroblasts comprising: 
Rothmund Thomson syndrome (RTS), Bloom syndrome (BS), Cockayne syndrome 
A (CSA), Hutchinson-Gilford Progeria syndrome (HGPS), Nijmegen Breakage 
syndrome (NBS), Werner syndrome (WS), Seckel syndrome (SS), Dyskeratosis 
Congenita (DKC) and Ligase 4 syndrome (LIG4). The study revealed a 
commonality of response to p38 inhibitors -  increased clonogenicity and lifespan - 
for normal and Gl syndrome cells, suggesting that all cells undergo some degree of 
p38-mediated proliferation restraint/SIPS. A degree of inter-strain heterogeneity for 
reduced replicative potential and/or altered morphology was apparent for both 
normal and Gl syndrome primary fibroblasts. This study revealed truncated 
lifespans for LIG4, SS, HGPS, BS, RTS, DKC and NBS cells. GM18366(SS) and 
GM07166(NBS) cell strains show an altered morphology and increased p38 
inhibitor responses suggesting elevated SIPS operation. Growth and DNA damage 
studies using a newly created bank of hTert-immortalised cell strains [AG16409(N), 
AG18371 (RTS), GM02548(BS), GM07166(NBS), GM01856(CSA),
AG11498(HGPS) and GM17523(LIG4)] showed that Gl syndrome cells, alleviated 
from the stress of telomere attrition, remain susceptible to SIPS. Of these RTS 
cells were hTert-immortalised for the first time, showing that senescence in these 
strains is telomere-dependent. Cell cycle analysis revealed a common p38- 
associated mechanism that limits retention in cycle. The specific p38 inhibitor 
BIRB796 was found to increase clonogenic potential of both normal and Gl 
syndrome cells. The findings suggest that both RTS and WS cells show a higher 
proportion of cells that are non-dividing. Furthermore, the study suggests that WS 
cells have an altered cell cycle transit time that is reduced by BIRB796 treatment. 
Overall, the study highlights successful single cell analysis approaches for testing 
the impact of p38 inhibitors by teasing out the nature of cellular heterogeneity 
arising from different sources for specific cell strains. These findings support and 
expand previous evidence that WS cells undergo higher levels of SIPS compared 
to normal cells and provide new evidence that RTS cells may also show an 
increased propensity for SIPS.
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Chapter 1 General Introduction
It is widely accepted that cell proliferation involves numerous processes that 
need to be tightly coordinated to ensure the preservation of genome integrity and 
to promote faithful genome propagation. Numerous studies have established that 
efficient and error-free DNA replication is key for faithful duplication of 
chromosomes before their segregation (Smith and Jones 2000). Central to this is 
the need to coordinate DNA replication, DNA-damage sensing and repair and cell 
cycle progression to ensure genome integrity is maintained during cell division and 
genomic instability (Gl) is avoided. When coordination fails or fidelity is 
compromised, cells may accumulate genomic defects that initiate cancer and its 
progression (Anderson 2001; Kerzendorfer and O'Driscoll 2009; Negrini et al. 
2010). Indeed, multisystem syndromes, for example Bloom syndrome (German et 
al. 2007) often show signs of abnormalities in replication control at the cellular level 
resulting in disruption of normal physiology and function or the acquisition of 
cancer predisposition (Coppede and Migliore 2010; Duker 2002). Some disorders 
also show in vitro indicators of significant limitation on replicative potential (Capell 
et al. 2009), for example Werner syndrome. The enforcement of a normal limitation 
on replicative potential of cells can be viewed as a process of ‘cellular senescence’ 
with implications for dynamic tissue management and the suppression of neoplasia 
(Campisi 2005). This has lead to a search for molecular mechanisms involved in 
the limitation of replicative potential. There has been a recent focus on the 
signalling pathways potentially operating in senescence with evidence that p38 
pathway modulation may be critical in the commitment of cells to the senescence 
process (Davis et al. 2005; Deng et al. 2004; Haq et al. 2002; Iwasa et al. 2003; 
Wang et al. 2002). The p38 MAP kinases are a family of serine/threonine protein 
kinases. p38 MAP kinase (MAPK), also called RK or CSBP, is the mammalian 
orthologue of the yeast HOG kinase which participates in a signalling cascade 
controlling cellular responses to cytokines and stress. Such studies could reveal 
target proteins that may be available for manipulation in attempts to interfere with 
the senescence process. Recently, the availability of potent p38 inhibitors with
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different modes of action (Goldstein et al. 2010) has opened the possibility of 
exploring senescence pathway interference in different genetic backgrounds.
The conceptual framework for this thesis is that there are significant overlaps 
between the processes driving senescence (Figure 1.1), the control of the cell 
cycle under stress and the acquisition of genomic instability. This thesis addresses 
aspects of these interdependencies. Gl syndromes present an attractive group of 
relevant disorders with known, and in some cases well-characterised, molecular 
defects for such studies. The principal approach was to investigate the cell cycle 
and progression to senescence of dermal fibroblasts derived from normal and Gl 
syndrome individuals under p38 inhibitor exposure. The studies have employed 
techniques for single cell evaluation, immortalisation, stress induction, and cell 
cycle monitoring of p38 inhibitor responses.
Genomic
Instability
Senescence Cell Cycle
Figure 1.1. Thesis framework:
The interdependency of genomic instability, senescence and the cell cycle.
1.1 The cell cycle
In multicellular eukaryotic organisms, two fundamental types of cell division 
occur depending on the cell type and developmental stage involved. Mitosis is the 
process of cell division resulting in two identical nuclei and is performed by somatic 
cells during tissue development. During gametogenesis meiosis is a reductional 
division process, performed by diploid or haploid precursor cells undergoing cell
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division and differentiation to form mature haploid gametes. The sequence of 
stages that a given cell undergoes while progressing to division is known as the 
cell cycle, the functional structure of which was described in 1953 (Howard and 
Pelc 1953), has been extensively reviewed [for example: (Schafer 1998; Sclafani 
and Holzen 2007; Vermeulen et al. 2003)].
The somatic cell cycle can be defined as the temporal sequence of structural 
and functional transitions that a cell undergoes during processes of cell growth, 
replication of genetic material, nuclear division, and cytoplasmic separation (Smith 
et al. 2006). Its most basic function is to duplicate accurately the vast amount of 
DNA in the chromosomes and then segregate the copies into two genetically 
identical daughter cells. These processes define the two major phases of the cell 
cycle. In mammalian cells replication of DNA occurs during the synthesis phase (S- 
phase), normally requiring up to 12 hours and occupies approximately half of the 
cell cycle time depending upon the cell type and origin. Following S-phase, 
chromosome segregation and cell division occur during mitosis (M), which is 
usually complete within less than one hour in mammalian cells. Mitosis can be 
further subdivided into prophase, metaphase, anaphase and telophase (Alberts et 
al. 2002). During this process the duplicated chromosomes become more 
condensed and compact to make it easier for segregation into the respective 
daughter cells. Subsequently, the nuclear envelope breaks down, and the 
chromosomes attach to the microtubules of the mitotic spindle. As mitosis 
proceeds, the cell pauses briefly in metaphase, when the chromosomes are 
aligned at the equator of the mitotic spindle, awaiting segregation. The sudden 
separation of sister chromatids marks the beginning of anaphase, during which the 
chromosomes move to opposite poles of the spindle, where they decondense and 
reform intact nuclei. The cell is then pinched in two by cytoplasmic division 
(cytokinesis) and cell division/daughter separation is complete. There are also two 
“gap” phases (Gi prior to S-phase, and G2 between S-phase and mitosis), which 
allow time for the cell to grow and double their mass of proteins and organelles 
required to replicate their DNA and divide. The balance between the cell cycle 
stages and the timing of S-phase is modified during early embryogenesis and as
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homeostatic mechanisms control tissue formation. Thus, the eukaryotic somatic 
cell cycle is traditionally divided into four phases: Gi, S-phase, G2 and M. G1 , S- 
phase and G2 together are often referred to as interphase since they make up the 
interlude between mitoses (Figure 1.2). Although the duration of the cell cycle 
varies from organism to organism and within tissue lineages, it typically takes at 
least 24 hours for mammalian cell to complete a full cell cycle, for example as 
found for explanted human dermal fibroblasts in vitro.
The two gap phases serve as more than simple time delays to cell growth, they 
also provide time for the cell to monitor the internal and external environment to 
ensure that conditions are suitable and allow time for repair of DNA damage and 
replication errors, before the cell commits to DNA replication or cell division. G1 is 
of particular importance in this respect (Massague 2004). Its length can vary 
greatly depending on external conditions and extracellular signals from other cells. 
If extracellular conditions are unfavourable, cells can delay progress through G1 
and may enter a resting state called Go prior to commitment to DNA replication. 
Cells can remain for extended periods of time in this state before resuming 
proliferation. Indeed, cells in Go account for the majority of non-growing, non­
proliferating cells in the human body (Vermeulen et al. 2003). Conversely, if 
extracellular conditions are favourable and signals to grow and divide are present, 
cells in early G1 or Go progress through a commitment point near the end of G1 
known as the restriction point. The restriction point is thought to be regulated 
largely by pRb (Zetterberg et al. 1995). After passing this point, cells are committed 
to DNA replication, even if the extracellular signals that stimulate cell growth and 
division are removed.
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Figure 1.2. Schematic representation of the human cell cycle.
Actively dividing cells pass through a series of stages known collectively as the cell cycle: two 
gap phases (Gi and G2); a synthesis (S) phase, in which the genetic material is duplicated; and 
mitosis (M), in which the chromosomes are segregated and the cell divides. A series of DNA 
checkpoints act at different stages of the cell cycle to ensure the fidelity of cell division. DNA 
damage checkpoints are positioned before S-phase (Gi/S checkpoint), after DNA replication 
(G2/M checkpoint) and during S-phase (Intra-S checkpoint). Defects in mitotic spindle assembly 
activate the spindle checkpoint and arrest cells in anaphase.
1.1.1 Cell cycle regulation
Regulation of the cell cycle involves processes crucial to the survival of a cell, 
including the detection and repair of genetic dam age as well as the prevention of 
uncontrolled cell division. The transition from one cell cycle phase to another is a 
highly ordered process that is regulated by a number of different cellular proteins. 
Two key classes of regulatory molecules, cyclins and cyclin-dependent kinases
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(Cdks), determine a cell’s progress through the cell cycle (Morgan 2007). In 2001, 
Hartwell, Hunt and Nurse were awarded a Nobel Prize in Physiology and Medicine 
for their discovery of these central molecules (Hartwell et al. 2001). Many of the 
genes encoding cyclins and Cdks are conserved among all eukaryotes, but in 
general complex organisms have more elaborate cell cycle control systems that 
incorporate more individual components. In yeast, there is one major Cdk 
(designated Cdk1, equivalent to p34Cdc28 in Saccharomyces cerevisae and p34Cdc2 
in Schizosaccharomyces pombe), the activity of which oscillates during cell cycle 
progression and is capable of regulating diverse cell cycle transitions by 
associating with different cell cycle stage-specific cyclins (Satyanarayana and 
Kaldis 2009). In contrast, approximately 20 Cdk-related proteins have been 
identified higher eukaryotes. In higher eukaryotic cells the problems of 
coordinating the growth and proliferation of multicellular states results in additional 
complexity in cell cycle events although the cell cycle ‘engine’ is still driven by Cdks 
and cyclins.
Cdks are a family of serine/threonine protein kinases that require binding to a 
cyclin subunit to become catalytically competent (Morgan 1995, 1997; Murray 
2004). The role of Cdks in cell cycle regulation and in particular their role in cancer 
has been extensively studied [reviewed by (Malumbres and Barbacid 2005; 
Sanchez and Dynlacht 2005; Satyanarayana and Kaldis 2009)]. Different members 
of the Cdk family, in association with different cyclins, regulate progression through 
the cell cycle (Figure 1.3). The principal Cdks in most mammalian cells are Cdk1, 
Cdk2, Cdk4 and Cdk6, whereas other Cdks regulate transcription, differentiation, 
nutrient uptake and other functions (Massague 2004). Cyclin-Cdk complexes are 
regulated by post-translational modifications (phosphorylation/dephosphorylation) 
and protein interaction events that tightly control the timing and extent of Cdk 
activation. When activated, Cdks induce downstream processes by 
phosphorylating selected proteins (Morgan 1995; Pines 1995). Whereas Cdk 
protein levels remain stable during the cell cycle, the levels of cyclin proteins rise 
and fall and in this way periodically activate the necessary Cdks required for cell 
cycle progression (Evans et al. 1983; Pines 1991). Different cyclins are required at
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different phases of the cell cycle; for instance, cyclins A and B function in the S- 
phase, G2 , and early mitosis, whereas D-type cyclins (Cyclin D1, D2 and D3) and 
cyclin E are expressed in G1 (Figure 1.3).
The prototypic Cdk, Cdk1, associates with cyclins A and B, and acts at the 
G2/M interface. Synthesis of cyclin A begins as cells approach the G1 to S-phase 
transition, and the protein is immediately transported into the nucleus. Cyclin A 
binds to Cdk2 and is required for the cell to progress through S-phase (Pagano et 
al. 1992). In late G2 and early M-phase, cyclin A complexes with Cdk1 to promote 
entry in to mitosis (Pagano et al. 1992). Mitosis is further regulated by cyclin B in 
complex with Cdk1 (Arellano and Moreno 1997; King et al. 1994). In cycling 
mammalian cells, cyclin B is first synthesised during S-phase and increases in 
concentration as cells proceed through G2 , peaking in early mitosis and dropping 
after anaphase. Thus, the progressive accumulation of cyclins A and B during the 
cell cycle and their abrupt degradation at the onset of anaphase, mediates entry 
and exit from mitosis, respectively. The G1 cyclin, Cyclin D, forms an active 
complex with Cdk4 and Cdk6 and is required for cells to pass through the 
restriction point and enter G1 (Sherr 1994; Sherr et al. 1994). Unlike the other 
cyclins, cyclin D is not expressed periodically, but is synthesised as long as growth 
factor stimulation persists (Assoian and Zhu 1997). Another G1 cyclin is cyclin E 
which associates with Cdk2 to regulate progression from G1 to S-phase (Ohtsubo 
et al. 1995). Cyclin A binds with Cdk2 and this complex is required during S-phase 
(Girard et al. 1991; Walker and Mailer 1991). Thus, a cycling cell exits the cell 
cycle phases in association with the synthesis and degradation of specific cyclins. 
In general, before a cell can enter the next cell cycle phase, the appropriate cyclin 
of the previous phase is degraded, and the cyclin of the next phase is synthesised. 
Cyclins A and B contain a destruction box and cyclins D and E contain a PEST 
sequence [protein motifs rich in proline (P), glutamine (E), serine (S), and threonine 
(T) residues], which target them for ubiquitin-mediated degradation at specific 
times (Glotzer et al. 1991; Rechsteiner and Rogers 1996).
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Figure 1.3. Schematic representation of the activity of mammalian Cdk-cyclin 
complexes and the oscillating expression levels of cyclins throughout the cell cycle.
Cyclin D refers to all three D-type cyclins.
The activities and functions of Cdk/cyclin complexes under normal, as well as 
extreme conditions, such as stress, DNA damage, telomere dysfunction and 
others, are regulated by Cdk inhibitors (Cdkls). Two distinct families of Cdkls have 
been discovered: the INK4 family (p15INK4b, p16INK4a, p18INK4c, p19INK4d) specifically 
bind to Cdk4 and Cdk6 (Guan et al. 1994; Hirai et al. 1995) and prevent D-type 
cyclin activity, thus preventing the phosphorylation and activation of pRb (Carnero
8
and Hannon 1998); and the Cip/Kip family (p21Waf1/C,p1, p27Kip1, p57Kip2) 
(Toyoshima and Hunter 1994; Xiong 1996) inhibit Cdk2/cyclinE, Cdk2/cyclin A, 
Cdk1/cylin A, as well as Cdk1/cyclin B activity (Harper et al. 1995; Resnitzky et al.
1995) thereby preventing the Cdk from phosphorylating pRb and inducing its 
dissociation from E2F (Chen et al. 1996; Hall et al. 1995).
Cdk activity is further regulated by post-translational modification 
(phosphorylation). Phosphorylation on conserved threonine and tyrosine residues 
is required for full activation of Cdks, for example, Cdk1 requires phosphorylation 
of Thr-161 (Thr-172 in Cdk4 and Thr-160 in Cdk2), by the Cdk7-cyclin H complex 
(CAK) (Drapkin et al. 1996; Jeffrey et al. 1995). Conversely, phosphorylation of 
Cdk1 at Tyr-15 and/or Thr-14, which are located within the active site of the kinase, 
prevents kinase activity (Borgne and Meijer 1996). This phosphorylation is 
performed by the weel and Myt1 kinases (Heald et al. 1993; McGowan and 
Russell 1993, 1995; Mueller et al. 1995). The weel kinase phosphorylates Cdk1 
upon entry of the Cdk-cyclin complex into the nucleus, thereby protecting the 
nucleus from premature exposure to an active mitotic kinase (Heald et al. 1993). 
When the cell is ready to divide, Cdc25 dephosphorylates Cdk1 at Tyr-15 and Thr- 
14, thereby activating Cdk1 and allowing further progression through the cell cycle 
(Devault et al. 1991; Honda et al. 1993; Lew and Kornbluth 1996). Intracellular 
localisation of different Cdks and cyclins may also contribute to cell cycle regulation 
(Vermeulen et al. 2003). For example, in human cells, cyclin B first accumulates in 
the cytoplasm then enters the nucleus just before the nuclear envelope breaks 
down early in mitosis.
1.1.2 The Restriction Point and Checkpoints
Cell cycle checkpoints are control mechanisms that ensure the fidelity of cell 
division that have been extensively studied [reviewed by (Hartwell and Weinert 
1989; Satyanarayana and Kaldis 2009; Warmerdam and Kanaar 2010)] (Figure 
1.2). Growth factors primarily act on cells in Go and Gi. The point in Gi after which 
cells no longer respond to withdrawal of growth factors has been termed the 
restriction point. Studies show that cells starved of serum before the restriction
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point enter a Go-like state, while cells starved after are unaffected and continue 
through mitosis (Pardee 1974). Additional ‘checkpoints’ exist further in the cell 
cycle that monitor the integrity of DNA and serve to coordinate DNA replication with 
repair, chromosome segregation and cell cycle progression, ensuring an orderly 
sequence of events in the cell cycle (Hartwell and Weinert 1989). As an example, 
the completion of cellular DNA replication is a checkpoint that must be passed 
before the biochemically unrelated event of chromosome separation in mitosis can 
begin (Hartwell and Weinert 1989). Cell cycle arrest is produced by a variety of 
factors that may be intrinsic or extrinsic and may affect several different 
checkpoints according to the pathway affected. Understanding the downstream 
consequences of unresolved events, supra-threshold levels of genomic damage or 
abnormal checkpoint maintenance appears to be critical in determining the 
dynamic responses of cellular systems undergoing commitment to senescence.
In response to DNA damage, checkpoints arrest the cell in order to provide 
time for DNA repair. DNA damage checkpoints are positioned before the cell 
enters S-phase (Gi/S checkpoint) or after DNA replication (G2/M checkpoint). In 
addition, there appear to be DNA damage checkpoints during S-phase and mitosis, 
for example the spindle assembly checkpoint arrests cells in anaphase if the 
mitotic spindle is assembled improperly (Rudner and Murray 1996). Under normal 
conditions, DNA is most vulnerable to DNA breaks during S-phase. This is mainly 
due to the fact that during replication the replisome must overcome obstacles (such 
as DNA adducts, secondary structures or tightly bound proteins) that can cause 
replication fork stalling and can compromise genomic integrity if not properly 
processed. The S-phase checkpoint responds to replication fork stalling and intra- 
S-phase damage by preventing replication fork collapse and breakdown, and is 
therefore crucial for maintaining genome integrity (Segurado and Tercero 2009).
At the G1/S checkpoint, cell cycle arrest induced by DNA damage is p53- 
dependent. This is supported by the observation that cells derived from p53-null 
transgenic mice do not arrest in Gi in response to DNA damage such as ionising 
radiation (Little et al. 1995). Under normal conditions, the cellular level of p53 is low
10
but DNA damage can lead to rapid induction of p53 activity (el-Deiry et al. 1993; 
Perry et al. 1993). This stabilisation and activation of p53 is achieved by ATM- 
mediated phosphorylation (Sancar et al. 2004; Shiloh 2003). ATM (ataxia 
telangiectasia mutated) and ATR (ATM-related) protein kinases sense and respond 
to DNA damage by activating the transducer checkpoint kinases Chk2 and Chk1, 
respectively. ATM/ATR and Chk1/Chk2 phosphorylate p53 at serine 15 and serine 
20, respectively (Jowsey et al. 2004). These events increase the stability and 
transcriptional activity of p53 causing upregulation of p53 target genes. These 
include p21, various pro-apoptotic factors (Puma, Bax, Noxa) (Clarke et al. 1994), 
DNA-repair and oxidative stress response genes, and the negative feedback 
regulator Hdm2 (Agarwal et al. 1998). The induction of p21 results in Cdk inhibition 
and cell cycle arrest, preventing the replication of damaged DNA (Ko and Prives
1996). The p53 protein also has an autoregulatory feedback loop in which p53 
stimulates the transcription of Hdm2, which in turn contributes to the proteolytic 
degradation of p53 by facilitating its ubiquitination (Oren 1999). When DNA 
damage occurs during G2 , cells are able to initiate cell cycle arrest in the presence 
or absence of p53. The entry into mitosis is prevented by maintaining Cdk1 in its 
inhibited form through inhibitory phosphorylation (Devault et al. 1991; Honda et al. 
1993; Lew and Kornbluth 1996), as discussed previously, or by sequestration of 
components of the Cdk1-cyclin B complex out of the nucleus (Vermeulen et al.
2003).
Regulation of the cell cycle is therefore a complex process involving the 
coordination of a number of pathways and is crucial to the survival of a cell. Failure 
of cell cycle checkpoints and repair processes can lead to uncontrolled proliferation 
and the accrual of genomic defects leading to GI and chromosomal instability (CIN) 
that can contribute to carcinogenesis (Negrini et al. 2010). Therefore, in order to 
preserve genomic integrity and prevent carcinogenesis, damaged cells rely on two 
different mechanisms to halt their progression: they can either enter into a 
permanent cell cycle arrest (cellular senescence) or trigger programmed cell death 
(apoptosis). Although it is not clear what determines whether a cell undergoes
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senescence or apoptosis it is thought to depend largely on the nature and duration 
of the stress, as well as the cell type (Rebbaa et al. 2003; Seluanov et al. 2001).
1.2 Genomic Instability (GI)
Genomic instability refers to a range of genetic alterations from point 
mutations to chromosomal rearrangements and can be divided into classes 
according to the type of event stimulated (Aguilera and Gomez-Gonzalez 2008). 
Chromosomal instability (CIN) is defined as a persistently high rate of loss and gain 
of whole chromosomes (Draviam et al. 2004) and is caused by mis-segregation of 
chromosomes during mitosis (Thompson et al. 2010).The consequence of CIN is 
aneuploidy, which is widely known to be a hallmark of tumour cells (Lengauer et al.
1997). Micro- and minisatellite instability (MIN) leads to repetitive DNA expansions 
and contractions and can occur by replication slippage, by mismatch repair (MMR) 
impairment or by homologous recombination (HR) (Aguilera and Gomez-Gonzalez
2008). Instability leading to mutations, including base substitutions, micro­
insertions, and micro-deletions, is mainly associated with replication errors, 
impairment of base excision repair (BER) and MMR, or error-prone translesion 
synthesis (Friedberg et al. 2006). Instability, leading to rearrangements refers to 
events that involve changes in the genetic linkage of two DNA fragments. 
Increases in HR-mediated events, such as unequal sister-chromatid exchange 
(SCE) and ectopic HR between non-allelic repeated DNA, or in end-joining 
between non-homologous DNA fragments can result in gross chromosomal 
rearrangements such as translocation, duplications, inversions or deletions. The 
downstream consequences of GI have been described previously (Aguilera and 
Gomez-Gonzalez 2008; Anderson 2001; Negrini et al. 2010) but can include a 
drive towards aneuploidy, a mutator phenotype, loss of integrity of proliferation 
control pathways (e.g. checkpoints), insufficiencies of biological responses or 
biochemical problems due to segregation of material and abnormalities in 
progression to senescence or programmed cell death. These differ depending on 
the cell type and the extent to which cell types normally have lifespan control.
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1.2.1 DNA Damage and Repair
Genomic instability can arise either from increased rates of damage that 
overwhelm the ability of normal repair systems to restore genomic integrity, or 
defective repair systems being unable to cope with normal rates of damage being 
generated through normal cellular and environmental mechanisms, or a 
combination of the two. Increased rates of damage may arise from either 
exogenous or endogenous sources. DNA is subject to continuous modification 
from exogenous factors such as radiation damage, industrial genotoxins, food 
agents and chemical agents (such as chemotherapy drugs) (Lindahl 1993). While 
these are highly relevant to therapy-induced secondary cancers, exogenous 
damage cannot directly underlie the ongoing heritable GI seen within cultured 
tumour cells. Endogenous factors that actively increase genomic damage can 
include by-products of metabolism, including reactive oxygen species (ROS) (such 
as superoxide anions, hydrogen peroxide and hydroxyl radicals) (De Bont and van 
Larebeke 2004) and telomere deficiencies that can generate breakage-fusion- 
bridge events (Davoli et al. 2010; McEachern et al. 2000; Russo et al. 1995).
DNA repair is essential to preserve the fidelity of genomic information, 
removing damage generated by naturally occurring environmental insults as well 
as inevitable replication errors that may occur. Inefficient or defective repair that is 
unable to cope with normally occurring damage is well documented as a means of 
generating GI (Kerzendorfer and O'Driscoll 2009; Lindahl and Wood 1999; Zha et 
al. 2007). This can arise from deficiencies in the repair proteins themselves, or 
from checkpoint defects that fail to halt the cell cycle until repair can be completed. 
In recent years, the characterisation of many proteins involved in sensing and 
responding to DNA damage has enhanced our understanding of DNA damage 
responses extensively (Wood et al. 2001). Mutations in the genes that encode 
DNA damage response proteins are associated with a number of GI syndromes 
(Coppede and Migliore 2010; Hoeijmakers 2009; Musich and Zou 2009). 
Interestingly, these disorders often result in a predisposition to cancer and/or 
premature ageing (Duker 2002) and highlight the clinical significance of pathways
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that sense, relay, or transduce signals associated with DNA damage (Capell et al. 
2009). Ataxia telangiectasia (AT), for example, provides an example of how defects 
in DNA damage sensing can contribute to genomic instability and malignancy 
(Peltomaki 2001). Briefly, AT is caused by mutations in ATM, a protein kinase 
involved in cell cycle checkpoint and genotoxic stress responses (Abraham 2001; 
Shiloh 2003) particularly those responses elicited by exposure to ionising radiation 
(IR) or ‘radiomimetic’ agents (e.g. neocarzinostatin and bleomycin). At a clinical 
level, AT presents a complex multisystem disorder characterised by 
immunodeficiency, neurodegeneration, premature ageing, striking sensitivity to 
ionizing radiation delivered at therapeutic doses, and susceptibility to cancer, in 
particular lymphoma and leukaemia (Boder and Sedgwick 1958). Xeroderma 
pigmentosum (XP) is another human disorder that is associated with defects in 
DNA repair genes associated with nucleotide excision repair (NER) genes. The 
impact of the defect(s) is a deficiency in the repair of cyclobutane pyrimidine 
dimers and 6-4 photo products, major DNA photoproducts resulting from ultraviolet 
(UV) light exposure (Friedberg et al. 2006). Individuals with XP are extremely 
sensitive to UV and display an increased incidence of skin cancer, such as basal 
cell carcinoma (Friedberg 2001; Peltomaki 2001). In an attempt to reveal the 
environmental relevance of inducers of carcinogenesis and to reveal the molecular 
pathways involved in responding to these types of damage syndromes, such as AT 
and XP have become paradigms for studying the cellular responses to IR and UV, 
respectively. The question therefore remains as to whether the wider role of GI at 
the cellular level can be studied in other syndromes that show hallmarks at a 
chromosomal and genome level of putative abnormalities in stress response 
pathways. In the following section a prospective panel of GI syndromes is 
described and their relevance to the aims of this thesis.
1.3 Genomic Instability Syndromes
1.3.1 Werner Syndrome (WS)
Werner syndrome (WS) was first characterised by Dr Otto Werner (Werner 
1904) and is a rare autosomal recessive disorder affecting approximately ten per
14
million individuals (Thannhauser 1945). The first sign of this disorder is often the 
lack of the pubertal growth spurt and WS individuals are typically short in height 
(Kipling et al. 2004; Martin et al. 1999). WS is characterised by juvenile bilateral 
cataracts, skin atrophy and sclerosis, premature hair-greying and thymic atrophy. 
The premature ageing phenotypes associated with WS usually manifest 
themselves in the twenties or thirties with the median age of diagnosis being the 
early thirties. WS individuals show increased predisposition to age-related 
diseases such as type II diabetes mellitus, osteoporosis and atherosclerosis. An 
elevated incidence of cancer is observed in WS, although this is generally limited 
to rare non-epithelial cancers, especially mesenchymal cancers such as sarcomas 
(Epstein et al. 1966; Goto et al. 1996). Several of the clinical features are much 
more severe that seen in normal ageing, including calcification of the cardiac 
valves and atrophy of the testicles and skin appendages. WS individuals do not 
seem to have any obvious immune system dysfunction despite the thymic atrophy, 
and they lack notable pathology of the central nervous system (Postiglione et al. 
1996), although there are some reports of premature senile dementia (Hofer et al.
2005). Death generally occurs in the fourth or fifth decade of life, primarily from 
cancer or cardiovascular disease.
1.3.1.1 Properties of the WRN protein
WS is caused by mutations in the WRN gene that encodes a 1432 amino acid 
protein with several functional domains, including a helicase domain with 
significant homology to the RecQ helicases, and a 3’ to 5’ exonuclease activity 
(Hickson 2003; Moser et al. 1997; Yu et al. 1996). The vast majority of known 
mutations in the WRN gene result in the creation of premature stop codons that 
would produce truncated proteins and lead to complete absence of WRN (Moser et 
al. 1999).
The WRN protein has numerous interacting partners, including replication 
protein A (RPA), p53, proliferating cell nuclear antigen, topoisomerase I, DNA 
polymerases p and 5, the Ku complex, the MRN complex, the telomeric proteins 
TRF1 and TRF2, and telomeric DNA in human cells (Blander et al. 1999;
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Constantinou et al. 2000; Johnson et al. 2001; Kamath-Loeb et al. 2000; Li and 
Comai 2000; Opresko et al. 2004; Opresko et al. 2002; Shen and Loeb 2001). A 
number of studies have indicated that WRN can unwind and/or hydrolyse a number 
of distinctive DNA structures, such as duplex DNA, branched DNA structures, 
displacement loops (D-loops), and four-way DNA junctions (Brosh et al. 2002; Fry 
and Loeb 1999; Kamath-Loeb et al. 2001; Mohaghegh et al. 2001; Opresko et al. 
2002; Orren et al. 2002), although recent data suggest that WRN is not necessary 
for D-loop processing, at least in vitro (Verdun and Karlseder 2006). Of particular 
interest is the ability of WRN to efficiently resolve G-quadruplexes that are 
thermodynamically stable intramolecular structures containing four hydrogen- 
bonded guanine residues on G-rich telomeric sequences (Chang et al. 2004; 
Mohaghegh et al. 2001). Many of these structures may form during processes of 
DNA metabolism, suggesting that WRN plays a role in DNA replication, 
recombination and repair processes. In normal human cells WRN is localised to 
the nucleolus (Marciniak et al. 1998); however, in cells with DNA damage or 
undergoing ALT (alternative telomere lengthening), a significant fraction of WRN 
re-localises to the sites of damage or to telomeres (Johnson et al. 2001; Opresko 
et al. 2004; Opresko et al. 2002). More recent data suggests that the localisation of 
WRN changes throughout the cell cycle, for example WRN was shown to localise 
to sites of DNA replication (Rodriguez-Lopez et al. 2003). The observed 
interactions between WRN and telomere binding proteins (Opresko et al. 2002), 
and its ability to metabolise many telomeric substrates, suggests that WRN plays a 
central role in telomere biology. Mounting evidence suggests that WRN may also 
play a critical role in the rescue of replication fork stalls (Franchitto et al. 2008; 
Pichierri and Franchitto 2004; Sidorova et al. 2008).
1.3.1.2 Cellular phenotype
Primary WS cells display genomic instability, manifested by an elevated rate 
of chromosomal translocation and genomic deletions (Fukuchi et al. 1989), and are 
hypersensitive to a subset of DNA damaging agents, including 4NQO, 
camptothecin and cisplatin (Comai and Li 2004; Pichierri et al. 2000; Poot et al. 
2002; Poot et al. 2001), suggesting that the WRN protein plays a key role in the
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cellular response to specific types of DNA damage. WS is also associated with an 
increased level of pro-oxidant stress (Pagano et al. 2005), which has been 
connected to increased genomic instability and premature cellular senescence 
(Passos et al. 2010). Furthermore it has been linked to ageing, diabetes, cancer, 
atherosclerosis and osteoporosis, all of which are features of WS (Pagano et al.
2005). In addition, cultured fibroblasts from WS individuals have an aged 
appearance (Davis et al. 2005; Davis et al. 2006) and undergo premature 
replicative senescence, with 90% of WS cultures tested having a lifespan of less 
than 20 population doublings (PDs) (Salk et al. 1981; Tollefsbol and Cohen 1984). 
This compares to a lifespan for normal adult dermal fibroblasts that ranges from 20 
to 85 PDs (Cristofalo et al. 1998a). Similarly, WS fibroblasts manifest a poor rate of 
growth compared to normal cells (Davis et al. 2005; Salk et al. 1981), partially due 
to a delayed passage through the S-phase of the cell cycle (Fujiwara et al. 1977; 
Rodriguez-Lopez et al. 2002). Moreover, WS fibroblasts, even at low population 
doublings, have an enlarged cellular morphology with extensive F-actin stress 
fibres and resemble senescent normal fibroblasts (Davis et al. 2005; Davis et al.
2006). Overall, WS fibroblasts resemble normal cells that have undergone stress- 
induced premature senescence (SIPS) (Brack et al. 2000). Evidence in the 
literature suggests that activation of the p38 signalling pathway is involved in 
commitment to SIPS (Huot et al. 1997; Wang et al. 2002). In addition, WS cells 
have been shown to have high levels of activated p38 (Davis et al. 2005) (See 
Appendix A). This together with the genome instability, increased pro-oxidant state, 
and the frequent replication fork stalling seen in WS cells, provides a plausible 
trigger for intracellular stress in WS cells.
1.3.2 Bloom Syndrome (BS)
A second syndrome associated with mutations in a member of the RecQ 
family, in this case the BLM protein, is Bloom syndrome (BS). BS is an extremely 
rare autosomal recessive disorder that is characterised by proportional dwarfism 
with a disproportionately small head, sun-sensitive facial skin erythema, learning 
disabilities, and occasional mental deficiency. Major clinical features are immune
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deficiency and cancer (German 1969; German and Ellis 1998). BS is unique 
among cancer predisposition syndromes in that the frequencies of most types of 
cancer are elevated, including leukaemias, lymphomas and the common solid 
epithelial cancers, although lung and prostate cancers are rare (Hickson et al. 
2001). However, although classified as a progeroid syndrome, there is little 
evidence of a premature ageing defect apart from a high incidence of type II 
diabetes in young individuals, and the elevated cancer incidence.
1.3.2.1 Properties of the BLM protein
The gene mutated in BS encodes a 1417 amino acid DNA helicase member 
of the RecQ family (BLM). Most mutations lead to truncation of BLM, and BS 
individuals usually lack detectable BLM protein, although some mis-sense 
mutations have been found (German et al. 2007). The BLM protein has numerous 
interacting partners including, BRCA1, PML, p53, RAD51, Topllla, MLH1, RPA, 
WRN, TRF2, and telomeric DNA in human cells (Bachrati and Hickson 2003). A 
number of studies have indicated that BLM is a structure-specific helicase that can 
unwind a large array of substrates, such as synthetic Holliday junctions, D-loops, 
and G-quadruplexes (Mohaghegh et al. 2001), although recent data suggest that 
BLM is not necessary for D-loop processing, at least in vitro (Verdun and Karlseder
2006). Many of these structures may form during processes of DNA metabolism, 
suggesting that that BLM plays a role in DNA replication, recombination and repair 
processes. The BLM protein localises with TRF2 and telomeric foci in telomerase 
negative cells undergoing ALT and promotes telomeric DNA synthesis, but not in 
telomerase positive cells or primary cell strains (Stavropoulos et al. 2002). As no 
telomeric association of BLM is seen in normal cells, it is perhaps not surprising 
that no telomere defects have yet been reported in BS.
1.3.2.2 Cellular phenotype
Cells from BS have a markedly increased level of genomic instability that is 
characterised by the formation of spontaneous genetic exchanges, which are 
apparently error prone, with gaps, breaks, and structurally rearranged 
chromosomes occurring at an elevated frequency (German 1969; Poppe et al.
18
2001; Wang et al. 2000a). However, the hallmark of BS cells, which is used in 
human diagnosis, is the ten-fold increase in SCEs, with isolated ES cells, 
lymphoblasts, and fibroblasts all showing this phenotype (Chaganti et al. 1974; 
German et al. 1977). The SCEs are thought to represent HR events occurring 
between sister chromosomes during S-phase or G2 phase of the cell cycle, as HR 
is elevated in BS cells (Sonoda et al. 1999; Wu et al. 2001). Surprisingly, BS cells 
are only moderately deficient in the known DNA repair pathways, although non- 
homologous end-joining (NHEJ) processes are abnormal with an increased 
frequency of inaccurate rejoining of DSBs found in BS cells (Bachrati and Hickson 
2003; Friedberg et al. 1979).
1.3.3 Rothmund-Thomson Syndrome (RTS)
RTS is a rare autosomal recessive genetic disorder, first described in 1866 
(Rothmund 1868; Thomson 1936). The most characteristic feature of RTS is 
cutaneous poikiloderma (dry and colour-flecked flesh), which usually appears in 
infancy, with red oedematous plaques and blistering occurring on the cheeks, 
forehead and ears, and is most severe in sun-exposed areas. Other features 
include short stature, hair greying, alopecia, sparse eyebrows and eyelashes, and 
juvenile cataracts, all of which are associated with normal ageing; thus, RTS is 
classified as a premature ageing syndrome. Two clinical subforms of RTS have 
been defined: RTS type I characterised by poikiloderma, ectodermal dysplasia and 
juvenile cataracts, and RTS type II characterised by poikiloderma, congenital bone 
defects and an increased risk of osteosarcoma in childhood and skin cancer in 
later life. Despite its long history only 300 individuals with RTS have been 
described in the literature, and relatively little is known about it. Moreover, whether 
RTS I and II represent distinct syndromes with overlapping clinical signs or 
intersecting nosological entities involving genes acting on the same pathway, 
remains to be assessed.
1.3.3.1 Properties of the RECQL4 protein
Approximately two-thirds of individuals with RTS have mutations in the 
RECQL4 gene that are predicted to result in a truncated protein due to premature
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termination of protein synthesis (Lindor et al. 2000; Wang et al. 2003). The 
RECQL4 gene is located on chromosome 8q24.3 and encodes a 1208 amino acid 
protein with a central helicase domain that is characteristic of RecQ helicases 
(Kitao et al. 1998). However, RECQL4 does not share homology to two other 
conserved RecQ motifs; RQC and helicase and RNaseD C-terminal (HRDC) 
(Burks et al. 2007; Singh et al. 2010), which are present in human BLM and WRN 
helicases. Recently, RECQL4 was shown to possess two N-terminal nuclear 
localisation signal sequences (Burks et al. 2007). In addition, RECQL4 has an 
intrinsic ATPase activity and single-stranded DNA annealing activity and has been 
shown to interact with the ubiquitin ligases UBR1/2 (Macris et al. 2006; Yin et al.
2004). Since RECQL4 expression is cell cycle regulated, the association with UB1 
and 2 in the cytoplasm may be linked to the process of RECQL4 degradation at 
specific times during the cell cycle. More recently, RECQL4 has also been shown 
to have helicase activity in vitro (Capp et al. 2009; Suzuki et al. 2009; Xu and Liu
2009).
Although the precise role of RECQL4 is largely unknown, recent evidence 
suggests its involvement in multiple DNA metabolic pathways. The RECQL4 
protein is significantly expressed in the S-phase of the cell cycle, suggesting a role 
in DNA replication (Sengupta et al. 2005). Indeed, RECQL4 N-terminal region 
plays a role in recruiting DNA polymerase a to nascent DNA replication forks in 
Xenopus egg extract (Matsuno et al. 2006; Sangrithi et al. 2005). The possible 
involvement of RECQL4 in the repair of DNA DSBs has been demonstrated by the 
localisation of RECQL4 nuclear foci with the foci formed by RAD51, a crucial 
protein which functions in homologous recombination of DNA DSBs (Petkovic et al.
2005), as well as by the sensitivity of RTS fibroblasts from RTS patients to ionising 
radiation (Vennos et al. 1992), and by the participation of RECQL4 in DSB repair in 
Xenopus egg extracts (Kumata et al. 2007). In addition, RECQL4 interacts with 
poly (ADP-ribose) polymerase-1 (PARP-1), which is implicated in DNA 
recombination, DNA repair (Wang et al. 2006), transcriptional regulation and BER 
(Malanga and Althaus 2005). Similarly, RECQL4 colocalises with XPA in human 
cells treated with UV, suggesting that RECQL4 might facilitate NER-mediated
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repair of UV-induced damage (Fan and Luo 2008). It has also been reported that 
RECQL4 plays a role in oxidative stress and its amount increases in the nucleolus 
after treatment of cells with agents that induce ROS (Woo et al. 2006).
1.3.3.2 Cellular phenotype
At a cellular level, defects in RECQL4 manifest themselves as CIN that is 
mainly represented by mosaic aneuploidies and isochromosomes (Larizza et al.
2006). For example, multiple evidence for in vivo mosaicism of trisomy 8 and/or 7 
and /or 2 has been found (Der Kaloustian et al. 1990; Lindor et al. 1996; Miozzo et 
al. 1998; Ying et al. 1990). As compared to chromosomal instability features of 
other RecQ helicase defects, RTS has apparently no overlap with BS. No increase 
in SCE, which is characteristic of BS, has been recorded in RTS cells (Mann et al.
2005). Although RTS resembles WS with regards to a few clinical features, the 
spectrum of chromosomal rearrangements appears to be more restricted in RTS 
than in WS (Ouyang et al. 2008). It is conceivable that accumulation of CIN can 
drive neoplastic transformation in RTS cells and may explain the predisposition of 
RTS individuals to developing osteosarcoma. Inconsistencies have been found in 
the in vitro response of RTS cells to different genotoxic agents and this aspect will 
be reviewed in a later chapter.
1.3.4 Cockayne Syndrome A (CSA)
CS is a rare autosomal genetic disorder characterised by failure to grow, 
abnormal sun sensitivity and premature ageing. Hearing loss, cataracts, and 
severe tooth decay are other common features (Nance and Berry 1992). 
Individuals with CS are often normal at birth but experience failure of brain growth 
which progresses during the first year of life (Kraemer et al. 2007). They have a 
characteristic facial appearance, with large ears and nose, sunken eyes and 
thinning hair, and are thin due to progressive loss of subcutaneous fat (Nance and 
Berry 1992). However, they do not have the pigmentary changes and increased 
frequency of skin cancers seen in XP (Rapin et al. 2000). The vast majority of CS 
individuals have defects in either the CKN1 (CSA) or CSB gene (Licht et al. 2003). 
Here only the CSA subtype is discussed.
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1.3.4.1 Cellular phenotype
At a cellular level, cultured CSA fibroblasts cells show increased sensitivity 
to UV irradiation, and display dramatic delay in the recovery of RNA synthesis after 
DNA damage, and impaired repair of actively transcribed genes or transcription- 
coupled nucleotide excision repair (TC-NER), (Anindya et al. 2010; Mayne and 
Lehmann 1982; van Hoffen et al. 1993; Venema et al. 1990).
1.3.4.2 Properties of the CSA protein
The 44 kDa CSA protein is encoded by the CKN1 gene located on 
chromosome 5 and contains multiple WD-repeats (tryptophan-aspartate repeats) 
(Henning et al. 1995). Approximately 70% of the mutations reported in CSA are 
mis-sense, nonsense, or splice site mutations in the CKN1 gene, whereas the 
other 30% are large, partial deletions of CKN1 (Cao et al. 2004; Ren et al. 2003; 
Ridley et al. 2005). The CSA protein is a component of a ubiquitin ligase complex 
(Anindya et al. 2010; Groisman et al. 2003), that plays a role in TC-NER (de Waard 
et al. 2004), a DNA repair process that preferentially removes UV-induced 
pyrimidine dimers and other transcription-blocking lesions from actively transcribed 
genes; however, the exact role of CSA in TC-NER remains unclear. The deficiency 
of TC-NER is sufficient to explain the cutaneous photosensitivity observed in CSA 
individuals; however, it does not explain the growth failure and neurodegeneration 
that typify CSA, therefore it is likely that CSA has other functions that are yet to be 
elucidated.
1.3.5 Nijmegen-Breakage Syndrome (NBS)
Nijmegen breakage syndrome (NBS) was first described in two Dutch 
brothers with microcephaly, mental retardation, and immunodeficiency, and is a 
rare autosomal recessive condition (Hustinx et al. 1979; Ochs et al. 1997). The 
hallmarks of NBS are growth retardation, microcephaly, mental retardation, and 
immunodeficiency, accompanied by recurrent infections and a predisposition to 
lymphoid malignancy, in particular B and T cell lymphomas (van der Burgt et al.
1996). Interestingly, despite severe immunodeficiency, life expectancy is reduced 
most commonly due to malignancy, and the frequently occurring infections rarely
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lead to complications and are only occasionally fatal. NBS individuals also have 
progeroid-like features, such as sparse hair and distinctive ‘bird-like’ facial 
appearance, characterised by a receding forehead, a prominent mid-face with a 
long nose and a receding mandible, all of which become more pronounced with 
age (Seemanova et al. 1985). Other common symptoms include skin 
abnormalities, particularly cafe-au-lait spots, sun-sensitivity of the eyelids, and 
congenital malformations, particularly clinodactyly and syndactyly (Hiel et al. 2000).
1.3.5.1 Properties of the NBS1 protein
NBS is caused by mutations in the NBS1 gene located on chromosome 8 
that encodes the protein nibrin (Carney et al. 1998; Matsuura et al. 2004; Varon et 
al. 1998). The N-terminal part of nibrin has two domains; an FHA (forkhead- 
associated domain) and an adjacent BRCT (BRCA1 carboxy-terminal) domain, that 
are shared by many proteins involved in DNA replication, cell-cycle regulation or 
responses to DNA damage (Featherstone and Jackson 1998; Varon et al. 1998). It 
is generally accepted that nibrin plays a role in DSB repair (Zhang et al. 2006), 
although its exact roles in this process, and the effect of lack of nibrin in the 
aetiology of NBS, are not fully understood. Briefly, nibrin, together with RAD50 and 
Mre11, make up the MRN complex that co-localises with yH2AX at sites of DSBs, 
or at sites of V(D)J rearrangement processes (Kobayashi et al. 2002; Nelms et al.
1998). Nibrin is required for both nuclear localisation of Mre11/RAD50, and foci 
formation at sites of DNA damage, particularly DSBs (Carney et al. 1998; Desai- 
Mehta et al. 2001). In addition, nibrin physically interacts with ATM, which recruits it 
to sites of DNA damage and facilitates its activation (Digweed et al. 1999; Maser et 
al. 1997; Matsuura et al. 2004; Petrini 1999). Although the interaction between 
ATM and MRN is complex, studies clearly show that both ATM and nibrin are 
required for proper cell cycle regulation and DNA repair in response to DSBs 
(Petrini 2000). Therefore NBS illustrates how defects in proteins involved in DSB- 
repair can contribute to genomic instability and the development of cancer 
(Antoccia et al. 2006; Varon et al. 1998). A more recent report also provides 
evidence for a role of NBS1 in DNA maintenance by the BER pathway, with NBS
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cells showing impaired processing of damaged bases by BER following genotoxic 
treatment with H2O2 (Sagan et al. 2009).
To date, seven mutations in NBS1 have been found in NBS individuals 
(Maraschio et al. 2001; Resnick et al. 2002; Varon et al. 1998). The founder 
mutation, also known as the Slavic mutation, is a 5 bp deletion (657del5) in exon 6 
of the NBS1 gene resulting in a premature stop codon. The other NBS mutations 
also lead to premature protein truncation downstream of the FHA/BRCT domains. 
In Nbs1657del5/657del5 cells no wild-type nibrin is seen, however, abbreviated 
polypeptides of both N-terminal (~ 26 kDa) and C-terminal (~ 70 kDa) nibrin are 
expressed at low levels, and appear to be sufficient to allow cell survival (Maser et 
al. 2001). The C-terminal protein (nibrinp70) is produced by internal translation and 
has the ability to interact with Mre11, which could be crucial for embryogenesis and 
cell growth. This may explain why embryonic-viable NBS1 mutations are all in the 
limited region from exon 6 to exon 10, and suggests that a null mutation would be 
embryonic lethal. Thus NBS individuals are effectively hypomorphic for nibrin 
expression.
1.3.5.2 Cellular phenotype
At a cellular level, cultured lymphocytes and fibroblasts from NBS 
individuals show a marked hypersensitivity to the cytotoxicity and clastogenic 
effects of IR and radiomimetic drugs compared with normal cells (Tauchi et al. 
2002; Yamazaki et al. 1998). Following y-irradiation, NBS cells exhibit abnormal 
cell-cycle regulation, including radioresistant DNA synthesis (RDS) in which cells 
have an inability to halt or slow S-phase progression (DAmours and Jackson 2002; 
Hiel et al. 2000; Shiloh 1997), and delayed induction of p53 at the G1/S phase 
checkpoint; however, NBS cells apparently only exhibit mild defects in the DNA- 
damage dependent G2 checkpoint following IR (Buscemi et al. 2001; Shiloh 1997). 
Primary NBS lymphocytes and fibroblasts typically show slow growth in culture and 
undergo premature replicative senescence (Ranganathan et al. 2001). This may 
reflect the in vivo situation, where lymphocytes are defective in T cell dependent 
antibody responses and show reduced responses to mitogenic signals, such as
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phytohaemagglutinin, leading to failure of clonal T cell expansion resulting from 
infection (Digweed et al. 1999; Hiel et al. 2000). In addition, NBS Lymphocytes are 
predisposed to chromosomal translocations that interrupt the immunoglobulin 
heavy (IgH) chain loci and the T cell receptor loci TCRp and TCRy (Shiloh 1997; 
van der Burgt et al. 1996), a phenotype not seen in NBS fibroblasts. Many of these 
aberrations occur at sites that undergo V(D)J recombination, however V(D)J 
recombination is apparently not deficient in NBS individuals (Harfst et al. 2000). 
The failure of T cell clonal expansion, and the premature senescence of fibroblasts, 
may well underlie some of the phenotypic characteristics of NBS, such as 
immunodeficiency and skin abnormalities.
1.3.6 Hutchinson-Gilford Progeria Syndrome (HGPS)
Hutchinson-Gilford progeria syndrome (HGPS) is a rare disorder associated 
with a characteristic aged appearance very early in life, and was originally 
described more than 100 years ago (Gilford 1904; Hutchinson 1886). The reported 
incidence is one in eight million and since 1886 just over 100 cases have been 
reported (Pollex and Hegele 2004). Children born with HGPS typically appear 
normal at birth but within a year they begin to display the effects of ageing, and as 
such HGPS is termed a childhood progeria that is distinct from the adult progeroid 
syndromes such as WS. The initial symptoms of HGPS include severe growth 
retardation and individuals are short in stature and below average weight. In 
addition, HGPS individuals have micrognathia, craniofacial disproportion, alopecia, 
arteriosclerosis, prominent eyes and scalp veins, and dystrophic nails. A lack of 
subcutaneous fat makes the skin appear wrinkled and aged. Moreover, HGPS 
individuals show skeletal abnormalities that may reflect deficient osteogenesis, 
principally in the extremities, and severe osteolysis (Fernandez-Palazzi et al. 
1992). In short, children with HGPS appear several decades older than they 
actually are, showing signs of respiratory, cardiovascular and arthritic conditions 
similar to those seen in senior citizens. The average age of death is 13, with at 
least 90% of HGPS individuals dying from atherosclerosis (Baker et al. 1981; 
Brown 1992).
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1.3.6.1 Cellular phenotype of HGPS
At the cellular level, HGPS is associated with significant changes in the 
interphase nucleus, including blebbing of the nuclear envelope, thickening of the 
nuclear lamina, loss of peripheral heterochromatin, and clustering of nuclear pores 
(Goldman et al. 2004). Additional analyses describe HGPS lymphocytes as having 
‘strikingly altered nuclear sizes and shapes with envelope interruptions 
accompanied by chromatin extrusion’ and expressing only 25% of the lamin A 
levels seen in normal controls (De Sandre-Giovannoli et al. 2003). Cells from 
HGPS individuals show an accumulation of prelamin A, either as a full-length 
protein or as various truncated forms, and the nuclei have a reduced deformability 
(Dahl et al. 2006) similar to that observed in ageing normal cells (Lans and 
Hoeijmakers 2006).
Premature replicative senescence is popularly considered a canonical 
feature of HGPS cells, although early studies gave mixed results, showing 
impaired proliferation compared to normal age-matched controls but not to the 
same extent as seen in other progeroid syndromes, such as WS. More recent 
studies suggest that HGPS fibroblasts undergo approximately 20-30 PDs 
compared to approximately 60 PDs in the controls (Bridger and Kill 2004), although 
lifespans up to 53 PDs have been recorded. These studies also suggest that 
HGPS fibroblasts undergo a period of hyperproliferation, followed by rapid 
apoptotic death (Bridger and Kill 2004).
The telomeres of skin fibroblasts derived from HGPS individuals are seen to 
be shorter that those of age-matched controls (Allsopp et al. 1992), and telomere 
shortening is accelerated in HGPS cells, or in normal cells ectopically over­
expressing normal lamin A (Huang et al. 2008). In addition, ectopic expression of 
TERT results in the immortalisation of HGPS cells, although there are some cell 
clones that fail to immortalise (Ouellette et al. 2000; Wallis et al. 2004). These data 
suggest that that the premature senescence may be due to accelerated telomere 
shortening. However, these studies did not take into account the much-elevated 
rate of apoptosis seen in HGPS cells that would result in altered dynamics of
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cellular growth, similar to that proposed for WS cells (Section 1.7, Figure 1.6). 
Thus, it is possible that the shortened telomeres in recently explanted HGPS cells 
and the accelerated telomere erosion rates seen in vitro, are due simply to 
elevated cell turnover resulting from cell loss, and there are, as yet, no data 
definitively linking the shortened cellular lifespan to defects in telomere biology.
1.3.6.2 Properties of the Lamin A protein
HGPS is caused by mutations in the LMNA gene that encodes the nuclear 
lamina component lamin A/C. Nuclear lamins are intermediate filament proteins 
that constitute major components of the nuclear lamina, a dynamic filamentous 
meshwork comprising A- and B-type lamins that forms an interface between the 
nuclear membrane and chromatin (Aebi et al. 1986). The nuclear lamina has long 
been thought to protect the genome from mechanical stress. More recently, it has 
been shown that lamin A interacts with chromatin in the nucleoplasm, suggesting a 
regulatory role in chromatin organisation, assembly and disassembly of the 
nucleus during cell division, and gene expression, (Goldman et al. 2002; 
Gruenbaum et al. 2005): indeed transcriptional misregulation has been reported in 
HGPS fibroblasts (Ly et al. 2000).
The most common mutation in HGPS, G608G (GGC>GGT), is a silent de 
novo single nucleotide substitution in exon 11 (-90% HGPS cases). A second 
mutation in the same codon, G608S (GGOAGC), that results in a conservative 
substitution of serine for glycine is also observed in HGPS, although this mutation 
is less common (-10% HGPS cases). Both of these mutations activate a cryptic 
splice site and result in deletion of the 3’ terminal 150 nucleotides of exon 11 
mRNA, causing a 50 amino acid internal truncation near the C-terminus of 
prelamin A, denoted LAA50/progerin (De Sandre-Giovannoli et al. 2003; Eriksson 
et al. 2003). The mutant progerin protein becomes inserted into the nuclear 
membrane rather than the lamina (Navarro et al. 2006) and acts in a dominant 
negative fashion, causing the aberrant nuclear morphology and shortened lifespan 
seen in HGPS cells, even in the presence of wild-type lamin A (Goldman et al. 
2004). Support for this theory comes from studies showing that the these
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phenotypes can be corrected using RNA interference against the truncated mRNA 
(Huang et al. 2005), and by the use of specifically targeted oligonucleotides to 
block the HGPS splice site (Scaffidi and Misteli 2005).
1.3.7 Dyskeratosis Congenita
Dyskeratosis congenita (DKC) is a rare inherited disorder characterised by 
multisystem failure of highly proliferating tissues (Drachtman and Alter 1992; 
Morgan 1997). Individuals with DKC typically present with progressive bone 
marrow failure and a classic triad of mucocutaneous features, including abnormal 
skin pigmentation, nail dystrophy and oral leukoplakia (Dokal 1996, 2000; Knight et 
al. 1998). Other features include signs of premature ageing, such as hair loss, 
early hair greying, aplastic anaemia, osteoporosis, and pulmonary and hepatic 
fibrosis (Dokal 2000). DKC individuals have a predisposition to malignancy, 
although bone marrow failure is the main cause of early mortality. The prevalence 
is approximately one in a million individuals with death occurring at the median age 
of 16 with a maximum of 50 years (Drachtman and Alter 1995; Marciniak et al.
2000). DKC is clinically heterogeneous displaying a range of cutaneous, dental, 
gastrointestinal, neurological, ophthalmic and pulmonary abnormalities (Marrone 
and Dokal 2004). This reflects the genetic heterogeneity of DKC in which X-linked 
recessive, autosomal dominant (AD) and autosomal recessive (AR) forms have 
been identified.
The X-linked recessive is the most severe subtype of DKC, with over 85% of 
affected males having a peripheral cytopenia of at least one lineage and 76% 
develop pancytopenia at a median age of 10 years (Garcia et al. 2007). A severe 
variant of X-linked DKC, known as Hoyeraal-Hreidarrson syndrome, is 
characterised by intrauterine growth retardation, microcephaly, cerebellar 
hypoplasia, mental retardation, progressive combined immune deficiency, and 
aplastic anaemia (Bessler et al. 2007). Conversely, AD-DKC is often much milder, 
with a later onset of disease manifestations and a longer life expectancy. 
Individuals with AD-DKC display bone marrow failure, pulmonary fibrosis and liver 
cirrhosis, but the mucocutaneous manifestations characteristic of the X-linked
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disease are often absent or very mild (Armanios et al. 2007). Interestingly, 
myelodysplatic syndrome and acute myeloid leukaemia, which are rare in X-linked 
DKC, are more frequent in AD-DKC, perhaps reflecting the time required for 
malignant transformation (Garcia et al. 2007).
1.3.7.1 Aetiology of DKC
The aetiology of DKC is complex as it caused by mutations in at least five 
separate genes. In those cases of DKC where the aetiology is known, the vast 
majority of causative mutations are in components of the telomerase multimeric 
ribonucleoprotein (RNP) complex. This complex consists of two core components: 
the telomerase reverse transcriptase (TERT) that catalyses the addition of 
telomeric repeats to the end of chromosomes (Feng et al. 1995), and an RNA 
component (TERC) that contains the template region complementary to the 
telomeric sequence (Greider and Blackburn 1985). Several other proteins 
associate with the core RNP of telomerase, including dyskerin, NOP10, GAR1 and 
NHP2, and are thought to aid the function and localisation of the telomerase core 
(Tollervey and Kiss 1997). Although mutations in a number of these proteins have 
been associated with DKC approximately 60% of clinically diagnosed DKC 
individuals have uncharacterised mutations.
The X-linked form makes up 35% of diagnosed cases of DC and is caused by 
mis-sense mutations in DKC1, the gene encoding the highly conserved nucleolar 
protein dyskerin (Heiss et al. 1998). Dyskerin is thought to have a structural role in 
the telomerase complex as it physically interacts with TERC (Heiss et al. 1999; 
Mitchell et al. 1999b), and DKC1 mutations result in lower TERC levels. AD-DKC is 
a rare subtype (approx 5% of cases) that has been linked to mutations in TERC 
(Vulliamy et al. 2001a; Vulliamy et al. 2004), although in some cases TERT 
mutations have been recorded (Armanios et al. 2005; Vulliamy et al. 2005). The 
majority of mutations in AD-DKC are predicted to reduce telomerase activity when 
present in vivo (Chen and Greider 2004). Another common mutation in AD-DC is a 
3’ truncation of the last 74 bases of TERC (Westin et al. 2007). Interestingly, this 
region is important for binding to dyskerin, thus potentially linking the X-linked and
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AD forms of DC (Mitchell et al. 1999a). Until recently the genetic basis of AR-DKC 
was completely unknown. However, a recent study identified mutations in the RNP 
component, NOP10 (Walne et al. 2007). Individuals with homozygous mutations in 
NOP10 have short telomeres and reduced levels of TERC (Walne et al. 2007). 
Heterozygous individuals also have reduced TERC levels, but to a lesser extent 
than the affected homozygotes. Recently, individuals with DKC that lack mutations 
in DKC1, NOP10, TERC or TERT, were found to have mutations in the TINF2 
gene that encodes TIN2, a component of the shelterin complex that protects the 
ends of chromosomes (Savage et al. 2008). As these individuals are 
heterozygotes, this is a form of AD-DC. The TINF2 mutations disrupt the TIN2- 
TRF1-TRF2 complex resulting in telomere instability, and these individuals have 
very short telomeres. This represents the first time that mutations in the shelterin 
complex have been linked to human disease.
The tissues that are most affected in DKC are those that require constant 
renewal, including skin, oral mucosa, and bone marrow (Garcia et al. 2007; 
Luzzatto and Karadimitris 1998). This is reflected by the in vitro behaviour of cells 
from DKC individuals, and it has been reported that skin fibroblasts grow poorly in 
vitro (Dokal et al. 1992; Marsh et al. 1992). In separate reports, fibroblasts derived 
from individuals with AD-DKC were shown to proliferate at rates similar to normal 
cells at early passage but undergo premature replicative senescence, with a 
proliferative lifespan of approximately half that of their normal counterparts (Westin 
et al. 2007). Similarly, fibroblasts from individuals with X-linked DKC have a 
reduced replicative lifespan but also show reduced growth rates at early passage 
(Wong and Collins 2006). Thus, it appears that all DKC fibroblasts have a 
replicative defect, whereas the growth rate defects are variable and depend on the 
genetic origin of the cells. Cultured primary DKC fibroblasts have also been 
reported to have an abnormal morphology, (including polygonal cell shape, 
ballooning, and dendritic-like projections), a longer doubling time and abnormal 
chromosomal rearrangements (Dokal et al. 1992). Finally, female carriers of the X- 
linked mutant allele show a skewed pattern of X-chromosome inactivation that is 
also consistent with a proliferative defect (Devriendt et al. 1997; Vulliamy et al.
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1997). These data all support the hypothesis that the clinical manifestations of 
DKC can be explained by a defect in cellular proliferative capacity.
An additional cellular phenotype is genomic instability, with fibroblasts and 
lymphocytes from DKC individuals showing an age-dependent increase in 
chromosomal rearrangements that are consistent with telomere shortening 
(Davidson and Connor 1988). As the disease progresses, unbalanced 
chromosomal rearrangements including dicentrics, Robertsonian translocations, 
and ring-chromosomes become detectable in the skin, bone marrow and peripheral 
blood cells; however, there is no elevated sensitivity of DKC cells to most DNA 
damaging agents (Dokal 1996; Dokal et al. 1992). This suggests that the molecular 
defects predispose DKC cells to developing chromosomal rearrangements (Dokal 
et al. 1992) but do not affect DNA repair processes.
1.3.8 Ligase 4 syndrome
1.3.8.1 Clinical and cellular phenotype of LIG4 syndrome
Ligase 4 (LIG4) syndrome is a rare autosomal recessive disorder that 
exhibits microcephaly, unusual facial features, growth retardation, developmental 
delay, skin abnormalities and pancytopenia (O'Driscoll et al. 2001) and shares 
similar clinical phenotypes with NBS (Ben-Omran et al. 2005; O'Driscoll et al.
2004). LIG4 is characterised by, genomic instability, malignancy, immunodeficiency 
and bone marrow abnormalities. LIG4 syndrome cells also show pronounced 
radiosensitivity, however, unlike NBS cells, they show normal cell cycle checkpoint 
responses but impaired DNA DSB rejoining (O'Driscoll et al. 2001).
1.3.8.2 Aetiology of LIG4 syndrome
LIG4 syndrome is caused by mutations in the LIG4 gene that encodes DNA 
ligase IV, a component of the DNA NHEJ machinery (O'Driscoll et al. 2001), which 
represents the major process in mammalian cells for the repair of DNA DSBs 
(Jeggo 1998). In the current model of NHEJ [reviewed by (Hartlerode and Scully 
2009; Poplawski et al. 2009)], the first step involves binding of the heterodimeric 
Ku protein (comprising two subunits, Ku70 and Ku80) to double stranded DNA
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ends. DNA-bound Ku recruits the DNA-dependent protein kinase catalytic subunit 
(DNA-PKcs) and activates its kinase activity. DNA-bound Ku also serves to recruit 
DNA ligase IV and Xrcc4, which is tightly associated with it. The DNA ligase 
IV/Xrcc4 complex then carries out the final ligation step (Grawunder et al. 1997; 
Wilson et al. 1997). DNA ligase IV has been shown to be essential for development 
and knock out mice die at an early embryonic stage (Barnes et al. 1998; Frank et 
al. 2000). Thus, biallelic null mutations have not been described in LIG4 syndrome 
to date, and instead LIG4 syndrome individuals have hypomorphic mutations that 
retain some residual DNA ligase IV function and allow viability (O'Driscoll et al.
2001).
1.3.9 Seckel syndrome
Seckel syndrome (SS) is a rare autosomal recessive disorder that is 
characterised by marked microcephaly and developmental delay (Seckel 1960). 
Other clinical features of SS include severe proportionate dwarfism evident even in 
utero, a characteristic facial appearance (small chin, protruding nose, receding 
forehead), mental retardation and isolated skeletal abnormalities (Faivre and 
Cormier-Daire 2001; O'Driscoll et al. 2004). Since it was first described in 1960, 
>70 cases have been reported, but there is considerable heterogeneity in their 
clinical characteristics (Faivre et al. 2002). This disorder shares many clinical 
features with NBS (Section 1.3.5) and LIG4 syndrome (Section 1.3.8), both of 
which are syndromes involving DNA damage response genes.
1.3.9.1 Aetiology of SS
Given the varied clinical presentation of SS it is not surprising that several 
loci have been linked to SS. Several homozygosity mapping studies using different 
SS families have shown that it was likely that at least three different genes 
(designated as SCKL1, SCKL2 and SCKL3 loci) are responsible for this disorder. 
Recently, mutations in ATR were identified as the gene mutated at the SCKL1 
locus (O'Driscoll et al. 2003). Sequencing of ATR cDNA revealed a silent A2101G 
transition in exon 9 that results in low levels of ATR activity allowing viability, 
although with severe clinical features. Whilst not all SS individuals are mutated in
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ATR, all classical SS individuals are defective in ATR-pathway function (Alderton et 
al. 2004). More recently a second genetic defect in ATR-pathway defective SS was 
identified, namely mutations in the pericentrin(PCNT2)/kendrin gene, which 
encodes a structural centrosomal protein, (Griffith et al. 2008).
1.3.9.2 Cellular phenotype of SS
SS fibroblasts are reported to have slow cycling time (Alderton et al. 2004) 
and are associated with increased chromosome breakage following replication 
stress, particularly at fragile sites (Casper et al. 2004; Casper et al. 2002). In 
addition, SS cells have been reported to show impaired phosphorylation of a range 
of ATR-dependent substrates (H2AX, p53 Nbs1 and Rad17) following exposure to 
UV irradiation but a normal ATM-dependent response to IR (O'Driscoll et al. 2003). 
A similar response was observed in SS following exposure to hydroxyurea 
(O'Driscoll et al. 2004). However, reports of CIN in SS cells are inconsistent. For 
example, spontaneous CIN has been reported in some SS individuals (Woods et 
al. 1995), whereas others show increased CIN following exposure to mitomycin C 
(MMC) (Bobabilla-Morales et al. 2003; Syrrou et al. 1995). However, other SS 
individuals have been reported to be resistant to MMC (Abou-Zahr et al. 1999). In 
addition, increased SCE has been observed in some SS individuals (Cervenka et 
al. 1979; Syrrou et al. 1995). Despite the heterogeneous cellular phenotype of SS 
cells, it is generally accepted that SS cells are unusually sensitive to agents that 
cause replication stalling (Casper et al. 2004), suggesting that the low levels of 
ATR present in SS individuals are insufficient to respond appropriately to 
replication stress.
1.4 Cellular senescence
Normal human fibroblasts undergo only a limited number of divisions in 
culture and eventually enter a state of irreversible cell cycle arrest designated 
senescence or mortality stage 1 (M1) (Hayflick 1965; Hayflick and Moorhead 
1961). Even at low passage numbers cell cultures are made up of a mixture of 
highly replicating cells and senescent cells, although replicating cells make up the 
greater proportion. Over time the percentage of senescent cells progressively
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increases as clones reach the end of their lifespan and arrest, until the whole 
culture stops dividing (Ostler et al. 2000). This is thought to be due to the selective 
repression of growth-promoting genes and the overexpression of repressive 
factors. In fibroblasts, this includes repression of the c-fos proto-oncogene 
(Seshadri and Campisi 1990) and components of the E2F transcription factor 
(Dimri et al. 1995), amongst others, and overexpression of the cell cycle inhibitors, 
p21WAF1 and p16INK4A (Noda et al. 1994). This is likely to lead to hypo- 
phosphorylation of the retinoblastoma gene product, pRb, in senescent cells and 
ultimately trigger growth arrest.
Cellular senescence was first described in human fibroblasts, which were 
shown to senesce after approximately 60-80 PD. Since then a number of other cell 
types, including keratinocytes (Noda et al. 1994; Rheinwald and Green 1975), 
endothelial cells (Mueller et al. 1980), and lymphocytes (Tice et al. 1979) have 
been shown to undergo replicative senescence. The replicative lifespan of normal 
cells can be measured in cumulative PDs and depends on the age and genetic 
background of the donor, and also the species and cell type (Hayflick 1965). In 
contrast to quiescent cells which exhibit transient and reversible growth arrest, 
senescent cells are arrested in the G1/G0 phase of the cell cycle and do not re­
enter the S-phase, even when they are treated with strong mitogenic stimuli 
(Campisi and d'Adda di Fagagna 2007; Cristofalo et al. 1989).
There are two types of cellular senescence: replicative senescence and 
stress-induced premature senescence (SIPS). Replicative senescence is thought 
to be induced by progressive telomere shortening and is often referred to as a 
telomere-dependent process (see section 1.4.2). SIPS, on the other hand, is 
induced when cells are exposed to stressful stimuli (including DNA damage, 
overexpression of oncogenes and oxidative stress) and is thought to be a 
telomere-independent process (see section 1.4.3). Although this distinction is 
useful, it probably does not refer to two independent cellular mechanisms but, 
rather, to the fact that disparate signals can elicit a common cellular response. 
Most studies indicate that senescence is activated once a cell has suffered a
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critical level of damage. It is therefore possible that senescence can result from the 
cumulative effect of multiple stresses acting on a population of cells. Moreover, 
extrinsic stresses, such as oxidative stress, may affect intrinsic factors, such as 
DNA damage accumulation and telomere shortening rates (Passos et al. 2010). 
Thus, a combination of various stressors may exert a complex cumulative effect on 
a heterogeneous population of cells, ultimately triggering the senescence of the 
population as a whole. Here, the terms replicative senescence and SIPS are used 
to make a distinction between the different inducers of senescence with particular 
attention given to the signalling pathways involved in senescence and specifically 
of the role of p38 MAPK in senescence.
1.4.1 Characteristics of senescent cells
At senescence, the most obvious change is irreversible growth arrest. Whilst 
the hallmark of senescent cells is the cessation of responsiveness to mitogens 
(Seshadri and Campisi 1990), the senescent phenotype is typically characterised 
by marked alterations in growth kinetics, morphological appearance and 
dysregulation of biological processes. Senescent cells maintained under routine 
culture conditions are morphologically characterised by an increase in cell size, 
with a marked flattened and vacuolated appearance coupled with an associated 
increase in nucleus and nucleoli size (Cristofalo and Kritchevsky 1969; Greenberg 
et al. 1977; Mitsui and Schneider 1976). A marked increase in the number of 
lysosomes and golgi (Cristofalo and Kabakjian 1975; Maciera-Coelho et al. 1971) 
and a pronounced increase in the number of cytoplasmic microfilaments are also 
features indicative of senescence (Brandes et al. 1972; Lipetz and Cristofalo
1972). In addition to the morphological alterations, senescent cell populations 
exhibit a pronounced increase in the number of multinucleated cells (Matsumura 
1980; Yanishevsky and Carrano 1975) and heterochromatic foci are observed 
(Narita et al. 2003). Although senescent cells remain metabolically active, the 
progressive accumulation of senescent cells causes attenuation in tissue function 
(Dimri et al. 1995; Minamino et al. 2002).
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The complete cessation of proliferation in senescent fibroblasts is 
associated with alterations in gene expression patterns and posttranslational 
modifications in a cell-type specific manner, resulting in an altered phenotype 
compared to their young isogenic counterparts (Cristofalo et al. 1998b; Park et al. 
2001; Shelton et al. 1999). For example, altered patterns of gene expression are 
seen in the transduction and secretory pathways. Impairment in cell mobility, 
secretion of matrix degrading proteins, secretion of growth factors and pro- 
inflammatory cytokines are considered as significant changes associated with 
cellular senescence. These changes are thought to have a detrimental impact on 
neighbouring cells, the surrounding extracellular matrix and other structural 
components, leading to aged tissues (Burton et al. 2005; Burton et al. 2007; 
Campisi 1997a).
Microarray analysis of senescent dermal fibroblasts, retinal pigment 
epithelial cells and vascular endothelial cells demonstrate overlap in gene 
expression changes but overall display cell-type specific changes (Shelton et al.
1999). In particular, the differential regulation of proteases and constituents of the 
extracellular matrix, such as: extracellular matrix (ECM)-degrading secreted 
proteases, collagenase (West et al. 1989), and tissue plasminogen activator (West 
et al. 1996); ECM-modifying proteins, matrix metalloproteinases (MMPs) and tissue 
inhibitor of metalloproteinase family (Millis et al. 1992a; Millis et al. 1992b); growth 
factors and inflammatory cytokines, have been reported (Campisi 1998; Faragher 
and Kipling 1998; Shay and Wright 2005). Additionally, senescent fibroblasts 
express reduced levels of MMP inhibitors, tissue inhibitor of metalloprotease 
(TIMP1) (Millis et al. 1992b) and Ras-related C3 botulinium toxin substrate 1 
(MIG5) (Wick et al. 1994), a reduction in ECM components, including elastin, 
laminin (Linskens et al. 1995) and constituents of collagen (Furth 1991). Secreted 
levels of growth factors, such as vascular endothelial growth factor (VEGF), are 
also reported to be elevated in senescent cell cultures (Coppe et al. 2006). These 
findings lead to the idea that while cellular senescence may be a mechanism to 
suppress tumourigenesis early in life, it may promote cancer in aged organisms
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(Campisi 1997a). Indeed, co-cultivation of senescent fibroblasts with epithelial cells 
can promote the growth of pre-neoplastic cells (Krtolica and Campisi 2002).
One of the most commonly used markers of senescence is the upregulation 
of senescence associated p-galactosidase (SA p-gal) activity. It was proposed that 
SA p-gal, which is active at pH 6.0, was distinct from the lysosomal p-gal with an 
optimum pH of 4.5 (Dimri et al. 1995). Results showed an age-dependent increase 
in SA p-gal staining in dermal fibroblasts and epidermal keratinocytes at 
senescence (Dimri et al. 1995). Despite the extensive application of the SA p-gal 
assay as an indicator of senescence, the validity and reliability of the assay has 
been challenged. An increase in SA p-gal has been reported in immortalised cells 
following serum starvation (Yegorov et al. 1998) and oxidative stress induced by 
H2 O2 , and can even be reversed under some conditions (Cristofalo 2005).
More recently, studies have used novel biomarkers to detect cellular 
senescence in mitotic tissues in order to re-evaluate the significance of cellular 
senescence in organismal ageing (Herbig et al. 2006; Jeyapalan et al. 2007). 
These studies investigated markers of cellular senescence such as telomere 
damage, active checkpoint kinase ATM, high levels of heterochromatin proteins 
and elevated levels of p16 in skin biopsies from baboons with advancing age. The 
number of dermal fibroblasts containing damaged telomeres reached a value of 
over 15% of total fibroblasts in very old animals (26-30 years) compared to young 
(5-6 years) where DNA damage was rarely detected.
1.4.2 Replicative senescence
Telomere attrition is thought to be the predominant mechanism by which a 
cell ultimately becomes “replicatively” senescent (Harley et al. 1990; Olovnikov
1973). Telomeres are the DNA-protein structures that cap the ends of eukaryotic 
linear chromosomes. They function to protect chromosomal ends from normal 
cellular activity and genome instability promoting events. Human telomeres consist 
of TTAGGG repeat sequences, the lengths of which vary greatly among 
mammalian species and interestingly in the same individual depending on cell type 
(Allshire et al. 1989; Campisi 2001; de Lange et al. 1990; Moyzis et al. 1988).
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Telomeres form a higher-order chromatin structure that physically hides the 3’- 
overhang at the chromosome end. Studies suggest that the double-stranded 
telomere folds back on itself to form large terminal loops known as a T-loop (de 
Lange 2005; Greider 1999). The 3’ G-rich single-stranded overhang at the end of 
the T-loop then invades the double-stranded telomere and produces a D-loop. 
This structure performs a number of essential roles in chromosome preservation. 
For example, capping allows the cell to differentiate chromosome ends from DSBs 
in the genome. This is essential since uncapped chromosome ends are susceptible 
to degradation (leading to loss of genetic information), recombination (leading to 
chromosomal rearrangements) or fusion (resulting in the formation of dicentric 
chromosomes and breakage-fusion-bridge cycles) (Stansel et al. 2001; van 
Steensel et al. 1998).
During the replicative lifespan of normal diploid somatic cells, telomere 
attrition is thought to occur at approximately 50-200 base pairs (bp) per cell division 
(Harley et al. 1990). The progressive attrition of telomeric sequences has been 
attributed to the inability of DNA polymerase to completely replicate chromosome 
ends during lagging strand synthesis (Harley et al. 1990; Olovnikov 1973). This 
phenomenon is known as the end replication problem and occurs when somatic 
diploid fibroblasts undergo each cell division. Telomeres can be extended by 
addition of TTAGGG repeats onto pre-existing telomeres. Telomerase, a cellular 
reverse transcriptase, provides the main regulator of telomere length and facilitates 
the replication of telomeric DNA. Telomerase is composed of two essential 
constituents: the reverse transcriptase subunit, hTert, and the RNA component, 
hTERC, the latter of which contains the template for the synthesis of new tandem 
repeats (Blasco 2003). Most normal human somatic cells either completely lack 
telomerase activity or possess residual levels that are insufficient for telomere 
maintenance (Harley et al. 1990; Kim et al. 1994). This, coupled with the end 
replication problem, leads to progressive telomere shortening with each round of 
replication.
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Support for this theory comes from the observations that the mean telomere 
length in cells that do not express telomerase, such as primary human fibroblasts, 
decreases with subcultivation (Harley et al. 1990). In contrast, telomerase activity 
is reactivated in approximately 90% of human cancers, which may contribute to the 
continued growth of cancer cells (Artandi 2006). Similarly, the introduction of 
telomerase into normal somatic cells, such as retinal pigment epithelial cells and 
foreskin fibroblasts, has been shown to extend replicative lifespan (Bodnar et al. 
1998).
1.4.2.1 Immortalisation by ectopic expression of hTert
The observation that normal human somatic cells have a finite life span and 
enter senescence after a limited number of divisions (Hayflick 1965; Hayflick and 
Moorhead 1961) is the main drawback of working with primary cultures. It 
represents an obstacle to the study of normal human cells, especially since large 
quantities of cells are often required for analysis. This limitation is of particular 
concern for the study of rare hereditary human diseases, such as those studied 
here, since the volume of the biological samples collected from biopsies is often 
small and contain limited numbers of cells. The establishment of permanent cell 
lines is one way to avoid this lack of material. Conventional methods of 
immortalisation involve the utilisation of oncogenic viral proteins to establish 
permanent fibroblast cell lines. However, such transformed cells typically exhibit 
significant alterations in physiological and biological properties from their normal 
counterparts (Ouellette et al. 2000). Most notably, these cells are associated with 
aneuploidy, spontaneous hypermutability, loss of contact inhibition and alterations 
in biochemical functions related to cell cycle checkpoints (Ouellette et al. 2000). 
These differences pose significant limitations to the analysis of many cellular 
functions, in particular those related to genomic integrity and the study of genomic 
instability syndromes. To overcome the technical barrier of senescence whilst 
avoiding problems associated with transformation, immortalisation of cells by 
ectopic expression of hTert can be achieved. The utilisation of hTert permits an 
extension of proliferative lifespan whilst maintaining normal cell cycle controls, 
functional p53 and pRb checkpoints and retention of contact inhibition and
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anchorage dependence (Jiang et al. 1999; Morales et al. 1999). Specifically, the 
ectopic expression of hTert cDNA in normal fibroblasts and retinal pigment cells 
has been shown to bypass the senescence barrier leading to immortalisation 
(Bodnar et al. 1998; Vaziri and Benchimol 1998) without inducing alterations that 
resemble a malignant phenotype (Jiang et al. 1999; Morales et al. 1999; Vaziri and 
Benchimol 1998).
1.4.3 Stress-induced premature senescence (SIPS)
While it is widely recognised that telomere shortening is a universal 
mechanism that limits proliferative potential of normal cells lacking telomerase, 
evidence of telomere-independent senescence processes have been reported. 
Studies have shown that mouse embryonic fibroblasts (MEFs) have functional 
telomerase and long telomeres but they exhibit replicative senescence-like cell 
cycle arrest after several rounds of cell division (Wright and Shay 2000). In 
addition, exposure to stressful stimuli can elicit a permanent state of growth arrest 
that is indistinguishable from replicative senescence. Furthermore, expression of 
hTert does not prevent SIPS in normal human fibroblasts in response to UV, y- 
irradiation or H2O2 (Gorbunova et al. 2002), suggesting that SIPS is not triggered 
by telomere shortening but rather that nonspecific DNA damage serves as a signal 
for the induction of SIPS.
An early observation linking DNA damage to premature senescence was the 
permanent and irreversible proliferation arrest observed in irradiated human 
fibroblasts (Di Leonardo et al. 1994). Since then, a number of other DNA damaging 
agents have been shown to induce senescence. The most frequently reported 
causes of SIPS include: oxidative DNA damage (Chen and Ames 1994; Parrinello 
et al. 2003) or nucleotide damage (Rai 2010), DNA damage induced by genotoxic 
agents (Schmitt et al. 2002; te Poele et al. 2002), oncogenic dysregulation 
(Serrano et al. 1997), and suboptimal culture conditions (Ramirez et al. 2001).
Oxidative stress and the accumulation of intracellular ROS play an important 
role in the induction of senescence (Chen and Ames 1994). Human fibroblasts are
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shown to undergo premature senescence when grown at high oxygen conditions 
(40-50% oxygen) (Ben-Porath and Weinberg 2005). Conversely, a reduced partial 
pressure of oxygen (equivalent 2-3% oxygen) allows an increase in growth rate 
and an increased frequency in colony formation (Balin et al. 1977; Honda and 
Matsuo 1983; Packer and Fuehr 1977). Similarly, an increase in intracellular ROS 
levels through H2O2 treatment or through the inhibition of ROS scavenging 
enzymes, such as superoxide dismutase (Sod1), causes premature senescence 
(Blander et al. 2003). Although there is some evidence that minimal doses of H2 O2 
(10 nM) stimulate growth of transformed and normal fibroblasts (Bladier et al. 1997; 
Burdon et al. 1989), exposure to higher doses (50-100 p,M) is shown to induce 
growth arrest with cells displaying a characteristic senescent-like morphology 
(Bladier et al. 1997).
The direct damaging of DNA, either achieved by irradiating cells or 
treatment with DNA-damaging agents, can induce cells to undergo senescence 
(Wahl and Carr 2001). However, often the cellular response to such damage is cell 
death or reversible cell-cycle arrest, depending on the type of agent, the dose, and 
the cell type (Wahl and Carr 2001). Many chemotherapeutic drugs that cause 
severe DNA damage have been shown to induce senescence in normal cells. For 
example, exposure of human dermal fibroblasts to anti-neoplastic molecules such 
as MMC and bleomycin has been shown to result in a marked decrease in 
proliferation capacity, appearance of SA p-gal activity and a senescent-like 
morphology (Niggli et al. 1989; Rodemann et al. 1989). However, the distinction 
between arrested cells and those undergoing senescence as indicated by SA p-gal 
may not be clear. It has also been reported that topoisomerase inhibitors, such as 
doxorubicin (DOX), can induce irreversible growth arrest in tumour cells along with 
morphological and biochemical changes that are associated with senescence (te 
Poele et al. 2002). In conclusion, several lines of evidence suggest that the 
exposure of normal human cells to sub-cytotoxic stress triggers the appearance of 
a senescent-like phenotype.
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The introduction of activated oncogenes into primary cells triggers defence 
responses that prevent cell growth. Some oncogenes, such as c-Myc, trigger 
apoptosis, whereas others, such as activated Ras, trigger a permanent and 
irreversible arrest that is reminiscent of senescence (Serrano et al. 1997). 
Oncogene-induced senescence is conserved not only in fibroblasts (Serrano et al. 
1997), but also in epithelial cells of human and murine origin (Jones et al. 2000; Lin 
and Lowe 2001). This response has been suggested to represent a tumour- 
suppressive mechanism by which cells prevent uncontrolled proliferation in 
response to the aberrant activation of proliferation-driving oncogenes.
1.4.4 Regulators of senescence
There are two major signalling pathways that have been implicated in the 
activation and regulation of senescence including the p53/p21WAF1/CIP1 and 
pRb/16INK4A tumour suppressor pathways (Alcorta et al. 1996; Beausejour et al. 
2003; Lin et al. 1998; Serrano et al. 1997). These pathways interact but can 
independently halt cell cycle progression. To some extent, they also respond to 
different stimuli. In addition, there are both cell-type specific and species-specific 
differences in the propensity with which cells engage one or the other pathway, 
and in the ability of each pathway to induce senescence (Campisi and d'Adda di 
Fagagna 2007). Finally, although most cells senesce due to engagement of the 
p53 pathway, p16 pathway, or both, there are some examples of senescence that 
appear to be independent of these pathways (Olsen et al. 2002). In these cases 
there is evidence that the p38 pathway plays a role in cell cycle arrest. For 
example, the cell cycle checkpoint function of p38 was shown to be essential for 
cell cycle arrest in cells with defective p53 (Reinhardt et al. 2007).
Stimuli that generate a DNA-damage response, for example ionizing 
radiation and telomere dysfunction, induce senescence primarily through the 
p53/p21WAF1/CIP1 pathway (Campisi and d'Adda di Fagagna 2007). p53 is an 
important downstream target of the DNA damage response pathway, which is 
activated via ATM through several mechanisms (Kastan and Bartek 2004). ATM 
activates downstream kinases Chk1 and Chk2, which mediate the phosphorylation
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of p53 at Ser20. Subsequently, the interaction of p53 with Mdm2 is disrupted 
leading to the stabilisation of p53. In this way, p53 regulates cellular proliferation 
and senescence, which is thought to provide a protective mechanism that 
suppresses tumourigenesis (Campisi 2005). p2 iWAF1/CIP1 is a crucial transcriptional 
target of p53 that mediates p53-dependent senescence (Brown et al. 1997). 
However, p2 iWAF1/CIP1 also mediates a transient DNA-damage-induced growth 
arrest. It is currently unknown what determines whether cells senesce or arrest 
transiently. It is possible that rapid DNA repair quickly terminates p53/p21WAF1/CIP1 
signalling, whereas, slow, incomplete or faulty repair results in sustained signalling 
and induces senescence (Campisi and dAdda di Fagagna 2007; Passos et al. 
2010). The role of p2 iWAF1/CIP1 in senescence is highlighted by the finding that the 
level of p2 iWAF1/CIP1 gradually increases as cells progress into a state of 
senescence (Alcorta et al. 1996). Furthermore, targeted deletion of p2 iWAF1/CIP1 in 
fibroblasts results in the bypass of cellular senescence (Brown et al. 1997).
Stimuli that produce a DNA-damage response can also engage the 
pRb/16INK4A pathway. Although this is usually secondary to activation of the 
p53/p21WAF1/CIP1 pathway, there are some senescence-inducing stimuli, such as 
oncogenic Ras, that act primarily through the pRb/16INK4A pathway (Jacobs and de 
Lange 2004; Lowe and Sherr 2003; Stein et al. 1999). p16 is an inhibitor of cyclin 
D/Cdk4,6 complexes (Lowe and Sherr 2003) that is induced in various situations of 
stress and is highly expressed in senescent cells (Alcorta et al. 1996; Palmero et 
al. 1997). Active p16 prevents the phosphorylation of pRb, thus keeping it in the 
active hypophosphorylated form, thereby preventing E2F from transcribing genes 
that are required for proliferation (Sherr and McCormick 2002). The final outcome 
is irreversible senescence.
1.4.5 Significance of senescence in vivo
Hayflick’s original observations of cellular senescence were made using 
cultured cells, and much of the current understanding of the causes and 
consequences of senescence still derives from cell cultures. It has only been in
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recent years that cellular senescence has been shown to occur and to be important 
in vivo.
Senescence-associated markers (see section 1.4.1) have been used to 
identify senescent cells in vivo, with the caveat that none of these markers are 
exclusive to the senescent state. In rodents, primates and humans, senescent cells 
are found in many renewable tissues, including the vasculature, haematopoietic 
system, many epithelial organs and the stroma (Campisi 2005; Dimri et al. 1995; 
Jeyapalan et al. 2007; Krishnamurthy et al. 2004). Notably, cells that express one 
or more senescence markers are relatively rare in young organisms, but their 
number increases with age (Herbig et al. 2006). Among the senescence markers 
that accumulate with age are senescence-associated DNA-damage foci (SDFs) 
that co-localise with telomeres, suggesting that, at least in some tissues, telomere 
dysfunction causes senescence in vivo (Campisi and d'Adda di Fagagna 2007). 
Cells that express senescence markers are also found at sites of age-related 
pathology, such as osteo-arthritis and atherosclerosis (Chang and Harley 1995; 
Price et al. 2002; Vasile et al. 2001). As discussed previously, prior to senescence, 
dermal fibroblasts express high levels of matrix-producing genes and low levels of 
matrix degrading enzymes, such as collagenase and stromelysin. However, upon 
senescence these expression levels reverse, reflecting a clear switch to a matrix- 
degrading phenotype (Campisi 1997a). This can have profound effects on tissue 
function and is postulated to contribute to the progression of disease and the 
overall functional decline that is associated with ageing in vivo. In particular, 
secretion of matrix metalloproteases by senescent cells has been suggested to 
play a role in the pathogenesis of coronary heart disease (Nanni et al. 2007), and 
osteoporosis (Logar et al. 2007). In addition, some studies suggest that this 
process may be responsible for the thinning and wrinkling of the skin during ageing 
(Furth 1991). Another change that occurs when a cell becomes senescent is the 
increased secretion of pro-inflammatory cytokines. These not only affect local 
tissue but also have much wider impacts throughout the organism. Enhanced 
inflammation during ageing is thought to contribute to many of the diseases of 
ageing. For example, vascular smooth muscle cells that have become senescent
44
due to the activation of Ras have been shown to drastically increase the 
expression of pro-inflammatory cytokines, such as Interleukin 1a (IL1 a), IL 1(3, IL-6 
and IL-8, which are thought to contribute to the progression of atherosclerosis 
(Minamino et al. 2003). Thus, senescent cells are associated with ageing and age- 
related diseases in vivo.
The demonstration of a senescent-like arrest mediated by p53 and p16INK4A 
after ectopic expression of oncogenic Ras in primary normal human and rodent 
cells introduced the concept of oncogene-induced senescence as a mechanism to 
restrain the growth of potentially cancerous cells (Serrano et al. 1997). This idea is 
further supported by the fact that essentially all human cancer cells have acquired 
mechanisms to maintain telomeres, generally through the expression of high levels 
of telomerase (Stewart and Weinberg 2006). Recently, replicative senescence has 
been shown to act as a tumour suppressor mechanism in telomerase-deficient 
mice expressing the oncogene Myc in B cells (Feldser and Greider 2007). Short 
telomeres reduced the incidence of cancer in these animals even when apoptosis 
was blocked by overexpression of the anti-apoptotic protein Bcl2. Examination of 
the lymph nodes of these apoptosis-resistant mice revealed clear signs of 
senescence induction, demonstrating that telomere-dependent senescence is an 
efficient mechanism to suppress cancer in vivo (Feldser and Greider 2007). 
Moreover, senescent cells are associated with benign dysplastic or pre-neoplastic 
lesions (Braig et al. 2005; Collado et al. 2005) and benign prostatic hyperplasia 
(Castro et al. 2003), but not with malignant tumours. They are also found in normal 
and tumour tissues following DNA-damaging chemotherapy (Roninson 2003; 
Schmitt et al. 2002; te Poele et al. 2002). These findings support the idea that 
cellular senescence has evolved as a tumour-suppression mechanism and that 
ageing may simply be an unwanted by-product of this.
1.5 Stress signalling, MAPKs and senescence
Cells respond to stress in a variety of ways ranging from activation of 
pathways that promote survival to those eliciting senescence or programmed cell 
death (apoptosis). One of the major pathways that is activated in response to
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stress is the mitogen-activated protein kinase (MAPK) pathway. Here the focus is 
on the p38 MAPK pathway and its role in senescence.
All eukaryotic cells possess multiple MAPK pathways, which are activated in 
response to a variety of extracellular stimuli and mediate signal transduction from 
the cell surface to the nucleus. They regulate diverse physiological and 
pathological cellular activities, including inflammation, apoptotic cell death, 
oncogenic transformation, tumour cell invasion, and metastasis thereby exerting a 
profound effect on cell physiology (Kyriakis and Avruch 2001; Pearson et al. 2001; 
Roux and Blenis 2004). MAPKs, in combination with several other signalling 
pathways, can differentially alter the phosphorylation status of transcription factors 
in a pattern unique to a given external signal. Although MAPKs are expressed in all 
eukaryotic cell types, they regulate very specific biological responses that differ 
between cell types.
To date, four distinct groups of MAPKs have been reported in mammalian 
cells that respond synergistically to different upstream signals: extracellular signal- 
regulated kinases (ERKs), c-jun N-terminal or stress-activated protein kinase 
(JNK/SAPK), ERK5/big MAPK1 (BMK1), and the p38 group (Chen et al. 2001; 
Kyriakis and Avruch 2001). Each of these MAPKs form part of a three-tiered 
phospho-relay cascade along with a MAP kinase kinase (MKK), and a MAP kinase 
kinase kinase (MAP3K) (Kyriakis and Avruch 2001; Widmann et al. 1999). Signals 
are transmitted through the module by sequential phosphorylation and activation of 
these components. The MAP3Ks are often activated through phosphorylation 
and/or interaction with small GTPase proteins of the Ras/Rho family in response to 
extracellular stimuli (Kolch 2000; Marinissen et al. 2001; Zhang et al. 1995). Upon 
activation, the MAP3Ks phosphorylate a MKK on conserved serine and threonine 
residues, which in turn stimulates MAPK activity through dual phosphorylation on 
threonine and tyrosine residues located in the activation loop of kinase subdomain 
VIII (Crews et al. 1992; Kosako et al. 1992; Wu et al. 1993). Once activated, the 
MAPK proteins elicit a cellular response by transferring the y-phosphate of ATP to
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a serine or threonine residue in specific S(T)P sequences in target proteins within 
the cell (Roux and Blenis 2004).
The ERK cascade is activated mainly by growth factors and induces cell 
proliferation, survival and differentiation (Pearson et al. 2001; Roux and Blenis 
2004). Conversely, JNKs and p38 were originally identified as kinases activated in 
response to a diverse array of cellular stresses such as proinflammatory cytokines, 
UV irradiation, ROS, heat, osmotic shock, and DNA damage, and are therefore 
known as stress-activated MAPKs (Derijard et al. 1994; Han et al. 1994; 
Raingeaud et al. 1995). The JNK and p38 pathways have been shown to be 
critically involved in the control of cellular stress responses such as cell death and 
survival (Kyriakis and Avruch 2001; Widmann et al. 1999). It has gradually become 
clear that the involvement of these stress-activated MAPK cascades in cellular 
senescence is dependent on the cellular context and cell type (Maruyama et al. 
2009). In the following sections, the focus is on the roles of stress-activated 
MAPKs, in particular the p38 pathway, in cellular senescence.
1.5.1 The p38 pathway
p38a was first isolated as a 38-kDa protein that is rapidly tyrosine 
phosphorylated in response to lipopolysaccharide (LPS) stimulation and osmotic 
shock (Freshney et al. 1994; Han et al. 1994; Rouse et al. 1994). Later, p38 was 
identified as the molecular target of pyridinyl-imidazole cytokine inhibitors, which 
are known to inhibit biosynthesis of inflammatory cytokines such as interleukin-1 
(IL-1) and tumour necrosis factor (TNF) in LPS stimulated monocytes (Lee et al. 
1994). Since then, three other isoforms have been isolated: p38(3 (Jiang et al. 
1996; Stein et al. 1997), p38y (Li et al. 1996) and p386 (Jiang et al. 1997). The 
p38a and p38j3 are ubiquitously expressed while the p38y and p385 are 
differentially expressed depending on tissue type. The p38y isoform is 
predominantly expressed in skeletal muscle (Li et al. 1996), whereas p385 is 
enriched in lung, kidney, pancreas, testis and small intestine and is thought to be 
developmental^ regulated (Hale et al. 1999; Kumar et al. 1997). The four isoforms 
of p38 share high sequence homology and a signature Thr-Xaa-Tyr (TXY)
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phosphorylation motif in the activation loop (Wilson et al. 1996). The p38 MAPK 
isoforms appear to mediate distinct functions in vivo due, in part, to differences in 
substrate phosphorylation by individual p38 MAPKs and also to selective activation 
by MKKs.
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Figure 1.4. The role of p38 in the G2/M (A) and Gi/S (B) checkpoints.
Stress signals are delivered to this cascade by members of the Rho family 
small GTPases (Rac, Rho, Cdc42). A large group of proteins, acting as MAP3Ks, 
activate the MKK/p38 pathway, which explains why this cascade can be activated 
by such a variety of stimuli. Downstream of the MAP3Ks in the p38 signal 
transduction cascade are the dual kinases known as MKKs. There are two main 
MKKs that are known to activate p38, MKK3 and MKK6, which show a high degree 
of specificity for p38 and do not activate ERK1/2 or JNK. In addition, MKK4, an 
upstream kinase of JNK, can also contribute to the activation of p38a and p38S in 
specific cell types, suggesting that MKK4 represents a site of integration for the 
p38 and JNK pathways (Brancho et al. 2003; Meier et al. 1996). Despite conserved
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dual phosphorylation sites among p38 isoforms, selective activation by distinct 
MKKs has been observed. For example, while MKK6 activates all p38 isoforms, 
MKK3 is somewhat selective, as it preferentially phosphorylates the p38a and p38y 
and p385 isoforms, but not p38p (Enslen et al. 1998). Furthermore, p38a is 
activated by low levels of MKK6 activity, whereas other p38 isoforms are only 
activated by high levels of MKK6 activity (Alonso et al. 2000). This suggests a 
mechanism for the specific activation of p38 MAPKs depending on the level of 
MKK6 activity triggered by a given stimulus. In addition, whereas MKK6 is 
activated by all known p38 activators, MKK3 appears to be more restricted with 
regard to activation by upstream stimuli (Kyriakis and Avruch 2001).
The p38 MAPK pathway regulates diverse biological functions by 
phosphorylation of specific target molecules found within the cell membrane, 
cytoplasm and nucleus. In particular p38 MAPK substrates include protein kinases 
and transcription factors, such as ATF-2 (Tan et al. 1996). The first p38a substrate 
to be identified was the MAPK-activated protein kinase 2 (MAPKAPK2 or MK2) 
(Stokoe et al. 1992a) and its closely related family member MK3. MK2 and MK3 
are serine/threonine kinases with proline rich N-termini, highly conserved catalytic 
domains, and C-terminal autoinhibitory regions, both of which are shown to 
activate various substrates including small heat shock protein 27 (HSP27) (Stokoe 
et al. 1992b). HSP27 is an F-actin binding protein involved in cytoskeletal structure. 
Unphosphorylated HSP27 normally exists in high molecular multimers that serve 
as molecular chaperones; however, upon phosphorylation on conserved serine 
residues (Ser 15, 78, 82 and 90) HSP27 disassociates into monomers and dimers. 
This leads to redistribution of HSP27 to the actin cytoskeleton and the formation of 
actin stress fibres (Guay et al. 1997; Huot et al. 1997). Transcription factors 
activated by p38 include CREB homologous protein (CHOP), which is 
transcriptionally induced in response to genotoxic and inflammatory stresses 
(Wang and Ron 1996). Activation of CHOP mediates in part cell cycle arrest at 
Gi/S, an important consequence of DNA damage in that it allows for DNA repair 
before DNA replication (Kyriakis and Avruch 2001). This provides evidence for a 
role of p38 in the preservation of genomic integrity.
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1.5.1.1 The p38 pathway and senescence
The role of p38a in inflammatory and stress responses is well established 
(Coulthard et al. 2009; Schieven 2005, 2009). However, recently, several lines of 
evidence suggest that p38 also negatively regulates cell cycle progression and 
plays a crucial role in replicative senescence (Davis et al. 2010; Han and Sun 
2007; Maruyama et al. 2009) and in SIPS induced by overexpression of 
oncogenes, oxidative stress and inappropriate culture conditions (Chen and Ames 
1994; Han and Sun 2007; Ishikawa 2006). It was suggested that p38 is activated 
not directly by the initial stimuli, but in response to unidentified cellular conditions 
caused by these stimuli. Importantly, this p38-activating condition appears to be 
defined quantitatively as a sum of continuous and low-level stresses and remains 
even after the initial stimuli are withdrawn (Passos et al. 2010). As previously 
discussed, overexpression of oncogenic Ras has been reported to promote cell 
proliferation in transformed cell lines but to induce premature senescence in 
normal primary cells (Lin et al. 1998). Inhibition of p38 by the inhibitor SB203580 
(see section 1.6.1.1) or by expression of a dominant-negative mutant of MKK3 or 
MKK6 abrogated Ras-induced premature senescence, suggesting that Ras- 
induced premature senescence requires activation of the p38 pathway (Iwasa et al. 
2003; Wang et al. 2002). Moreover, constitutive activation of p38 by expression of 
an active mutant of MKK3 or MKK6 is shown to induce premature senescence in 
primary human fibroblasts (Iwasa et al. 2003; Wang et al. 2002). Similarly, the 
depletion or inactivation of Wip1 phosphatase, a p53-regulated gene product that 
suppresses p38 activity (Takekawa et al. 2000), is shown to activate the p38 
pathway causing cells to enter premature senescence (Bulavin et al. 2004; Iwasa 
et al. 2003; Wang et al. 2002). In addition, inhibition of p38 activity by SB203580 is 
shown to increase the lifespan and rescue the senescent-like phenotype of 
fibroblasts from individuals with WS (Davis et al. 2005; Davis et al. 2006) (see 
Appendix A). These findings demonstrate that the p38 pathway plays a crucial role 
in inducing SIPS. In addition, treatment of WI38 cells with SB203580 has been 
shown to increase the growth rate and lifespan of cells that were almost senescent, 
but has no effect on young cells (Iwasa et al. 2003), suggesting that shortened
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telomeres in cells approaching replicative senescence may provide a stress signal 
in addition to the telomere-driven p53 activating signal. Support for this theory 
comes from the finding that PD-matched cells that have been immortalised by 
hTert expression, show a reduction in activated p38 levels (Iwasa et al. 2003).
1.6 Methodologies and choices
The techniques chosen were considered to be the best options given the 
problems of temporal heterogeneity, asynchronous events, differences in stages of 
the cell cycle that can lead to subset responses, differences in senescence 
commitment and variations in pharmacokinetic and pharmacodynamic responses 
of inhibitors:
1 Cell Growth Analysis by taking cell counts at each subculture giving the 
population doubling (PD) allows analysis of the variations in growth rate 
throughout the lifespan of a culture (Frisa and Jacobberger 2010).
2 Flow Cytometric Analysis with the advantages of rapid assessment of cell cycle 
dynamics in large population samples (~10,000 cells analysed).
3 Live cell Imaging and Time-Lapse with the advantage of allowing 
morphological and time dependent single cell analysis of adherent cell 
populations. Time-lapse has the advantage that each acquisition setting can 
be applied as a function of time, thus providing moving videos of visual events 
(such as mitoses) within the monitored cell population.
1.6.1 Studying p38 pathway: Use of selective inhibitors
Small cell-permeable inhibitors of protein kinases have become invaluable 
reagents with which to investigate the physiological roles of protein kinases, 
because they can be used simply and rapidly to block endogenous kinase activity 
in normal cells and tissues, as well as transformed cell lines. Since the initial 
discovery in 1994 of p38 as the molecular target for a novel class of cytokine 
suppressive inhibitors (Lee et al. 1994), hundreds of p38 inhibitors have been 
developed. These compounds are thought to be promising therapeutic tools in the
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treatment of inflammatory diseases and as such several compounds have 
progressed to clinical trials and have dropped but for various reasons. More 
recently, there have been some positive phase II trials in inflammatory diseases 
such as rheumatoid arthritis and psoriasis (Lee and Dominguez 2005; Regan et al. 
2003).
The majority of small-molecule inhibitors of p38 target the ATP binding site 
(Lee and Dominguez 2005) (Figure 1.5). p38a has a classical bi-lobar structure 
wherein the ATP binding site consists of a flexible P-loop, a hinge region 
(connecting the lobes) and a substrate-binding groove designed to accommodate 
protein substrates for phosphorylation. X-ray crystallographic structures of p38 and 
other kinases co-complexed with ATP suggest that bound ATP forms hydrogen 
bonds to His-107 and Met-109 at the hinge region. In addition, highly conserved 
residues such as Lys-53, Glu-71, and Asp-168, in concert with metal ions, are most 
likely involved in the coordination of the triphosphate group (Figure 1.5A). All of the 
potent p38a inhibitors to date fill an additional non-polar pocket known as the 
gatekeeper pocket, which mediates ligand binding. In p38a, the important residue 
is a relatively small amphiphilic threonine (Thr-106). Conversely, both p38y and 
p386 possess a larger methionine residue at the same position in the ATP binding 
pocket that prevents inhibitor binding (Cuenda and Rousseau 2007; Lee and 
Dominguez 2005). It is reported that the molecular basis for the specificity of the 
p38 inhibitors is attributed largely to Thr-106 in p38a, and that Met-109 contributes 
to increased binding affinity for imidazole-based inhibitors (Lisnock et al. 1998).
While there have been several reviews of p38 inhibitors (Lee et al. 1999; 
Lee and Dominguez 2005; Lisnock et al. 1998), this section will focus on three 
inhibitors, SB203580, BIRB796 and VX-745, and their relevant binding interactions 
with p38.
1.6.1.1 SB203580
The first p38 inhibitor to be released was SB203580, published by 
SmithKline & French in 1994, and is classified as a pyrimidinyl imidazole inhibitor 
(Lee et al. 1994). Since its discovery, SB203580 has been used widely to elucidate
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the role of p38 in various physiological processes (Lee et al. 1999; Lee et al. 1994). 
The basis of inhibition was revealed by the crystal structure of p38a bound to 
SB203580. These studies showed that SB203580 contains an aryl ring that 
functions to fill the gatekeeper pocket and a heterocyclic aromatic ring that serves 
to form the critical hydrogen bond with the Met-109 linker residue. While bound to 
p38, SB203580 adopts a three-dimensional shape that is analogous to that of a 
teardrop, in which the aromatic ring filling the gatekeeper pocket forms the teardrop 
apex and the remainder of the inhibitor sits in the adenosine pocket and forms the 
large convex base of the teardrop (Figure 1.5B) (Lee and Dominguez 2005). In 
addition, the gatekeeper residue (Thr-106) in the hinge of the p38a ATP-binding 
pocket interacts with a fluorine atom in the SB203580 structure. This orients the 
drug to interact with His-107 and Leu-108 of the pocket, preventing ATP binding 
and thereby, specifically inhibiting p38 enzymatic activity (Eyers et al. 1998; Gum 
et al. 1998). Interestingly, studies show that treatment with SB203580 has no effect 
on Thr-180 and Tyr-182 phosphorylation, and hence activation of p38 in vivo. 
SB203580, however, potently inhibits the activity of p38 as demonstrated by the 
inhibition of activation of MK2 and HSP27, specific physiological substrates of p38. 
These data clearly indicate that SB203580 specifically inhibits the activity of p38 
but not its activation by upstream MKKs (Kumar et al. 1999).
SB203580 has been reported to inhibit JNKs, as well as p38, and some 
additional targets in the epidermal growth factor receptor pathway were identified 
(Mayer and Callahan 2006). SB203580 has been shown to inhibit GAK (cyclin G- 
associated kinase) and CK1 (casein kinase) with similar potency to p38 and RIP2 
(receptor-interacting protein 2) with even greater potency (Godl et al. 2003). In 
addition, SB203580 inhibits c-Raf (Hall-Jackson et al. 1999) and GSK3 in vitro, 
albeit less strongly, and inhibits the formation of ZMP (aminoimidazole-4- 
carboxamide-1-P-D-ribofuranoside monophosphate), an activator of AMPK, from its 
inactive precursor AICAR (aminoimidazole-4-carboxamide-1-p-D-ribofuranoside), 
probably by inhibiting adenosine transporters (Fryer et al. 2002). Thus there is a 
danger that the observed effects of SB203580 on cells result from the inhibition of 
a target(s) distinct from p38a/p38p MAPKs. Mechanistic studies with SB203580,
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therefore, must be interpreted carefully and even repeated with more selective 
compounds.
1.6.1.2 BIRB796
A second p38 inhibitor, BIRB796, was developed by Boehringer Ingelheim 
and is a more potent inhibitor of human p38a and p38p than SB203580 (Pargellis 
et al. 2002). It is a member of the pyrazole-naphthyl urea class of p38 inhibitors. 
These compounds interact with p38a in a manner distinct from that exhibited by 
SB203580, in which binding induces a slow conformational change that locks the 
kinase into an inactive conformation (Bain et al. 2007; Pargellis et al. 2002). This is 
achieved by binding of another allosteric binding pocket on the kinase that is 
spatially distinct from the ATP pocket that allows a large conformational change in 
the conserved DFG (Asp168-Phe169-Gly170 in p38a) motif of the kinase activation 
loop (extended binding mode) (Pargellis et al. 2002). In all of the known protein 
Ser/Thr kinase structures, the DFG motif assumes a conformation with the Phe 
residue buried in a hydrophobic pocket in the groove between the two lobes of the 
kinase (DFG-in conformation). When bound to BIRB796, however, the Phe side 
chain moves to a new position (DFG-out conformation) revealing a large 
hydrophobic pocket in the kinase (Pargellis et al. 2002). Subsequently, the vacated 
Phe pocket is filled with the f-butyl group of the inhibitor (Regan et al. 2003). Figure 
1.5C graphically depicts key interactions made between BIRB796 and p38.
The selectivity of BIRB796 for p38a is high. In contrast to SB203580, 
BIRB796 does not inhibit CK16, GSK3p, RIP2 or GAK in vitro (Bain et al. 2007). 
However, unlike SB203580, BIRB796 also inhibits p38y, p38S and JNK2a2. 
Although BIRB796 is a potent inhibitor of JNK2 in vitro, it does not affect the 
phosphorylation of JNK substrates (c-Jun and ATF2) in cells at the low (0.1 jxM) 
concentration that abolishes p38a activity in cells (Bain et al. 2007). This is 
probably due to the fact the JNK1 is the dominant isoform that phosphorylates c- 
Jun and activates the AP1 transcription factor in cells that have been studied 
(Jaeschke et al. 2006). In conclusion, some reports recommend using SB203580
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and BIRB796 in parallel to assess the physiological roles of p38 in cell-based 
assays (Bain et al. 2007).
1.6.1.3 VX745
In 1999, Vertex Pharmaceuticals disclosed a new class of p38a, ATP 
competitive inhibitors, including the clinical candidate VX745 (Natarajan and 
Doherty 2005). This compound displayed potent activity at 5.0 nM concentration 
and 1000-fold selectivity for p38 over closely related kinases, including ERK1, 
JNK1-3 and MK2, adopting a linear rather than a teardrop or extended binding 
mode (Figure 1.5D) (Lee and Dominguez 2005). Since VX745 does not inhibit 
JNKs this compound can be used in parallel with SB203580 and BIRB796 to 
assess the role of p38 whilst reducing the issue of off-target effects.
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Figure 1.5. Schematic representation of ATP-binding site of p38 protein and binding 
mode of p38 inhibitors.
(A) shows the binding of ATP (B) SB203580, (C) BIRB796 and (D) VX745 and their 
different binding modes.
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1.7 Rationale and Aims
• The thesis is based on a background of evidence that WS cells show evidence 
of SIPS, including reduced proliferative potential, senescent-like morphology 
and activation of p38. The hypothesis here is that other cells with underlying Gl 
may trigger a common pathway leading to SIPS -  namely the p38 pathway. 
The primary aim of this thesis is therefore to assess the potential impact 
of SIPS in a panel of cells derived from individuals with defined 
genetically determined conditions associated with genomic instability. In 
terms of a contribution to knowledge, addressing such complexity should 
improve our understanding of the nature of senescence barrier operation in 
premature ageing and possibly the breaching of senescence barriers at early 
stages of neoplasia.
• The approach adopted is to employ both primary and hTert-immortalised Gl 
syndrome cells to determine whether these show evidence of differences in the 
level of commitment to cell cycle exit compared to normal fibroblasts. The focus 
of the project was to reveal the impact of exposure to p38 inhibitors in the 
modulation of replicative potential. Thus the study draws upon a panel of Gl 
syndrome cells, in which normal DNA replication may be disrupted and genome 
integrity compromised. Accordingly Gl panel cells provide an opportunity to 
study the effects of p38 inhibition on replicative potential.
• The Introduction outlines the known in vitro and/or in vivo characteristics for 
human conditions that present evidence of premature aging and aspects of Gl. 
Whilst much attention has been given to the mutational consequences of the 
molecular defects in Gl syndrome cells, there is little information in the literature 
about the cellular responses to ongoing Gl in these cells. Furthermore, the 
evidence of a restriction of replicative potential in Gl syndrome cells is limited. 
Taking the paradigm of Werner Syndrome, it was hypothesized that human 
disorders presenting evidence of progeroid characteristics and/or evidence of
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underlying Gl, may also present common features for the limitation of 
replicative potential. Therefore there is a need to determine whether Gl cells 
express significant limitations on their replicative potential in vitro.
• The concept brought to this thesis is that there is a hierarchy of influences that 
result in the limitation of lifespan. The driving principle is that of ongoing 
telomere attrition. However, given current evidence there appears to be a role 
for SIPS in Gl cells. It appears that ongoing disturbances in replication related 
pathways are modified in Gl cells and therefore provide additional routes to 
increase the likelihood of cell cycle exit. The contribution of these pathways 
may be additive or perhaps synergistic to the telomere-driven limitations on in 
vitro lifespan. The population dynamics model for the impact of SIPS is 
outlined in Figure 1.6. This model assumes that SIPS is realised through a finite 
probability of cell cycle exit exercised pre- or post-mitosis, although it is 
unknown whether daughter cells show similar characteristics for future cell 
cycle exit. The timing and probability of cell cycle exit clearly generates 
complexity and heterogeneity in populations progressing to senescence and a 
challenge for attempts to determine the impact of ongoing Gl at any given stage 
in that process.
• The working hypothesis, based on previous studies highlighted in the 
Introduction, is that underlying stress signalling -  arising from ongoing 
replicative stress - could drive p38-dependent signalling in the active restriction 
of replicative potential at the population level. The model for the potential p38- 
mediated restraint on cell cycle progression and replicative potential in cells 
responding to genomic stress is outlined in Figure 1.7. This model proposes 
that replicative stress can arise from extrinsic factors (such as DNA damage 
induced by genotoxic agents), telomere uncapping at senescence, or an 
increase in replication errors associated with DNA repair defects (as seen in Gl 
syndromes) and is realised by the activation of stress response pathways. 
Furthermore, the activation of stress response pathways is likely to restrain cell 
cycle progression and increase the probability of cell cycle exit. Thus, it was
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proposed that there could be common roles for p38 in Gl syndrome cells in 
restraining replicative potential and that their relative contribution within a given 
Gl cell strain could be revealed by the degree of responsiveness to p38 
inhibition.
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Figure 1.6. Population dynamics model for the impact of SIPS.
This model assumes that a cell in a given population has a small probability of undergoing SIPS 
at each cell division. In the model the green circles represent division competent cells that at the 
end of their replicative lifespan senesce and adopt an altered morphology. The other colours 
represent cells that undergo premature senescence at each division. For normal cells in culture, 
the majority of cells are division competent and the degree of premature senescence is low, thus 
after three divisions a colony of 48 cells, containing 42 division competent cells and 6 cells that 
have undergone SIPS, is produced. For Gl syndrome cells however, this model predicts that the 
level of SIPS is much greater, thus after three divisions a colony of only 26 cells, containing 14 
division competent and 12 cells that have undergone SIPS, is produced. Thus simply by 
increasing the rate of SIPS the model produces a much-reduced replicative capacity and a 
reduced growth rate.
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To examine the hypotheses the following studies were undertaken:
• As a fundamental basis for the thesis, the growth patterns and replicative 
potential of primary fibroblasts from normal and Gl syndrome individuals were 
measured to determine the prevailing limitations on proliferation in cells with 
different genetic backgrounds (Chapter 3). Given the extended period over 
which studies needed to be undertaken the pragmatic decision was made to 
simultaneously determine the impact of different p38 inhibitors on the growth 
potential of primary cells. Here the aim was to investigate whether there is a 
commonality of involvement of p38-driven pathways in limiting replicative 
potential.
• It was recognised that there is an ongoing need to identify morphological 
biomarkers for SIPS, with recent findings suggesting that changes in 
morphology and stress fibre presentation as shown by cells undergoing lifespan 
limitation. The potential of such biomarkers for use in correlative studies on the 
impact of inhibitors was assessed (Chapter 4). The aim was to assess 
morphological changes and stress fibre presentation in primary cells as 
candidate biomarkers for the extent of commitment to SIPS was made -  a 
unique study given the range of disorders investigated.
• A significant activity was to undertake the establishment of a new resource 
(Chapter 5). The aim was to generate a panel of hTert-immortalised cells in 
which lifespan was not limited that could be used in more extensive 
studies. Pragmatically, this effort addressed the problems associated with 
working with primary fibroblasts that have a limited replicative lifespan, by 
removing the restriction on generating sufficient cell numbers for various 
analyses. Conceptually, the removal of the stress signals arising from telomere 
attrition also allows for an analysis of the role of SIPS and the functionality of 
p38 in these cells without the background of stress signals leading to replicative 
senescence.
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• Having established the hTert panel, the aim was to determine the limitations 
on replicative lifespan in these cells. The approach was to identify common 
features of lifespan limitation by screening the entire hTert panel and to use 
individual strains of interest to identify specific differences in lifespan limitation. 
Here flow cytometry and colony forming assays were undertaken to:
o Test whether hTert-immortalised cells remain susceptible to SIPS. Here 
Gl cell strains are exposed to a range of genotoxic agents, that are 
known to induce SIPS, and evidence of cell cycle arrest and reduced 
colony forming ability is assessed (Chapter 6).
o Reveal any differences in cell cycle dynamics between members of the 
Gl panel, with a particular focus on identifying evidence of cell cycle 
arrest, and the impact of p38 inhibition on these dynamics (Chapter 7).
o Assess the impact of potential differences in the level of SIPS on the 
colony-forming ability, as a monitor of lineage viability and proliferation, 
of the Gl panel members and whether these parameters can be 
modulated by p38 inhibition (Chapter 7).
The topics in the following chapters are given a brief introduction and materials and 
methods specific to the techniques used are provided within those chapters. 
Tables and figures are provided at the end of each chapter for ease of reference. 
The final chapter (Chapter 9) addresses hypotheses generated during the course 
of the study.
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Chapter 2 Materials and Methods
All general chemicals were purchased from Fisher (Leicestershire, UK) and all 
molecular biology grade chemicals and reagents obtained from Sigma® (chemical 
Co., Dorset, UK) or Invitrogen™ (Paisley, UK) unless otherwise stated. Water was 
prepared by reverse osmosis (Millipore).
2.1 Cell Strains and Routine Culture Conditions
All cells were grown as monolayer cultures in either T25cm2 flasks to which 3 
ml medium was added, or T75cm2 flasks to which 10 ml medium was added 
(Becton Dickinson) and maintained in a humidified incubator at 37°C, 20% O2 and 
5% CO2 . All cells were cultured in Eagle’s minimum essential medium with Earle’s 
salts (EMEM; Gibco) supplemented with 10% foetal calf serum (FCS; Autogen 
Bioclear), 1X MEM non-essential amino acids (NEAA) without L-glutamine 
(Sigma®), 2mM MEM L-glutamine (Invitrogen™), 0.002% NaHCOs (Invitrogen™), 
1M NaOH, 1X vitamins (Invitrogen™), 1 mM sodium pyruvate (Sigma®) and 
10,000U/ml penicillin (Sigma®) and 10mg/ml streptomycin (Sigma®). Medium was 
prepared to the correct concentration with autoclaved milliQ H2O. For drug 
treatments, cells were fed daily with medium containing 2.5nM SB203580 (Tocris 
Chemical Co. Bristol, U.K), 2.5pM BIRB796 or 0.5p,M VX745 (both produced ‘in- 
house’ as part of a BBSRC funded project: Bagley et al 2006; Bagley et al 2007), 
dissolved in dimethyl sulphoxide (DMSO). Control cells were supplemented with an 
equivalent volume of DMSO, added to the medium. p38 inhibitor concentrations 
were chose based on previous studies (see Appendix B).
Fibroblasts were sub-cultured close to confluence (-80-90%). Briefly, the 
medium was removed, cells washed with a mixture of 0.05% Trypsin; 0.2% EDTA 
(Invitrogen™) to remove any residual medium, this was then discarded and 1ml of 
fresh trypsin/EDTA was added. The cells were incubated at 37°C for approximately 
5 minutes, or until the cells had visibly detached. 9 ml of fresh medium was added 
and cells were transferred to a 15 ml Falcon tube (Becton Dickinson). To determine 
total cell numbers, 10 \i\ of the cell suspension was added to a haemocytometer,
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cell counts were taken, and the number of cells per ml was calculated. Cumulative 
PDs were calculated according to the formula: PD=log(Nt/No)/log2, where Nt is the 
number of cells counted and No is the number of cells seeded. The number of 
population doublings (PDs) for each passage (P) was calculated from the cell 
count by comparing the total cell count following trypsinisation with the initial 
number of cells seeded. For routine passaging of cells, fibroblasts were reseeded 
into a fresh T25cm2 flask at a density of 6x104/flask.
At each passage, excess cells were cryo-stored in liquid nitrogen for future 
use. Briefly, cells were centrifuged at 90 x g for 5 minutes at room temperature in a 
Centaur 2 centrifuge (Sanyo). The supernatant was discarded and the cell pellet 
was re-suspended in 0.5 ml culture medium before mixing with 0.5 ml of freezing 
mix (1:4 FCS:DMSO), thus permitting the cryopreservation of cell cultures. The cell 
suspension was transferred to a freezing CryoTube™ (Nunc™, Denmark) and 
stored at -80°C in a storage box containing isopropanol for a minimum of 2 hours 
to reduce the temperature by 1°C/min over 120 minutes to a final temperature of - 
80°C, before transferring the ampoule to liquid nitrogen. When recovering viable 
cell cultures from liquid nitrogen, the ampoule was rapidly thawed in a 37°C sterile 
water bath. Once thawed, the cell suspension was transferred to a 15 ml Falcon 
tube and 9 ml of warm (~37°C) medium was added in a drop-wise manner. The 
cell suspension was centrifuged at 90 x g for 5 minutes at room temperature and 
the pellet resuspended in fresh culture medium.
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Table 2.1. Cell Strains
Donor
Syndrome Strain Age! P* PD Mutation Reference
Normal AG16409 12 2 4 Donor is clinically normal
Normal AGQ6234
Normal AG013152
1? 7 15 Donor is clinically normal
80 5 6 Donor is clinically normal
Mendonsa 
et al 2008; 
Cristofalo 
et al 1998 
Kipling 
2008; 
Cristofalo 
etal 1998
RTS AG18371 12
RTS AG18375 22
RTS AG17524
Donor is homozygous for a truncating mutation in the RECQL4 
gene: an 11 bp deletion at nucleotide g.2746 (g.2746del11) in 
intron 8 which results in an intron that is too short to be efficiently 
spliced.
Donor is a compound heterozygote; in allele one at nucleotide 
g.2626 there is a G>A substitution (g.2626G>A) in exon 8 of the 
RECQL4 gene which leads to disrupted splicing; in allele two 
there is a 1 bp deletion at g.2886 (g.2886delT) in exon 9 of the 
RECQL4 gene which leads to a truncation.
Donor is a compound heterozygote; both alleles carry truncating 
mutations in the RECQL4 gene: allele one carries a G>A 
substitution at g.2626 (g.2626G>A) in exon 8 resulting in 
alternative splicing; allele two carries a 2 bp deletion at 
g.4644delAT in exon 15 resulting in a frameshift; in addition, there 
are three mutations which result in amino acid changes: a 
homozygous substitution at g.1551G>T in exon 5 resulting in an 
amino acid change GLU267ASP (E267D), a heterozygous 
substitution at g.4470G>A in exon 14 resulting in an amino acid 
change GLU>ASP (E>D), and a homozygous substitution at 
g.5321G>A in exon 17 resulting in an amino acid change 
ARG1005GLN (R1005Q); there was one silent homozygous 
mutation at nucleotide g.1488C>T in exon 5 resulting in no 
change S246S.
Petkovic et 
al 2005
Wang et al 
2003;
Lindor et al 
2000
BS GM02520 10 11
BS GM02548 6 8
BS GM02932 28 6
Donor is a compound heterozygote: one allele has a deletion at Trikka et al
nucleotide 2923 of the RECQL3 gene [2923delC] resulting in a 2002; Lu et
frameshift [fs:974+23-X] and a second allele has a deletion of al 1993
exon 15 resulting in a frameshift [fs:941+26-X].
Donor is a compound heterozygote: one allele has a 1-bp Lu et al
insertion at nucleotide 1544 of the RECQL3 gene [1544insA] 1993;
resulting in a frameshift and premature termination [fs:514+1-X] Warren et
and a second allele has a C>T transition at nucleotide 2328 of the al 1981
RECQL3 g
Donor is homozygous for a 6-bp deletion/7-bp insertion [6-bp 
del/7-bp ins] at nucleotide 2,281 of the open reading frame of the 
RECQL3 gene, which results in a frameshift and a stop codon
Schawalder 
et al 2003; 
Collister et 
al 1998
HGPS AG10677 4 11 6 Donor has a Glu-to-Lys substitution at codon 145 [Glu145Lys
(E145K)] in exon 2 of the Lamin A gene (LMNA).
HGPS AG11498 14 6 10
HGPS AG01972 14 11
Donor has a de novo single base substitution, a C>T change at 
nucleotide 2036 (2036OT), which results in a silent change at 
codon 608 [Gly608Gly (G608G)] in exon 11 of the Lamin A gene 
(LMNA).
Donor has a de novo single base substitution, a C>T change at 
nucleotide 2036 (2036OT), which results in a silent change at 
codon 608 [Gly608Gly (G608G)] in exon 11 of the Lamin A gene 
(LMNA).
Bridger and 
Kill 2004; 
Eriksson et 
al 2003 
Moulson et 
al 2007; 
Scaffidi and 
Misteli 
2005
Moulson et 
al 2007; 
Scaffidi and 
Misteli 
2006;
Huang et al 
2005
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Table 2.1 continued. Cell Strains
Syndrome Strain
Donor
Age
(yr) P* PD Mutation Reference
NBS RO202 Der
Kaloustian
1996
NBS
NBS
R0242
GM07166 20 10 6 Donor is homozygous for a deletion of 5 nucleotides in exon 6 of 
the NBS1 gene, resulting in a frameshift and a premature 
termination at codon 218 [657-661 delACAAA (657del5)].
Der
Kaloustian 
1996 
Alt et al 
2005; Nove 
et al 1986
LIG4 GM17523 10 10 Donor is a compound heterozygote: one allele carries a G-to-A 
transition at nucleotide 1406 (1406C>A) of the LIG4 gene 
resulting in a gly469-toglu substitution (GLY469GLU; the other 
allele has a C-to-T transition at nucleotide 2440 (2440OT, 
resulting in a nonsense codon at amino acid 814 [ARG814TER 
(R814X)].
Muylaert et 
al 2007; 
O’Driscoll 
et al 2001
LIG4 GM16088 15 Donor carries an Arg278 to His mutation in the LIG4 gene 
[ARG278HIS (R278H)], resulting from a G-to-A transition at 
nucleotide 833 (833G>A).
Al Rashid 
et al 2005
CSA GM01856 13 7 Donor is CS3BE; complementation group A. Ridley etal 
2004;
Andrews et 
al 1978
DKC GM01774 7 7 7 Donor is hemizygous for an in frame 3 bp deletion of nucleotides 
201_203 of the DKC1 gene (201_203delCTT) resulting in the 
deletion of leucine at position 37 [Leu37del].
Agarwal et 
al 2010; 
Wong et al 
2006
SS GM09812 15 5 Donor is clinically affected but the mutation has not been 
confirmed.
SS GM 18366 6 15 Donor carries a mutation at nucleotide 2101A>G, which causes 
increased levels of skipping exon 9 and activation of two cryptic 
splicing events from sites in exon 9 leading to termination in exon 
10. Splicing of exon 9 is inefficient in mutant cells, but a small 
amount of correctly spliced mRNA is observed. Cells showed a 
low level of expression of the ATR protein.
Stokes et 
ah 2007
WS AG03141 30 8 6 The donor had features of premature aging, pigmented and 
atrophic skin, cataracts and hyperlipidemia type V. The biopsy 
was taken ante-mortem on 9/20/78. The culture was initiated 
using explants of minced skin tissue. The cell morphology is 
fibroblast-like. The karyotype is 46,XX with 80% of cells examined 
showing random chromosomal abnormalities. Homozygous for a 
C to T transition at nucleotide 2476 in the WRN gene (2476C>T), 
resulting in a stop codon at 748 {Gln748TER (Q748X)}.
Li et al 
2008,
Kipling et al 
2008,
Faragher et 
al 1993
All cell strains were obtained from Coriell Cell Repositories (Camden, New Jersey), unless 
otherwise stated (Note AG = NIA; GM = NIGMS).
*P refers to passage information provided by the repository
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2.1.1 p38 Inhibitors
2 .1 1.1 SB203580
F
\
Figure 2.1. Chemical structure of SB203580.
(4-(4-Fluorophenyl)-2-(4-methylsulfonylphenyl)-5-(4-pyridyl)-1H-imidazole) was obtained from 
Tocris Chemical Co. Bristol, U.K (Lee et al. 1994).
2.1.1.2 BIRB796
Figure 2.2. Chemical structure of BIRB796.
(1-[3-tert-Butyl-1-p-tolyl-1H-pyrazol-5-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]urea) was 
produced 'in-house’ as part of a BBSRC funded project (Bagley et al. 2006).
2.1.1.3 VX745
F
Figure 2.3. Chemical structure of VX745.
(S-^.e-Dichlorophenyl^-^^-difluorophenylthioJ-eH-pyrimidoJI.e-bjpyridazin-e-one) was produced 
‘in-house’ as part of a BBSRC funded project (Bagley et al. 2007)
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2.2 Phalloidin-FITC Staining of Stress Fibres
Actin staining for fluorescence microscopy was performed essentially as 
previously described (Huot et al. 1997) and specific details are given in chapter 3 
material and methods. Imaging was performed as described in section 2.9.1.
2.3 Western Blotting
20 mM Tris (pH7.5), 150 mM NaCI, 1 mM EDTA, 1 mM 
EGTA, 1% (v/v) Triton X-100, 2.5 mM sodium 
pyrophosphate, 1 mM p-glycerolphosphate, 1 mM 
Na3V0 4 , 1 pg/ml leupeptin (#9803, Cell Signaling®). 
Made by diluting 10X stock with MilliQ H20.
50 mM Tris (pH 6.8), 30% (v/v) glycerol, 3% (w/v) SDS, 
0.6% (w/v) bromophenol blue and 0.3% (v/v) p- 
mercaptoethanol.
124 mM Tris base, 250 mM glycine and 5% SDS, pH
8.3
25 mM Tris base, 192 mM glycine, 200 ml methanol, 
made up to 1 litre with water, pH 8.1-8.4
10% acrylamide:bis (29:1), 0.5 M Tris (pH 6.8), 10% 
SDS, 10% APS and 100 \i\ TEMED.
4% acrylamide:bis (29:1), 1.5 M Tris (pH 8.8), 10% 
SDS, 10% APS and TEMED.
2.3.2 Sample Preparation and Protein Extraction
Fibroblasts were seeded in 100 mm Petri dishes at a density of -1x106 
cells/dish and maintained under routine culture conditions for 1-3 days prior to 
protein extraction. Sub-confluent (-80-90% confluence) cell monolayers were
2.3.1 Reagents
1X ELISA lysis buffer:
3X loading buffer:
5X running buffer: 
1X transfer buffer: 
Stacking Gel: 
Resolving Gel:
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washed twice with ice-cold, sterile 1X PBS to remove residual media. The PBS 
was removed and ~100 pi 1X ELISA lysis buffer supplemented with 100 mM PMSF 
(Sigma®) was added to the dishes. Cells were incubated in lysis buffer on ice for 5 
minutes. The cells were then scraped into the 1X ELISA lysis buffer and 
transferred to an Eppendorf tube. Whole cell extracts (WCEs) were centrifuged at 
20,000 rpm for 15 minutes at4°C in a refrigerated Falcon 6/300 (Sanyo). Following 
centrifugation, the supernatant was removed, transferred to a fresh Eppendorf tube 
and stored at -80°C.
2.3.3 Protein Quantification
WCEs lysates were quantified by the Bradford colorimetric method, using the 
Coomassie® Plus Protein Assay Reagent (Pierce). ELISA lysis buffer, previously 
used to obtain the WCEs, was diluted 1/10 with sterile water and used to prepare a 
series of BSA standards with final concentrations in the range of 0-400 pg/ml. A 
1/10 dilution of each WCE was prepared by adding 5 pi of WCE to 45 pi H2O. 40 pi 
of each WCE and BSA standard were transferred to 1.6 ml plastic cuvettes, to 
which 1 ml of Coomassie Plus Protein Assay Reagent (Pierce) was added. The OD 
(at 595 nm) of WCEs and BSA standards was determined using an UltraSpec 
31000 PRO (Amersham Biosciences) and linear regression analysis of the BSA 
standards was used to calculate the concentration of protein (jxg/jxl) present in 
each WCE.
2.3.4 SDS-PAGE Electrophoresis and Transfer
A Biorad mini-protean II electrophoresis cell system or Biorad Criterion kit (for 
larger gels) was used to separate and transfer protein lysates to a 0.45 pm 
nitrocellulose membrane (Millipore). WCEs were electrophoresed on 10 % (w/v) 
polyacrylamide, SDS resolving gels. Aliquots containing 20 pg of the soluble WCEs 
were made up to a final volume of 14 pil with sterile water and 7 pi of 3X loading 
buffer was added to give a final loading volume of 21 pi. The WCEs were 
denatured at 100°C for 5 minutes and centrifuged for 30 seconds at 12,000 X g 
before being loaded into the gel. Precision plus protein dual colour standards
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(Biorad, Cat 161-0374) were loaded in parallel to confirm the molecular weight of 
the protein of interest. Protein extracts were electrophoresed and separated at 100 
V for -  1 hour (or until the dye front reached the bottom of the gel) in 1X running 
buffer. Following electrophoresis the SDS-PAGE gel was washed and allowed to 
equilibrate for several minutes in transfer buffer to prevent shrinkage and to 
remove any contaminating electrophoresis buffer salts and neutralisation salts.
Immediately prior to protein transfer methanol was added to the transfer 
buffer. The methanol serves two main purposes: it promotes the dissociation of 
SDS from the protein and improves absorption of proteins onto the membrane. The 
nitrocellulose membrane was washed in sterile de-ionised water for -30 seconds 
and incubated in transfer buffer prior to use to prevent drying and to facilitate 
equilibration between the transfer buffer and the membrane. The gel/membrane 
sandwich was assembled in the transfer cassette by placing a piece of filter paper 
on top of on a fibre pad, followed by the pre-equilibrated gel, followed by the 
membrane, another piece of filter paper and another fibre pad. The cassette was 
then placed into the transfer apparatus and the proteins were transferred to the 
nitrocellulose membrane at 100 V for 1 hour in 1X transfer buffer with an ice block 
to prevent over-heating.
2.3.5 Immuno-detection
Following protein transfer, nitrocellulose membranes were incubated in 
Enhanced chemiluminescence (ECL) Advance Blocking Agent (GE Healthcare, 
Buckinghamshire, UK) according to the manufacturer’s guidelines for 1 hour at 
room temperature to reduce non-specific antibody binding. Membranes were 
incubated at 4°C overnight on a roller in primary antibody (Table 2.2) diluted in 
blocking buffer. The nitrocellulose membrane was washed with 0.1 % (v/v) Tween 
20 in PBS at room temperature with gentle agitation for 5 minutes, followed by two 
5 minute washes and a 15 minute wash with fresh 0.1 % (v/v) Tween 20 in PBS. 
The membrane was then incubated with the appropriate HRP-conjugated 
secondary antibody (Table 2.2) diluted in blocking buffer for 1 hour at room 
temperature and the wash procedure repeated. The protein-antibody complexes
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were detected using the Amersham ECL™ Advance Western Blotting Detection kit 
(GE Healthcare, Buckinghamshire, UK) according to the manufacturer’s 
recommendations. Briefly, ECL Advance Solution A and B were equilibrated at 
room temperature prior to use and then mixed in a 1:1 ratio. Residual wash buffer 
was removed from the nitrocellulose membrane and the combined ECL solutions 
spread to cover the membrane and then left for 5 minutes at room temperature. 
Any residual reagent was removed from the membrane and proteins were 
visualised using an AutoChemi System (UVP, Upland, CA, USA) or by exposing 
the membrane to autoradiography hyperfilm (Amersham Pharmacia Biotech). In 
the case of the latter method, following exposure, the autoradiography hyperfilm 
was developed and fixed using an XOGRAPH Compact X4 Automatic X-ray Film 
Processor (X-Ograph Imaging System, Ltd., Gloucestershire, UK).
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Table 2.2. Antibodies used during Western Blot analysis.
Antibody Supplier Source Dilution 2° antibody Con
p38 MAPK Cell Signaling 
(Cat No. 9212)
Rabbit 1/1000 GAR 1/1000
Phospho-p38 
(Thr180/Tyr182)
Cell Signaling 
(Cat No. 9211)
Rabbit 1/1000 GAR 1/1000
HSP27 (G31) Cell Signaling 
(Cat No. 2402)
Mouse mAb 1/1000 RAM 1/1000
Phospho-HSP27
(Ser82)
Cell Signaling 
(Cat No. 2401)
Rabbit 1/1000 GAR 1/1000
SAPK/JNK Cell Signaling 
(Cat No. 9252)
Rabbit 1/1000 GAR 1/1000
Phospho-SAPK/JNK 
(Thr183/Tyr185)
Cell Signaling 
(Cat No. 4668)
Rabbit 1/1000 GAR 1/1000
Cofilin Cell Signaling 
(Cat No. 3312)
Rabbit 1/1000 GAR 1/1000
Phospho-Cofilin
(Ser3)
Cell Signaling 
(Cat No. 3311)
Rabbit 1/1000 GAR 1/1000
Abbreviations: GAR, goat anti-rabbit; RAM, rabbit anti-mouse.
Secondary antibodies are from Amersham ECL kit and are HRP-linked.
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2.4 Detection of telomerase Activity by the Telomeric Repeat 
Amplification Protocol (TRAP) Assay
The TRAPeze® Gel-Based Telomerase Detection Kit (Millipore, UK), which is 
based on an improved version of the original method described by (Kim et al. 
1994), was used to detect telomerase activity. This assay is a one buffer, two 
enzyme system that utilises the polymerase chain reaction (PCR). In the first step,
telomerase adds a number of telomeric repeats (TTAGGG) on the 3’ end of a
substrate oligonucleotide (TS). In the second step, the extended products are 
amplified by PCR using the TS and RP (reverse) primers, generating a ladder of 
products with 6 base increments starting at 50 nucleotides. Amplification products 
are resolved on a polyacrylamide gel and detected by fluoro-imaging.
2.4.1 Preparation of cell extracts
Wash Buffer: 10 mM HEPES-KOH (pH 7.5), 1.5 mM MgCI2, 10
mM KCI, 1 mM dithiothreitol (DTT),
diethylpyrocarbonate (DEPC) water.
Lysis Buffer: 10 mM Tris-HCI (pH 7.5), 1 mM MgCI2, 1 mM
EGTA, 0.1 mM Benzamidine, 5 mM p-mercapto
ethanol, 0.5% (v/v) 3-([3-cholamidopropyl]-
dimethyl-ammonia)-1 -propanesulfonate (CHAPS; 
Pierce), 10% (v/v) glycerol, DEPC water.
1X reaction buffer: 20 mM Tris-HCI (pH 8.3), 1.5 mM MgCI2, 63 mM
KCI, 0.005% Tween 20 (v/v), 1 mM EGTA (pH 
8), 50 p,M dNTP’s (Promega), 0.1 mg/ml bovine 
serum albumin (BSA; Promega). 1X reaction 
buffer is made by diluting 10X stock in DEPC 
water.
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Polyacrylamide Protean II gel: 45 ml distilled water, 30 ml 5X TBE buffer (54 g
Tris base, 27.5 g boric acid and 20 ml 0.5 M 
EDTA made up to 1 litre with water), 25 ml 19:1 
bis acrylamide (BIO-RAD Laboratories, Inc.), 500 
pi 100 mg/ml APS and 100 pi TEMED.
50X dNTP Mix: 2.5 mM each dATP, dTTP, dGTP and dCTP
Primer Mix: RP primer, K1 primer and TSK1 template
Exponentially growing hTert-immortalised fibroblast cultures were 
trypsinised and resuspended in 8 ml of medium and counted. The cells were 
centrifuged at 277 X g for 5 minutes at room temperature and the medium was 
discarded. The cell pellets were resuspended and washed in 10 ml of 1X sterile 
PBS. The cells were centrifuged at 202 X g for 5 minutes at room temperature and 
the supernatant was aspirated. The pellets were resuspended in 1 ml of 1X PBS 
and transferred to a 1.5 ml RNase-free Eppendorf tube. The samples were 
centrifuged at 15,000 X g for 2 minutes at 4°C and the supernatant was discarded. 
The pellets were stored at -80°C.
The cells were thawed on ice and resuspended in 1 ml of wash buffer. The 
cell suspension was centrifuged at 15,000 X g for 2 minutes at 4°C and the 
supernatant aspirated. Cell pellets were resuspended in 20 jil of fresh lysis buffer 
and incubated on ice for 30 minutes. Lysates were centrifuged at 12,000 X g for 30 
minutes at 4°C and supernatants were aliquoted into fresh tubes. The supernatants 
were snap frozen on dry ice and stored at -80°C. To prepare negative controls (and 
destroy telomerase activity), the diluted cell lysates were divided into two equal 
aliquots. One aliquot from each sample was incubated at 85°C for 10 minutes to 
destroy telomerase activity, and the other aliquot was placed on ice for 10 minutes. 
Positive control cell extracts [derived from adenovirus transformed human 
embryonic kidney cells (HEK 293) (Graham et al. 1977)] were prepared by diluting 
stock aliquots 1:20 with 1X lysis buffer (2 pl/assay). All cell lysates, were thawed on 
ice, diluted in lysis buffer to give approximately 5000 cell equivalents/pi.
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2.4.2 TRAP assay -  Stage 1 (extension of TS primer)
A ‘Master Mix’ containing 50 \i\ 1X reaction buffer, 1 \i\ of 50X dNTP mix, 1 
\x\ TS primer (5-AATCCGTCGAGCAGAGTT-3’), 1 \i\ TRAP Primer Mix, 1 pi (2 
Units) Taq Polymerase and 39.6 pi dFfeO was prepared and incubated on ice. 48 pi 
of the ‘Master Mix’ was aliquoted into RNase-free PCR tubes to which 2 pi of either 
heat-treated and non-heat treated cell extracts were added and incubated on ice. 
Cell extracts were transferred to a GRI MJ Tetrad Thermocycler, and incubated for 
30 minutes at 30°C.
2.4.3 TRAP assay -  Stage 2 (PCR amplification)
Following the initial extension, PCR amplification was performed at 94°C in a 
GRI MJ Tetrad Thermocycler. The amplification conditions were 31 cycles of 
denaturation (92°C, 30 seconds), annealing (50°C, 30 seconds) and extension 
(72°C, 90 seconds).
Following amplification, 5 pi of loading dye containing bromophenol blue (Sigma®) 
and xylene cyanol (Sigma®) (0.25% each in 50% glycerol/50 mM EDTA) was 
added to each sample. 25 pi of each sample was electrophoresed at 400 V on a 
10% polyacrylamide 20 cm Protean II gel in a tank containing 1.5X TBE buffer, for 
approximately 4 hours or until the bromophenol blue electrophoresed to ~3 cm 
from the bottom of the gel. The gel was incubated in SYBR® Green (Cambridge 
Bioscience) diluted 1:10,000 in water for 10 minutes at room temperature with 
agitation. The gel was washed for 5 minutes in water at room temperature to 
remove excess SYBR® Green. After washing, the gel was scanned on a STORM 
imager (Amersham Biosciences), employing the blue fluorescence mode.
2.5 Clonogenic assay
Fibroblasts were seeded at 4x103 cells in quadruplicate in 10 cm cell culture 
dishes and were maintained under routine culture conditions for 10 days. Cells 
were re-fed every 3 days during this period. Following incubation, cells were 
washed twice with PBS and fixed for 5 minutes with 70 % (v/v) ethanol, and left to
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air-dry overnight at room temperature. The plates were subsequently stained in 
Giemsa’s solution (pH 6.8; BDH, Poole, Dorset) diluted 1:10 in water for ~30 
minutes or until the colonies were visible. The plates were washed with tap water 
to remove any residual Giemsa solution and colonies were visualised using a light 
microscope. Colonies with a minimum of 50 cells were scored and plating 
efficiency was calculated as a percentage of the number of colonies formed 
compared to the initial number of cells seeded.
2.6 Cell Survival Determination by Colony Forming Assay
Sub-confluent, exponentially growing human fibroblasts were trypsinised from 
T75 flasks and 4000 cells were seeded in 10 cm culture dishes and allowed to 
attach for 24 hours under standard culture conditions. Cells were treated with the 
following DNA damaging agents for 24 hours: Doxorubicin (DOX) at 2.5, 5, 10 and 
20 nM; Cisplatin (CisPt) at 1, 1.5, 2 and 12.5 jxM; Camptothecin (CPT) at 2.5, 5, 10 
and 20 nM; 4-Nitroquinoline 1-oxide (4NQO) at 5, 10, 15 and 20 nM; Hydrogen 
Peroxide (H2O2) at 10, 20, 40 and 80 pM. Following treatment fibroblasts were 
washed twice with PBS to remove any residual agent, re-fed with fresh growth 
medium and maintained under routine culture conditions for 10 days. Cells were 
re-fed every 3 days during this period. Following incubation, cells were fixed and 
stained as described in section 2.5. Colonies with a minimum of 50 cells were 
scored unless otherwise stated. Plating efficiency was calculated as a percentage 
of the number of colonies formed compared to the initial number of cells seeded.
2.7 Flow Cytometry
2.7.1 Cell Cycle Analysis
The general flow cytometric method has been previously described (Smith 
et al. 2007). Briefly, cells were seeded at a density of 5x105 as a monolayer in T75 
flasks and allowed to attach for a minimum of 24 hours. Cell monolayers were 
detached using trypsin and cell numbers were determined using a Coulter counter 
(Beckman Coulter Z1). Cells were centrifuged at 90 X g for 5 minutes at room 
temperature in a Centaur 2 centrifuge (Sanyo) and the pellet was re-suspended in
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temperature in a Centaur 2 centrifuge (Sanyo) and the pellet was re-suspended in 
the appropriate volume of fresh medium to give ~5x105 cells/ml. Cells were 
incubated on ice prior to the addition of RNase A (final concentration of 0.5 mg/ml; 
SIGMA) and Ethidium Bromide (Eb) in Triton X-100 (final concentration of 50 \ig/rr\\ 
cells at 5x105; SIGMA) and cells were analysed within 1 hour. The investigational 
agent CyTRAK Orange™ (Biostatus, Leicestershire, UK) has been used for 
nuclear versus cytoplasmic discrimination or as a cell location dye to define the 
perimeter of the cell (www.biostatus.com/product/cytrak_orange/). CyTRAK 
Orange™ was supplied as an aqueous stock solution of 5 mM and routinely stored 
at 4°C without freezing and used at 20 ^M for all experiments. The standard 
protocol was to incubate cells with CyTRAK Orange™ for 10-15 minutes at 37°C 
prior to direct analysis.
For cell cycle profiling, a FACS Vantage flow cytometer (Becton-Dickinson 
Immunocytometry Systems, San Jose, CA, USA) equipped with a Coherent 
Enterprise II laser (Coherent, Inc., Santa Clara, CA, USA) simultaneously emitting 
at multiline UV (351-355 nm range) and 488-nm wavelengths with the beams 
made noncolinear using dichroic separators, was used. The laser power was 
regulated at 30 mW (monitored on the multiline UV output). All parameters were 
collected using CellQuest software (Beckton-Dickinson Immunocytometry 
Systems, San Jose, CA, USA). Unless stated otherwise data were collected for 
1x104 events using the FSC parameter as the master signal. Optics used are listed 
in (Table 2.3).
Table 2.3. Flow cytometry fluorescence optics
FACS Vantage
Probe / drug Excitation (nm) Parameter & 
emission filter (nm)
Eb 488 FL2 585 /42
CyTRAK
Orange™
488 FL2 585 /42
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Data were analysed using CellQuest software (Beckton-Dickinson 
Immunocytometry Systems, San Jose, CA, USA) or WinMDI 
(htto://facs.scipps.edu/software.htmI: authored by Dr. J. Trotter, The Scripps 
Research Institute, California, USA), with forward scatter (FSC), side scatter (SSC) 
and pulse width gated to exclude any cell debris and/or doublets. Cell cycle 
analysis was carried out using Cylchred.
(www.cardiff.ac.uk/medicine/haematology/cvtonetuk/documents/software.html); 
authored by Dr. T. Hoy, Department of Haematology, Cardiff University; School of 
Medicine, Cardiff, UK). Cell cycle distributions were determined using an algorithm 
for the normal distribution of fluorescence intensity profiles for fluorochrome- 
stained G1 and G2 cells.) Flow data was then exported into spreadsheets for 
further analysis.
2.8 Immunofluorescence detection of p38 MAPK
Cells were seeded at a density of 2 x 104 on glass coverslips (No 1.5, Fisher) 
and allowed to attach for 24 hours prior to treatment. Immunofluorescence was 
performed according to the Cell Signaling Immunofluorescence protocol 
(www.cellsignal.com/support/protocols/IF.html). Briefly, the medium was removed 
and cells were fixed in 4% (w/v) paraformaldehyde [made from stock solution of 
16% (w/v) diluted in PBS; Thermo Scientific, Rockford, USA, Cat No. 28908] for 30 
minutes at room temperature. Cells were washed three times with PBS to removed 
residual fixative prior to permeabilisation with 0.2% (v/v) Triton X100 in PBS for 20 
minutes at 4°C. Coverslips were washed three times before being incubated with 
blocking buffer [5% (w/v) BSA/PBS] overnight at 4°C. Coverslips were incubated 
with primary antibody against p38 MAPK (Cell Signaling, Cat No. 9212) at 1/25 
dilution [in 0.6% (w/v) BSA/PBS] for 1 hour at room temperature. Coverslips were 
washed three times in PBS prior to incubation with secondary antibody [Goat Anti- 
Rabbit IgG (H+L), F(ab’)2  Fragment (Alexa Fluor® 488 Conjugate): Invitrogen A- 
11034], diluted in 0.6% (w/v) BSA/PBS for 1 hour at room temperature in the dark. 
Coverslips were rinsed a further three times in PBS. To label the nuclei of these 
cells, the coverslips were incubated with DRAQ5™ (Biostatus, Leicestershire, UK)
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for 10 minutes at room temperature in the dark. DRAQ5™ was supplied as an 
aqueous stock solution of 5 mM and routinely stored at 4°C without freezing and 
used at 20 pM for all experiments. Coverslips were mounted on glass slides 
(Thermo Scientific) with ProLong® Gold Antifade Reagent (Invitrogen, Cat No. 
P36930), sealed with nail varnish and stored at 4°C in the dark prior to analysis. 
Imaging was performed as described in section 2.9.1.
2.9 Imaging
2.9.1 Fluorescence imaging
Images from fluorescently stained slides were captured using an Axiovert 
S100 TV microscope (Carl Zeiss, Inc., Welwyn Garden City, UK) with Hamamatsu 
camera (model C4742-95-12, Hamamatsu Photonics, Welwyn Garden City, UK), 
fluorescent lamp (model ebx75 isolated, Carl Zeiss, Inc., Welwyn Garden City, UK) 
and shutter lambda 10-2 (Kinetic Imaging Ltd, Wirral, UK) using suitable filter 
blocks (Table 2.4). Image analyses were conducted using MetaMorph Offline 
Version 7 (Molecular Devices, Downingtown, PA, USA).
Table 2.4. Fluorescence filters
Filter Excitation (nm) Emission (nm)
Alexa Fluor 488 480 / 30 535/40
DAPI 350 / 50 630/60
FITC 480 / 30 460 / 50
DRAQ5™ 620/60 700 / 75
2.9.2 Time-lapse imaging
For live cell imaging of different cell types or treatments over short or long 
periods of time, time-lapse imaging was used. A standard multi-well culture dish 
containing the cells was incubated on a stage of a time-lapse instrument as 
previously described (Errington et al. 2005a; Marquez et al. 2003) (Figure 2.4).
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Specific conditions, including drug treatment, cell type, field numbers and time 
delay, are described in the relevant chapter material and methods.
Figure 2.4. Time-lapse instrument
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Chapter 3 Replicative Growth Capacity of Adult 
Dermal Fibroblasts from Normal and Gl Syndrome
Individuals
3.1 Introduction
Primary mammalian cells have a finite proliferative capacity in culture after 
which they enter a state of irreversible growth arrest known as senescence 
(Hayflick 1965; Hayflick and Moorhead 1961). An approach to studying inducers 
and modifiers of cellular senescence requires the establishment of primary culture 
models for dermal fibroblasts. It can be considered that senescence of such 
primary cultures arises from both extrinsic and intrinsic signals, but must eventually 
be enacted through an exit from the ‘normal’ cell cycle employing mechanisms of 
arrest typically realised by cells under different forms of stress (e.g. the 
appearance and non-resolution of genomic damage). As with all in vitro systems it 
is likely that the culture conditions are suboptimal (e.g. lack of 3-D tissue context) 
or indeed supra-normal (e.g. frequent use of hyperoxia rather than the limited 
oxygenation conditions found in tissues). Therefore there is an assumption that 
cells in culture are attempting to accommodate to in vitro conditions and this may 
be reflected in a degree of engagement of stress response pathways. Further, 
continual in vitro passage characteristically selects for cells with proliferative 
potential thus imparting heterogeneity to the cell culture at different passage ages. 
There is mounting evidence that cells also experience considerable levels of 
endogenous stress (see Introduction) not least a progressive shortening of 
telomeres realised as a genomic stress response. Telomere attrition is thought to 
act as a mitotic clock eventually leading to senescence (Harley et al. 1990; 
Olovnikov 1973) -  effectively limiting cellular replicative potential. Several models 
have been proposed to explain how telomere shortening can lead to cellular 
senescence. However, it is widely accepted that shortened telomeres are 
perceived by the cell as DNA damage which triggers a stress response (Vaziri 
1997). For example, telomere dysfunction can result in telomeric fusion events that
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lead to genomic rearrangements, such as nonreciprocal translocations, thus 
generating Gl (Capper et al. 2007; Gisselsson et al. 2001). In Gl syndrome cells it 
is possible that increased levels of genomic instability also gives rise to replication 
stress and promotion of senescence. Here the focus is on the growth potential of 
normal adult dermal fibroblasts against a panel of Gl syndromes fibroblasts to 
identify any unusual growth (kinetic) phenotypes that may be indicative of higher 
levels of SIPS in these cells.
In the 1970’s it was shown that fibroblasts from individuals with WS have a 
reduced proliferative capacity when compared with control cells from donors of the 
same age (Martin 1978; Martin et al. 1970). In 1979 Goldstein compared the 
growth potential of fibroblasts from individuals with WS and progeria (Goldstein 
1979). Here the mean lifespan for WS fibroblasts was found to be 6.6 PDs 
compared to a 50.3 PDs for normal controls (Goldstein 1979). These findings are 
supported by subsequent studies that also show WS cells to have limited growth 
potential and reduced growth rates in culture (Faragher et al. 1993; Salk et al. 
1981). It has been argued that it is this reduced growth that underlies the 
accelerated ageing seen in WS (Kipling et al. 2004). Although less is known about 
the cellular growth potential of the other Gl syndromes described here there is 
evidence to suggest that some display reduced replicative potential. For example, 
fibroblasts from HGPS are reported to show reduced growth capacity compared to 
normal controls (Goldstein 1979). Here the mean lifespan of HGPS fibroblasts was 
shown to be 33 PDs, however there was a large variation between the different 
strains tested ranging from 6 PDs to 52 PDs (Goldstein 1979). Interestingly, it was 
also noted that HGPS show increased levels of apoptosis (Bridger and Kill 2004), 
which may contribute to the shortened lifespan observed in these cells. These data 
suggest there is marked heterogeneity between different cell strains from the same 
syndrome and may reflect differences due to individual genetic backgrounds. In 
addition, it was reported that BS and CSA cultures have shortened lifespans, 
although only a single strain was used for each syndrome (Thompson and Holliday 
1983).
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Initial evidence suggested that the accelerated senescence seen in WS was 
due to increased telomere erosion (Kruk et al. 1995). When analysed, telomeres in 
WS cells were found to be shorter than those in normal cells (Kruk et al. 1995), and 
telomere erosion appeared to be accelerated in four WS fibroblast strains (Schulz 
et al. 1996). However, the erosion rates overlapped with those seen in normal 
strains and no increase in erosion rate was seen in two further WS strains (Choi et 
al. 2001). These data were further challenged by the observation that telomeric 
erosion is not accelerated at the single cell level in WS clones (Baird et al. 2004), 
suggesting that accelerated telomere erosion is not responsible for the shortened 
replicative lifespan of WS fibroblasts. An alternative hypothesis was put forward by 
Davis (Davis et al. 2005) based on the observation that WS fibroblasts in culture 
resemble cells that are grown under conditions of stress (Wang et al. 2002). This 
together with the fact that exposure to stressful stimuli, such as H2 O2 (Huot et al. 
1997) or activation of oncogenes (Wang et al. 2002) is known to trigger premature 
senescence in normal cells, led to the hypothesis that WS may be undergoing 
SIPS (Davis et al. 2005).
Evidence in the literature shows that oncogenic ras- or arsenite-induced 
premature senescence of fibroblasts is due to activation of p38 (Guay et al. 1997; 
Huot et al. 1997) and that constitutive activation of p38 can induce proliferative 
arrest that is very similar to normal senescence (Haq et al. 2002). The genomic 
instability and increased levels of replication fork stalling (Rodriguez-Lopez et al. 
2002) seen in WS cells provides a plausible trigger for replication stress in WS 
cells and a possible involvement for p38 signalling in inducing the shortened 
replicative lifespan (Davis et al. 2005). Support for this theory came from the 
observation that the growth rate and replicative lifespan of WS cells could be 
significantly increased by treatment with the potent p38 inhibitor, SB203580 (Davis 
et al. 2005; Davis et al. 2006) (reference data for AG03141(WS) cells given in 
Appendix A). Primary AG05229(WS) fibroblasts treated daily with SB203580 
showed an increased growth rate from 0.13 to 0.34 PD/day and an extension in 
lifespan from 18.0 to 43.7 PDs, which is now within the range expected for normal 
fibroblasts (Davis et al. 2005) . Interestingly, this effect is reversible as removal of
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the drug results in a reduction in growth rate to that seen for untreated cells. 
Furthermore, restoration of the drug supplementation once again increases the 
growth rate and extends the lifespan of AG05229(WS) cells, although the lifespan 
extension is less than that seen in cells treated continuously with SB203580 (Davis 
et al. 2005). In the same study, high levels of p21WAF1 were observed in WS cells, 
suggesting that p38 signalling via p21WAF1 may induce a significant degree of cell- 
cycle arrest in young WS cells, thus causing the slow growth rate of WS cultures.
One of the criticisms of these studies was that long-lived foetal lung cells 
(MRC5) were used as a control. As the WS cells were short-lived adult dermal 
cells, it is possible that the effects seen with SB203580 were due to a combination 
of adult dermal cell-specific effects and a short lifespan. As a result a second study 
was undertaken using normal adult dermal fibroblasts for comparison. Although the 
effect of SB203580 was greater in these cells compared to the MRC5 cells, the 
effect on WS remained significantly higher (Davis and Kipling 2009). Collectively 
the findings provide strong supporting evidence that the effects of SB203580 on 
WS cellular lifespan are mainly due to the loss of WRN resulting in SIPS via p38 
activation.
The importance of using appropriate control cells is highlighted by the 
observation that normal human fibroblasts show large variability in proliferative 
potential (Goldstein et al. 1978; Martin et al. 1970; Schneider and Mitsui 1976). 
This variability was attributed to differences in donor health status and the 
conditions and timing of the biopsy (Goldstein et al. 1978). However, in a study of 
124 cell cultures established from human skin biopsies, which were explanted 
using the same experimental technique as part of the Baltimore Longitudinal Study 
of Aging (BLSA), a high degree of variability in replicative lifespan was also 
observed (Cristofalo et al. 1998a). This study showed that the lifespan of normal 
dermal fibroblasts grown under standard conditions ranged from 19-67 PD and no 
correlation was observed between replicative lifespan and donor age. This 
variation suggests that there are differences between different normal fibroblast 
strains that affect their ability to grow in culture. The degree of participation of p38
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signalling might be expected to be different in these strains and as such the impact 
of p38 inhibition may vary between strains. Support for this hypothesis comes from 
a recent study showing that there is variation in the growth potential of normal adult 
dermal fibroblasts: four strains of adult dermal fibroblasts had growth rates ranging 
0.15-0.35 PDs/Day and replicative lifespans ranging from 24-47.8 PDs (Davis and 
Kipling 2009). Furthermore, SB203580 had a differential effect on the lifespan of 
these cells, showing a lifespan extension of between 14.7 and 41%. As a result it is 
necessary to characterise the growth patterns and impact of p38 inhibition of 
normal adult dermal fibroblasts in order to use them as a comparison to study and 
identify any alterations in fibroblast behaviour in the Gl syndromes panel.
The aim of this chapter is to characterise the growth rates and lifespans of a 
panel of normal and Gl syndrome fibroblasts in the presence and absence of p38 
inhibitors. To address this, a pragmatic screening approach of all syndromes in the 
presence and absence of p38 inhibitors was undertaken using cumulative PDs to 
calculate the growth rate and maximum lifespan.
3.2 Specific Materials and Methods
3.2.1 Cell culture
All cells were grown as monolayer cultures in EMEM and were maintained 
in a humidified incubator at 37°C, 20% O2 and 5% C02. For drug treatments, cells 
were fed daily with EMEM containing 2.5 jiM SB203580, 2.5 jaM BIRB796 or 0.5 
p,M VX745, dissolved in DMSO. Control cells were supplemented with an 
equivalent volume of DMSO, added to the medium. p38 inhibitor concentrations 
were chosen based on previous studies (see Appendix B).
3.2.2 Growth curves
Growth curves were constructed for each cell strain using population 
doublings (PDs) per day. Population doublings were calculated according to the 
formula: PD=log(Nt/No)/log2, where Nt is the number of cells counted and No is the 
number of cells seeded. The number of population doublings (PDs) for each
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passage (P) was calculated from the cell count by comparing the total cell count 
following trypsinisation with the initial number of cells seeded. For cumulative PDs, 
the number of PDs calculated following each subcultivation was added to the 
previous count.
3.2.3 Calculation of maximum growth rate
Cells in early passage cultures tend to divide more rapidly than do those in 
late passage cultures. When the cumulative PDs were plotted against the time in 
culture, a clear decrease in the slope of the resulting line (change in growth rate) 
was observed. This initial slope over the first 30 days was calculated using linear 
regression as a measure of maximal growth rate of each cell strain. The R2 values 
for each growth curve were > 0.90.
3.2.4 Statistical analysis
Differences in both the replicative lifespan of untreated Gl syndrome cells and 
in the impact of p38 inhibitors on replicative lifespan of Gl syndrome cells were 
compared to the mean for normal cells using a two-tailed z-test. p-values were 
calculated from the z-value and a significance level of <0.05 was used. This 
approach was chosen as it allowed comparison of lifespan data on a strain-by- 
strain basis compared to the mean effect for the three normal strains.
3.3 Results: Altered Growth Kinetics in Normal Dermal and Gl 
Syndrome Fibroblasts Treated with p38 inhibitors
3.3.1 Normal Dermal Fibroblasts
To assess the effect of treatment of primary normal adult dermal fibroblasts 
with SB203580, BIRB796 and VX745, cells were grown continuously in the 
presence or absence the drugs until they reached M1 senescence. Three strains of 
adult dermal fibroblasts were chosen for use in this study. As shown in Figure 3.1 A 
the strain with the shortest lifespan, AG06234(N), has an initial growth rate of 0.28 
PD/day and a replicative lifespan of 19.1 PDs. This growth rate increases to 0.40, 
0.43 and 0.33 PD/day in the presence of SB203580, BIRB796 and VX745,
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respectively. The replicative lifespan of AG06234(N) cells increases to 26.6, 27.8 
and 22.8 PDs, which equates to a lifespan extension of 40%, 46% and 20% in the 
presence of SB20358, BIRB796 and VX745, respectively. The strain with an 
intermediate lifespan, AG13152(N), has an initial growth rate of 0.20 PDs/day and 
a replicative lifespan of 22.1 PDs (Figure 3.1B). In the presence of SB203580, 
BIRB796 and VX745 respectively, these increase to 0.35, 0.37 and 0.29 PDs/day 
and the replicative lifespan increases to 29.6, 32.3 and 25.7 PDs. This equates to a 
lifespan extension of 34%, 47% and 17% in the presence of SB20358, BIRB796 
and VX745, respectively. These data are consistent with previous reports in the 
literature for the replicative lifespan of AG13152(N) cells as 26 PDs (Cristofalo et 
al. 1998a) and 24.0 PDs (Davis and Kipling 2009). Similarly, AG13152(normal) had 
an initial growth rate of 0.15 PDs/day that increased to 0.18 PDs/day in the 
presence of SB203580, and the replicative lifespan to 29.5 PDs, which equates to 
a lifespan extension of ~28% (Davis and Kipling 2009). This strain can therefore be 
used as a reference to allow comparison of the growth of normal cells observed 
both in this study and previously in the literature. The longest-lived strain, 
AG16409(N) has an initial growth rate of 0.45 PDs/day and a replicative lifespan of
50.3 PDs (Figure 3.1C). The initial growth rate of AG16409(N) cells increases to 
0.60, 0.68 and 0.53 with continued treatment with SB203580, BIRB796 and 
VX745, respectively. The lifespan of AG16409(N) cells increases to 56.5 and 63.2 
when treated with SB203580 and BIRB796, which equates to a lifespan extension 
of 12% and 26%. However, VX745 treatment has a marginal effect on the growth 
rate and lifespan of AG16409(N) cells. These data are summarised in section
3.3.10 and in tables 3.1 and 3.2.
The data presented here represents the experimental lifespans observed for 
normal cells; however, information provided by the repository shows that 
AG16409(N), AG06234(N) and AG13152(N) have achieved 4, 15 and 6 PDs, 
respectively, prior to receipt of the cells. The maximum lifespan of AG16409(N), 
AG06234(N) and AG13152(N) is therefore 54.3 PDs, 34.1 PDs and 28.1 PDs, 
respectively. The following data obtained for the Gl syndromes represents the 
experimental data; however, the starting PD is noted for any strains with known
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replicative histories and the corrected lifespan data is used for the statistical 
analysis.
3.3.2 Rothmund Thomson Syndrome (RTS)
The RTS strain with the shortest lifespan, AG18375(RTS), has an initial 
growth rate of 0.30 PD/day and a replicative lifespan of 10.3 PDs (Figure 3.2A). 
This growth rate increases to 0.39 and 0.37 PDs/day in the presence of SB203580 
and BIRB796 but is unchanged in VX745. The replicative lifespan of 
AG18375(RTS) cells also increases to 14.3, 17.5 and 10.4 PDs in the presence of 
SB20358, BIRB796 and VX745, which equates to a lifespan extension of 39%, 
70% and 1%, respectively. The strain with an intermediate lifespan, 
AG17524(RTS), has an initial growth rate of 0.33 PDs/day and a replicative 
lifespan of 28.8 PDs (Figure 3.2B). In the presence of SB203580, BIRB796 and 
VX745 respectively, the growth rates increase to 0.47, 0.50 and 0.43 PDs/day and 
the replicative lifespan increases to 42.0, 46.2 and 36.0 PDs. This equates to a 
lifespan extension of 46%, 60% and 25% in the presence of SB203580, BIRB796 
and VX745, respectively. The longest-lived strain, AG18371 (RTS) has an initial 
growth rate of 0.38 PDs/day and a replicative lifespan of 37.9 PDs (Figure 3.2C). 
The initial growth rate of AG18371 (RTS) cells increases to 0.69, 0.76 and 0.55 with 
an increase in lifespan to 43.2, 51.5 and 38.6 PDs in continued treatment with 
SB203580, BIRB796 and VX745, respectively. This equates to a 14%, 36%, 2% 
extension in lifespan in the presence of SB203580, BIRB796 and VX745.
3.3.3 Bloom Syndrome (BS)
The BS strain with the shortest lifespan, GM02520(BS), has an initial growth 
rate of 0.18 PDs/day and a replicative lifespan of 19.3 PDs (Figure 3.3A). 
Treatment with SB203580, BIRB796 and VX745 results in an increase in growth 
rate to 0.40, 0.43 and 0.30 PDs/day, respectively. The replicative lifespan of 
GM02520(BS) also increases to 29.3, 34.9 and 28.2 PDs in the presence of 
SB203580, BIRB796 and VX745, which equates to a lifespan extension of 52%, 
81% and 46%, respectively. The strain with the intermediate lifespan, 
GM02548(BS), has a growth rate of 0.37 PDs/day and a replicative lifespan of 23.8
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PDs (Figure 3.3B). With SB203580, BIRB796 and VX745 treatment, the growth 
rate increases to 0.48, 0.51 and 0.47 PDs/day and the lifespan to 35.5, 41.5 and
37.2 PDs, respectively. This equates to a lifespan extension of 49%, 74% and 57% 
in drug treated GM02548(BS) cells. Finally, the strain with the longest lifespan, 
GM02932(BS), has a growth rate of 0.32 PDs/day and a replicative lifespan of 24.5 
PDs (Figure 3.3C). Treatment of GM02932(BS) cells with SB203580, BIRB796 and 
VX745 results in an increase in the growth rate to 0.43, 0.42, and 0.37 PDs/day, 
and an increase in lifespan to 33.7, 37.8 and 29.5 PDs. This equates to a lifespan 
extension of 38%, 55% and 21% in SB203580, BIRB796 and VX745 treated 
GM02932(BS) cells, respectively.
3.3.4 Hutchinson Gilford Progeria Syndrome (HGPS)
The HGPS strain with the shortest lifespan, GM01972(HGPS), has an initial 
growth rate of 0.13 PDs/day and a replicative lifespan of 3.8 PDs (Figure 3.4A). 
Treatment of GM01972(HGPS) cells with SB203580, BIRB796 and VX745 results 
in an increase in the growth rate to 0.18, 0.25 and 0.17 PDs/day and an increase in 
replicative lifespan to 5.5, 7.7 and 4.7 PDs, respectively. This equates to a lifespan 
extension of 46%, 102% and 23% in drug treated GM01972(HGPS) cells. The 
strain with the intermediate lifespan, AG10677(HGPS) has an initial growth rate of 
0.29 PDs/day and a replicative lifespan of 14.4 PDs (Figure 3.4B), although was 
shown previously in the literature to have a replicative lifespan of only 6.3 PDs 
(Bridger and Kill 2004). With SB203580, BIRB796 and VX745 treatment, the 
growth rate increases to 0.41, 0.45 and 0.38 PDs/day and the lifespan increases to 
20.9, 21.9 and 17.5, respectively. This equates to a lifespan extension of 45%, 
52% and 22% in drug treated AG10677(HGPS) cells. Finally, the strain with the 
longest lifespan, AG11498(HGPS), has an initial growth rate of 0.38 PDs/day and a 
replicative lifespan of 14.8 PDs (Figure 3.4C). Treatment of AG11498(HGPS) cells 
with SB203580 and BIRB796 results in an increase in the growth rate to 0.39 and 
0.46 PDs/day and a lifespan extension of 49% and 61%. Treatment with VX745 
had no effect on the initial growth rate of AG11498(HGPS) cells but extends the 
lifespan by 13%.
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The information provided by the repository shows that AG10677(HGPS) and 
AG11498(HGPS) have achieved 6 PDs and 10 PDs, respectively, prior to receipt 
of the cells; however, no information is provided for AG01972(HGPS). The 
maximum lifespan of AG10677(HGPS) and AG11498(HGPS) is therefore 20.4 PDs 
and 24.8 PDs, respectively.
3.3.5 Nijmegen-Breakage Syndrome (NBS)
The NBS strain with the shortest lifespan, GM07166(NBS), has an initial 
growth rate of 0.22 PDs/day and a replicative lifespan of 17.8 PDs (Figure 3.5A). 
Treatment with SB203580, BIRB796 and VX745 results in an increase in growth 
rate to 0.41, 0.38 and 0.33 PDs/day, respectively. The replicative lifespan of 
GM07166 also increases to 39.5, 41.7 and 30.0 PDs in the presence of SB203580, 
BIRB796 and VX745, which equates to a lifespan extension of 122%, 135% and 
69%, respectively. The strain with the intermediate lifespan, RO202(NBS), has an 
initial growth rate of 0.35 PDs/day and a replicative lifespan of 43.1 PDs (Figure 
3.5B). With SB203580 and BIRB796 treatment, the growth rate increases to 0.49, 
0.54 and 0.40 PDs/day. The lifespan of RO202 cells increases to 48.8, 53.7 and
46.5 PDs, which equates to a lifespan extension of 13%, 25% and 7% in the 
presence of SB203580, BIRB796 and VX745, respectively. Finally, the strain with 
the longest lifespan, R0242(NBS), has an initial growth rate of 0.34 PDs/day and a 
replicative lifespan of 53.5 PDs (Figure 3.5C). Treatment of R0242(NBS) cells with 
SB203580 and BIRB796 results in an increase in the growth rate to 0.38 PDs/day; 
however, VX745 treatment results in a slight reduction in the initial growth rate to 
0.32 PD/day. The lifespan of R0242(NBS) cells also increases to 67.9, 65.9 and
62.6 PDs. This equates to a lifespan extension of 27%, 23% and 17% in 
SB203580, BIRB796 and VX745, respectively.
The information provided by the repository shows that GM07166(NBS) has 
achieved 5.65 PDs prior to receipt of the cells and therefore have a maximum 
lifespan of 23.5 PDs; however, no information is provided for the other two NBS 
strains.
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3.3.6 Ligase 4 Syndrome (LIG4)
The LIG4 strain with the shortest lifespan, GM17523(LIG4), has an initial 
growth rate of 0.23 PDs/day and a lifespan of 11.6 PD (Figure 3.6A). Treatment 
with SB203580, BIRB796 and VX745 results in an increase in growth rate to 0.37, 
0.40 and 0.30 PDs/day and an increase in lifespan to 19.4, 22.5 and 15.7 PD, 
respectively. This equates to a lifespan extension of 68%, 95% and 36% in drug 
treated GM17523(LIG4) cells. The strain with the longer lifespan, GM16088(LIG4), 
has an initial growth rate of 0.25 PDs/day and a lifespan of 15.9 PD (Figure 3.6B). 
Treatment of GM16088(LIG4) cells with SB203580, BIRB796 and VX745 results in 
an increase in the growth rate to 0.36, 0.49 and 0.29 PDs/day and an extends the 
lifespan to 23, 28.3 and 20 PD, respectively. This equates to a lifespan extension 
of 45%, 79% and 26% in drug treated GM16088(LIG4) cells.
3.3.7 Cockayne Syndrome A (CSA)
Untreated GM01856(CSA) cells have a growth rate of 0.40 PDs/day and a 
replicative lifespan of 21.1 PDs/day. Treatment of GM01856(CSA) cells with 
SB203580, BIRB796 and VX745 results in an increase in the growth rate to 0.50,
0.58 and 0.46 PDs/day, and an increase in replicative lifespan to 30.0, 34.5 and
24.3 PDs, respectively (Figure 3.7). This equates to an increase in growth rate of 
27%, 46% and 17% and a lifespan extension of 42%, 64% and 15% in the 
presence of SB203580, BIRB796 and VX745, respectively.
3.3.8 Dyskeratosis Congenita (DKC)
GM01744(DKC) cells have a growth rate of 0.15 PDs/day and a replicative 
lifespan of 5.9 PDs (Figure 3.8). Treatment of GM01744 cells with SB203580, 
BIRB796 and VX745 results in an increase in the growth rate to 0.22, 0.27 and
0.17 PDs/day, respectively. The replicative lifespan of GM01744 also increases to 
10.4, 11.8 and 8.2 PDs, which equates to a 77%, 100% and 39% lifespan 
extension when treated with SB203580, BIRB796 and VX745, respectively. The 
information provided by the repository shows that GM01774(DKC) has achieved
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6.74 PDs prior to receipt of the cells and therefore have a maximum lifespan of
12.6 PDs.
3.3.9 Seckel Syndrome (SS)
The SS strain with the shortest lifespan, GM18366(SS), has an initial growth 
rate of 0.19 PDs/day and a replicative lifespan of 11.2 PDs (Figure 3.9A). 
Treatment with SB203580, BIRB796 and VX745 increases the initial growth rate of 
GM18366(SS) cells to 0.31, 0.36 and 0.25 PDs/day, respectively. The replicative 
lifespan of GM18366(SS) also increases to 21.4, 29.6 and 19.8 PDs in the 
presence of SB203580, BIRB796 and VX745, which equates to a lifespan 
extension of 91%, 164% and 77%, respectively. The strain with the longer lifespan, 
GM09812(SS), has a growth rate of 0.5 PDs/day and a replicative lifespan of 32.9 
PDs (Figure 3.9B). With SB203580, BIRB796 and VX745 treatment, the growth 
rate of GM09812(SS) cells increases to 0.63, 0.73 and 0.60 PDs/day and the 
lifespan is extended to 39.1, 44.4 and 36.9 PDs, respectively. This equates to a 
lifespan extension of 19%, 35% and 12% in drug treated GM09812(SS) cells.
3.3.10 Summary of Growth Potential of Normal Dermal and Gl Syndrome 
Fibroblasts
The following section provides a summary of:
1. The lifespan and growth rate data for untreated normal and Gl
syndrome cells.
2. The effect of p38 inhibitors on lifespan and growth rate of normal and
Gl syndrome cells.
1. Comparison of lifespans
In order to compare the lifespans of Gl syndrome and normal cells the 
replicative history of each strain, as provided by Coriell, is added to the 
experimental data collected in this study. In cases where the replicative histories 
are unknown, passage history has been used as an indicator of replicative history.
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Consistent with evidence from the literature (Cristofalo et al. 1998a; Davis 
and Kipling 2009), inter-strain heterogeneity with regard to growth rate and lifespan 
was observed in normal cells. AG16409(N) had the fastest growth rate (0.45 
PDs/day) and longest lifespan (54.3 PDs) of the three normal strains, AG06234(N) 
had an intermediate growth rate (0.28 PDs/day) and lifespan (34.1 PDs), whereas 
AG13152(N) had the slowest growth rate (0.20 PDs/day) and shortest lifespan 
(28.1 PDs). The mean growth rate and lifespan of normal cells was 0.31 PDs/day 
and ~39 PDs, respectively. These data suggest that there are differences in the 
growth potential of dermal fibroblasts that have no known defect, and thus provide 
a baseline against which to compare the growth of Gl syndrome fibroblasts.
Figure 3.10 provides a visual representation of the range of growth rates 
(panel A) and lifespans (panel B) observed for the Gl panel, and allows simple 
observations of trends and differences to be made. The majority of Gl syndrome 
cell strains have growth rates within the normal range with the exception of 
GM02520(BS), AG01972(HGPS), GM01774(DKC) and GM18366(SS) that have 
slower than normal growth rates and GM09812(SS) which has a faster than normal 
growth rate (Figure 3.10A). Given that growth rate will change over time and is 
therefore dependent on where in the replicative lifespan the measurement is taken, 
a more in-depth analysis of lifespan was undertaken.
Figure 3.10B shows that the majority of Gl syndrome cell strains have 
lifespans that are at the bottom end of the normal range [AG18371 (RTS), 
AG17524(RTS) and GM09812(SS)J or are below the normal range 
[AG18375(RTS), all three BS strains, all three HGPS strains, GM07166(NBS), both 
LIG4 strains, GM01856(CSA), GM01774(DKC) and GM18366(SS)], with the 
exception of RO202(NBS) and R0242(NBS) which have lifespans that are above 
the normal mean lifespan. Statistical analysis of the differences in lifespan for each 
of the Gl syndromes fibroblast strains compared to the mean lifespan for the three 
normal strains was performed using a two-tailed z test. Figure 3.10C shows that 
AG18375(RTS), AG01972(HGPS), GM17523(LIG4) and GM18366(SS) have a 
significantly shorter lifespan compared to normal cells, suggesting that these cell
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strains are replicatively compromised compared to normal cells, perhaps reflecting 
an increased commitment to SIPS.
2. Impact of p38 inhibitors
Treatment with p38 inhibitors was shown to increase the growth rate and 
extend the lifespan of all cells irrespective of their genetic background, suggesting 
that all cells are undergoing some degree of p38-mediated proliferation restraint. 
Although inter-strain heterogeneity in the effect of each inhibitor was observed 
(summarised in Table 3.1), in general BIRB796 was shown to have the greatest, 
whereas VX745 had the least impact on growth rate and lifespan. Given the issues 
associated with changing growth rates over time (discussed previously), a more in- 
depth analysis of the impact of p38 inhibitors on lifespan was performed (Table 3.1 
and Figure 3.11).
Statistical analysis of the impact of SB203580, BIRB796 and VX745 on the 
lifespan of each individual Gl syndrome cell strain was compared to the mean 
effect for normal cells in the presence of each inhibitor. Table 3.1 shows that 
AG18375(RTS) show a statistically significant lifespan extension in response to 
BIRB796 (p=0.008). GM02548(BS) and GM02520(BS) show a statistically 
significant lifespan extension in the presence of BIRB796 and VX745. 
GM01972(HGPS) shows a significant lifespan extension in response to BIRB796 
only (p<0.001). GM07166(NBS) shows a significant lifespan extension in the 
presence of all three p38 inhibitors (p<0.001 for all). Similarly, GM17523(LIG4) 
show a significant lifespan extension in response to all p38 inhibitors (p=0.006, 
p<0.001 and p=0.20, respectively), whereas GM16088(LIG4) only show a 
significant lifespan extension in response to BIRB796 (p<0.001). GM01856(CSA) 
shows a significant lifespan extension in response to BIRB796 only (p=0.035), 
whereas both GM01774(DKC) and GM18366(SS) show a significant lifespan 
extension in response to all three p38 inhibitors.
The observation was also made that in normal cells there appears to be a 
correlation between the growth potential and the response to p38 inhibitors. For
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example, AG13152(N) cells showed the slowest growth rate and shortest lifespan 
but showed the greatest response to p38 inhibitors, whereas AG16409(N) had the 
fastest growth rate, the longest lifespan but showed the smallest response to p38 
inhibitors. The data suggest that AG13152(N) cells are undergoing a greater 
degree of p38-restraint on growth potential compared to the other two normal 
strains. The same pattern is observed in Gl syndrome cells, in that the strains with 
the slowest growth rate and shortest lifespan show the greatest response to p38 
inhibitors. For example, GM07166(NBS) has a much reduced growth rate and 
lifespan compared to the other two NBS strains and show a far greater response to 
p38 inhibitors. Figure 3.12 shows that there is a negative correlation between 
lifespan extension in BIRB796 and the maximum lifespan of untreated cells, 
suggesting that the cells with the shortest lifespan have the greatest response to 
BIRB796 and that this is not weighted by the presence of normal cells. A similar 
effect was seen for SB203580 and VX745 (data not shown).
3.4 Discussion
Given the extensive number of strains, the pragmatic option was taken of an 
unbiased screen of growth potential in all of the cells using the standard technique 
described. This approach was critical for valid comparisons in such extended 
longitudinal studies. The maximum growth rate of each culture was calculated by 
linear regression at early growth stages while maximum lifespan represents an 
endpoint and is not as affected by passage fluctuations in growth rate.
Heterogeneity in growth potential and in p38 inhibitor responses were 
observed between normal strains and between strains from the same Gl 
syndrome. p38 inhibitors extended the lifespan and increased the growth rate of all 
cell strains irrespective of their genetic background, suggesting that all cells strains 
undergo some degree of p38-mediated proliferation restraint. Whilst the observed 
heterogeneity in growth potential between cell strains could indicate differences in 
the level of commitment to SIPS, it is possible that it could also reflect differences 
in progression towards replicative senescence due simply to differences in 
replicative histories. Given the uncertainties in replicative history for the majority of
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strains used, the passage history was used to give some indication of replicative 
history. Typically the passage history of the strains, as provided by the repository, 
is 2-15; however, this is not provided for all of the strains used.
Other factors that could contribute to inter-strain heterogeneity include 
differences in the micro-anatomical localisations from which the cells are 
explanted. For example, it has been reported that cultured fibroblasts isolated from 
the upper and deeper dermis, at the same anatomical site, exhibit differences in 
proliferative potential (Azzarone and Macieira-Coelho 1982). These areas are 
subject to current collaborations to investigate the age-related modifications of 
distinct dermal fibroblast populations (Dr. Terence Davis unpublished data). 
Controversies over the impact of donor age on the growth potential of primary cells 
remain (Cristofalo et al. 1998a; Pignolo et al. 1992). The current data set does not 
have the power to resolve this issue, however, the relationship between donor age 
and replicative lifespan of the panel are shown for illustrative purposes (Figure 
3.13). Here, no correlation between donor age and lifespan is observed and this 
does not appear to be weighted by the presence of normal cells. To further assess 
impact of donor age in primary cells with different genetic backgrounds, a wider 
screen using more strains would be required. Finally, uncertainties in disease 
status for some cell strains could also contribute to inter-strain differences. For 
example, the disease status of R0242(NBS), RO202(NBS) and GM09812(SS) was 
determined by clinical diagnosis and to date the mutation status of these cells have 
not been characterised. Moreover, evidence in the literature suggests that 
R0242(NBS) cells are derived from a patient that represents a possible variant of 
NBS that shows some differences in clinical presentation and some unusual 
cytogenetic features compared to other NBS patients (Der Kaloustian et al. 1996). 
Therefore, it is possible that the inter-strain heterogeneity in growth potential 
observed for NBS and SS cells is due to fact that these represent different 
disorders with different growth characteristics.
The observation that some strains such as AG01972(HGPS) and 
GM01774(DKC) have very short experimental lifespans suggest that these strains
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may be close to replicative senescence. This gives rise to the issue that small 
differences in growth parameters will be translated into large percentage 
differences in these strains. Furthermore, it is known that telomeres are very short 
in all forms of DKC (Gupta and Kumar 2010; Vulliamy et al. 2001b), therefore the 
increase in stress signals that arise due to telomere attrition in DKC may cause the 
increased response to p38 inhibitors observed here.
Despite the known caveats of this approach, the main findings presented in 
this chapter are as follows:
• AG18375(RTS), all three HGPS strains, GM07166(NBS), both LIG4 strains, 
GM01774(DKC) and GM18366(SS) have truncated lifespans compared to 
normal cells
• Of these AG18375(RTS), AG01972(HGPS), GM17523(LIG4) and
GM18366(SS) were shown to have a statistically shorter lifespan compared 
to normal cells, suggesting that these strains are replicatively compromised.
• Treatment with p38 inhibitors consistently increases the growth rate and 
extends the lifespan of all cell strains, irrespective of their genetic 
background, suggesting that all of these cell strains are undergoing some 
degree of p38-mediated proliferation restraint.
• The following cell strains showed a significant lifespan extension in 
response to at least one p38 inhibitor, suggesting that these strains are 
undergoing a higher level of p38-mediated proliferation restraint (or SIPS) 
compared to normal cells: AG18375(RTS), GM02548(BS), GM02520(BS), 
GM01972(HGPS), GM07166(NBS), GM16088(LIG4), GM17523(LIG4), 
GM01856(CSA), GM01774(DKC) and GM18366(SS).
Whilst, the current screen has provided valuable information regarding the 
heterogeneity in growth potential of both normal and Gl syndrome fibroblasts, the 
findings underline the need to clarify several issues: The need to identify the target 
cells for p38 inhibitor action, the potential contribution of cells induced to re-enter
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the cell cycle, the difficulty in identifying degrees of commitment in primary systems 
for progression to cell cycle exit/senescence, the complication of ongoing 
proliferation of cells -  perhaps not affected by p38 inhibitors -  resulting in an 
effective dilution of responding cells as the culture progresses and the difficulty of 
comparing Gl panel strains that may have different degrees of commitment to 
senescence due to telomere attrition. These issues are addressed in the 
subsequent chapters.
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Figure 3.1. Growth (cumulative population doublings) of normal adult dermal fibroblasts with 
SB20580, BIRB796 and VX745.
Fibroblasts AG06234(N) (panel A), AG13152(N) (panel B) and AG16409(N) (panel c) were 
grown in standard EMEM with no supplementation (dotted line), or with continuous daily 
supplementation with SB203580 (-■ -), BIRB796 (-A-), or VX745 (-X-). Growth is measured 
as population doubling (PDs) versus days. Panel D shows an example of the linear regression 
used to calculate the maximum growth rate of the cultures. The R2 values for each was > 0.9.
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Figure 3.2. Growth (cumulative population doublings) of RTS fibroblasts with SB20580, 
BIRB796 and VX745.
Fibroblasts AG18375(RTS) (panel A), AG17524(RTS) (panel B) and AG18371(RTS) (panel c) 
were grown as in 3.1.
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Figure 3.3. Growth (cumulative population doublings) of Bloom syndrome (BS) fibroblasts with 
SB20580, BIRB796 and VX745.
Fibroblasts GM02520(BS) (panel A), GM02548(BS) (panel B) and GM02932(BS) (panel c) 
were grown as in 3.1.
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Figure 3.4. Growth (cumulative population doublings) of Hutchinson-Gilford Progeria 
syndrome (HGPS) fibroblasts with SB20580, BIRB796 and VX745.
Fibroblasts AG01972(HGPS) (panel A), AG10677(HGPS) (panel B) and AG11498(HGPS) 
(panel c) were grown as in 3.1.
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Figure 3.5. Growth (cumulative population doublings) of Nijmegen Breakage syndrome 
(NBS) fibroblasts with SB20580, BIRB796 and VX745.
Fibroblasts GM07166(NBS) (panel A), RO202(NBS) (panel B) and R0242(NBS) (panel 
c) were grown as in 3.1.
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Figure 3.6. Growth (cumulative population doublings) of Ligase 4 syndrome (LIG4) 
fibroblasts with SB20580, BIRB796 and VX745.
Fibroblasts GM17523(LIG4) (panel A) and GM16088(LIG4) (panel B) were grown in were 
grown as in 3.1.
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Figure 3.7. Growth (cumulative population doublings) of Cockayne Syndrome A (CSA) 
fibroblasts with SB20580, BIRB796 and VX745.
Fibroblasts GM01856(CSA) were grown as in 3.1.
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Figure 3.8. Growth (cumulative population doublings) of Dyskeratosis Congenita (DKC) 
fibroblasts with SB20580, BIRB796 and VX745.
Fibroblasts GM01774(DKC) were grown as in 3.1.
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Figure 3.9. Growth (cumulative population doublings) of Seckel Syndrome (SS) 
fibroblasts with SB20580, BIRB796 and VX745.
Fibroblasts GM18366(SS) (panel A) and GM01982(SS) (panel B) were grown as in 3.1.
107
_  0.60 >.
05Q
£  0.40
05
5|  0.20
2O)
ED
E 
x
05
♦
¥
♦
i
♦
I
ft
X
A i
0.00
o *V °
B 60
<0 ▲ 
£  50
Q 40 x  a  A
00 4
£ 3 0  M 
E 20
1 4 ~
05 2
♦
*
0
jsat
V fir ^ <#>
Syndrome
Cell strain
Replicatve
Lifespan
(PDs) z value3 p valueb
AG16409( Normal) 
AG13152(Normal) 
AG06234(Normal)
54.26
28.05
34.05
AG18375(RTS) 10.26 -2.08 0.038
AG17524(RTS) 28.77 -0.73 0.465
AG18371(RTS) 37.92 -0.06 0.952
GM02932(BS) 24.45 -1.04 0.298
GM02548(BS) 23.78 -1.09 0.276
GM02520(BS) 19.29 -1.42 0.156
AG11498(HGPS) 24.77 -1.02 0.308
AG10677(HGPS) 20.36 -1.34 0.180
GM01972(HGPS) 3.8 -2.55 0.011
R0242(NBS) 43.05 0.31 0.757
RO202(NBS) 53.51 1.07 0.285
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Figure 3.10. Summary of growth rates and lifespans of Gl syndrome and normal fibroblasts.
Panel A and B provide a graphical representation of the range of growth rates and lifespans 
observed for Gl syndrome and normal fibroblast cell strains. The mean growth rate and lifespan 
for each syndrome is indicated by x . The shaded regions represent the range of growth rates 
(panel A) and lifespans (panel B) observed for normal dermal fibroblasts. The dotted line in panel 
B represents the significance level as tested by Z-test: any strains that are on or below this line 
are considered to have statistically shorter lifespans compared with normal cells. Panel C shows 
the results for the statistical analysis of Gl syndrome cell lifespans compared to normal cells. 
Individual Gl cell strains were compared to the normal mean using a two-tailed z-test and any 
strains with a significantly shorter lifespan compared to normal cells are highlighted in red.
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Table 3.1. Impact of p38 inhibitors on growth rate and lifespan of Gl syndrome and normal 
fibroblasts.
Maximum Increase Replicatve Lifespan P value for
Drug growth rate in growth Lifespan extension lifespan
Cell strain Treatment (PDs/Day)a rate (% )b (PDs) (% )b z valuec extension*1
AG16409(Normal) - 0.45 50.3
SB203580 0.60 33.3 56.5 12.3
BIRB796 0.68 51.1 63.2 25.6
VX745 0.53 17.8 50.3 0.0
AG13152(Normal) - 0.20 22.1
SB203580 0.35 75.0 29.6 33.9
BIRB796 0.37 83.3 32.3 46.2
VX745 0.29 43.3 25.7 16.3
AG06234(Normal) - 0.28 19.1
SB203580 0.40 42.4 26.6 39.3
BIRB796 0.43 52.9 27.8 45.5
VX745 0.33 17.6 22.8 19.4
AG18375(RTS) - 0.30 10.26
SB203580 0.39 31.3 14.27 39.1 0.74 0.460
BIRB796 0.37 24.8 17.47 70.3 2.67 0.008
VX745 0.29 -2.9 10.38 1.2 -1.03 0.303
AG17524(RTS) - 0.33 28.77
SB203580 0.47 40.7 42.02 46.1 1.23 0.219
BIRB796 0.50 49.9 46.16 60.4 1.83 0.067
VX745 0.43 27.5 36.03 25.2 1.28 0.201
AG18371(RTS) - 0.38 37.92
SB203580 0.69 82.3 43.24 14.0 -1.01 0.313
BIRB796 0.76 101.3 51.51 35.8 -0.28 0.780
VX745 0.55 44.8 38.63 1.9 -0.96 0.337
GM02932(BS) - 0.32 24.45
SB203580 0.43 34.8 33.69 37.8 0.65 0.516
BIRB796 0.42 33.5 37.79 54.6 1.32 0.187
VX745 0.37 17.3 29.46 20.5 0.83 0.407
GM02548(BS) - 0.37 23.78
SB203580 0.48 29.4 35.45 49.1 1.44 0.150
BIRB796 0.51 39.2 41.45 74.3 3.02 0.003
VX745 0.47 28.7 37.23 56.6 4.29 <0.001
GM02520(BS) - 0.18 19.29
SB203580 0.40 126.5 29.34 52.1 1.65 0.099
BIRB796 0.43 144.5 34.91 81.0 3.59 <0.001
VX745 0.30 71.5 28.17 46.0 3.28 0.001
AG11498(HGPS) - 0.38 14.8
SB203580 0.39 3.1 22.03 48.9 1.43 0.153
BIRB796 0.46 21.7 23.70 60.1 1.80 0.072
VX745 0.38 0.1 16.65 12.5 0.06 0.952
AG10677(HGPS) - 0.29 14.4
SB203580 0.41 40.2 20.9 45.1 1.17 0.242
BIRB796 0.45 53.1 21.9 52.1 1.11 0.267
VX745 0.38 28.3 17.5 21.5 0.93 0.352
GM01972(HGPS) - 0.13 3.80
SB203580 0.18 34.6 5.53 45.5 1.19 0.234
BIRB796 0.25 95.3 7.69 102.4 5.42 <0.001
VX745 0.17 27.4 4.69 23.4 1.11 0.267
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T a b le  3.1 co n tin ued
Maximum Increase Replicatve Lifespan P value for
Drug growth rate in growth Lifespan extension lifespan
Cell strain Treatment (PDs/Day)a rate (% )b (PDs) (% )b z valuec extensiond
RO202(NBS) - 0.35 43.05
SB203580 0.49 40.3 48.81 13.4 -1 .06 0.289
BIRB796 0.54 54.8 53.67 24.7 -1 .24 0.215
VX745 0.40 16.8 46.49 8.0 -0.37 0.711
R0242(NBS) - 0.34 53.51
SB203580 0.38 12.6 67.91 26.9 -0.11 0.912
BIRB796 0.38 12.9 65.91 23.2 -1.37 0.171
VX745 0.32 -5.5 62.56 16.9 0.48 0.631
GM07166(NBS) - 0.22 17.8
SB203580 0.41 81.2 39.5 121.9 6.55 <0.001
BIRB796 0.38 67.1 41.7 134.3 8.15 <0.001
VX745 0.33 47.3 30 68.5 5.44 <0.001
GM16088(LIG4) - 0.25 15.86
SB203580 0.36 42.1 22.99 45.0 1.15 0.250
BIRB796 0.49 92.1 28.33 78.6 3.39 <0.001
VX745 0.29 15.8 19.96 25.9 1.34 0.180
GM17523(LIG4) - 0.23 11.56
SB203580 0.37 57.1 19.42 68.0 2.77 0.006
BIRB796 0.40 72.9 22.53 94.9 4.78 <0.001
VX745 0.30 27.1 15.73 36.1 2.32 0.020
GM01856(CSA) - 0.40 21.1
SB203580 0.50 27.0 29.88 41.6 0.92 0.358
BIRB796 0.58 46.1 34.54 63.7 2.11 0.035
VX745 0.46 16.5 24.32 15.3 0.32 0.749
GM01774(DKC) - 0.15 5.9
SB203580 0.22 46.7 10.4 76.3 3.35 <0.001
BIRB796 0.27 82.2 11.8 100.0 5.22 <0.001
VX745 0.17 15.6 8.2 39.0 2.60 0.009
GM18366(SS) - 0.19 11.22
SB203580 0.36 87.8 21.4 90.7 4.36 <0.001
BIRB796 0.31 61.9 29.57 163.5 10.66 <0.001
VX745 0.25 32.0 19.82 76.6 6.22 <0.001
GM09812(SS) - 0.50 32.9
SB203580 0.62 24.7 39.11 18.9 -0.68 0.497
BIRB796 0.73 45.3 44.42 35.0 -0.35 0.726
VX745 0.60 19.3 36.87 12.1 0.02 0.984
a The maximum growth rate is based on the linear regression part of the curve at early 
growth stages (30 days in culture) and is calculated by linear regression.
bThe increase in growth rate and lifespan following treatment with SB203580, BIRB796 and 
VX745 is calculated as a percentage increase compared to the untreated control.
c Two-tailed z-test
d p-value is calculated based on the z-value. A significance level of 0.05 is given and any 
strains showing a significantly different response to p38 inhibitors compared with the normal 
mean are highlighted in red.
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Figure 3.11. Relative lifespan extension in SB203580-, BIRB796- and VX745-treated cells.
The lifespan extension is given as the percentage increase compared to untreated controls. 
The black line indicates the mean lifespan extension for each drug. A two-tailed z-test was 
performed to assess the impact of SB203580, BIRB796 and VX745 on the lifespan of Gl 
syndrome cell strains compared to the mean lifespan extension for normal cells (see table 
3.1). Those strains that were shown to have a statistically different response to p38 
inhibitors compared to the normal mean are indicated by *.
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Figure 3.12. Relationship between in vitro lifespan 
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A regression line (R2=0.45) is shown. Normal strains 
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fibroblasts are represented by (♦ ).
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Chapter 4 Cellular Morphology of Dermal Fibroblasts
from Normal and Gl Syndrome Individuals and the 
effects of p38 inhibitors
4.1 Introduction
There is a growing consensus that the senescent cellular phenotype 
correlates with cells that are enlarged, flattened and granular (Burton 2009; 
Campisi 1997b; Campisi and d'Adda di Fagagna 2007; Rubin 1997). Although 
morphological change is associated with the senescent phenotype the 
mechanisms underlying such changes have not been well studied. It has been 
reported that WS fibroblasts early in their replicative lifespan show an altered, 
enlarged cellular morphology with extensive networks of F-actin stress fibres 
(Davis et al. 2005), and resemble normal fibroblasts that have undergone stress- 
induced premature senescence (SIPS) as a result of oncogenic ras expression or 
arsenite treatment (Deng et al. 2004; Guay et al. 1997; Huot et al. 1997; Wang et 
al. 2002). These observations support the hypothesis that WS cells may be 
undergoing SIPS triggered by increased levels of replication stress (Davis et al. 
2005). The aim of this section of work was to determine if morphological changes, 
possibly indicative of SIPS, could be consistently observed in a panel of other Gl 
syndrome cells.
According to current definition, stress fibres are bundles of numerous 
contractile acto-myosin filaments that are involved in adhesion, motility and 
morphogenesis (Naumanen et al. 2008). These transient structures form in 
response to tension and disappear when tension is released (Naumanen et al. 
2008; Pellegrin and Mellor 2007). It has been suggested that the formation of 
stress fibres is a protective mechanism in which stabilisation of actin filaments 
results in increased resistance to stresses (Landry et al. 1989; Mehlen et al. 1996). 
Stress fibres have been reported in cells that have undergone SIPS, for example in
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response to H2O2 (Chen et al. 1998; Toussaint et al. 2002); however, the 
usefulness of stress fibre presentation as a predictive marker of cells that have 
undergone SIPS remains unclear. A link between stress fibre presentation and 
entry into a senescence phenotype would therefore provide a valuable biomarker 
approach to investigating of the induction of SIPS.
The small heat-shock protein 27 (HSP27) is constitutively expressed in a 
variety of mammalian cell types (Benndorf et al. 1994) and its expression has been 
shown to increase in response to sub-lethal stresses including heat shock, toxins, 
and oxidative stress (Landry et al. 1989; Lavoie et al. 1995). Activation of HSP27 is 
therefore widely accepted to be a protective mechanism that allows a cell to 
respond to stressful stimuli (Franklin et al. 2005; Jaattela and Wissing 1992; Stetler 
et al. 2009). Evidence in the literature suggests that HSP27 phosphorylation is 
involved in the regulation of microfilament dynamics, modifying the actin response 
to physiological agonists and stabilising the actin cytoskeleton under stressful 
conditions (Huot et al. 1996; Huot et al. 1995; Lavoie et al. 1995). Furthermore, 
phosphorylation of HSP27 has been shown to be regulated by MK2 via p38 MAPK 
(Guay et al. 1997; Huot et al. 1997; Shi et al. 2003) leading to the hypothesis that 
the altered morphology, including increased level of stress fibres, in WS cells, 
reflects the increased activation of p38 and its downstream target HSP27. Support 
for this theory comes from the observation that treatment of young WS cells with 
the p38 inhibitor SB203580 reduced the appearance of stress fibres, reverted the 
cellular morphology to that resembling young normal cells, and reduced the 
phosphorylation of HSP27 seen in these cells (Davis et al. 2005).
The aim of this chapter is to assess whether there are any differences in 
cellular morphology and stress fibre presentation in Gl syndromes cells compared 
to normal cells. To address this a semi-quantitative examination of cellular 
morphology of the Gl syndrome panel members in the presence and absence of 
p38 inhibitors was undertaken. Furthermore, the impact of p38 inhibitors on a 
known downstream target of p38, HSP27, was assessed.
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4.2 Materials and Methods
4.2.1 Cell culture conditions
All cells were grown as monolayer cultures in EMEM and were maintained in 
a humidified incubator at 37°C, 20% O2 and 5% CO2 . For drug treatments, cells 
were fed daily with EMEM containing 2.5jaM SB203580, 2.5fxM BIRB796 or 0.5|iM 
VX745, dissolved in DMSO. Control cells were supplemented with an equivalent 
volume of DMSO added to the medium. All cells were photographed under a phase 
contrast microscope (using 10X eyepiece and 10X objective).
4.2.2 Visualisation of stress fibres
Actin staining for fluorescence microscopy was performed essentially as 
previously described (Huot et al. 1997). Cells were plated onto glass coverslips in 
EMEM and allowed to settle for 48 hours at 37°C. The cells were washed in PBS, 
fixed in 3.7% (w/v) paraformaldehyde for 20 minutes, and permeabilised with 0.1% 
(v/v) Triton X-100 for 20 minutes. F-actin was detected using fluorescein 
isothyocynate-conjugated phalloidin (33p,g/ml), diluted 1:50 in PBS for 20 minutes 
in the dark. Cells were then washed with PBS and the coverslips mounted onto 
glass slides using ProLong Gold Antifade reagent.
4.2.3 Semi-quantitative analysis of stress fibres presentation and 
morphological features
Careful observations were made of each cell strain throughout their lifespans. 
Pictures were taken at early growth stages (approximately 30 days in culture) to 
provide semi-quantitative analysis of the differences in cellular morphology and 
stress fibre presentation in each strain. An attempt was made to describe the inter- 
and intra-strain heterogeneity with regard to cell morphology and visual estimates 
of the proportions of different cellular morphologies present were made. The term 
majority refers to a feature that was shown in > 50% of the cells, and the term 
minority refers to a feature shared by < 10% of cells.
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4.2.4 Analysis of activation of HSP27 by ELISA
The following reagents are provided as part of the PathScan™ Sandwich 
ELISA kit (Cell Signaling, NEB UK).
1X ELISA lysis buffer:
1X Wash Buffer:
Sample Diluents:
TMB Substrate:
STOP Solution:
20 mM Tris (pH7.5), 150 mM NaCI, 1 mM EDTA, 1 mM 
EGTA, 1% (v/v) Triton X-100, 2.5 mM sodium 
pyrophosphate, 1 mM p-glycerolphosphate, 1 mM 
Na3V0 4 , 1 ng/ml leupeptin (#9803, Cell Signaling®). 
Made by diluting 10X stock with MilliQ H2O.
Made by diluting 20X Wash Buffer [1% (v/v) Tween-20 , 
0.5% (v/v) Kathon® (CAS# 55965-84-9) in 20X PBS] in 
MilliQ H20.
0.1% (v/v) Tween-20, <0.1% (w/v) sodium azide in 20X 
PBS.
0.05% (w/v) 3,3’,5,5’ tetramethylbenzidine, 0.1% (v/v) 
H2O2 , complex polypeptides.
0.05% (w/v) a and p unsaturated carbonyl compound.
Sample preparation, protein extraction and quantification were performed as 
previously described in Methods section 2.3.2 and 2.3.3. The level of total and 
phosphorylated HSP27 was assessed using the PathScan® Total HSP27 
Sandwich ELISA (Cat No. #7295, Cell Signaling) and PathScan® Phospho-HSP27 
(Ser78) Sandwich ELISA (Cat No. #7290, Cell Signaling) according to the 
manufacturers guidelines. Briefly, microwell strips were allowed to reach room 
temperature prior to use. WCE were diluted 1:1 in Sample Diluent and vortexed to 
mix thoroughly. 100 jaI of each diluted WCE was added to the appropriate well, 
sealed with tape and incubated overnight at 4°C to allow for best detection of the 
target protein. 100 \i\ of Sample Diluent alone was added to one well as a negative 
control for the background detection levels for each ELISA. Following incubation, 
the contents of the plate was discarded and wells were washed four times with 1X
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Wash Buffer. Following each wash the plates were tapped firmly on paper towels 
to remove any residual solution from the wells. Care was taken not to allow the 
wells to completely dry at any time and the underside of the plate was wiped to 
remove any solution that may affect the later analyses. 100 \i\ of Detection 
Antibody was added to each well and incubated for 1 hour at 37°C. Plates were 
washed as previously described before 100 \i\ of HRP-linked secondary antibody 
was added to each well and incubated for 1 hour at 37°C. Plates were washed 
again as previously described before 100 \x\ of TMB Substrate was added to each 
well for 30 minutes at room temperature and a blue colour was observed. 100 i^l of 
STOP Solution was added to quench the reaction and plates were shaken gently to 
ensure the solutions were mixed. A colour change from blue to yellow was 
observed. Spectrophotometric analysis of samples was performed at 450 nm within 
30 minutes of the STOP Solution being added. The data generated was transferred 
into Excel for further analysis. The background signal for each ELISA, given as the 
OD for the Sample Diluent alone, was subtracted from all experimental values and 
the activation of HSP27 was calculated as a ratio of the phospho-HSP27 signal: 
Total-HSP27 levels.
4.3 Results
To assess whether Gl syndrome cells show any features of cells undergoing 
stress the cellular morphology and degree of stress fibre presentation for the Gl 
panel members were compared to normal adult dermal fibroblasts. Furthermore, to 
assess whether p38 inhibitors can modulate cellular morphology, the pragmatic 
approach was taken to simultaneously grow these cells in a range of different p38 
inhibitors and perform a semi-quantitative analysis of changes in cellular 
morphology and stress-fibre presentation. Comments are made on cell size, cell 
shape and on other aspects of cellular morphology including granularity and stress 
fibre presentation; however, quantitative measurements of these features were not 
made in this chapter. Note that for the Gl panel, only cells that show some notable 
differences compared to normal cells have been described in detail in this chapter, 
full details of the cellular morphologies and stress-fibre presentation are provided
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on the accompanying disk. This chapter thus serves as a screen to identify any cell 
strains that show obvious morphological changes associated with SIPS. The 
results are summarised in section 4.3.10
4.3.1 Normal Dermal Fibroblasts
Given the variation in morphology of normal dermal fibroblasts reported in the 
literature, the cellular morphology of three strains of normal dermal fibroblasts was 
examined to provide a view of how normal cells appear in culture. In a population 
of AG16409(N) cells there is a spectrum of morphological types including small 
spindle-like cells, larger irregular-shaped cells, and enlarged, flattened cells that 
are granular in appearance (Figure 4.1b). The majority of AG16409(N) cells are 
small and spindle-like or small irregular-shaped cells (>95%) and the enlarged, 
granular cells are relatively infrequent (~2%). When stained with phalloidin-FITC, 
the majority of cells lack F-actin stress fibres; however, some stress fibres are 
observed in the enlarged cells (indicated by arrow in Figure 4.1a). Treatment with 
SB203580 has a minor effect on the size distribution of AG16049(N) cells, with the 
enlarged cells remaining in the population (Figure 4.1d). When stained with 
phalloidin-FITC, the SB203580-treated cells resemble their untreated counterparts 
(Figure 4.1c). A similar response is observed using VX745 (Figure 4.1 g, h). 
BIRB796 has the biggest effect on AG16409(N) cells (Figure 4.1f), with the 
majority of cells appearing less granular and very few enlarged cells remaining. 
This change is confirmed when stained with phalloidin-FITC as nearly all cells are 
small and lack stress fibres (Figure 4.1e).
A similar result is seen for the normal strain AG06234(N), although more 
enlarged cells are observed (~15%) compared to AG16409(N) cells. Some small 
spindle-like cells are also observed (indicated by arrow in Figure 4.2b). When 
stained with phalloidin-FITC, stress fibres are observed in some of the enlarged 
cells but these are not extensive and do not tend to be seen in the small cells 
(Figure 4.2a). Treatment with p38 inhibitors has a minor effect on the size 
distribution and cellular morphology of AG06234(N) cells, with SB203580- (Figure
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4.2 c, d), BIRB796- (Figure 4.2 e, f) and VX745- (Figure 4.2 g, h) treated 
populations showing a reduction in the number of enlarged cells.
In the third normal strain, AG13152(N),the majority of cells are enlarged and 
granular (-60%) (Figure 4.3b). Some stress fibres can be seen in the enlarged 
cells even in the bright-field images, but not in the small cells (Figure 4.3b), and 
these are oriented mostly parallel to the long axis of the cell (Figure 4.3a). 
Treatment with p38 inhibitors has a greater effect on the cellular morphology of 
AG13132(N) cells than was seen for the previous two strains, reducing the 
proportion of enlarged cells to ~10%.
In summary, inter-strain heterogeneity is observed in normal cells with regard 
to the proportion of enlarged cells. Stress fibres are observed in all three strains 
but these only occur in enlarged cells. p38 inhibitors have a minor effect on all 
three strains, reducing the proportion, but not completely removing, enlarged cells 
from the population. A consistent pattern of response to each inhibitor is observed, 
with BIRB796 having the greatest impact on cellular morphology and VX745 
having the least effect. These observations provide a view on how normal adult 
fibroblasts appear in culture, and provide a baseline against which to compare the 
morphologies and responses to p38 inhibitors in the Gl panel members.
4.3.2 Rothmund Thomson Syndrome
Young AG17524(RTS) cells resemble AG06234(N) cells, with the majority of 
cells being small and spindle-like or with an irregular shape (-90%), although some 
enlarged, granular cells (-10%) are observed (Figure 4.4b). As seen in normal 
cells, stress fibres are only observed in the enlarged cells (Figure 4.4a). A 
characteristic feature of AG17524(RTS) appears to be the presence of granular 
structures resembling abnormal Golgi structures and short, multi-directional stress 
fibres around the nuclei of some of the enlarged cells that are visible under bright- 
field microscopy (indicated by inset in Figure 4.4b). Treatment with p38 inhibitors 
has a minor effect on the morphology of AG17524(RTS) cells, similar to that seen 
for AG06234(N) cells. Some enlarged cells remain following treatment with p38
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inhibitors and these retain their stress fibre phenotype and characteristic granular 
structures around the nucleus (See accompanying disk).
AG18371 (RTS) cells are more similar to AG13152(N) cells in that the cells 
are more enlarged compared to AG17524(RTS) cells. However, AG18371(RTS) 
cells also display granular structures around the nucleus (Figure 4.4d), similar to 
those observed in AG17524(RTS) cells. In addition, prominent stress fibres that 
extend across the long-axis of the cell are observed in the enlarged cells in 
AG18371 (RTS) (as indicated by arrows Figure 4.4c). p38 inhibitors appear to have 
a slightly greater effect on AG18371 (RTS) cells compared to AG17524(RTS) cells 
but is similar to the response seen for AG13152(N) cells (See accompanying disk).
The third strain, AG18375(RTS), differs from the previous two RTS strains, 
with ~50% of cells having an unusual polygonal shape with lamellipodial-like or 
filopodial-like extensions (Figure 4.5a). Some of the enlarged AG18375(RTS) cells 
have a granular region surrounding the nucleus, similar to that seen in 
AG18371 (RTS) cells, although this is more pronounced (indicated by inset in 
Figure 4.5b). Stress fibres were observed in enlarged cells but not in the smaller 
cells (Figure 4.5a). Treatment of AG18375(RTS) cells with SB203580 and VX745 
has a similar effect as seen for AG13152(N) cells; however, BIRB796 appears to 
have a greater effect, reducing cell size and granularity of AG18375(RTS) cells 
compared to normal cells (Figure 4.5 e and f).
4.3.3 Bloom Syndrome
Young GM02932(BS) and GM02520(BS) cells resemble AG16409(N) or 
AG06234(N) cells, with the majority of cells being small with a spindle-like or 
irregular shape and only a few enlarged cells present (Figure 4.6 b and d). As seen 
in normal cells, stress fibres are only observed in the enlarged cells (Figure 4.6 a 
and c). GM02548(BS) cells contain a higher proportion of enlarged cells (~20%) 
compared to the other two BS strains, and have a similar morphology to 
AG13152(N) cells (Figure 4.6e and f). Treatment with p38 inhibitors has a similar 
effect on all three BS strains as was observed for normal cells, with a reduction in
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the proportion of enlarged cells but those that remain retaining their stress fibre 
phenotype (See accompanying disk).
4.3.4 Hutchinson-Gilford Progeria Syndrome
Young AG11498(HGPS) cells have a similar morphology to AG06234(N), 
with some enlarged cells present but the majority of cells are small and irregularly 
shaped (Figure 4.7b). The second strain AG10677(HGPS) also resembles 
AG06234(N) cells and is relatively indistinguishable from the AG11498(HGPS) 
strain (Figure 4.7d). The third strain AG01972(HGPS) shows some differences 
compared to the previous two strains in that it contains more enlarged cells 
(-35%). In addition, some cells that are very enlarged compared to normal cells, 
with an unusual cytoplasmic patterning are observed in AG01972(HGPS) cells 
(indicated by arrow in Figure 4.7f). When stained with phalloidin-FITC, extensive 
stress fibre networks are observed only in the very enlarged cells in all three 
strains (Figure 4.7 a, c and e). Treatment with p38 inhibitors had a minor effect on 
the morphology of both AG11498(HGPS) and AG10677(HGPS) cells, similar to 
that observed for AG06234(N) cells but a slightly greater impact on 
AG01972(HGPS), similar to that observed for AG13152(N) cells (See 
accompanying disk).
4.3.5 Nijmegen-Breakage Syndrome
Young RO202(NBS) and R0242(NBS) cells have a similar morphology to 
AG16049(N) cells, with the majority of cells being small (-90%) with only a few 
enlarged cells with stress fibres present (-10%) (Figure 4.8 a-d). Treatment with 
p38 inhibitors has a minor effect on the morphology of RO202(NBS) and 
R0242(NBS) cells, reducing the proportion of enlarged cells to <5% in each case, 
with only minor differences being observed between the different inhibitors used 
(See accompanying disk).
However, the third strain GM07166(NBS) has a strikingly different 
morphology to the previous two strains. Although some small spindle-like cells are 
observed, in young GM07166(NBS) cells the majority of cells are enlarged and
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granular (~85%) with extensive stress fibre networks that are visible under bright 
field microscopy (Figure 4.9b). GM07166(NBS) cells have a characteristic 
cytoplasmic pattern similar to that seen in RTS cells; however, these patterns 
appear to occur throughout the cytoplasm rather than be focussed around the 
nucleus as was seen in RTS cells (Figure 4.4 and Figure 4.5 a and b) and are 
more prominent in the enlarged cells (indicated by inset in Figure 4.9b). When 
stained with phalloidin-FITC, extensive stress fibres are observed only in the 
enlarged cells (Figure 4.9a), with the majority of stress fibres oriented parallel to 
the long axis of the cell but some being more irregularly oriented in other cells. 
Treatment with all three p38 inhibitors has a striking effect on the cellular 
morphology of GM07166(NBS) cells, reducing the proportion of enlarged cells in 
the population (Figure 4.9 c-h). In particular, BIRB796 reduces the proportion of 
enlarged cells in the population to <5% (Figure 4.9f).
4.3.6 Ligase 4 Syndrome
Young GM17523(LIG4) and GM10688(LIG4) cells resemble AG06234(N) 
cells, with the majority of cells being small and spindle-like or irregularly shaped 
and only a few enlarged cells with stress fibres (<5%) present (Figure 4.10 a-d). 
Treatment with p38 inhibitors has a minor effect on the morphology of both 
GM17523(LIG4) and GM10688(LIG4) cells, similar to that observed for normal 
cells (See accompanying disk).
4.3.7 Cockayne Syndrome A
Young GM01856(CSA) cells resemble AG06234(N) or AG16409(N) cells, 
with the majority of cells being small and spindle-like or irregularly shaped (~90%) 
(Figure 4.11b) and only a few enlarged cells with stress fibres being observed 
(~10%) (Figure 4.11a). Treatment with p38 inhibitors has a minor effect on the 
morphology of GM01856(CSA) cells (See accompanying disk), similar to that 
observed in normal cells.
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4.3.8 Dyskeratosis Congenita
In a young population of GM01774(DKC) the majority of cells are enlarged, 
flattened and granular (Figure 4.11d). Stress fibres are present in all enlarged cells 
and can be seen even in the bright-field images (Figure 4.11c and d). Staining with 
phalloidin-FITC shows that the F-actin stress fibres are mostly oriented along the 
long axis of the cell (indicated by arrows in Figure 4.11c). Treatment with p38 
inhibitors has a minor effect on cellular morphology, with cells having a less 
granular appearance overall; however, the proportion of enlarged cells in the 
population is relatively unchanged and these still have stress fibres (See 
accompanying disk).
4.3.9 Seckel Syndrome
Young GM09812(SS) cells are reminiscent of AG16409(N) and AG06234(N) 
cells, with the majority of cells being small (>95%) with only very few enlarged cells 
observed (<5%) (Figure 4.11f). When stained with phalloidin-FITC, stress fibres 
are observed only in the few enlarged cells (Figure 4.11e). Treatment with p38 
inhibitors has a minor effect on the morphology of GM09812(SS) cells (See 
accompanying disk).
In contrast, the GM18366(SS) strain has a strikingly different morphology to 
that observed for GM09812(SS) cells, with -50% of cells being enlarged and 
granular with few small spindle-like cells observed (<5%) (Figure 4.12b). Stress 
fibres are only observed in the enlarged cells (Figure 4.12a) and although the 
majority of GM18366(SS) cells are enlarged with stress fibres these do not appear 
to be as extensive as seen in other strains, such as GM07166(NBS) cells (Figure 
4.9a). Treatment with p38 inhibitors has a striking effect on GM18366(SS) cells, 
reducing the proportion of enlarged cells with stress fibres and increasing the 
proportion of small cells (Figure 4.12 c-h). In particular, BIRB796 reduces the 
proportion of enlarged cells with stress fibres to <10% (Figure 4.12e and f).
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4.3.10 Summary of stress fibre presentation and cellular morphology
Given that stress fibre presentation appears to be related to cell size, a 
semi-quantitative analysis of the proportion of enlarged cells in Gl syndromes and 
normal cells was undertaken and the results are summarised in Table 4.1. The 
following comparison of cellular morphologies was undertaken at early growth 
stages (approximately 30 days in culture). The proportion of enlarged cells in 
AG16409(N) is relatively low (~5%), with the majority of cells being small and 
spindle-like. In contrast, AG13152(N) cells show a higher proportion of enlarged 
cells (~45%), whereas AG06234(N) have an intermediate morphology. These data 
suggest that heterogeneity in cell morphology can be detected between different 
primary fibroblast strains that have no known defect. It is therefore expected that 
Gl syndrome cells may have an added level of heterogeneity as a result of the 
underlying molecular defect. When comparing the morphology of Gl syndrome 
cells, the range of morphologies observed for normal cell strains were taken into 
account.
The following section provides a summary of:
1. The cellular morphology of young untreated normal and Gl syndrome cells.
2. The effect of p38 inhibitors on cellular morphology.
1. Comparison of cellular morphology
AG17524(RTS) cells were shown to have a relatively normal appearance 
with low numbers of enlarged cells. AG18371(RTS) cells had a higher proportion of 
enlarged cells than seen for AG17524 but these were estimated to be a similar size 
to those observed in AG13152(N) cells. The AG18375(RTS) strain showed some 
differences compared to the other two RTS strains in that the enlarged cells had an 
unusual polygonal shape and were present in higher numbers than observed in the 
other RTS strains; however, again these were estimated to be of a similar size to 
those observed in AG13152(N) cells. GM02520(BS) and GM02932(BS) had a 
similar morphology to AG06234(N), although the proportion of enlarged cells was
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slightly higher in these strains compared to AG06234(N) cells. GM02548(BS) cells 
also resembled normal cells, but had a higher proportion of enlarged cells 
compared to the other two BS strains. The proportion of enlarged cells in all three 
HGPS strains was at the top end of the normal spectrum, with AG10677(HGPS) 
and AG11498(HGPS) cells resembling AG13152(N) cells. AG01972(HGPS) cells 
also had a similar appearance to AG13152(N) cells; however, some very enlarged 
cells with unusual cytoplasmic patterning and prominent stress fibres were 
observed. In NBS, the RO202(NBS) and R0242(NBS) strains resembled 
AG16409(N) cells, with very few enlarged cells present. In contrast, 
GM07166(NBS) cells had a strikingly different morphology, with a much higher 
proportion of enlarged cells (-85%) with prominent stress fibres compared to all of 
the normal strains. GM01856(CSA) cells have a similar appearance to 
AG16409(N) or AG06234(N) cells with the majority of cells being small and 
spindle-like; however, the enlarged cells present appear to be larger than those 
observed in normal cells. Both GM17523(LIG4) and GM16088(LIG4) have a similar 
morphology to AG06234(N) cells, with the majority of cells being small and only a 
few enlarged cells observed. DKC cells show an altered morphology to normal 
cells, with a much higher proportion of enlarged cells (-60%) and prominent stress 
fibres. GM18366(SS) have a similar morphology to that observed for 
GM01774(DKC) cells, with a higher proportion of enlarged cells (-50%) than 
normal cells, whereas GM09812(SS) cells resemble AG06234(N) cells, with few 
enlarged cells observed.
To further assess the usefulness of changes in morphology as a biomarker 
of commitment to senescence, a correlative study of the proportion of enlarged 
cells versus the maximum lifespan of each of the cell strains was undertaken. 
Figure 4.13 shows a negative correlation between the proportion of enlarged cells 
and lifespan, suggesting that the strains that contain the greatest number of 
enlarged cells tend to have the shortest lifespan. Therefore, the proportion of 
enlarged cells appears to be a relatively reliable marker of commitment to 
senescence.
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2. Effects of p38 inhibitors
The effects of p38 inhibitors on cellular morphology are summarised in 
Table 4.2. In general, treatment with p38 inhibitors reduced the proportion of 
enlarged cells in both normal and Gl syndrome cells, with BIRB796 having the 
greatest impact and VX745 the least impact on morphology. p38 inhibitors have a 
minor effect on AG16409(N) cells with the proportion of enlarged cells being 
relatively unchanged. AG13152(N) cells show the greatest response, with the 
proportion of enlarged cells being reduced from -45% to -10% in response to all 
three inhibitors, and AG06234(N) cells have an intermediate response. Given the 
problems associated with this interstrain heterogeneity, the responses to p38 
inhibitors in the Gl panel members were assessed on a strain-by-strain basis using 
a two-tailed z-test. Although some cell strains, such as GM07166(NBS), showed a 
marked change in cellular morphology in response to p38 inhibitors, none of the 
differences observed were found to be statistical significant. It is likely that this is 
due to the heterogeneity in cellular morphologies observed for the three normal 
strains.
4.3.11 Activation of HSP27: A downstream target of p38
To assess the activation of p38-mediated stress pathways, the activation of 
a downstream target of p38, HSP27, was examined. These data show that p- 
HSP27 can be detected in all cells and that p38 inhibitors reduce the level of p- 
HSP27 (Figure 4.14). In general, BIRB796 was seen to have the greatest impact 
on p-HSP27 levels, whereas VX745 had the least effect. This is consistent with the 
pattern of effect of these inhibitors on both the morphology and growth potential 
(Chapter 3) of these cells. Inter-strain differences in p-HSP27 levels are observed 
in normal cells. AG16409(N) shows the lowest level of p-HSP27, AG06234(N) 
shows the intermediate level and AG13152(N) cells show the highest level of p- 
HSP27. Treatment with p38 inhibitors has the greatest effect on AG13152(N) cells 
and the least effect on AG16409(N) cells, reducing the levels of p-HSP27 to similar 
levels in all three strains. When compared to normal cells, GM01856(CSA) cells 
show a similar level of p-HSP27 to AG13152(N) cells, however, p38 inhibitors have
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a reduced effect on GM01856(CSA) cells compared to normal cells. GM09812(SS) 
cells have a low level of p-HSP27 and p38 inhibitors only have a minor effect on 
this, whereas GM18366(SS) cells have a higher level of p-HSP27, similar to that 
seen in AG13152(N) cells. Although, p38 inhibitors reduce the level of p-HSP27 in 
GM18366(SS) cells the effect is not as great as seen for normal cells. In NBS, 
RO202(NBS) and R0242(NBS) show low levels of p-HSP27, comparable to 
AG06234(N) cells, and have a normal response to p38 inhibitors; however, 
GM07166(NBS) cells show a higher than normal level of p-HSP27. Treatment of 
GM07166(NBS) has a larger impact on the level of p-HSP27 than seen for the 
other two NBS strains but is comparable to those seen for AG13152(N) cells. 
GM02520(BS) and GM02932(BS) show a normal level of p-HSP27, similar to the 
level observed for AG06234(N), and show a normal response to p38 inhibitors. 
Although the level of p-HSP27 in GM02548(BS) was higher than seen in the other 
two BS strains, it was still within the normal range. Treatment of GM02548(BS) 
with p38 inhibitors had a larger impact than seen for the other two BS strains but is 
comparable to those seen for normal cells. In RTS cells, inter-strain heterogeneity 
in p-HSP27 levels are observed, with AG17524(RTS) showing the lowest level of 
P-HSP27 and AG18375(RTS) showing the highest level, similar to that observed 
for AG13152(N) cells. AG11498(HGPS) and AG01972(HGPS) cells have a similar 
level of p-HSP27 to AG13152(N) cells, whereas AG10677(HGPS) has a lower 
level of p-HSP27, similar to that seen in AG06234(N) cells. Treatment with p38 
inhibitors reduces the level of p-HSP27 to a similar level in all three HGPS strains, 
therefore having the largest effect on AG11498(HGPS) and AG01972(HGPS) cells. 
Both strains of LIG4 cells and DKC show a low level of p-HSP27 and p38 inhibitors 
have a minor effect on these cells.
Overall there appears to be a correlation between the level of p-HSP27 and 
cellular morphology in these cells. In general the strains that show an enlarged 
morphology also show increased levels of p-HSP27. For example, GM18366(SS) 
cells have an enlarged morphology and show increased levels of p-HSP27 
compared to GM09812(SS) cells. Similarly, GM7166(NBS) cells show an enlarged 
morphology and increased p-HSP27 levels compared to the other two NBS strains.
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In RTS cells, AG18375 has the highest proportion of enlarged cells and the highest 
level of p-HSP27, AG18371 has the intermediate morphology and p-HSP27 levels 
and AG17524 has the smallest proportion of enlarged cells and the lowest levels of 
P-HSP27. A similar pattern is observed for HGPS cells, in which GM09172 cells 
have the highest proportion of enlarged cells and the highest p-HSP27 levels. 
However, DKC show an unexpectedly low level of p-HSP27 given the high 
proportion of enlarged cells observed in this strain. In addition, those strains that 
show the highest level of p-HSP27 tend to show the greatest response to p38 
inhibitors, for example GM7166(NBS), AG18375(RTS) and AG01972(HGPS).
4.4 Discussion
A full morphological characterisation of these cells has proved problematic 
considering the inter-strain heterogeneity in cellular morphology observed within 
the same syndrome and the difficulty in providing quantitative analysis of 
morphological characteristics. Another complication for the study was the uncertain 
passage history of the cell strains used as discussed in the previous chapter. The 
data presented here therefore provide a cross section of morphological changes 
that could arise from time in culture. Given the extensive number of strains, the 
pragmatic option was taken of an unbiased screen of cellular morphology and 
stress fibre presentation in all of the cells using the standard technique 
(summarised in Table 4.1).
Examination of the morphology of normal cells revealed inter-strain 
differences in the proportion of enlarged cells that was thought to be indicative of 
differences in the level of commitment to senescence. Given the uncertain 
replicative histories for some of these strains, it is also possible that the differences 
in morphology reflect differences in the level of replicative senescence since it is 
widely accepted that cells undergo morphological changes as they progress 
towards replicative senescence (Campisi 1999). Support for this theory came from 
the observation that the proportion of enlarged cells appears to correlate to the 
lifespan. For example, the AG13152(N) strain has the shortest lifespan and highest 
proportion of enlarged cells, whereas the AG16409(N) strain has the longest
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lifespan and lowest proportion of enlarged cells. The findings underline the 
complexity associated with morphological characterisation of primary fibroblasts 
with uncertain replicative histories
Despite the known caveats, the findings suggest that differences in 
morphology, given as the proportion of enlarged cells, correlates with p-HSP27 
levels. For example, the AG13152(N) strain show the highest level of p-HSP27, 
whereas the AG16409(N) strain show the lowest level. Moreover, the impact of p38 
inhibitors appears to correlate with changes in morphology, with AG16409(N) cells 
showing a minor response to p38 inhibitors, whereas AG13152(N) cells show the 
greatest response. Overall, the findings support the view that primary cell 
populations consist of a subset of cells that are undergoing replicative senescence 
and a subset of cells that are undergoing SIPS. The working hypothesis here is 
that primary Gl syndrome cell populations will also contain a subset of cells that 
are undergoing replicative senescence but may also contain a higher proportion of 
cells that are undergoing SIPS due to ongoing replicative stress.
As expected inter-strain heterogeneity in cellular morphology was observed in 
the Gl syndrome panel. Overall, the majority of Gl syndrome cell strains had a 
similar morphology to normal cells, with the exception of GM07166(NBS), 
GM01774(DKC), GM18366(SS) and AG18375(RTS), which had a higher 
proportion of enlarged cells that were granular and contained numerous stress 
fibres. The ratio of p-HSP27:HSP27 is higher than normal in both GM07166(NBS) 
and GM18366(SS), but is unexpectedly low in GM01774(DKC) given the enlarged 
morphology of DKC cells and impact of the inhibitors on growth potential of these 
cells. Analysis of the contribution of SIPS to DKC cells is complicated by the fact 
that DKC is caused by mutations in components of telomerase, suggesting that the 
truncated lifespan of DKC cells is due to the presence of very short telomeres. The 
observation that p38 inhibitors have a minor effect on the morphology of 
GM01774(DKC) cells suggests that these cells are indeed simply closer to the end 
of their replicative lifespan. In contrast, treatment of both GM07166(NBS) and 
GM18366(SS) with p38 inhibitors has a striking effect on both their morphology
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and on the level of p-HSP27, suggesting a role for p38-mediated SIPS in these 
cells.
In conclusion, the main findings of this chapter are:
• Stress fibre presentation appears to be related to cell size rather than 
differences in underlying stress signalling, therefore cell size rather than 
stress fibre presentation appears to be more reliable marker of differences 
in replicative potential.
• GM07166(NBS), GM18366(SS), AG18375(RTS) and GM01774(DKC) show 
an altered cellular morphology, including a higher proportion of cells that are 
enlarged and granular, indicating a potential increase in the degree of SIPS 
occurring in these cells.
• Treatment with p38 inhibitors consistently reduces the proportion of 
enlarged, granular cells, with BIRB796 having the greatest effect.
• GM07166(NBS) and GM18366(SS) show the change in cellular morphology 
(reduction in proportion of enlarged cells) following treatment with p38 
inhibitors.
• Differences in morphology, given as the proportion of enlarged cells, 
appears to correlate with the ratio of p-HSP27:HSP27, with GM07166(NBS) 
having the highest proportion of enlarged cells and the highest p-HSP27 
levels.
This chapter raises issues associated with qualitative assessment of cellular 
morphology in heterogeneous populations and the need for quantitative methods of 
measuring cell enlargement, as an indicator of proliferation restraint. These issues 
are addressed in chapter 8.
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Figure 4.1. Cellular morphology and stress fibre presentation in A G 16409(N ) 
fibroblasts.
Cells were grown in the absence (a and b) or presence of SB203580 (c and d), 
BIRB796 (e and f) or VX745 (g and h). Panels a, c, e and g show visualisation of F- 
actin stress fibres stained with phalloidin-FITC and DAPI staining of the nuclei. Panels 
b, d, f and h show phase contrast pictures. White bar represents 100 pm.
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Figure 4.2. Cellular morphology and stress fibre presentation in A G 06234(N ) 
fibroblasts.
Panels are as in Figure 4.1 White bar represents 100 ^im. Arrow in (b) indicates small 
spindle-like cell.
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Figure 4.3. Cellular morphology and stress fibre presentation in A G 13152(N ) 
fibroblasts.
Panels are as in Figure 4.1. White bar represents 100 fim.
Phase contrast
134
Phase contrastPhalloidin-FITC (actin)
AG17524(RTS)
AG 18371 (RTS)
Figure 4.4. Cellular morphology and stress fibre presentation in untreated 
AG 17524(R TS) and A G 18371(R TS ) fibroblasts.
Panels (a) and (c) show visualisation of F-actin stress fibres in A G 17524(R TS) 
and A G 18371 (R TS) cells stained with phalloidin-FITC, respectively. Panels (b) 
and (d) show phase contrast pictures of A G 17542(R TS) and A G 18371(R TS), 
respectively. White bar represents 100 urn.
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Figure 4.5. Cellular morphology and stress fibre presentation in A G 18375(R TS ) 
fibroblasts.
Panels are as in Figure 4.1. Inset in (b) shows a magnified image of an enlarged cell.
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Figure 4.6. Cellular morphology and stress fibre presentation in untreated 
G M 02932(BS), G M 02520(BS) and G M 02548(BS) fibroblasts.
Panels (a) and (c) show visualisation of F-actin stress fibres in G M 02932(BS), 
GM 02520(BS) and G M 02548(BS) cells stained with phalloidin-FITC, respectively. 
Panels (b) and (d) show phase contrast pictures of G M 02932(BS), G M 02520(B S) 
and G M 02548(BS), respectively. White bar represents 100 \ i m .
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Figure 4.7. Cellular morphology and stress fibre presentation in untreated 
A G 11498(H G PS), A G 10677(H G PS ) and A G 01972(H G PS) fibroblasts.
Panels (a, c and e) show visualisation of F-actin stress fibres in A G 11498(H G PS ), 
A G 10677(H G PS) and A G 01972(H G PS) cells stained with phalloidin-FITC, 
respectively. Panels (b, d and f) show phase contrast pictures of A G 11498(H G PS), 
A G 10677(H G PS) and A G 01972(H G PS), respectively. White bar represents 100 
nm. Arrow in (f) indicates presence of enlarged cell will unusual cytoplasmic 
patterning in A G 01972(H G PS) cells.
Phase contrast
138
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R0242(NBS)
RO202(NBS)
Figure 4.8. Cellular morphology and stress fibre presentation in untreated R 0242(N B S )  
and RO202(NBS) fibroblasts.
Panels (a) and (c) show visualisation of F-actin stress fibres in R 0242(N B S ) and 
RO202(NBS) cells stained with phalloidin-FITC, respectively. Panels (b) and (d) show 
phase contrast pictures of R 0242(N B S ) and RO202(NBS), respectively. White bar 
represents 100 pm.
139
Phalloidin-FITC (actin)
a
c
SB
e
BIRB
g
Figure 4.9. Cellular morphology and stress fibre presentation in G M 07166(N B S) 
fibroblasts.
Panels are as in Figure 4.1 Inset in (b) shows a magnified image of an enlarged cell.
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Figure 4.10. Cellular morphology and stress fibre presentation in untreated 
GM17523(LIG4) and GM16088(LIG4) fibroblasts.
Panels (a) and (c) show visualisation of F-actin stress fibres in GM17523(LIG4) 
and GM16088(LIG4) cells stained with phalloidin-FITC, respectively. Note that 
GM17523(LIG4) cells are also stained with DAPI. Panels (b) and (d) show phase 
contrast pictures of GM17523(LIG4) and GM16088(LIG4), respectively. White bar 
represents 100 pm.
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Figure 4.11. Stress fibre presentation and cellular morphology in untreated GM01856(CSA) 
(a and b), GM01774(DKC) (c and d) and GM09812(SS) (e and f) fibroblasts.
White bar represents 100 pm.
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Figure 4.12. Cellular morphology and stress fibre presentation in GM18366(SS) 
fibroblasts.
Cells were grown in the absence (a and b) or presence of SB203580 (c and d), BIRB796 
(e and f) or VX745 (g and h). Panels are as in Figure 4.1
Phase contrast
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Table 4.1. Summary of stress fibre phenotype of adult dermal fibroblasts from normal and Gl 
individuals
Syndrome
Proportion of 
enlarged cells
in the popn (%)
* Stress fibre phenotype
Normal 5-45%
Stress fibres only observed in the enlarged cells in the 
population.
RTS 10-30%
Stress fibres only observed in enlarged cells, but not all 
enlarged cells possess stress fibres. Most stress fibres are 
oriented parallel to long axis of the cell but in some cells stress 
fibres are shorter and their directionality is less regular. In 
some cells these irregularly orientated stress fibres are 
present throughout the cytoplasm but in others are 
concentrated around the nucleus.
BS 10-20%
Resemble normal cells, with stress fibres only being observed 
in the few enlarged cells in the population.
HGPS 30-40%
Inter-strain heterogeneity observed for stress fibre 
presentation. Some enlarged cells contain extensive stress 
fibres whereas others contain relatively few. Most stress fibres 
are oriented parallel to long axis of the cell.
NBS 5-85%
Inter-strain heterogeneity observed for stress fibre 
presentation. Stress fibres only observed in enlarged cells and 
these are oriented parallel to long axis of the cell.
LIG4 -10%
Resemble normal cells, with stress fibres only being observed 
in the few enlarged cells in the population.
CSA -10%
Resemble normal cells, with stress fibres only being observed 
in the few enlarged cells in the population.
DKC -60%
The majority of cells are enlarged with extensive stress fibres. 
Differences in the number of stress fibres in cells of similar 
sizes are observed. Most stress fibres are oriented parallel to 
the long axis of the cell.
SS 5-50%
Inter-strain heterogeneity observed for stress fibre 
presentation. Stress fibres only present in enlarged cells but 
these are not as extensive as seen in RTS or NBS cells.
* % of enlarged cells estimated from three fields each containing >30 cells quoting to an 
accuracy of +/- 5%.
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Figure 4.13. Correlation between cellular morphology and maximum lifespan.
The proportion of enlarged cells is estimated from single fields containing >50 cells 
quoting to an accuracy of +/- 5% and is used as a semi-quantitative measure of cellular 
morphology. The three normal strains are indicated by open symbols: AG16409 (A), 
donor age 12 years; AG06234 (□ ), donor age 17 years; AG13152 (O), donor age 80 
years. The trendline represents the logarithmic regression of these data and shows that 
there is a negative correlation between the proportion of enlarged cells and maximum 
lifespan. The form of this regression and the R2 value are given.
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Table 4.2. Summary of the impact of p38 inhibitors on the morphology of normal and Gl 
syndrome fibroblasts
Cell strain
Drug
Treatment
Proportion 
of enlarged 
cells in pop" 
(%) *
Change in 
proportion of 
enlarged cells 
(%) z value P-value b
AG16409(N) iigjiiiaij
SB2O3580 I M M I H N i
8IRB796 pillMlBIMf
VX745 MBllMll
AG13152(N)
S8203580 M M H j W i
BIRB796 i B i p B l
VX74S M p N IM W
AG0&3404) ipiilgis
$8203580
BIRB796
VX745 10
AG18375(RTS) - 30
SB203580 10 -67 -0.440 0.66
BIRB796 10 -67 -0.759 0.45
VX745 15 -50 -0.332 0.74
AG17524(RTS) - 10
SB203580 5 -50 -0.044 0.97
BIRB796 5 -50 -0.332 0.74
VX745 5 -50 -0.332 0.74
AG 18371 (RTS) - 20
SB203580 5 -75 -0.638 0.52
BIRB796 5 -75 -0.973 0.33
VX745 10 -50 -0.332 0.74
GM02932(BS) - 15
SB203580 5 -67 -0.440 0.66
BIRB796 5 -67 -0.759 0.45
VX745 15 0 0.949 0.34
GM02548(BS) - 20
SB203580 5 -75 -0.638 0.52
BIRB796 5 -75 -0.973 0.33
VX745 10 -50 -0.332 0.74
GM02520(BS) - 10
SB203580 10 0 1.145 0.25
BIRB796 10 0 0.949 0.34
VX745 10 0 0.949 0.34
AG11498(HGPS) - 30
SB203580 20 -33 0.352 0.73
BIRB796 25 -17 0.522 0.60
VX745 30 0 0.949 0.34
AG10677(HGPS) - 30
SB203580 10 -67 -0.440 0.66
BIRB796 10 -67 -0.759 0.45
VX745 20 -33 0.095 0.92
GM01972(HGPS) - 40
SB203580 15 -63 -0.341 0.73
BIRB796 5 -88 -1.293 0.20
VX745 10 -75 -0.973 0.33
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Table 4.2 continued
Cell strain
Drug
Treatment
Proportion 
of enlarged 
ceils in pop" 
<%) •
Change in 
proportion of 
enlarged cells 
(%) z value P-value b
RO202(NBS) - 5
SB203580 5 0 1.145 0.25
BIRB796 5 0 0.949 0.34
VX745 5 0 0.949 0.34
R0242(NBS) - 10
SB203580 5 -50 -0.044 0.97
BIRB796 5 -50 -0.332 0.74
VX745 5 -50 -0.332 0.74
GM07166(NBS) - 85
SB203580 15 -82 -0.813 0.42
BIRB796 5 -94 -1.463 0.14
VX745 25 -71 -0.860 0.39
GM16088(LIG4) - 10
SB203580 5 -50 -0.044 0.97
BIRB796 5 -50 -0.332 0.74
VX745 5 -50 -0.332 0.74
GM17523(LIG4) - 10
SB203580 5 -50 -0.044 0.97
BIRB796 5 -50 -0.332 0.74
VX745 5 -50 -0.332 0.74
GM01856(CSA) - 10
SB203580 10 0 1.145 0.25
BIRB796 5 -50 -0.332 0.74
VX745 10 0 0.949 0.34
GM01744(DKC) - 60
SB203580 40 -33 0.352 0.73
BIRB796 40 -33 0.095 0.92
VX745 30 -50 -0.332 0.74
GM18366(SS) - 50
SB203580 35 -30 0.431 0.67
BIRB796 0 -100 -1.614 0.11
VX745 10 -80 -1.101 0.27
GM09812(SS) - 5
SB203580 5 0 1.145 0.25
BIRB796 5 0 0.949 0.34
VX745 5 0 0.949 0.34
aThe proportion of enlarged cells is estimated from three fields each containing 
>30 cells. Enlargement is a subjective measurement and was not 
quantitatively measured.
b two-tailed z-test. A significance level of <0.05 is used.
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Figure 4.14. Activation of HSP27 in normal and Gl syndrome fibroblasts.
Cells were grown in the presence and absence of SB203580, BIRB796 and VX745. Activation of HSP27 in each strain is given as the ratio of 
phospho-HSP27/Total-HSP27 as measured by ELISA (OD measured at 450 nm). The dotted line indicates the mean HSP27 ratio for untreated 
normal cells.
Chapter 5 Immortalisation of primary fibroblasts: 
model systems not limited by in vitro lifespan
5.1 Introduction
The current model for primary somatic cell senescence is entry into an 
irreversible block in Gi and or G2/M phase, effectively representing an exit from the 
cell cycle that is realised as senescence (Hayflick 1965; Hayflick and Moorhead 
1961). Senescence as a phenomenon can be induced either by progressive 
shortening of telomeres during ongoing cell division (Harley et al. 1990; Olovnikov 
1973), or by exposure to stress (Chen et al. 2007). The finding that senescence 
can be induced in a telomere-independent manner has raised speculations about 
the existence of multiple ‘senescence clocks’ and ensuing lively debates about 
alternative explanations (Drayton and Peters 2002). Analysis of senescence 
mechanisms have been further complicated by recent reports that in vitro cultures 
of human dermal fibroblasts are not homogeneous but in fact appear to be mosaics 
of cells under going different mechanisms of senescence induction that progress in 
parallel (Beausejour et al. 2003; Itahana et al. 2003). To disassemble this 
complexity and the inherent heterogeneity of primary cell systems here it is 
proposed that removal of a primary senescence trigger, telomere attrition, will allow 
for a coherent comparison to be made between the Gl panel members without the 
prejudice associated with this origin of stress signalling. This would allow 
comparison of cells undergoing telomere attrition and those relieved of that origin 
of stress. Although this approach would remove the ability to study replicative 
senescence in these cells, it would allow comparison of cell cycle exit influences 
that is independent of stress signals arising from telomere shortening i.e. those that 
give rise to SIPS. Further, it would permit a more rational comparison of cell cycle 
dynamics and differences in constitutive levels of p38 activation associated with a 
given genetic background.
In WS, it is hypothesised that while the shortening of telomeres may be the 
main driving force for senescence, ongoing replication stress could trigger SIPS in
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a subset of WS cells. Support for this theory comes from the finding that ectopic 
expression of hTert prevents the accelerated senescence seen in WS fibroblasts 
(Choi et al. 2001; Ouellette et al. 2000; Wyllie et al. 2000), without correcting the 
slow growth and senescent-like morphology seen in their primary counterparts 
(Davis et al. 2005; Davis et al. 2006). In addition, a reduction, but not removal, of 
p38 activation is observed in hTert immortalised WS cells (Davis et al. 2005), 
consistent with the lack of telomere Shortening that is expected in a telomerase- 
expressing culture. The role of SIPS in other Gl syndromes is relatively unknown; 
however, evidence from the literature shows that ectopic expression of hTert can 
immortalise cells from other Gl syndrome cells without altering their phenotypic 
characteristics (Ouellette et al. 2000), suggesting a possible role for telomere- 
independent mechanisms of senescence induction in these cells.
Recent evidence has suggested that in addition to telomere shortening, stress 
signalling via p38 may play a role in establishing M1 senescence in normal cells. 
For example, activated p38 is present in normal WI38 and MRC5 cells at M1 but 
not in young cells (Iwasa et al. 2003). Late passage WS cells have also been 
shown to have activated p38 (Davis et al. 2005), suggesting that the pathways 
leading to M1 in WS cells resemble those in normal cells. The finding that the rate 
of telomere erosion per cell division is not increased in WS cultures (Baird et al. 
2004) suggests that telomere-independent mechanisms of senescence may 
contribute to the shortened replicative lifespan seen in WS cultures. The finding 
that activation of p38 plays a significant role in SIPS (Guay et al. 1997; Huot et al. 
1997), together with the observation that WS cells show features of cells 
undergoing stress (Davis et al. 2005), lead to the hypothesis that WS cells are 
subject to SIPS. Indeed, p38 was found to be activated in young WS cells as 
shown by presence of phosphorylated p38, associated with high levels of p21WAF1 
and phosphorylated HSP27 (Davis et al. 2005). To date, less is known about the 
activation status of p38 in other Gl syndrome cells. However, recently, Davis et al 
described low levels of phosphorylated p38 and its downstream target HSP27 in 
AT cells, comparable to those observed for normal controls (Davis and Kipling
2009). These data strongly suggest that the p38 pathway is not significantly
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activated in AT cells. The same study also assessed the activation of the JNKs in 
AT cells, since these are known to be activated in response to stress (Davis 2000), 
and showed that in AT fibroblasts activated JNK1/2 is barely detectable (Davis and 
Kipling 2009). Together these data suggest that the relative involvement of p38 to 
SIPS may differ between Gl syndromes.
Given the difficulties of comparing Gl syndrome fibroblasts that display 
differences in the degree of commitment to cell cycle exit/senescence the primary 
aim of this chapter is to generate a panel for more extensive studies in which 
lifespan is not limited. Conceptually, this provides a model in which the stress 
signals that may arise from telomere attrition are removed to allow further 
investigation into the level of commitment to SIPS in Gl syndrome cells. 
Furthermore, since there is no evidence in the literature that RTS cells can be 
immortalised by ectopic expression of hTert, this study will provide novel 
information on the ability of RTS cells to be immortalised. The experimental 
objectives of this chapter are therefore to generate hTert immortalised cultures for 
each panel member and to assess the p38 activation status of these cells 
compared to their primary counterparts.
5.2 Materials and Methods
5.2.1 Retroviral gene transfer
All manipulations during the retroviral infection procedure were undertaken 
with significant caution and in accordance with the Advisory committee on Genetic 
Modification (ACGM) guidelines.
Amphotropic retrovirus vectors expressing the HPV16 E6 oncoprotein from a 
pLXSN construct, packaged in PA317 cells (Halbert et al. 1991), were kindly 
provided by Dr. Denise Galloway (Seattle, Washington). pBABE-hTert (Wyllie et 
al. 2000) is an amphotropic retrovirus expressing the catalytic protein subunit of 
human telomerase (hTert) constructed by cloning the EcoRI insert of pGRN121 
(Nakamura et al. 1997) into a pBABE-puro vector (Morgenstern and Land 1990).
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For control infections pBABE-puro vectors packaged in ^CRIP cells were used 
(Wyllie et al. 2000).
Gene transfer was carried out as described previously (Bond et al. 1994).
100.000 cells were plated onto 100 mm culture dishes in EMEM and left to settle 
for 48 hrs at 37°C after which polybrene was added to a final concentration of 8 
pig/ml for 1 hour. The medium was then replaced with 5 ml viral supernatant in 
growth medium (either pBABE-hTert-puro or pBABE-puro at approximately 105 
viral particles per ml) and the cells incubated at 37°C for 24 hrs. For each gene 
transfer the retroviral infections were done twice. 24 hrs after the second infection, 
fibroblast cultures were passed into EMEM containing puromycin (2.5 M9/m0 and 
surviving cells after five days were transferred to T75 culture vessels and cultured 
in EMEM containing puromycin. Telomerase activity was subsequently confirmed 
by TRAP assay (as described in section 2.4) and immortality was determined by 
growth of the cells beyond the known replicative senescence limit for the primary 
cells.
5.3 Results
5.3.1 Ectopic expression of the catalytic subunit of telomerase, hTert, in
RTS primary adult dermal fibroblasts results in the reconstitution of
telomerase activity
AG18371(RTS) fibroblasts were transduced with an amphotropic pBABE 
retroviral vector co-expressing hTert cDNA, and the puromycin resistance gene. In 
parallel, primary AG18371(RTS) fibroblasts were also infected with an empty 
pBABE-puro (control) vector. RTS cells transduced with both the pBABE-hTert- 
puro or the empty control vector were designated as 0 PD post-transfection and 
were assayed for telomerase activity using the TRAP assay (Kim et al. 1994). 
Negative controls were prepared for each lysate by incubating an aliquot of each 
sample at 85°C for 10 minutes to destroy telomerase activity as previously 
described in section 2.4.1. In addition, cell extracts prepared from the adenovirus 
5-transformed 293 cell line, derived from HEK cells and known to express
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telomerase, were used as a positive control. TRAP reaction products appear as a 
ladder of bands with a periodicity corresponding to the size of the tandem telomeric 
repeats and indicate reconstitution of telomerase activity following ectopic 
expression of hTert.
The retroviral infection of primary RTS fibroblasts with the empty pBABE- 
puro vector did not confer telomerase activity (Figure 5.1, lanes 1 and 2). Similarly, 
telomerase activity was not detected in the heat-treated samples (Figure 5.1, lanes 
2, 4 and 6). Conversely, telomerase activity was detected in the non-heat treated 
samples prepared from primary RTS fibroblasts infected with pBABE- hTert-puro 
(Figure 5.1, lane 3). These data suggest that the ectopic expression of hTert is 
sufficient to restore telomerase activity in vitro in RTS primary fibroblasts.
5.3.2 Ectopic expression of hTert in primary RTS dermal fibroblasts extends 
proliferative lifespan
Following retroviral infection, AG18371 (RTS) fibroblast populations were 
propagated under routine culture conditions (see section 2.1). Primary 
AG18371 (RTS) cells, infected with an empty pBABE-puro (control) vector, were 
propagated as polyclonal populations and passaged continuously following 
puromycin selection until the cultures ceased proliferation. Primary AG18371 (RTS) 
cells, transduced with an empty pBABE-puro vector, ceased proliferation at 33.8 
PDs and 189 days in culture post retroviral infection. Between days 137 and 189 
no population doublings were achieved. Conversely, the polyclonal population of 
RTS cells infected with pBABE-hTert-puro, was propagated for 456 days in culture 
and achieved ~93 PDs. This culture displayed a logarithmic growth pattern with a 
growth rate of 0.23 PDs/Day.
5.3.3 Ectopic expression of hTert in Gl syndrome fibroblasts results in the 
reconstitution of telomerase activity
From the panel of Gl syndrome fibroblasts previously characterised in 
chapters 3 and 4, one strain from each syndrome was chosen for immortalisation 
by hTert. The criteria for selection of the Gl syndrome strains were based on
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observations of alterations in cellular morphology and/or growth potential that are 
indicative of SIPS in these cells. As such, the following strains were infected with 
an amphotropic retrovirus encoding hTert: GM02548(BS), GM01856(CSA), 
GM07166(NBS), GM17523(LIG4), AG18371(RTS), and AG11498(HGPS). The 
decision not to include DKC in this panel was made based on the fact that DKC 
has a known defect in hTert, therefore restoration of telomerase activity may 
confound the study. All cells were subsequently assayed for telomerase activity 
using the TRAP assay as previously described. Negative controls were prepared 
for each lysate (as previously described), by incubating an aliquot of each sample 
at 85°C for 10 minutes to destroy telomerase activity. Telomerase activity was 
detected in all of the non heat-treated samples (Figure 5.3, lanes 1, 3, 5, 7, 9, 11 
and 13), whereas telomerase activity was not detected in heat-treated samples 
(Figure 5.3, lanes 2, 4, 6, 8, 10, 12 and 14). These data suggest that the ectopic 
expression of hTert is sufficient to restore telomerase activity in vitro in primary Gl 
panel fibroblasts.
5.3.4 Ectopic expression of hTert in primary Gl syndrome fibroblasts
extends proliferative lifespan
Following retroviral infection, Gl syndrome fibroblast populations were 
propagated under routine culture conditions (see section 2.1) in media containing 
puromycin. Cultures, infected with an empty pBABE-puro (control) vector, were 
propagated as polyclonal populations and passaged continuously following 
puromycin selection until the cultures ceased proliferation.
Primary GM01856(CSA) cells ceased proliferation at 21 PDs and 95 days in 
culture after which no further lifespan extension was observed. Conversely, the 
GM01856(CSA) fibroblasts infected with pBABE-hTert-puro, were propagated for 
202 days and achieved 76 PDs (Figure 5.4). This culture displayed a logarithmic 
pattern and displayed no decline in growth rate. A similar pattern was observed for 
the other cell strains tested and these are given in Table 5.1.
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5.3.5 Characterisation of stress signalling pathways in primary fibroblasts
The p38 and JNK pathways are known to be activated in response to stress 
[reviewed by (Kyriakis and Avruch 2001)]. Therefore, the level of phosphorylated 
p38 and JNK in normal and Gl syndrome cells were compared by Western blot. 
Two sets of irnmunoblots are provided for primary fibroblasts (Figure 5.5 A and B). 
These were generated at different times but they both have a common control 
strain, AG16409(N) that acts as an internal marker enabling cross-comparison of 
the two series of blots. AG16409(N) cells (Figure 5.5A) and HCA2 cells (Figure 
5.5B) treated with anisomycin were used as internal controls so as to confirm the 
identity of the phosphorylated-p38 and phosphorylated-JNK1/2 proteins.
Anisomycin is an antibiotic that binds to the 60S ribosomal subunit and 
inhibits the peptidyl-transferase reaction, thus blocking translation. In addition, 
independently of its ability to inhibit protein synthesis, anisomycin is known to 
activate both JNK- and p38-pathways and is used widely in the literature as a 
positive control for p38 activation (Cano et al. 1994; Hazzalin et al. 1997; lordanov 
et al. 1997; Shifrin and Anderson 1999; Torocsik and Szeberenyi 2000; Xiong et al. 
2006). As expected, both AG16409(N) and HCA2 cells that have been stimulated 
with anisomycin show high levels of phosphorylated p38 and JNK1/2 (Figure 5.5A, 
lanes 1 and 2; B lanes land 2).
When Figure 5.5B is analysed, it is seen that Gl strains GM01774(DKC), 
GM18366(SS) and GM16088(LIG4) have a similar level of p-p38 (Figure 5.5B, 
lanes 5, 7, and 8) as that found in HCA2 cells and the normal dermal strains 
AG16409(N) and AG06234(N) (Figure 5.5B, lanes 1, 3 and 4). A much elevated 
level of p-p38 is observed for GM17523(LIG4) (Figure 5.5B, lane 9), suggesting 
these cells show activation of p38; however, this is most likely due to overloading 
of this lane as indicated by the high levels of JNK1/2 seen in this strain. 
Conversely, a much-reduced level of p-p38 is observed for GM09812(SS) (Figure 
5.5B lane 6) that may be due to under loading as indicated by the low levels on
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JNK1/2 seen in this strain. Alternatively, it is possible that p38 is activated to a 
lower extent in GM09812(SS). These data suggest that overall there is no 
activation of p38 in these syndromes above that seen in normal cells.
A similar pattern is seen in Gl strains AG18375(RTS), AG17524(RTS), 
GM02932(BS), GM07166(NBS) and AG10677(HGPS) (Figure 5.5A, lanes 4, 5, 6, 
12 and 13), indicating that there is little activation of p38 in these syndromes 
beyond that seen in the normal strain AG16409(N) (Figure 5.5A, lane 2). For Gl 
strains AG18371 (RTS), GM02548(BS), GM02520(BS), GM01856(CSA),
RO202(NBS), R0242(NBS), AG11498(HGPS) and AG01972(HGPS) a reduced 
level of p-p38 is seen (Figure 5.5A, lanes 3, 7-11, 14 and 15). As the levels of p- 
p38 appear to correlate with the levels of p38 across the gel, it is possible that the 
low levels of p38 seen in these samples simply reflects the degree of protein 
loading in these lanes, thus suggesting that the level of p38 activation in these cells 
may be similar to that observed in normal cells. Alternatively, p38 may be activated 
to a lower extent in these strains that would show considerable intra-GI syndrome 
differences.
In summary the data shown in Figure 5.5A and B suggest that the majority 
of primary Gl syndrome cells have p-p38 levels comparable with those observed 
for normal cells, although some strains appear to show a reduced p38 activation.
When the immunoblots were examined for the activation of JNK1/2, p- 
JNK1/2 is barely detectable in any of the normal or Gl strains (Figure 5.5A, lane 2, 
Figure 5.5B, lanes 1, 3 and 4). However, activated JNK1/2 (p-JNK1/2) can be 
detected in AG16409(N) and HCA2 cells that have been treated with anisomycin 
(Figure 5.5A, lanel and B, lane 2, respectively). In general, the level of p-JNK1/2 
detected is roughly proportional to the level of JNK1/2 seen in these cells, 
suggesting that any variation seen is due to differences in protein loading. The 
exceptions appear to be the RO202(NBS) and R0242(NBS) (Figure 5.5A, lanes 10 
and 11), AG11498(HGPS) (Figure 5.5A, lane 14) and GM01774(DKC) strains 
(Figure 5.5B, lane 5) which show low levels of JNK1/2 activation.
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Differences are observed in the JNK1/2 isoforms that are activated in some 
strains. For example, in DKC, it is the p46 isoforms of JNK1/2, which refer to the 
JNK1a1 and JNK2a1 isoforms (Liu et al. 2004), that are activated (Figure 5.5B 
lane 5), whereas RO202(NBS), R0242(NBS) and AG11498(HGPS) show low 
levels of activation of both p54 and p46 isoforms. Given the different roles of JNK 
isoforms in cell proliferation (Bode and Dong 2007) it was questioned as to whether 
the differences in JNK activation correlate with the growth rates of these cells; 
however, no clear correlation between growth rate and JNK activation was 
observed.
5.3.6 p38 activation status in hTert-immortalised fibroblasts
To assess the p38 activation status of the newly generated hTert panel, 
protein lysates from hTert cells soon after transfection (designated early passage 
hTert cells) were assessed for total p38 levels and its activating phosphorylation by 
western blot. Each syndrome strain has been analysed separately and compared 
with AG16409(N)hTert cells treated with and without anisomycin as positive and 
negative controls, respectively. As expected both p-p38 and p-JNK1/2 are detected 
in AG 16409(N)hTert cells treated with anisomycin (Figure 5.5C, lanes 1, 4, 7, 10, 14, 
17 and 20); however, little p-p38 or p-JNK1/2 is detected in untreated 
AG16409(N)hTert cells (Figure 5.5C lanes 2, 5, 8, 11, 15, 18 and 21). This appears 
to suggest that immortalisation with hTert has reduced the activation of p38 seen in 
primary AG16409(N) cells (Figure 5.5C), although this has not been compared 
directly. In contrast, p-p38 is detected in hTert-immortalised AG18371(RTS)hTert, 
GM01856(CSA)hTert, GM07166(NBS)hTert and GM17523(LIG4)hTert cells, with 
particularly high levels of p-p38 in the latter two strains (Figure 5.5C lanes 3, 9,12 
and 19). Very low levels of p38 activation are seen in GM02548(BS)hTert or 
AG11498(HGPS)hTert (Figure 5.5, lanes 6 and 16). This agrees with the apparent 
low levels of p38 activation seen in the corresponding primary cells (Figure 5A, 
lanes 7 and 14), suggesting that p38 may indeed be activated at low levels in these 
strains. For comparison, AG03141(WS)hTert cells that are known to express 
activated p38 are shown in lane 22 (Davis et al. 2006). These data suggest that
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hTert immortalisation does not prevent activation of p38 in Gl syndrome cells but 
does reduce the level of p-p38 in normal cells.
When these hTert-immortalised strains are analysed for the activation of 
JNK1/2, no p-JNK1/2 is found in any of the Gl syndrome cells used (Figure 5.5, 
lanes 2, 3, 6, 9, 12, 16, 19 and 22), supporting the observation of little JNK1/2 
activation seen in primary cells (see figure 5).
The apparent decline in p-p38 seen in AG16409(N)hTert cells prompted the 
question as to whether hTert populations gradually underwent an element of in 
vitro selection in which levels of p38 phosphorylation were seen to decline in 
accordance with increasing passage. Preliminary data on late passage (>30 
passages) hTert cells suggest that p-p38 levels were indeed decreased in Gl cells 
indicating the need to track passage age for hTert cultures (data not shown). All 
subsequent studies were thus performed on early passage hTert cells to remove 
this element of in vitro selection.
5.4 Discussion
This chapter shows the successful generation of an hTert-immortalised 
panel of Gl syndrome cells that can be used for further analysis of SIPS in these 
cells. In addition it has been shown that hTert is able to extend the lifespan of RTS 
cells beyond their normal senescence point, data that was not previously available.
An analysis of stress-signalling pathways in both primary and hTert systems 
give rise to three main conclusions:
Firstly, the Western Blot analysis of primary cells suggests that the level of 
p38 phosphorylation in Gl syndrome cells may be similar to that observed for 
normal cells, although some inter-strain (and intra-GI syndrome) variation is 
observed. If it is assumed that the biological outcomes observed for growth in p38 
inhibitors is driven by changes in p38 phosphorylation, the observation that p38 
inhibitors have very similar effects on the growth of primary cells from all 
syndromes despite the variations of p-p38 observed, suggests that only low levels
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of p38 activity are necessary to affect the replicative potential of cell cultures. Thus, 
it is possible that relatively small changes in p38 activation are translatable into 
significant changes in growth potential when assayed over long periods of time. If 
this is the case such changes may be beyond the resolution of the detection 
systems used. Alternatively, it is possible that the small changes in replicative 
potential observed for most cultures are not due to changes in p38 activation and 
that the inhibitors are having their effects due to off-target issues. This may be 
supported by the observation that VX745, which is very highly specific for p38 (Lee 
and Dominguez 2005), consistently shows the smallest effects on cell proliferation 
and lifespan.
Secondly, the level of p-p38 appears to be reduced following hTert- 
immortalisation in normal cells, but not in Gl syndrome cells. This suggests that in 
normal cells the major stress signals giving rise to growth restraint may be 
removed by ectopic expression of hTert, whereas Gl syndrome cells retain some 
degree of p38 stress signalling that could reflect ongoing SIPS in these cells i.e. Gl 
syndrome cells have the added burden of telomere independent senescence. The 
hypothesis therefore is that hTert-immortalised Gl cells should be a target for 
inhibitor action, whereas hTert-immortalised normal cells are likely to show a 
reduced response to p38 inhibitors compared to their primary counterparts. These 
data also indicate that the hTert system can be used to further study the role of 
SIPS in Gl syndrome cells with the stipulation that early passage cells are used, a 
hypothesis supported by the observation that SIPS can still occur in hTert- 
immortalised Ataxia Telangiectasia cells (Naka et al. 2004).
Finally, it is clear that JNK1/2 are not activated to any significant extent in 
any primary or hTert-immortalised Gl fibroblast strain, suggesting that any 
underlying stress signalling occurring in these cells does not significantly activate 
JNK1/2 and similarly, it is likely that any off-target effects of the p38 inhibitors 
towards JNK1/2 are unlikely to impact upon growth potential.
In summary, the main conclusions of this chapter are:
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• hTert-immortalisation can extend the lifespan of AG8371(RTS), 
GM17523(LIG4), GM01856(CSA), GM02548(BS), GM07166(NBS), 
AG11498(HGPS) and AG16409(N) cells beyond their normal 
senescence barriers, suggesting that senescence in these cell strains 
is driven by telomere shortening.
• Generation of the hTert panel can be used for further studies of SIPS 
in Gl sydrome cells.
• Gl syndrome cells have low levels of p-p38, similar to those observed 
for normal cells.
• The level of p-p38 appears to be reduced in hTert-immortalised Gl 
syndrome cells but not normal cells, suggesting that Gl syndrome 
cells have an added burden of stress signalling that is telomere- 
independent.
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Table 5.1. Growth potential of primary versus hTert-expressing cultures
Syndrome 1° /hTert Days in culture PD Senescence?
Normal 1° 170 49.6 ✓
hTert 212 85.7 X
BS 1° 95 21.0 ✓
hTert 154 56.8 X
NBS 1° 154 21.6 V
hTert 192 41.4 X
LIG4 1° 95 13.9
hTert 185 35.1 X
HGPS 1° 55 10.3 /
hTert 109 28.2 X
RTS 1° 189 33.8 ✓
hTert 456 93 X
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Figure 5.1. Reconstitution of telomerase activity in primary RTS fibroblasts 
(AG 18371) transfected with hTert.
Retroviral infection with pBABE-hTert-puro vector (Lanes 3, 4) or the empty 
pBABE-puro vector (Lanes 1, 2). HEK 293 cells were used as a positive control 
(Lanes 5, 6). TRAP assays were performed using the TRAPeze® Kit (Millipore) 
according to the manufacturer’s guidelines. The arrow indicates the position of the 
internal telomerase amplification standard as a control for the PCR inhibition. Each 
sample was assayed with (+) or without (-) prior heat treatment to destroy 
telomerase activity.
100 ; AG18371 (RTS)
0 100 200 300 400 500
Days
Figure 5.2. Extension of proliferative lifespan of polyclonal population of RTS (AG18371) 
fibroblasts transfected with hTert.
Cells infected with pBABE-hTert-puro (closed squares) or an empty pBABE-puro vector 
(open squares). All cells were propagated under routine culture conditions in selective 
media.
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Figure 5.3. Reconstitution of telomerase activity in fibroblasts derived from normal 
(AG16409) and Gl syndrome individuals transfected with hTert.
Retroviral infection with pBABE-hTert-puro vector. TRAP assays were performed as 
previously described (Kim et al. 1994). The arrow indicates the position of the internal 
telomerase amplification standard as a control for the PCR inhibition. Each sample was 
assayed with (+) or without (-) prior heat treatment to destroy telomerase activity. HEK 
293 cells were used as a positive control. Abbreviations: NC negative control.
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Figure 5.4. Extension of proliferative lifespan of polyclonal populations transfected with hTert.
Primary (open squares) and hTert-expressing (closed squares) fibroblasts from normal and Gl 
syndrome individuals were propagated under routine culture conditions and growth curves 
generated from cumulative population doublings.
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Figure 5.5. Immunoblot analysis of stress signalling proteins in Gl syndromes fibroblasts.
For Panels A and B protein lysates were prepared from primary fibroblasts grown under standard conditions. For Panels C protein lysates 
were prepared from hTert-immortalised fibroblasts grown under standard conditions. * in lane 6 of panel B indicates an under-loading of 
GM09182(SS). Expression levels for phosphorylated p38 (p-p38), p38, phosphorylated JNK1/2 (p-JNK1/2) and JNK1/2 were assessed. For 
JNK1/2 the p46 and p54 kDa versions are indicated. For each blot an equal amount (10ng) of protein was loaded per sample.
Chapter 6  Impact of p38 Inhibition on Response to 
DNA Damage
6.1 Introduction
As noted in the Introduction exposure of cells to genotoxic agents such as UV 
and chemotherapy drugs, such as DOX, cause multiple types of cell damage and 
have been shown to induce SIPS (see below). Evidence in the literature that 
expression of hTert does not prevent SIPS in normal human fibroblasts in 
response to UV, y-irradiation or H2O2 (Gorbunova et al. 2002), suggests that the 
hTert model can be used to study SIPS. Here, the proposal is to test the propensity 
for SIPS in hTert-immortalised Gl syndrome fibroblasts using a range of different 
genotoxic agents. These agents have a known capacity to induce cell cycle 
arrest/SIPS. This study provides a unique opportunity to determine the extent to 
which Gl panel cells have a compromised and possibly shared ability to deal with 
exogenously imposed genomic stress.
The rationale for the selection of the agents was based on their accepted 
mechanisms of action and the nature of the genomic lesion generated. The 
approach is similar to that adopted by others (Cabral et al. 2008; Fan and Luo 
2008) in the selection of agents (UV irradiation, 4-nitroquinoline 1-oxide, 
camptothecin, etoposide, hydroxyurea, and H2O2) for RECQL4 helicase gene 
function in human cells including Rothmund-Thomson syndrome. The agents 
studied here fall into two categories. First, agents that interfere with the modulation 
of DNA topology including inhibitors of DNA topoisomerase I (camptothecin; CPT) 
and DNA topoisomerase II (doxorubicin; DOX). Changes in topology are intimately 
connected with the assembly of chromatin during DNA replication, its packaging 
prior to progression to mitosis and decatenation prior to chromosome segregation. 
Furthermore, CPT is thought to generate S-phase specific stress through the 
generation of strand interruptions following replicon collision with trapped ternary 
complexes. The Topo II targeting agent DOX shows less cell cycle specificity and a
167
potential for multiple modes of action associated with DNA intercalation and 
inhibition of macromolecular biosynthesis. Second, agents that disrupt DNA 
integrity (e.g. base damage, SSBs/DSBs) potentially arising from radical induction 
(e.g. induced by H2O2). Third, those agents that induce more discrete forms of 
DNA damage at specific residues and require nucleotide removal processes and 
associated repair pathways [e.g. purine adducts induced by 4-nitroquinoline 1- 
oxide (4NQO)] or those that have the ability to generate lesions over long time 
periods and provide a chronic form of stress and disrupt cell cycle traverse [e.g. 
DNA cross-link formation by cisplatin (CisPt)].
Here the selected agents are overviewed in terms of their mechanism of 
action and induction of cellular senescence pathways:
1. CPT is a naturally occurring cytotoxic quinoline alkaloid with strong anti-tumour 
activity that was first isolated from the bark and stem of Camptotheca acuminata, a 
tree native in China. In eukaryotes CPT specifically inhibits DNA topoisomerase 
(Topo) I (Hsiang and Liu 1988) and is widely used as a tool in assessing the role(s) 
of the enzyme. CPT and its analogues form stable ternary complexes with DNA 
and the Topo I molecule (termed ‘cleavable complexes’ due to their ability to yield 
DNA strand breaks upon treatment with alkali). Analyses of CPT-induced DNA 
breaks show that Topo I is covalently linked to the 3' end of the broken DNA. CPT 
acts by blocking the rejoining step of the breakage-reunion reaction (Hsiang et al. 
1985) and this ‘trapping’ results in the accumulation of cleavable complexes which 
resemble the transient intermediates proposed for eukaryotic DNA Topo I. Toxicity 
of CPT is primarily attributed to the conversion of single-strand breaks into double­
strand breaks during the S-phase when the replication fork collides with the 
cleavage complexes formed by DNA and CPT (Pommier et al. 2003).
Differences in the response to CPT have been reported depending on the 
dose and p53 status of the cell types studied. Evidence suggests that high doses 
of CPT induce apoptosis in both p53 functional and non-functional human colon 
cancer cell lines (Han et al. 2002). However, low doses of CPT induce cell cycle 
arrest and senescence in p53 functional cells, but apoptosis in p53 nonfunctional
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cells (Han et al. 2002). In contrast to these observations, a robust SIPS response 
to CPT has been reported in non-small cell lung carcinoma (H1299) cells that are 
p53 nonfunctional (Roberson et al. 2005).
2. CisPt (Cisplatin; cis-diamminedichloroplatinum(ll) (CDDP) is a fully synthetic 
platinum-based chemotherapy, being the first member of a group of related drugs 
used widely to treat various types of cancer, including sarcomas, small cell lung 
carcinoma and lymphomas. The cytotoxic action of CisPt requires activation of 
CisPt by aquation involving the sequential replacement of the c/s-chloro ligands of 
CisPt with water molecules (el-Khateeb et al. 1999; Kelland 2000). The major 
forms of DNA adducts induced by CisPt are 1,2-intra-strand cross-links with purine 
bases, accounting for 85-90% of total lesions (Kelland 1993). Although often 
referred to as an alkylating agent, the co-ordination complex has no alkyl group 
and so cannot carry out alkylating reactions.
CisPt-induced DNA damage is known to activate a number of pathways, 
including activation of cell cycle checkpoints, which temporally induce a transient 
S-phase arrest, followed by a durable G2/M arrest (Shapiro and Harper 1999; 
Siddik 2003). Since the inhibitory effect of DNA adducts of CisPt on the Gi-phase 
cyclin-dependent kinases is a later event in the sequence of checkpoint activation 
(Siddik 2002), cells remain trapped in G2/M and accumulation of cells in G1 is rarely 
seen (Siddik 2003). Available data suggest that the primary responses to CisPt- 
induced DNA damage are induction of long-term growth arrest (premature cell 
senescence) and mitotic catastrophe, whereas acute apoptosis may be due to "off- 
target effects" not necessarily involving DNA damage (Havelka et al. 2007). The 
involvement of p53 in CisPt-induced senescence is inconclusive, as senescence 
has been observed in cells both with and without functional p53 (Chang et al. 1999; 
Roberson et al. 2005; Wang et al. 1998).
3. DOX (DOX; Adriamycin™; also known as hydroxydaunorubicin) is an 
anthracycline antibiotic, closely related to the natural product daunomycin isolated 
from Streptomyces peucetius. DOX is used as a chemotherapeutic agent in the 
treatment of a wide range of cancers, including Hodgkin’s and Non-Hodgkin’s
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lymphoma, multiple carcinomas and soft tissue sarcomas (Carter 1975). Though 
not completely elucidated, the anti-tumour activity of DOX is thought to be exerted 
in two ways: firstly by intercalating between base pairs leading to distortion of the 
helix (Momparler et al. 1976), which disrupts DNA synthesis and transcription, and 
secondly by inhibiting DNA Topo II, which is critical to DNA function. DOX 
stabilises the Topo II complex after it has broken the DNA chain for replication, 
thus preventing the DNA double helix from being resealed and generating breaks 
in genomic DNA. Both of these mechanisms result in DNA disruption that ultimately 
can lead to cell cycle arrest and death signalling.
Topo inhibitors such as DOX induce DNA damage in tumour cells, 
subsequently activating p53 and leading to cell cycle arrest or apoptosis (Lowe et 
al. 1994; Pommier et al. 1994). For example, it has been reported that breast 
tumour cells (MCF-7 cells) treated with DOX undergo SIPS that is dependent on 
functional p53 (Elmore et al. 2005; Elmore et al. 2002). It has also been shown that 
DOX is a potent inducer of a reversible senescent-like state in normal human 
fibroblasts (Michishita et al. 1998). Evidence suggests that the cytotoxic activity of 
DOX occurs predominantly in G2 (Potter et al. 2002).
4. 4NQO is a quinoline derivative. The exact mechanism of action of 4NQO is not 
clear, but it is known to be metabolically activated to 4-hydroxyaminoquinoline-1- 
oxide. The latter reacts with DNA to form purine adducts. Similar to UV 
photolesions, 4NQO DNA adducts are removed by the NER pathway in normal 
human cells (Zelle and Bootsma 1980). 4NQO also generates substantial amounts 
of ROS in the cell, thereby producing DNA strand breaks and alkali-labile sites 
(Nunoshiba and Demple 1993). In addition, it induces formation of irreversible 
topoisomerase cleavage complexes (Toplcc) that are converted into DNA breaks, 
similar to CPT (Miao et al. 2006).
Evidence suggests that treatment with 4NQO consistently reduces the levels of 
cyclin D1 in a dose-dependent manner in mouse embryonic fibroblasts (NIH 3T3), 
human osteosarcoma (U20S) cells and normal human fibroblast (WI38) cells 
(Suwaki et al. 2010) that is reminiscent of the rapid cyclin D1 degradation observed
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in cells treated with other DNA damaging agents such as IR and UV (Agami and 
Bernards 2000; Hiyama et al. 1997). Furthermore, following low doses of 4NQO, 
cells accumulated in S-phase and G2/M phases of cell cycle, indicating that low 
doses of 4NQO caused proliferative arrest, with no notable accumulation of cells 
with a sub-Gi content of DNA, suggesting that exposure to a low dose of 4NQO 
does not trigger apoptotic cell death (Suwaki et al. 2010). However, medium-high 
doses of 4NQO have been reported to trigger a strong G^  arrest that may be 
accompanied by apoptotic cell death (Suwaki et al. 2010).
5. H2O2 is naturally produced in organisms as a by-product of oxidative 
metabolism. Hydrogen peroxide can be converted to the highly damaging hydroxyl 
radical and can generate singlet oxygen, which is not itself a free radical, but acts 
as a catalyst for free radical formation. Reactive oxygen species (ROS) are known 
to damage proteins, nucleic acids and cell membranes. The most abundant DNA 
lesion caused by H2 O2 is a base modification to 7,8-dihydro-8-oxoguanine (8-oxoG) 
(Chatgilialoglu and O'Neill 2001). Conversion of 8-oxoG causes selective mis- 
incorporation of adenine opposite to 8-oxoG that can lead to a G-T transversion in 
the DNA (Wood et al. 1990; Wood et al. 1992). H2O2 is a ROS that is known to 
cause oxidative damage primarily through the hydroxyl radical that results from the 
Fenton reaction (Buda et al. 2003; Imlay et al. 1988).
Cytotoxic doses of H2O2 have been reported to induce necrosis or apoptosis 
(Frippiat et al. 2002), whereas sub-lethal H2O2 treatment induces senescence-like 
growth arrest of human fibroblasts (Duan et al. 2005; Frippiat et al. 2001; Frippiat 
et al. 2002). This cell cycle arrest has been shown to be associated with down 
regulation of cyclin D1 (Barnouin et al. 2002; Hiyama et al. 1997), which 
predominantly results in an immediate G1 arrest, allowing the damage to be 
repaired prior to further DNA replication. Furthermore, prolonged low doses of 
H2O2 induce senescent-like morphological changes, irreversible G1 cell cycle arrest 
and a significant increase in SA-p-gal in young human diploid fibroblasts (Dimri et 
al. 1995; Frippiat et al. 2002).
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The sensitivities of the Gl panel members to CPT, DOX, 4NQO, CisPt and 
H2 O2 , along with the experimental methods used to determine sensitivity, are 
summarised in Table 6.1.
The p38 pathway has been implicated in the DNA damage response and is 
reported to be activated in response to various DNA damage-inducing agents 
(Boldt et al. 2002; Bragado et al. 2007; Coffer et al. 1995; Kool et al. 2003; Lee et 
al. 2002; Wilhelm et al. 1997). Evidence suggests that p38 can be potently 
activated by drugs that induce DNA damage by either promoting the formation of 
DNA adducts (e.g. by CisPt) or inhibiting Topo II (e.g. by DOX), but not by 
therapeutically relevant doses of y-irradiation (Sanchez-Prieto et al. 2000). Further 
evidence suggests that apoptosis induced by CisPt requires the onset of a p53- 
mediated p38a pathway through the generation of ROS (Bragado et al. 2007). 
Oxidative stress, such as that caused by H2O2 , is widely known to activate the p38 
pathway via ASK1 (Matsukawa et al. 2004; Pan et al. 2010). Similarly, p38 
activation has been reported in response to CPT, where it is involved in CPT- 
induced cell death (Lee et al. 2002). p38 also regulates cell cycle checkpoints in 
response to DNA damage induced by UV radiation, including the G1/S and the 
early G2/M checkpoints (Bulavin et al. 2001; Manke et al. 2005). Although the 
importance of p38 in cell cycle checkpoints induced by IR is less well understood, 
MEK6 and p38 have been implicated in the IR-induced G2/M checkpoint (Wang et 
al. 2000b).
The working hypothesis is that different forms of genomic stress may result in 
common pathways for stress signalling, namely the p38 pathway, and in their 
impact on the probability of cell cycle exit. The approach was to screen all of the Gl 
panel members to identify hallmarks of cell cycle arrest (either of accumulation in 
G2/M or restricted exit from G1) as hallmarks of a stress response. The dose range 
for each drug was chosen based on previous evidence from the literature with the 
aim of inducing low-levels of stress for a prolonged period of time so that the 
frequency of arrest can report on sensitivity.
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6.2 Results
6.2.1 Sensitivity of hTert-immortalised genomic instability syndrome
fibroblasts to genotoxic agents
Clonogenic survival assays are commonly used to determine the sensitivity 
of cells to cytotoxic agents (Franken et al. 2006); however, these assays require 
cells to form discernible colonies that are subjectively defined. To assess the 
plating efficiency (PE) for each of the Gl panel members, colonies of £50 cells 
were counted in the absence of genotoxic agents. Figure 6.1 shows that the PE for 
normal cells is —11%, which is consistent with reports in the literature (Franken et 
al. 2006). CSA and BS cells show a similar PE to that observed for normal cells; 
however, the PE observed for NBS, LIG4, RTS and HGPS is much lower. Based 
on these observations the syndromes were grouped into those with normal PE 
(normal, BS and CSA) and those with sub-normal PE (NBS, LIG4, RTS and 
HGPS). Comparison of the PE by one tailed t-test showed that the PE for each 
group was significantly different (p=0.001).
Clonogenic survival was determined by counting the number of colonies of 
£50 cells. Differences in sensitivity to each of the agents for each of the Gl panel 
members were examined by comparing the shapes of the dose-response curves 
and IC5o values. IC50 values were defined as the dose at which 50% survival was 
achieved, and were retrieved graphically to avoid curve-fitting anomalies. In cases 
in which a 50% survival level was not achieved the dose at which 80% survival was 
achieved (IC2 0) value was compared.
No correlation was observed between intrinsic sensitivity and PE when IC50  
values were analysed on a drug-by-drug basis. Furthermore, by comparing the IC50  
values for each agent between the normal PE and sub-normal PE group, the 
difference in the inherent sensitivity of the two groups to the panel of agents could 
be analysed. Using a 1 tailed t-test, no significant difference in IC50 values for CTP 
(p=0.35), DOX (p=0.42), 4NQO (p=0.10), CisPt (p=0.24) and H20 2 (p=0.36), was 
observed between the two groups. These data suggest that any inherent
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differences in replicative potential in these cells do not contribute to their sensitivity 
to the panel of genotoxic agents.
The sensitivity of each of the Gl panel members to each of the agents was 
compared to the response observed for normal cells. The IC5o values for normal 
cells in response to CPT, DOX, 4NQO and H2 O2 were 7 nM, 4 nM, 5 jxM and 53 
pM, respectively (Table 6.2). An IC50 value was not obtained for normal cells in 
response to CisPt; however, an IC20 value of 1.2 |iM was recorded (Table 6.2). 
Using the same criteria the relative survival of Gl syndrome cells were studied and 
details of the pattern of responses observed are described. Table 6.2 shows a 
comparison of the IC50 (or 20% killing in the case of CisPt) values for each Gl 
syndrome relative to normal cells.
Survival curves are shown in Figures 6.2-6.8 where responses are 
compared to the normal strain AG16409(N)hTert. As expected, CSA cells showed a 
slight to moderate increase in sensitivity to CPT (Figure 6.2A) (Squires et al. 1993), 
DOX (Figure 6.2B) and 4NQO (Figure 6.2C) but normal responses to H20 2 (Figure 
6.2E). In contrast, CSA cells show relative resistance to CisPt compared to normal 
cells (Figure 6.2D) although absolute toxicity levels were insufficient for a definitive 
determination.
As expected BS cells were hypersensitive to CPT (Figure 6.3A) (Mao et al.
2010) and to a much lesser degree 4NQO (Figure 6.3C) (Prince et al. 1999). BS 
cells showed pronounced hypersensitivity to DOX (Figure 6.3B). The literature 
suggests that BS cells are also hypersensitive to CisPt (Mao et al. 2010), while the 
data shown in Figure 6.3D are unable to confirm that observation due to the low 
levels of drug toxicity achieved. Similarly, BS cells showed essentially normal 
response to H2O2 at low doses (Figure 6.3E). Overall, BS cells show the same 
pattern of responses as those observed for CSA.
Contrary to findings in the literature that NBS cells are hypersensitive to 
CPT (Kraakman-van der Zwet et al. 1999), Figure 6.4A shows that NBS cells 
respond normally to CPT. A similar response was observed in response to H2 O2
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(Figure 6.4E), whereas NBS cells show evidence of increased sensitivity to 4NQO 
(Figure 6.4C) and show relative resistance to CisPt (Figure 6.4D). NBS cells show 
slight resistance to DOX at low doses (2.5-10 nM) (Figure 6.4B).
LIG4 show a normal response to CPT at low doses (2.5-10 nM) but some 
evidence of increased sensitivity at a higher dose (20 nM) (Figure 6.5A). LIG4 cells 
show pronounced hypersensitivity to DOX (Figure 6.5B) but are relatively resistant 
to 4NQO (Figure 6.5C), CisPt (Figure 6.5D) and H2 O2 (Figure 6.5E).
Consistent with recent findings in the literature, Figure 6.6A shows that RTS 
cells are hypersensitive to high dose CPT (Jin et al. 2008). Contrary to findings in 
the literature that the RTS cells showed pronounced hypersensitivity to DOX (Jin et 
al. 2008) similar in extent to that shown by BS cells, Figure 6.6B shows that RTS 
cells show a normal response to DOX. Figure 6.6D shows RTS cells are 
hypersensitive to CisPt, however, this conflicts with previous reports in the 
literature that RTS cells show normal to moderate sensitivity to this agent (Cabral 
et al. 2008). RTS cells show moderate resistance to H2 O2 at low doses (10-40 i^M) 
but are hypersensitive to this agent at higher doses (40-80 p,M) (Figure 6.6E). 
Consistent with previous reports, RTS cells also show relative resistance to 4NQO 
(Jin et al. 2008) (Figure 6.6C).
HGPS cells show pronounced hypersensitivity to CPT (Figure 6.7A) and 
DOX (Figure 6.7B) and moderate hypersensitivity to CisPt (Figure 6.7D) but a 
normal response to 4NQO (Figure 6.7C) and H20 2 at low doses (10-20 piM) (Figure 
6.7E).
As expected, WS cells showed hypersensitivity to CPT (Figure 6.8A) (Mao 
et al. 2010; Poot et al. 1999) but showed a normal response to DOX, 4NQO and 
H2 O2 (Figure 6.8B, C and E). Contrary to previous findings (Mao et al. 2010; Poot 
et al. 2001), WS cells were relatively resistant to CisPt (Figure 6.8D).
In an attempt to identify patterns of response to the genotoxic panel in Gl 
syndrome fibroblasts these data are summarised in the form of a heatmap (Figure 
6.9). Overall, all cells are hypersensitive to CPT even at low doses, with the
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exception of NBS, which shows a normal response to the agent. All cells are also 
hypersensitive to DOX at higher doses (20 nM), although RTS and NBS cells are 
relatively resistant at lower doses and WS shows a normal response at lower 
doses. CSA, BS and NBS are hypersensitive to 4NQO at all doses, whereas WS 
are only hypersensitive at higher doses (15-20 jxM). In contrast, LIG4, RTS and 
HGPS are relatively resistant to 4NQO. RTS and HGPS show pronounced 
hypersensitivity to CisPt, whereas all other cells are relatively resistant to CisPt. 
The response of Gl syndromes to H2O2 is more variable: CSA, NBS and WS show 
a normal response to H2 O2 ; BS and HGPS show a normal response at lower doses 
but are hypersensitive at higher doses; LIG4 and RTS are relatively resistant to 
H20 2, although RTS is hypersensitive at the highest dose (80 ^M).
6.2.2 Cell cycle dynamics in response to DNA damage in hTert-immortalised 
genomic instability syndrome fibroblasts
To assess the short-term impact of the genotoxic panel on cell cycle exit, a 
single dose for each agent was selected for flow cytometric analysis based on the 
previous survival data. The following doses were used: CPT 10nM, DOX 10nM, 
4NQO 15 jaM, CisPt 2.5 p,M and H2 O2 80 pM representing clonogenic survival 
levels of -40%, -20%, -15%, -70% and -30% respectively for normal cells. 
Bright field imaging was used to review the cellular morphology and to allow simple 
observation of changes in growth parameters. To assess the impact of the drugs 
on population growth, the increase in cell number for each cell strain in the 
presence and absence of each drug was assessed.
In normal cells, cell cycle arrest in G2/M was observed following CPT and DOX 
(Figure 6.10C). However, treatment with 4NQO, CisPt and H2O2 had no effect on 
the percentage of cells in G2/M in normal cells (Figure 6.10C). In contrast, no cell 
cycle arrest in G1 is observed for normal cells in response to any agent (Figure 
6.10D). No differences were observed in the morphology of normal cells following 
treatment with these agents, suggesting that cell cycle arrest is not necessarily 
associated with clear morphology changes or commitment to loss of viability 
(Figure 6.10B). The cell cycle arrest observed following CPT and DOX treatment
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was associated with a slight reduction in population growth; however, this effect 
was relatively minor (Figure 6.10E).
Using the same approach, certain patterns were observed for the impact of the 
panel of genotoxic agents on G2/M and G1 arrest on Gl syndrome cells when 
compared to normal cells. Note that only cells that show differences in their 
response to the genotoxic panel have been described in detail in this chapter, full 
details of all Gl panel members are provided on the accompanying disk. Firstly, 
CPT and DOX consistently induce G2/M arrest in all cells irrespective of their 
genetic backgrounds. Secondly, a similar level of G2/M arrest (-3-fold) is induced 
by CPT and DOX in all cells, with the exception of BS and RTS cells, which show 
an increased level of G2/M arrest (7-fold and 5-fold for BS and 5-fold and 4.5-fold 
for RTS in response to CPT and DOX, respectively), suggesting that BS and RTS 
cells are hypersensitive to these agents (Figure 6.11C and Figure 6.14C). Thirdly, 
treatment with 4NQO, CisPt and H2O2 generally had little effect on the cell cycle 
dynamics of all cells compared to that seen for CPT and DOX, although there are 
some exceptions. These include, BS cells, which also show increased G2/M arrest 
in response to 4NQO (-2-fold) (Figure 6.11C), LIG4 that also show increased G2/M 
arrest in response to 4NQO and H2O2 (—2fold) (Figure 6.13C) and finally RTS cells 
that show increased G2/M arrest in response to all of the agents (Figure 6.14C). 
Fourthly, treatment with each of the agents did not induce G1 arrest in the majority 
of cell strains; however, some exceptions were observed. These include RTS, 
which shows an increase in G1 arrest in response to CPT, DOX and CisPt (Figure 
6.14D) and HGPS, which shows an increase in G1 arrest in response to all agents 
(Figure 6.12D).
6.2.3 Does BIRB796 alter post-treatment recovery from CPT?
To establish whether BIRB796 can overcome an arrest associated with DNA 
damage, the proportion of cells that accumulate in G2/M following CPT treatment 
was assessed in the presence and absence of BIRB796. Furthermore, the impact 
of BIRB796 on the longer-term viability of these cells following CPT treatment was 
assessed. Here, the working hypothesis is that cells undergoing low levels of DNA
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damage will show p38-restrained cell cycle exit. To test this, cells were treated with 
a single dose of CPT (10 nM) as previously described, washed and incubated with 
and without BIRB796 for a further 72 hours for short-term flow cytometric analysis 
or incubated for 10 days for clonogenic survival. The decision to temporally 
separate the addition of the CPT and BIRB796 was made in an attempt to reduce 
the issue of cross-reaction of the two agents. Three strains (normal, BS and CSA) 
were selected for analysis based on the previous observations that these cells 
showed the greatest response to CPT. Moreover, these cells were shown to 
consistently have the fastest growth rate therefore giving the best opportunity to 
observe significant shifts in cell cycle distribution over short periods for recovery 
from drug-induced cycle arrest.
Preliminary observations indicated that all three strains were in cycle at the 
start of the experiment, as reflected in the growth curves (Figure 6.15B). There was 
evidence of changes in the G2/M content to a minor extent in normal and BS cells, 
but evidence of synchronisation in CSA, which may be expected in short term 
cultures such as these. Despite any changes in cell cycle dynamics of control cells 
BIRB796 treatment alone consistently increased the growth rate and increased the 
proportion of cells in cycle (designated as G2+S) in all three strains (data not 
shown). As expected treatment with CPT induced accumulation in the proportion of 
cells in G2/M in all three strains; however, differences were observed between 
three strains in their response to CPT. Although these differences may reflect 
inherent differences in the sensitivity of these strains to CPT, it is possible that 
these differences simply reflect the proportion of cells that were available for CPT 
action (i.e. those traversing S-phase) during the course of the experiment. T=0 
data showed that there were differences in the proportion of actively dividing cells 
in the three strains, with CSA cells showing a reduced proportion of cells in S- 
phase (7%) compared to normal (31.7%) and BS cells (51.5%). The observation 
that CSA cells also show a reduced accumulation of cells in G2/M compared with 
normal and BS cells when treated with CPT (Figure 6.15A) and relative resistance 
to CPT when assessed for clonogenic potential (Figure 6.16), suggests that the 
observed differences in sensitivity between strains are due to differences in the cell
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cycle phase distribution at the time of addition of CPT and therefore the inter-strain 
differences were not assessed further.
As shown in Figure 6.15A, both normal and BS cells show early and 
sustained accumulation of cells in G2/M, suggesting a long-lived block to cell cycle 
progression. In keeping with this, the growth curves for both normal and BS cells 
show a sustained growth arrest following CPT treatment, although there is some 
evidence of recovery at T=96 in normal cells (Figure 6.15B). Addition of BIRB796 
reduced retention of cells in G2/M in normal cells at both early and later times post 
treatment. The sustained retention of cells in G2/M in BS was only affected by 
BIRB796 at later times (T=96) (Figure 6.15A), during which other effects of 
BIRB796 on cells that escaped CPT treatment could be occurring. CSA cells show 
a reduced accumulation of cells into G2/M compared to normal and BS cells 
following CPT treatment (Figure 6.15A). In keeping with this, the growth curve for 
CSA cells indicate continued proliferation following CPT, although this was reduced 
compared to their untreated counterparts (Figure 6.15B). In CSA, progressive 
recruitment of cells into G2 following CPT treatment occurs up to T=72 hours, after 
which there is evidence of recovery (confirmed by the increase in culture growth) 
(Figure 6.15). The recovery of CSA cells following CPT was demonstrably 
enhanced by BIRB796 treatment, shown by both a reduction in the G2/M proportion 
and an increase in growth rate compared to normal cells (Figure 6.15). Overall 
these data show that BIRB796 has the ability to reduce the G2/M accumulation in 
all three strains studied but the kinetics of that recovery may differ according to cell 
type.
As shown in Figure 6.16A, large differences in the clonogenic potential 
(given by the number of colonies of £50 cells) for the three strains are observed, 
with BS cells having a higher clonogenic potential compared to normal and CSA 
cells. Despite these differences, the sensitivity of the three strains to CPT does not 
appear to correlate with clonogenic potential perse (Figure 6.16B). Similarly, there 
does not appear to be a relationship between the overall clonogenic potential of 
untreated cells and the impact of BIRB796. As a result the differences in
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clonogenic potential were assumed not to alter the analysis although it was 
appreciated that a different proportion of the entire population is being analysed 
between strains.
As expected, pre-treatment with 10 nM CPT for 24 hours reduces the 
clonogenic potential of GM01856(CSA)hTert, AG16409(N)hTert and GM02548(BS)hTert 
cells compared to their untreated counterparts (Figure 6.16A). Conversely, 
treatment with BIRB796 alone increases the clonogenic potential of 
GM01856(CSA)hTert, AG16409(N)hTert and GM02548(BS)hTert cells compared with 
untreated cells (Figure 6.16A). This suggests that BIRB796 stimulates cells that 
were previously non-clonogenic to re-enter cycle so that they now report as being 
clonogenic. BIRB796 also increases the clonogenic potential of cells that were pre­
treated with CPT compared to CPT treatment alone, suggesting that BIRB796 
increases recovery of cells following CPT treatment; however, the clonogenic 
potential of cells treated with CPT+BIRB796 is lower than those treated with 
BIRB796 alone (Figure 6.16A). These data suggest that there are a proportion of 
cells that are BIRB796-recoverable (BR) and that pre-treatment with CPT reduces 
the proportion of BR-cells.
6.3 Discussion
Inconsistencies in the reported sensitivity of Gl syndrome cells to genotoxic 
agents in the literature suggest that the issues associated with using different 
experimental techniques or in the cell type studied (e.g. fibroblast or lymphoblast, 
primary or transformed) still stand. Therefore this study provided the opportunity to 
compare the drug sensitivities of each of these syndromes using a standard 
technique. The screen was undertaken with certain known limitations (e.g. 
pragmatically trying to assay all of the lines at the same time to reduce errors due 
to differences in conditions). In addition, differences in the PE of the different cell 
strains were observed. Although these differences were shown not to affect the 
sensitivity of each of the Gl panel members to the panel of genotoxic agents, 
clearly the informative population in this analysis is restricted to cells that have the 
potential to undergo at least 6 PDs (to give rise to colonies of >50 cells). In the
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case of NBS, for example, the PE is <1%, therefore >99% of the population cannot 
be analysed using this method.
Despite the differences in PE, the results indicate that some cell lines show 
hypersensitivity to major classes of damage, such as those induced by CPT and 
DOX. The screen has revealed high levels of sensitivity in BS, RTS, HGPS and 
LIG4 in response to DOX and similarly in RTS in response to CisPt. Moreover, 
RTS cells have previously been reported to show a normal response to CisPt 
(Cabral et al. 2008); however, different cell strains were studied, suggesting that 
there may be inter-strain heterogeneity amongst RTS cells in their response to 
genotoxic agents. In general, all of the Gl syndrome fibroblasts showed a normal 
response to H2O2 . This is consistent with the finding in the literature that only 
prolonged treatment with low doses of H2O2 induce senescence (Duan et al. 2005), 
therefore a 24 hour treatment may not be sufficient to induce long-term arrest in 
these cells. These data also suggest that the molecular defect in these cells does 
not sensitise to low levels of oxidative stress. Clearly further investigation is 
required to fully profile the sensitivity of these cells to genotoxic agents and may 
provide an insight into the molecular defect or pathways that are defective in these 
cells.
When analysed by flow cytometry, both CPT and DOX consistently induced a 
G2/M arrest in all cells, whereas the impact of 4NQO, CisPt and H2O2 on the cell 
cycle dynamics of all strains was slight. Agents that act across the cell cycle may 
result in ‘freezing’ of the DNA content distributions and therefore recruitment into 
arrest being less apparent. Given the differences in the populations available for 
clonogenic and flow cytometric analysis, concordance between early measures of 
drug response, for example cell cycle arrest was not expected to necessarily relate 
to clonogenic data. Despite these differences, the results showed that in general, 
those strains that showed an early drug response (i.e. arrest within 24 hours) also 
showed a reduction in clonogenic potential in the longer term. However, some 
exceptions were observed, for example, LIG4 cells showed a reduction in 
clonogenic potential in response to DOX but did not show an early cell cycle arrest.
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These results indicate that in LIG4 the cell cycle arrest induced by DOX cells takes 
longer than 24 hours to be realised. The results also identify an inherent problem 
when analysing fibroblasts from some of these syndromes. For example, using the 
standard cell cycle fitting approach, possible anomalies in cell cycle phase 
assignment were identified in some samples including WS cells. These issues 
include the presence of split peaks, possibly representing subpopulations with 
different cell cycle properties that cannot be analysed efficiently using the standard 
cell cycle fitting approach. This raises the need for alternative approaches of 
identifying cell cycle phases and as such region analysis was used in other studies.
Flow cytometric analysis of GM01856(CSA)hTert, AG16409(N)hTert and 
GM02548(BS)hTert cells that had been pre-treated with CPT and subsequently 
incubated in BIRB796 indicated that BIRB796 increased recovery, although the 
timing of this recovery appeared to differ between strains. It was also shown that 
BIRB796 increases the clonogenic potential of CPT pre-treated 
GM01856(CSA)hTert, AG16409(N)hTert and GM02548(BS)hTert cells compared to 
those incubated in CPT alone. This suggests that BIRB796 does indeed increase 
the recovery of GM01856(CSA)hTert, AG16409(N)hTert and GM02548(BS)hTert cells 
following exposure to CPT. However, the observation that BIRB796 alone also 
increases the clonogenicity of GM01856(CSA)hTert, AG16409(N)hTert and 
GM02548(BS)hTert cells, suggets that the increase in clonogenicity seen in CPT- 
treated cells may be due to the action of BIRB796 on cells that escaped the initial 
CPT treatment.
In summary, the main findings from this chapter are:
• Gl syndrome and normal cells show a reduction in clonogenic potential, 
reflecting long-term cell cycle arrest (potentially SIPS), in response to at 
least one of the genotoxic agents used here. This suggests that the hTert 
panel remain susceptible to SIPS and therefore provide a feasible model to 
study differences in endogenous levels of SIPS in these cells.
1 8 2
• The study revealed hypersensitivity of some strains to genotoxic agents 
(e.g. BS, RTS, HGPS and LIG4 are hypersensitive to DOX and RTS is 
hypersensitive to CisPt).
• 24 hour incubation with 10 nM CPT and 10 nM DOX consistently induces 
G2/M arrest in all cell strains tested.
• BIRB796 increases the clonogenic potential of hTert-immortalised CSA, BS 
and normal cells.
• BIRB796 increases the clonogenic potential of CPT pre-treated hTert- 
immortalised CSA, BS and normal cells. It is therefore possible that 
BIRB796 increases the recovery of these cells following CPT treatment; 
however, it is also possible that the increase in clonogenicity is due to the 
action of BIRB796 on cells that escaped the initial CPT treatment.
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Table 6.1. Summary of the sensitivity profiles for Gl panel members to 
genotoxic stress.
Syndrome Agent Cell type Assay Findings Ref
ws CPT SV40- 
transformed 
GM639 and U2 
OS cells
WRN depletion by shRNA Hypersensitivity
knockdown and treated
with 6-12 nM CPT for 24
hours and colonies
allowed to grow for 8
days prior to analysis.
Colonies of 26 cells were 
counted to determine 
survival.
Mao etal 2010
CPT Lymphoblastoid Cells were treated with 10- Hypersensitivity 
50 nM CPT for 24 hours . . . . . .  , ,
prior to flow cytometric ® er e'/e s 0 
analysis of cell survival aP°P 0SIS) 
and level of apoptosis.
Pootetal 1999
CPT ES cells Cells were treated for 1 
hour with 0.1-0.5 pM CPT 
and colonies allowed to 
form for 7 days prior to 
analysis.
Hypersensitivity Leder et al 1998
DOX Lymphoblastoid Cells were analysed for 
cell survival, cell cycle 
and entry to apoptosis by 
flow cytometry (cells 
treated with 100-400 nM 
DOX for 24 hours prior to 
analysis) and proliferative 
survival by BndU (cells 
exposed to 100-400 nM 
DOX for 72 hours prior to 
analysis)
Normal
sensitivity
Poot et al 2001
4NQO Primary 
fibroblasts from 
WS individuals 
and WRN-/- and 
WRN +/+ 
lymphoblastoid 
cells
Cells were treated with 
0.3-1.0 pM 4NQO for 24 
hours and 60 minutes, 
respectively. Proliferative 
survival and apoptosis 
rate was measured by 
BrdU and flow cytometry.
Hypersensitivity Poot et al 2002
4NQO SV40- 
transformed 
WRN fibroblast 
cell lines
Cells were treated with 
0.1-0.8 mg/ml for 24 
hours. Cells were 
trypsinised and replated 
for colony formation and 
left to grow for 10 days 
prior to analysis. Colonies 
of >50 cells were counted 
to determine survival.
Hypersensitivity Prince et al 
1999
CisPt Lymphoblastoid Cells treated with 0-2 pM 
CisPt for 24 hours prior to 
flow analysis and 72 
hours prior to proliferative 
survival assay
Hypersensitivity 
(1.5 fold)
Poot et al 2001
CisPt SV40- 
transformed 
GM639 and U2 
OS cells
Cells treated with 1-2 pM 
for 24 hours
Hypersensitivity Mao et al 2010
H20 2 Primary 
fibroblasts from 
WS individuals 
and WRN-/- and 
WRN +/+ 
lymphoblastoid 
cells
Cells treated with 10-80 
pM for 24 hours
Normal
sensitivity
Prince et al 
1999
H2O2 Primary WI-38 
and IMR-90.
Cells were depleted of 
WRN by siRNA. Cells 
were treated with 10-150 
pM H202 for 45 minutes.
Hypersensitivity Szekely et al 
2005
h2o2 Primary WS cells Cells were treated with 50- Resistance 
200 pM H202 for 1 hour.
Cabral et al 
2008
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Table 6.1 continued
Syndrome Agent Cell type Assay Findings R ef"...................
RTS CPT Primary RTS 
fibroblasts
Cells were treated with 
0.25-15 nM CPT for 72 
hours. Colonies of >50 
cells (or for slow growing 
strains >16 cells) were 
scored after 10-14 days.
Hypersensitivity Jin et al 2008
DOX Primary RTS 
fibroblasts
Cells were treated with 
0.1-1 pM DOX for 30 
minutes.
Hypersensitivity Jin et al 2008
4NQO Primary RtS 
fibroblasts
Cells were treated with 
0.2-1 pM 4NQO for 1
Normal
sensitivity
Cabral et al 
2008
4NQO Primary RTS 
fibroblasts
Cells were treated with 20- Resistance
80 nM 4NQO for 24
hours.
Jin et al 2008
CisPt Primary RTS 
fibroblasts
Cells were treated with 1- 8 mM CisPt for 4 hours. Normalsensitivity Cabral et al 2008
CisPt Primary RTS 
fibroblasts
Cells were treated with 
0.5-2.5 pM CisPt for 24 
hours.
Modest
sensitivity
Jin et al 2008
H2O2 Primary RTS 
(AG18371)
Cells were treated with 
0.1-1 mM H202 for 15 
minutes. Cell proliferation 
was measured to assess 
recovery.
Hypersensitivity Werner et al 
2006
H2O2 Primary RTS 
fibroblasts
Cells were treated with 50- Normal 
200 pM H202 for 1 hour, sensitivity
Cabral et al 
2008
BS CPT SV40- 
transformed 
GM639 and U2 
OS cells
Cells were depleted of 
BLM by shRNA 
knockdown and treated 
with 6-12 nM CPT for 24 
hours and colonies 
allowed to grow for 8 
days prior to analysis
Hypersensitivity Mao et al 2010
DOX Lymphoblastoids Cell viability was 
monitored at 4, 8, and 24 
h following treatment with 
5-25 mg/m! DOX
Resistance Wang et al 2001
4NQO SV40- 
transformed 
WRN fibroblast 
cell lines
Cells were treated with 
0.1-0.8 mg/ml for 24 
hours.
Hypersensitivity Prince et al 
1999
CisPt SV40- 
transformed 
GM639 and U2 
OS cells
Cells treated with 1-2 pM 
for 24 hours
Hypersensitivity Mao et al 2010
CSA CPT Primary and
SV40-
transformed
human
fibroblasts.
Cells were treated with 
0.13-2 pM CPT for 1 
hour. Colonies were 
allowed to form for 8-14 
days.
Hypersensitivity Squires et al 
1993
4NQO CSA fibroblasts Cells were treated with 1 
nm-1 pM 4NQO for 90 
minutes. Colonies were 
scored after 14-21 days.
Hypersensitivity Wade and Chu 
1979
NBS CPT SV40-
transormed NBS 
fibroblasts.
Hypersensitivity
(3-fold)
Kraakman-van 
der Zwet et al 
1999
HGPS CPT Spontaneously 
immortalised 
Zmpste24- 
deficient MEFs
Cells were treated with 1- 6 pM for 1 hour and 
assessed by colony 
forming assay.
Hypersensitivity Liu et al 2005
LIG4 CisPt Lig4—/— MEFs Cells were treated with 
2.5-15 pM CisPt for 3 
hours and assessed by 
colony forming assay.
Hypersensitivity Kondo et a I 2010
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Table 6.2. Sensitivity of Gl syndrome and normal fibroblasts to the panel 
of genotoxic agents.
Cell line
nM
CPT
nM
DOX
1C so
liM
4NQO
pM
H2O2
1C 20 
pM 
CisPt
Normal 7 4 5 52.5 1.2
CSA 6 2 4.5 52.5 2.05
BS 4.5 2 4 40 2.1
NBS 7 5 3 40 2.5
LIG4 10.5 1.2 19 80 -
RTS 7 2 13 55 0.54
HGPS 2 1.5 6 35 0.6
WS 1.5 3 8 53 2.5
Sensitivity of cells to genotoxic agents as indicated by 
the IC50 values (or IC 2o values for CisPt).
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Figure 6.1. PE of Gl syndrome cells.
PE was calculated as a percentage of the number of colonies of 
>50 cells/number of cells plated, and plotted as a mean of duplicate 
plates. Error bars represent the range of data obtained (n=2).
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Figure 6.2. Analysis of clonogenic survival of GM01856(CSA) 
to DNA damaging agents.
nrert fibroblasts following exposure
Panels A-E show responses to CPT, DOX, 4NQO, CisPt and H20 2 for CSA (solid lines)
compared to AG16409hT8rt (N) (dotted line). Survival was determined by counting colonies >50
cells. Data derived from a single experimental screen, n=2.
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Figure 6.3. Analysis of clonogenic survival of GM2548(BS)h7ert fibroblasts following 
exposure to DNA damaging agents.
Panels A-E show responses to CPT, DOX, 4NQO, CisPt and H20 2 for BS (solid lines)
compared to AG16409hT#rt (N) (dotted line). Survival was determined by counting colonies
>50 cells. Data derived from a single experimental screen, n=2.
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Figure 6.4. Analysis of clonogenic survival of GM07166(NBS) 
exposure to DNA damaging agents.
nrert fibroblasts following
Panels A-E show responses to CPT, DOX, 4NQO, CisPt and H20 2 for NBS (solid lines)
compared to AG16409hTcrt (N) (dotted line). Survival was determined by counting
colonies >50 cells. Data derived from a single experimental screen, n=2.
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Figure 6.5. Analysis of clonogenic survival of GM17523(LIG4)hlert fibroblasts following 
exposure to DNA damaging agents.
Panels A-E show responses to CPT, DOX, 4NQO, CisPt and H20 2 for LIG4 (solid lines)
compared to AG16409hTert (N) (dotted line). Survival was determined by counting
colonies >50 cells. Data derived from a single experimental screen, n=2.
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Figure 6.6. Analysis of clonogenic survival of AG18371 (RTS) 
exposure to DNA damaging agents.
hTert fibroblasts following
Panels A-E show responses to CPT, DOX, 4NQO, CisPt and H20 2 for RTS (solid lines)
compared to AG16409hTert (N) (dotted line). Survival was determined by counting colonies
>50 cells. Data derived from a single experimental screen, n=2.
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Figure 6.7. Analysis of clonogenic survival of AG11498(HGPS)hIert fibroblasts following 
exposure to DNA damaging agents.
Panels A-E show responses to CPT, DOX, 4NQO, CisPt and H20 2 for HGPS (solid
lines) compared to AG16409hTert (N) (dotted line). Survival was determined by counting
colonies >50 cells. Data derived from a single experimental screen, n=2.
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Figure 6.8. Analysis of clonogenic survival of AG03141(WS)n,er1 fibroblasts 
following exposure to DNA damaging agents.
Panels A-E show responses to CPT, DOX, 4NQO, CisPt and H20 2 for WS (solid 
lines) compared to AG16409hTert (N) (dotted line). Survival was determined by 
counting colonies >50 cells. Data derived from a single experimental screen, 
n=2.
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CPT (nM) DOX (nM) 4NQO (pM) CisPt (pM) H20 2(pM)
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CSA ■  ■
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Figure 6.9. Heatmap summarising the responses of Gl panel to genotoxic agents.
Red indicates that cells show hypersensitivity compared to normal, green indicates cells show 
relative resistance and blue indicates that cells show an equivalent response. Results are based 
on a comparison of the IC5 0  for all drugs with the exception of CisPt in which IC2o values were 
compared.
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Figure 6.10. Analysis of the impact of DNA damaging agents (24 h exposure) on cell cycle
progression, cell morphology and proliferation for AG16409(N)hTert fibroblasts.
Panels A show changes in relative DNA content distributions, compared with an untreated control 
(grey shaded), following exposure to CPT (10 nM x 24h, black line); DOX (10 nM x 24 h, red line), 
4NQO (15 pM x 24 h, green line), CisPt (2.5 pM x 24 h, blue line) and H20 2 (80 pM x 24 h, pink 
line). Panels B show the corresponding appearance of cultures at 24 h (bar = 100 pm) by phase 
contrast microscopy. Panel C and D show relative changes in G2/M and Gi for each drug 
treatment, respectively. Panel E shows the total cell number in the presence or absence of each 
drug treatment. 10,000 events were analysed and data was gated to remove cell debris. Mitotic 
index (Ml) is calculated based on the number of mitosis events observed in three fields.
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Figure 6.15. Impact of BIRB796 on recovery of cells following CPT pre-treatment.
AG16409(N)hTert, GM02548(BS)hTert and GM01856(CSA)hTert cells were seeded (5x105) and allowed 
to attach for 24 hours prior to treatment. Cells were treated with CPT (10 nM; T=0) for 24 hours 
(T=24), washed and incubated in media with or without BIRB796 for a further 72 hours. The cell 
cycle distributions of cells were analysed at T=48, T=72 and T=96 hours. Panel A shows flow 
cytometric analysis of the proportion of cells in G2/M and panel B shows the increase in cell 
number over the course of the experiment. The data represents the mean of 2 samples analysed in 
parallel and error bars represent the range of these values.
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Figure 6.16. Impact of BIRB796 on the clonogenic potential of CPT pre-treated normal, 
CSA and BS cells
AG16409(N)hTert, GM02548(BS)hTert and GM01856(CSA)hTert cells were pre-treated with 
CPT (10 nM) for 24 hours and washed prior to incubation in the presence or absence of 
BIRB796 for 10 days. Clonogenicity was measured by the number of colonies £50 cells. 
Panel A shows the shows the absolute number of colonies generated in untreated, CPT- 
treated, BIRB796-treated and CPT+BIRB796-treated cells. Panel B shows the sensitivity 
of the three strains to CPT, given as a ratio of the number of colonies in untreated:CPT- 
treated cells in the presence and absence of BIRB796. n= 4 ± SD.
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Chapter 7  BIRB796 Inhibitor Effects: Cell Cycle 
Dynamics and Clonogenic Potential of hTert 
Immortalised fibroblasts
7.1 Introduction
The generation of the hTert panel in Chapter 5 provides the opportunity to 
determine whether there are differences in the level of commitment to cell cycle 
exit in cells derived from individuals with defined genetically determined conditions 
associated with genomic instability. Furthermore, the finding in Chapter 6 that 
hTert-immortalised cells remain susceptible to cell cycle arrest in response to 
genotoxic agents suggests that this is a feasible approach. Clearly replicative 
potential is determined by cell cycle alterations and the working hypothesis is that 
differences in the limitation of replicative potential reflect the degrees of 
commitment to long-term exit from the cell cycle. It is proposed that constitutive 
levels of endogenous stress (e.g. arising from the appearance and incomplete 
resolution of genomic damage) can affect the probability of transition between out 
of cycle and subsequent re-entry. It is plausible that Gl syndrome cells will show 
subtle differences in cell cycle dynamics as a result of endogenous stress.
Support for this hypothesis comes from the finding that WS cells show cell 
cycle alterations that may be associated with their slow growth and reduced 
replicative lifespan (Poot et al. 1992). Specifically, WS lymphoid cell lines displayed 
a 2.4 hour prolongation in the minimum duration of the S-phase. Moreover, the 
fraction of proliferating cells irreversibly arrested in S-phase was shown to be 
significantly elevated in WS (5.4 % versus 1.4 % in normal controls), although 
other cell cycle compartments were not significantly affected (Poot et al. 1992). 
Some evidence also exists to suggest that BS cells have altered cell cycle 
progression; however, these data are limited and variations in cell types used are 
common (Bamezai and Shiraishi 1986).
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In recent years, the p38 MAPK pathway has been shown to be involved in the 
induction of both the Gi/S and G2/M checkpoints [reviewed by (Ambrosino and 
Nebreda 2001; Thornton and Rincon 2009; Wilkinson and Millar 2000)], although 
its role in the G2/M checkpoint is better established. p38 is activated in response to 
DNA DSBs, induced by exposure to UV, y-irradiation and chemotherapeutic drugs 
such as etoposide, leading to the establishment of a G2/M cell cycle checkpoint 
(Bulavin et al. 2002; Mikhailov et al. 2004) (Figure 1.4A). Although the mechanism 
of activation of p38 in response to DNA DSBs is not completely clear, it has been 
reported to be dependent on the activation of ATM and ATR that serve as DNA 
damage sensors (Reinhardt et al. 2007). While the activation of ATM is required for 
activation of p38, it does not appear to be able to directly phosphorylate p38. 
Instead, activation of p38 appears to be mediated by the Thousand and one (Tao) 
kinases, which activate p38 via MKK3/6 (Raman et al. 2007). The observation that 
activation of p38 can occur in the presence of the ATM inhibitor caffeine and in 
ATM knockout cell lines in response to topoisomerase II inhibitors an UV 
(Mikhailov et al. 2004; Reinhardt et al. 2007), suggest that there are other not yet 
established mechanisms that activate p38 in response to DNA damage.
Two main pathways have been described for the involvement of p38 in the 
induction of the G2/M checkpoint (Figure 1.4A). The first involves phosphorylation 
and activation of p53 by p38 and subsequent induction of a p53-dependent G2/M 
checkpoint (Bulavin et al. 1999; She et al. 2000; Thornton and Rincon 2009). The 
activation and stabilisation of p53 by p38 leads to the transcription of p53-target 
genes such as Growth arrest and DNA damage inducible 45a (GADD45a), 
p 2 1 C D K N i  and 14-3-3 (el-Deiry et al. 1993; Hermeking et al. 1997; Zhan et al. 1999). 
p38 also associates with GADD45a proteins and promotes their association with 
p53, further increasing p53 stability (Bulavin et al. 2003). These proteins enforce a 
G2/M checkpoint by either directly or indirectly inactivating the cdkl/cyclinB 
complex, which is the major engine driving the transition from G2 to M-phase 
(Taylor and Stark 2001). The second mechanism by which p38 induces a G2/M 
checkpoint is through the phosphorylation and inhibition of the phosphatase 
Cdc25B (Bulavin et al. 2001). Cdc25B dephosphorylates cdkl and activates the
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cyclin/cdkl complex driving progression of the cell cycle. It has been proposed that 
phosphorylation of Cdc25B inhibits its activity by promoting its association with 14- 
3-3 proteins and sequestering it in the cytoplasm (Lopez-Girona et al. 1999; Morris 
et al. 2000). While it was initially reported that p38 could directly phosphorylate 
Cdc25B in vitro, more recent studies have shown that p38 promotes the 
phosphorylation of Cdc25B indirectly through activation of MK2 (Lemaire et al. 
2006; Manke et al. 2005). More recently, however, the role of p38 in G2 delay has 
been challenged. Contrary to prior reports, a new study suggests that although p38 
activation is strongly induced by DNA damage, its activity is not required to induce 
a G2/M checkpoint in human cancer cells (Phong et al. 2010).
p38 activation can also contribute to the induction of a G1/S checkpoint in 
response to osmotic stress, ROS and DNA damage (Figure 1.4B) [reviewed by 
(Ambrosino and Nebreda 2001; Thornton and Rincon 2009; Wilkinson and Millar 
2000)]. Similar to G2/M checkpoint regulation, several mechanisms by which p38 
mediates a G1/S checkpoint have been described. Firstly, p38 can induce a G1/S 
checkpoint through the activation of p53 resulting in the accumulation of p21 (Kim 
et al. 2002; Kishi et al. 2001). p21 is thought to induce a G1/S checkpoint by 
inactivating Cdk2 (Brugarolas et al. 1999; Poon et al. 1996). Recent evidence also 
suggests that p21 can inhibit Cdk1 in the absence of Cdk2 to establish a G1/S 
checkpoint in response to DNA damage (Satyanarayana et al. 2008). Secondly, 
p38 can induce a G1/S checkpoint by reducing the levels of cyclin D1, which is 
known to form complexes with Cdk4/6 and is essential for the transition to S- 
phase. p38 has been shown to reduce the levels of cyclin D1 by two independent 
mechanisms: either at a transcriptional level by phosphorylation and stabilisation of 
HMG-box protein 1 (HBP1), which subsequently inhibits cyclin D1 gene expression 
(Yee et al. 2004); or by directly phosphorylating cyclin D1 and targeting it for 
ubiquitination and proteosomal degradation (Casanovas et al. 2000). Thirdly, p38 
can phosphorylate and promote degradation of Cdc25A and thus contribute to 
establishment of a G1/S checkpoint (Goloudina et al. 2003). Fourthly, p38 can 
mediate a G1/S checkpoint by upregulating expression of p16INK4A, which inhibits 
Cdk4/6 activation (Roussel 1999), and p19ARF, which regulates p53 (Tao and
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Levine 1999). Overall, p38 can play a significant a role in cell cycle arrest. It is 
highly plausible, therefore, that cells that show chronic activation of p38, such as 
WS cells, will show abnormal cell cycle dynamics.
Conceptually one model for progression to ‘senescence’ is that a cell in a 
given population has a small but finite probability of exiting the cell cycle following 
each division. Once a cell is arrested there are two possibilities, either that cell can 
re-enter the cell cycle or it can remain in an arrested state. The model in figure 1.6 
suggests that the probability of re-entry decreases with time spent out of cycle. It 
is possible that during a period of cell cycle exit a cell acquires further features that 
act to reduce the probability of re-entry and the cell therefore appears to be 
irreversibly arrested. Therefore the replicative potential of a cell or a population is 
dependent on the rate of exit from the cell cycle and the probability of re-entry. 
Given the potential role of p38 in cell cycle regulation and the observed effect of 
p38 inhibitors on relieving growth limitation (chapters 3 and 6), this simple model 
proposes that the probability of re-entering the cell cycle is limited by increased 
p38 expression.
Previously, it has been proposed that increased replicative stress in WS cells 
leads to increased numbers of senescent cells at each division compared to 
normal cells (Faragher et al. 1993; Kill et al. 1994). The model shown in Figure 1.6 
can be used to suggest how a slightly increased exit rate could contribute to the 
reduced replicative potential of WS cells. An issue for compromised WS cell 
populations could be that elevated telomere erosion rates may reflect the capacity 
of cells with replicative potential effectively dividing more frequently to attain an 
overall population doubling -  i.e. a single PD requires the dividing cells to divide 
more than once. As shown in this model, the long-term effect of this increased exit 
from cell cycle provides a plausible mechanism for the reduced proliferative 
capacity of WS cells in culture.
Here it is proposed that the replicative potential of cells is determined by cell 
cycle dynamics, including the transition between in and out of cycle and that this 
can be affected by changes in endogenous levels of stress. The primary aim of this
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chapter is to examine the cell cycle dynamics of a panel of cells that show different 
levels of putative endogenous ‘replication stress’. The approach was to determine 
whether altered cell cycle dynamics could be distinguished in populations of Gl 
panel cells over relatively short time periods representing 1-3 cell cycle traverse 
events. Studies include examination of the transition between in and out of cycle 
and the effects of p38 inhibitor exposure. There is the possibility that differences in 
the rate of exit from cell cycle in the Gl panel will not be seen in a short-term 
analysis, therefore, the longer-term replicative potential of Gl syndrome cells will be 
assessed by colony forming assays.
7.2 Results
7.2.1 Impact of BIRB796 on cell cycle dynamics and on exit/re-entry
The previous studies suggest that the greatest opportunity to identify p38 
impact over a limited number of cell cycle transits would require the most potent 
inhibitor, namely BIRB796. Preliminary experiments were also undertaken to 
determine suitable timing of the experiment and to address issues such as optimal 
cell density to ensure that cells had the opportunity to undergo cell divisions and 
providing sufficient sample size for event detection. Cell quality of the informative 
populations analysed by flow cytometry were defined using conventional light 
scatter characteristics that differentiate between intact cells and cell debris. A 
significant range of side scatter signal was observed for Gi cells suggesting that 
differences in nuclear structure (and extent of dye intercalation) could reflect the 
presence of quiescent cells.
To assess the ability of BIRB796 to change cell cycle distribution, for 
example reduction in cells in Gi, flow cytometric analysis was performed on hTert- 
immortalised fibroblasts grown continuously in the presence or absence of 
BIRB796 for a period of 72 hours. There was evidence of culture-mediated cell 
density issues at 72 hours; therefore data from the 24 hour time-point was used. 
The proportion of cells that were in cycle as designated as G2/M+S versus the 
proportion of cells that were out of cycle in Go or traversing Gi are shown in Figure
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7.1B. The majority of strains show a similar cell cycle distribution with >60% of 
cells being in G1/G0 . RTS cells appear to show a reduction in the proportion of cells 
in cycle (18%) compared to the other strains, suggesting that RTS cells may 
contain a higher proportion of quiescent cells. The observation that a 24 hour 
BIRB796 treatment consistently reduces the percentage of cells in Gi across the 
board suggests that BIRB796 can promote cells to re-enter the cell cycle within 
one cell cycle transit. The reduction in the Gi fraction was on average in the order 
of <5% of the entire population in all cell strains.
Cell cycle analyses depend upon a correlation between fluorescence 
intensity (as determined by the area of the nominated fluorescence pulse signal; 
e.g. FL2-A) and cellular DNA content. DNA content distributions using the ethidium 
bromide (Eb) technique can be compromised by variations in the size and form of 
nuclei presented to the laser during the FACS analysis. One approach to analysing 
such variation is to determine the time of flight (TOF; e.g. FL2-W) of the object 
during its passage through the laser beam. Accordingly, an increase in TOF not 
matched by an increase in total fluorescence, as given by the integration of the 
height (FL2-H) and width (FL2-W) measurements of the pulses providing an area 
measurement (FL2-A), would indicate non-spherical nuclear structure. This 
analytical approach revealed an increased frequency (at ~5%) of cells with 
extended TOF values in both Gi and G2 compartments in RTS and WS compared 
to normal cells, suggesting a burden of quiescent or arrested cells (Figure 7.2). 
The possibility that this extended TOF was due to cell doublets (with abnormally 
long TOF values) was excluded by our analysis.
7.2.2 Impact of BIRB796 on clonogenic potential
To assess the medium-term impact of increased SIPS on replicative 
capacity and the role of p38 in this, the clonogenic potential of the Gl panel was 
assessed using a standard colony forming assay. Colonies arising from single cells 
were counted and plating efficiency (PE) was initially calculated for each as 
described in section 2.5. However, using this approach the PE of all strains was 
low (<10%), particularly for RTS in which no colonies containing >50 cells were
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colonies containing >50 cells were observed. It was therefore considered that 
calculation of PE using a threshold of >50 cells/colony following a fixed incubation 
period was problematic for the slower growing strains. Therefore a new definition 
that divides the population into cells that have minimal clonogenic potential (MCP), 
full clonogenic potential (FCP) or are non-clonogenic (NC) was proposed. The 
functional definition of a cell with MCP is one that must have divided at least twice 
during the time of the experiment and thus gives rise to a colony of >4 (but <50) 
cells. A cell with FCP is designated as one that gives rise to a colony of >50 cells. 
The NC fraction are seen as single cells or those that give rise to colonies of <4 
cells and are estimated from the proportion of MCP and FCP cells in the population 
(data not shown). Given this new functional definition, the PE for each strain based 
on colonies containing >4 cells was shown to be between -4-20% for these cells 
(Figure 7.3B). The differences in PE observed between Gl panel members may 
reflect differences in the level of commitment to senescence in these cells over the 
clonogenic period.
To assess the impact of BIRB796 on the clonogenic potential, cells were 
grown continuously in the presence or absence of BIRB796 and the PE for each 
strain was calculated. These data show that continuous treatment with BIRB796 
consistently increases the PE of all strains, with the possible exception of BS cells, 
suggesting there is a commonality of response to p38 inhibition in these cells 
(Figure 7.3B). Furthermore, these data suggest that BIRB796 stimulates cells that 
were previously non-clonogenic to divide so that they are now counted as having 
MCP and are included in the calculation of PE. There are two possible 
explanations for this. Firstly, BIRB796 may act on the division competent cells and 
cause them to divide more often thus resulting in an increase in colony sizes that is 
perceived as an increase in the proportion of cells with MCP and/or FCP. 
Secondly, BIRB796 may act on the subset of cells within a candidate colony that 
would normally have exited the cell cycle and cause them to remain in cycle so that 
they contribute to colony growth again resulting in an increase in the proportion of 
cells with FCP and/or causing cells that were previously non-clonogenic to re-enter 
resulting in an increase in the MCP fraction.
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Analysis of the clonogenic fraction was undertaken to identify the target 
population for BIRB796 action. To address this, the question of whether BIRB796 
changes the relative proportions of MCP or FCP cells in each strain was asked. In 
all cell strains, the percentage of cells showing FCP was increased following 
BIRB796 treatment, suggesting that BIRB796 increases the clonogenic potential of 
those cells that previously showed MCP so that they now report as having FCP. In 
WS, RTS, HGPS, NBS and LIG4 the percentage of cells showing MCP also 
increases (Figure 7.3A), suggesting that BIRB796 stimulates cells that were 
previously non-clonogenic to re-enter cycle so that they now report as having MCP. 
The observation that in these cell strains the increase in the proportion of cells that 
show FCP is relatively small suggests that there is a subpopulation of cells that are 
non-responsive to BIRB796 over the time course of the experiment. In normal, 
CSA and BS cells, the proportion of cells showing FCP is increased, again 
suggesting that BIRB796 increases the clonogenic potential of cells that previously 
showed MCP so that they now show FCP. However, the proportion of cells 
showing MCP is decreased following treatment with BIRB796 in these strains. 
Given the assumption that any cell that previously showed FCP would also show 
FCP in the BIRB treated sample, there are two possible explanations for this: 
firstly, that BIRB796 stimulates cells that previously showed MCP so that they all 
now report as having FCP; or secondly BIRB796 also stimulates cells that were 
previously non-clonogenic so that they both now report as having FCP.
To further assess the target population for BIRB796 action, a full distribution 
of colony sizes in a chosen syndrome, namely WS, in the presence and absence of 
BIRB796 was undertaken. These data revealed that the distribution of WS 
proliferative potential was weighted towards the generation of small colonies, with 
the majority of cells being designated as NC, -40% showing MCP and relatively 
few cells (<10%) showing FCP (Figure 7.4). The data clearly show BIRB796 not 
only increases the total number of colonies (i.e. PE), it also results in a shift in 
colony size towards larger colonies, perceived as a greater proportion of cells 
showing FCP and fewer cells showing MCP (Figure 7.4; right panel). This suggests 
that the main action of BIRB796 is to increase the likelihood of a cell reporting as
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‘clonogenic’ when defined at a specific colony size (e.g. FCP). These data also 
show that BIRB796 did not increase the maximum colony size observed (130 
cells), suggesting that there is a limit on the maximal population doubling rate 
observed in WS populations and that this is not affected by exposure to BIRB796.
7.3 Discussion
The proportion of cells in cycle was <40% for all cells, suggesting that the 
majority of cells are either in transit in Gi or are quiescent in dermal fibroblasts. 
Inter-syndrome differences were observed, for example RTS cells have a higher 
proportion of cells in Gi (>80%) compared to all other strains (>60%), suggesting 
that RTS cells have a fundamentally compromised ability to progress through the 
cell cycle.
The overall observation that BIRB796 consistently reduces the proportion of 
cells in Gi, suggests that BIRB796 can trigger cells to re-enter the cell cycle within 
one cell cycle transit. Furthermore, it suggests that that there is a common 
mechanism of restraint and cells may differ from each other on the basis of the 
proportion of cells available for such modulation. The studies do not, however, 
address whether there are intrinsic differences in p38 inhibitor sensitive pathways 
operating in the different Gl syndrome strains. The finding that the reduction in the 
Gi fraction was in the order of <5% of the entire population in all cell strains 
suggests that whole population analyses do not have the resolution to assess the 
early effect of BIRB796 on cell cycle dynamics and therefore small differences in 
BIRB796 effect between syndromes may not have been observed using this 
approach.
The observation that there are differences in PE between Gl panel members 
suggests that there may be differences in the level of commitment to cell cycle exit 
in these cells that subsequently impacts on their clonogenic potential. For example, 
compared to normal cells, RTS, NBS, LIG4, WS and HGPS syndromes had a 
lower PE suggesting that these cells show a greater proportion of cells in which 
restraint operates. Given the functional definition of NC, MCP and FCP, it was
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shown that the majority of cells (<80%) in all cell strains were NC. The simplest 
explanation for this is that the conditions for clonogenic analysis require cells to be 
seeded sparsely which is known to reduce the growth potential of these cells. 
However, these findings are consistent with the observation that the majority of 
cells were seen to be in Gi when analysed by flow cytometry.
The observation here that BIRB796 increases the PE of all cells is 
consistent with the findings from the flow cytometric analysis that BIRB796 reduces 
the percentage of cells in Gi. These findings suggest that there is a common 
mechanism that limits retention in or re-entry into cycle in all cells that it is 
dependent, at least in part, on p38. Furthermore the findings suggest that the 
target population for BIRB796 action include cells that are both non-clonogenic and 
those that show MCP. However, there appear to be subpopulations of cells within 
each cell strain that are non-responsive to BIRB796 and the proportion of these 
subpopulations appear to differ between syndromes. The differences in the effect 
of BIRB796 on different cell strains suggest that there are inter-strain differences in 
the target population for BIRB796 action and in the presence of non-responsive 
subpopulations; however, it is also possible that these differences are due to 
differences in growth rate of cells between strains.
Further analysis of WS revealed that the main action of BIRB796 is to 
increase the likelihood of a cell reporting as ‘clonogenic’ when defined at a specific 
colony size (e.g. FCP). The observation that BIRB796 did not increase the 
maximum colony size suggests that there is a limit on the maximal population 
doubling rate observed in WS populations and that this is not affected by exposure 
to BIRB796. The population doubling rate is a function of cell cycle transit time 
(e.g. inter-mitotic time or IMT) and the probability of cell division (asymmetry). 
Distinction between these factors would require single cell tracking analysis. 
Overall the data suggest that subfractions of WS populations should be capable of 
presenting a normal population doubling rate (at least over a period of 10 days) 
and that such subfractions might be refractory to BIRB796. These findings would
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warrant further investigation using single cell tracking analysis to test this 
hypothesis.
To further assess the role of increased levels of SIPS on the clonogenic 
potential of cells it may be possible to use a known biomarker, such as SA-|3gal, to 
identify the proportion of senescent cells within each colony in an attempt to 
identify whether there is a relationship between the level of SIPS and colony size. 
As a preliminary study, simple observation of the differences in cellular morphology 
of MCP and FCP colonies was undertaken, and appears to suggest that the 
majority of cells in MCP colonies are enlarged, which is suggestive of early 
senescence compromising the clonogenic lineage, whereas the majority of cells in 
the larger colonies are small and spindle-like (data not shown). These data suggest 
that a more in depth analysis of cell lineages could be informative.
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Figure 7.1. Impact of BIRB796 on cell cycle dynamics of hTert-immortalised Gl 
syndrome cells.
Cells were grown continuously in the presence (+) or absence (-) of BIRB796 for 24 
hours prior to analysis. (A) shows the full cell cycle analysis, (B) shows the proportion of 
cells in cycle (designated as G 2 +S). Data obtained from a single experiment analysing 
>9000 gated events with a sampling error of <5%.
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Figure 7.2. Time of flight (TOF) for normal, RTS and WS cells.
TOF (FL2-A) versus total cellular fluorescence associated with DNA (FL2-A) of A) 
AG16409(N)hTert, B) AG18371(RTS)hTert and C) AG3141(WS)hTert cells. Cells were plated 24 
hours prior to the experiment start time to allow time for attachment and grown for 24 hours 
prior to analysis.
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Figure 7.3. Impact of BIRB796 on the clonogenic potential of hTert-immortalised Gl cells.
A) shows the proportion of cells showing MCP [>4(but <50 cells)] and FCP (>50 cells) in the 
presence (+) and absence (-) of BIRB796, calculated as a percentage of the total cells 
seeded (4000 cells). B) shows the plating efficiency (PE), given as the percentage of 
colonies containing >4 cells out of the total cells seeded. n=4 ±SD; single experiment.
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Figure 7.4. Impact of BIRB796 on colony size distribution for hTert-immortalised W S cells.
W S cells were grown continuously in the presence (closed squares) or absence (open 
squares) of BIRB796 as previously described for clonogenic assays. The number of cells 
in every colony in the dish was counted and the cumulative frequency of colonies of each 
size was plotted. Panel B shows the same data as panel A on an expanded axis showing 
that treatment with BIRB796 results in an excess of colonies of approximately >50 cells. 
Data represent an average for 4 dishes.
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Chapter 8 Single cell analysis
8.1 Introduction
The thesis so far has revealed the problems for interpretation associated with 
studying heterogeneous cell cultures at a whole population level. The findings have 
shown that some Gl syndrome cells have a reduced replicative potential compared 
to normal cells, however, these studies are complicated by inter-strain 
heterogeneity. Despite the known caveats of the previous studies, the findings 
support the hypothesis that a given population of cells in culture comprises cells 
with different replicative capacities and the relative proportions of these contribute 
to the replicative capacity of the population as a whole. Furthermore, the findings 
suggest that the reduced replicative potential observed for some of the Gl 
syndromes is due to a reduction in the proportion of cells that have clonogenic 
potential (Chapter 7). BIRB796 has been shown to increase the clonogenic 
potential of all cell strains and appears to act by allowing cells to re-enter the cell 
cycle. However, the extent of the differences in the proportions of these 
subpopulations in Gl syndrome cells compared to normal cells remains unclear. A 
solution addressed in this chapter is to study the Gl syndrome populations at a cell- 
by-cell level to assess the differences in the proportion of subpopulations with 
different division capacities.
Time-lapse microscopy can be described as the repeated collection of a field 
of view from a microscope at discrete time intervals (Allen 1985). The duration of 
the time interval defines the temporal resolution, which in turn characterises the 
type of event detected. Dynamic in vitro cell-based assays derived from high- 
content time-lapse microscopy, where time is the quality parameter, allow 
interrogation of spatio-temporal cellular events in a population context to be 
analysed (Khan et al. 2007; Marquez et al. 2003). Time-lapse has been used 
extensively to study the division capacity of single cells within heterogeneous 
populations (Errington et al. 2010; Errington et al. 2005b; Forrester et al. 2000;
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Marquez et al. 2003). Transmission phase time-lapse offers a relatively non- 
perturbing method that allows individual cells to be tracked and cellular events 
such as mitosis to be recorded. Furthermore, this approach provides information 
on cell morphology (essentially cell shape and cell size) and cell motility and 
changes in these basic features can be used to indicate cell behaviour interacting 
on a two-dimensional substrate. By tracking sequential events on a cell-by-cell 
basis, time-lapse microscopy provides high-content, multi-level descriptors of cell 
dynamics that can be mined through bioinformatics tools (Khan et al. 2007). 
Pragmatically, time-lapse also provides a means of independently tracking highly 
informative (often minority) subpopulations using only relatively small populations. 
Given the limited access to and reduced replicative potential of many of the Gl 
syndrome cells, the application of such techniques was deemed to be critical to the 
further study of these cells. Therefore, a subsidiary aim was to assess the 
feasibility of application of this technique to the study of Gl syndrome cells.
Here an extensive study of Gl syndrome fibroblasts at the single cell level has 
been undertaken using time-lapse. The banked images provide a future resource 
for additional hypothesis testing, while the data gathered here were used to 
address the focus of the thesis. The study provides extensive information regarding 
the division capacity and motility of these cells. However, the data analysis in this 
chapter aims to answer three fundamental questions that have been brought into 
focus by previous findings in the thesis using selected cell strains. These are 
outlined below.
8.2 Materials and Methods
8.2.1 Time-lapse imaging
The objective of this study is to track mitosis events for every cell in the start 
field. Images were taken at 30-minute intervals to satisfy the Nyquist sampling 
criteria for ensuring that all of the mitotic events are captured in the analysis. Given 
the recent observation that cells tend to show a Gumbel distribution (used to model 
extreme values) of inter-mitotic times (IMTs) (Errington et al. 2010), with some 
outliers that have elongated cell cycle transit times, cells were imaged over a 72
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hour period for hTert-immortalised cells, and 96 hours for primary cells to provide 
the best opportunity to track multiple mitotic events. Images were collected for four 
independent fields for hTert-immortalised cells and for six independent fields for 
primary cells. Time-lapse images were stacked and saved as *.stk or *.AVI format. 
MetaMorph software (Molecular Devices) was used to view the stacked image as a 
sequence of images that were then were analysed manually.
8.3 Aims
The aims address three fundamental questions (Figure 8.1).
1. Is there a difference in the probability of entering mitosis in RTS and WS 
cells compared to normal cells? Is this affected by BIRB796?
2. Is there a difference in the time taken to traverse the cell cycle (nominally 
the range of IMT values) in RTS and WS compared to normal cells? Is this 
affected by BIRB796?
3. What are the lineage characteristics of RTS and WS cells compared to 
normal cells? For example is there a difference in the proportion of cells that 
are capable of 2 or more divisions, reflecting how many cells show MCP. Is 
this affected by BIRB796?
The strategy here is to use 
time-lapse imaging to: 1,
determine the proportion of 
dividing and non-dividing cells in 
RTS, WS and normal cell
populations; 2, determine the IMT
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allows a more thorough characterisation of cellular morphology in these 
heterogeneous cultures and allows a correlative investigation of cell size and 
division capacity.
8.4 Results
8.4.1 WS and RTS fibroblasts show a higher probability of cell cycle exit 
compared to normal fibroblasts.
To investigate the potential differences in commitment to division in RTS, WS 
and normal cells, the proportion of dividing and non-dividing cells in both primary 
and hTert-immortalised cultures was assessed. AG18371(RTS) and AG03141(WS) 
were chosen as examples of cell strains that show consistent differences in 
morphology and growth potential compared to normal cells. This study also 
provides a unique opportunity to investigate the cellular responses to a RECQL4 
mutation, something that has not previously been studied. The approach was to 
use a standard plating regime resulting in a range of cell densities for the start field 
(160-597 cells) according to cell strain. Table 8.1 shows that primary 
AG18371 (RTS) and AG03141(WS) cells contain a higher proportion of non­
dividing cells compared to AG16409(N) cells. These data suggest that both 
AG18371 (RTS) and AG03141(WS) cells have a higher propensity for senescence 
compared to normal cells; however, it is not clear whether this is due to replicative 
senescence (induced by telomere shortening) or due to SIPS. To investigate this, 
the proportion of dividing and non-dividing cells in hTert-immortalised cells was 
assessed. These data show that hTert-immortalised cells consistently show a 
lower proportion of non-dividing cells than their primary counterparts (Table 8.1), 
suggesting that some of the non-dividing cells in primary cultures from all three 
strains represent cells that are undergoing replicative senescence. Although the 
overall proportion of non-dividing cells is lower in hTert cells, the pattern across the 
three cell strains is the same, with both AG18371(RTS)hTert and AG03141(WS)hTert 
cells containing higher proportions of non-dividing cells compared to 
AG16409(N)hTert cells. Here it is postulated that the difference in the proportion of 
non-dividing cells in the hTert-immortalised cells compared to primary cells is due
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to the removal of one set of stress signals (i.e. those arising from shortened 
telomeres) so that that non-dividing cells in hTert populations could be subject to 
ongoing SIPS. Accordingly, the findings suggest that both AG18371(RTS)hTert and 
AG03141(WS)hTert cells contain a higher proportion of cells that are undergoing 
SIPS compared to AG16409(N)hTert cells.
Treatment with BIRB796 consistently reduces the proportion of enlarged cells 
in both primary and hTert cells; however, the effect of BIRB796 is greater in 
primary cells (Figure 8.2). In primary AG16409(N) cells treatment with BIRB796 
results in a reduction in the proportion of non-dividing cells, although this effect is 
minor. The proportion of non-dividing cells in AG16409(N)hTert cells following 
BIRB796 treatment is relatively unchanged. Both primary AG18371 (RTS) and 
AG03141(WS) cells show a greater reduction in the proportion of non-dividing cells 
following BIRB796 treatment when compared to normal cells. Although the effect of 
BIRB796 in hTert cells is reduced compared to primary cells, both 
AG18371(RTS)hTert and AG03141(WS)hTert cells show a greater reduction in the 
proportion of non-dividing cells following BIRB796 treatment when compared to 
AG16409(N)hTert cells.
Given the issues associated with characterising cellular morphologies that may 
be indicative of differences in the level of SIPS in Gl syndrome cells (Chapter 3), 
this study provided the opportunity to undertake a quantitative assessment of cell 
size in the three cell strains. Although not one of the primary objectives of this 
analysis, the method of data recording trialled here permitted a preliminary analysis 
of the relationship between proliferative potential and progenitor cell size with 
indications that this approach could have sufficient resolution to profile dividing and 
non-dividing subpopulations. Figure 8.3 shows that WS and RTS cell populations 
consist of some cells that are with the normal size range; however, there appear to 
be other cells that are much larger than those observed in normal cells. Overall, 
the mean cell size is greater in RTS and WS cells compared to normal cells, 
suggesting that these cells contain more arrested/senescent cells compared to 
normal cells. Differences in the shape of the cell also appears to relate to division
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potential, for example, some cells have a large area due to their elongated 
morphology, whereas other cells are polygonal in shape. Preliminary studies show 
that it is the enlarged, polygonal-shaped cells that tend to be non-dividing (data not 
shown).
8.4.2 WS traverse the cell cycle more slowly than normal cells.
To determine the IMT of AG16409(N)hTert, AG18371(RTS)hTert and 
AG03141(WS)hTert cells, only progenitor cells that committed to at least one mitosis 
qualified for analysis. These were manually tracked and the time between 
subsequent mitoses were calculated. By definition, only those cells that underwent 
a second division were informative for this study. Therefore the IMT given for the 
three cell strains does not take into account those cells that divided once but failed 
to divide again over the course of the experiment. To avoid any issues associated 
with changing IMT in successive generations, the IMT of first generation events 
alone were studied. Figure 8.4 shows that AG16409(N)hTert and AG18371(RTS)hTert 
cells have a similar IMT (-20 hours), whereas AG03141(WS)hTert cells have an 
extended IMT of -28 hours (Rodriguez-Lopez et al. 2002; Rodriguez-Lopez et al. 
2003). Treatment with BIRB796 has a very minor effect on the IMT of both 
AG16409(N)hTert and AG18371(RTS)hTert cells, but has a greater effect on the IMT 
of AG03141 (WS)hTert, reducing it to -24 hours. These data suggest that the 
progression of AG03141(WS)hTert cells, but not AG18371(RTS)hTert cells, through 
the cell cycle are restrained in some way by p38-dependent processes.
8.4.3 Proliferative success of WS cells
Given that there is a higher proportion of non-dividing cells in WS, the cells 
must have exited the cell cycle at a greater rate (higher probability). Therefore the 
question arises -  can a signature of loss of proliferative potential be seen in cells 
that initially show proliferative capacity? More importantly can this be examined 
under normal culture conditions and not the challenging low densities required for 
conventional clonogenic assays? Lineage tracking allows this to be achieved 
providing an ‘in situ’ clonogenic assay. Given that the mean IMT for 
AG03141(WS)hTert was found to be -28 hours, it was decided that a 72 hour time
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course would be sufficient to see two subsequent mitoses (28 + 28 = 56 plus a 14 
hour buffer). Pragmatically, the decision was made to extend the analysis to a 
more in depth lineage analysis to study the proliferative potential of 
AG03141(WS)hTert cells over a short period of time. To qualify for this analysis a 
cell must divide at least once. Consistent with this, Table 8.2 shows that all cells 
undergo one division, designated generation 1. These data also show that -80% of 
both AG03141(WS)hTertand AG16409(N)hTert cells divide a second time, designated 
as generation 2. Treatment with BIRB796 increases the proportion of progenitor 
cells that undergo two divisions in both AG03141(WS)hTert and AG16409(N)hTert 
(Table 8.2). Figure 8.5 shows the impact of BIRB796 on the clonal potential of 
AG03141(WS)hTert and AG16409(N)hTert cells given by the number of progeny 
produced from a single progenitor cell. In AG16409(N)hTert cells the majority of 
progenitor cells give rise to small numbers of progeny (2-4). As expected there is a 
decline in the proportion of progenitor cells that give rise to larger numbers of 
progeny, with a maximum of 15 progeny being generated from a single progenitor 
cell (Figure 8.5A). A similar pattern is observed for AG03141(WS)hTert cells in which 
the majority of progenitor cells generate small numbers of progeny (2-3) (Figure 
8.5B); however, a maximum of only 10 progeny are produced from a single 
progenitor in AG03141(WS)hTert cells, suggesting that the maximal clonal expansion 
potential of AG03141(WS)hTert cells is restrained. In general, BIRB796 reduces the 
proportion of progenitor cells that generate highly restricted progeny numbers (2-3) 
but increases the proportion of progenitor cells that generate larger numbers of 
progeny in AG16409(N)hTert cells; however, BIRB796 does not increase the 
maximum number of progeny produced from a single progenitor (having already 
qualified as having proliferative potential). A similar effect is observed for the 
impact of BIRB796 on AG03141(WS)hTert cells, although the BIRB796 does 
increase the maximum number of progeny produced from a single progenitor from 
10 to 11 progeny.
8.5 Discussion
Previous findings in the thesis suggest that the reduced clonogenic potential 
of RTS and WS cells is due to the dual effects of an increase in the proportion of
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cells that are non-clonogenic and a reduced clonal expansion potential of cells that 
have clonogenic potential. The data presented in this chapter demonstrate the 
extent to which WS and RTS populations consist of dividing and non-dividing cells 
compared to normal cells (aim 1). Indeed, primary RTS and WS cultures show a 
significant increase in the proportion of non-dividing cells. The observation that the 
proportion of non-dividing cells is reduced in all hTert-immortalised cultures 
compared to their primary counterparts suggests that replicative senescence 
contributes to the reduced replicative capacity of all three strains. Despite the 
known caveats associated with differences in the fraction of cells from which the 
hTert populations are drawn from, it was assumed that the non-dividing cells in 
hTert-immortalised cultures represented those that were undergoing SIPS. Given 
this assumption, the findings that both AG18371(RTS)hTert and AG03141(WS)hTert 
cultures contained a higher proportion of such non-dividing cells suggest that RTS 
and WS cultures contain more cells that are undergoing SIPS compared to normal 
cells. Clearly, the proportions of and progression within these states contribute to 
overall replicative capacity.
The observation that BIRB796 consistently increases the number of dividing 
cells in normal, RTS and WS cells suggests that all three strains contain a fraction 
of cells that are “out of cycle” and whose re-entry into the cell cycle is restrained by 
p38. This is consistent with earlier observations made in chapter 7 that BIRB796 
can increase clonogenic potential by recruiting a subpopulation of cells that were 
previously non-clonogenic. These findings also suggest that BIRB796 has the 
same effect on normal cells as it does on RTS and WS at the single cell level; but 
because there is a greater proportion of cells that are available for BIRB796 action 
(i.e. a greater number of non-dividing cells) in RTS and WS cultures, BIRB796 has 
a greater apparent effect at the population level.
The second major finding was that WS cells appear to have an elongated cell 
cycle transit time as indicated by a longer average IMT compared to normal cells, 
whereas RTS cells have an IMT comparable to that of the normal reference. The 
limited comparison with a single ‘normal’ stain is noted. BIRB796 was shown to
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reduce the IMT of WS cells but did not affect the IMT of normal or RTS cells, 
suggesting that WS cells, but not RTS cells, show some degree of p38 restraint on 
their progression through the cell cycle.
Lineage analysis allowed clonal expansion to be tracked. Once a cell has been 
identified as being capable of division, the number of progeny produced from a 
single progenitor cell is similar in both WS and normal cells. However, there is 
some evidence that the maximum number of progeny produced from a single 
progenitor cell is reduced in WS compared to normal cells. These findings suggest 
that the reduced replicative potential of WS cells may be due to the dual effects of 
a greater proportion of non-dividing cells and a reduced clonal expansion potential 
for cells having residual division capacity. However, it is possible that the reduction 
in the maximum number of progeny generated from a single progenitor cell in WS 
may simply reflect the extended IMT and given more time the same number of 
progeny would be generated as seen for normal cells. Extended time-lapse studies 
could address this point. For example, in order to generate 15 progeny in a 72 hour 
period, a lineage must be highly branched, synchronised and have a relatively 
short IMT. Therefore, it is not clear as to whether the reduction in clonal potential 
for some progenitor cells is due to increased asymmetry in the division potential of 
sister cells in subsequent generations or an increasing IMT. Data recording of 
extended lineage analysis would allow a bioinformatics approach to study such 
complexity.
Overall, these data suggest that the reduced replicative potential observed for 
WS cells is due to a slightly extended cell cycle traverse time and a higher 
propensity for cell cycle exit due to SIPS. Similarly, a higher rate of SIPS is shown 
to occur in RTS cells, however, these cells traverse the cell cycle normally. These 
findings suggest that analysis of population growth of WS should take into account 
the impact of the increased drop out rate, since the division-competent cells are 
required to undergo more divisions for the population to double, therefore it is likely 
that replicative senescence of the division-competent subpopulation is realised
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more quickly and therefore appear to increase when viewed at the whole 
population level versus passage age.
Clearly, models that account of the abnormal growth WS cells need to take into 
account the dual impact of the increased probability of cell cycle exit and 
compromised cell cycle traverse. In such models, the impact of p38 inhibition 
appears to have a greater impact on recruitment of cells into cycle rather than on 
regularising any underlying defect in cell cycle traverse. This leads to a model in 
which p38 restraint has selective effects in cell cultures with underlying differences 
in endogenous stress signalling. These aspects are discussed below.
In summary the main findings of this chapter are:
• AG03141(WS)hTert and primary AG03141(WS) cells show an increased 
proportion of non-dividing cells compared to primary and hTert-immortalised 
AG16409(N) cells.
• Similarly, AG18371(RTS)hTert and primary AG18371 (RTS) cells show an 
increased proportion of non-dividing cells compared to primary and hTert- 
immortalised AG16409(N) cells, although the proportions on non-dividing 
cells are not as high as those seen in AG03141(WS) cells.
• hTert-immortalisation reduces the proportion of non-dividing cells in RTS 
and WS cells suggesting that telomere-independent senescence (i.e. SIPS) 
may contribute to the reduced division capacity of these strains.
• AG18371(RTS)hTert cells have a normal IMT (-20 hours) but 
AG03141(WS)hTert cells have an elongated IMT (-28 hours), suggesting that 
WS AG03141(WS)hTert cells traverse the cell cycle slower than normal.
• AG03141(WS)hTert cells show a reduced clonogenic potential as assessed 
by lineage analysis compared to AG16409(N)hTert cells.
• BIRB796 consistently reduces the proportion of non-dividing cells in both 
hTert-immortalised and primary AG03141(WS), AG18371 (RTS) and
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AG16409(N) cells, suggesting that BIRB796 stimulates cells to re-enter the 
cell cycle.
• BIRB796 reduces the IMT of AG03141(WS)hTert cells but has little effect on 
the IMT of AG18371(RTS) and AG16409(N) cells, suggesting that 
AG03141(WS)hTert cells show some degree of p38-mediated restraint on cell 
cycle progression.
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Table 8.1. Proportion of dividing and non-dividing cells in normal, RTS and 
W S cells.
Cell strain
No. cells in 
start field* % Dividing
% Non­
dividing
AG16409(N) 597 71.7 28.3
AG16409(N)nTERT 267 81.0 12.4
AG18371(RTS) 398 55.0 45.0
AG18371 (RTS)hTERT 160 57.5 42.5
AG03141(WS) 315 39.0 61.0
AG03141 WS)hTERT 173 45.7 53.8
* Pooled data were obtained from 6  independent fields for primary cells 
and 4 independent fields for hTert-immortalised cells. The number of 
cells in the nominal start field is given as the sum of all fields minus the 
number of cells lost from the field during the analysis.
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Table 8.2. Proportion of progenitor cells that undergo one 
or two divisions in 72 hours.
Cell strain n* BIRB
% progenitor cells that 
give rise to: 
gen 1 gen 2
Normal 42 - 100 79
23 + 100 91
WS 23 - 100 78
21 + 100 86
*n= number of lineages analysed.
Gen1 represent progenitor cells that undergo one division, 
and gen 2  represent progenitor cells that undergo two 
divisions.
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Figure 8.2. Impact of BIRB796 on commitment to division.
Panel A shows the proportion of dividing and non-dividing 
cells in primary normal, RTS and WS cells, Panel B shows the 
same for hTert-immortalised cells. Data were obtained from 6  
independent fields for primary cells and 4 independent fields 
for hTert-immortalised cells.
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A B
No. progenitor Mean cell Max cell Min cell
Cell strain cells (n») size size size
AG16409(N)
AG16409(N)hTERT
AG18371(RTS)
AG18371(RTS)hTERT
AG03141(WS)
AG03141(WS)hTERT
625 4022 22896 1200
267 3634 24656 1008
490 5860 43280 1520
197 8611 23968 1792
321 9997 48720 1776
260 7784 28413 1392
Figure 8.3. Quantitative analysis of cell size in 2D culture.
Panel A shows a typical field with regions traced to identify individual cell size of the 
progenitor cells. Panel B shows a table of the mean cell size, given as the mean of all of 
the cells in all of the fields, and of the maximum and minimum sizes observed in each 
population.
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Mean 
IMT ± SD
AG16409(N)hTERT - 20.63 ± 3.6
AG16409(N)hTERT + 20.71 ± 6.3
AG8371(RTS)hTERT - 19.49 ± 5.5
AG8371(RTS)hTERT + 19.21 ± 3.0
AG03141 (WS)hTERT - 26.78 ± 13.2
AG03141(WS)hTERT + 23.61 ± 10.5
BIRB
Figure 8.4. Impact of BIRB796 on inter-mitotic time for normal, RTS and WS fibroblasts.
Cells are grown in the presence or absence of BIRB796 and imaged using time-lapse 
microscopy. A: Range of IMTs observed, mean is indicated by large black cross. B: Mean IMT ± 
SD. Data obtained from 4 independent fields. Inter-mitotic times are calculated based on 1st 
generation events.
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Figure 8.5. Impact of BIRB796 on the clonal potential of (A) A G 16409(N )niert and (B) 
A G 03141(W S )hTert cells.
Bars represent the proportion of progenitor cells that generate a given number of 
progeny within 72 hours, n = number of lineages analysed. Schematic 
representations of example lineages that generate 3 or 15 progeny are indicated 
above panel A.
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Chapter 9 General Discussion
This study arises from a background of evidence that suggests that WS cells 
undergo increased levels of SIPS. This includes the observation that WS cells 
have a truncated lifespan, senescent-like morphology including prominent stress 
fibres and elevated levels of activated p38 (Davis et al. 2005; Davis et al. 2006). 
Here, the proposal was that Gl syndrome cells could share similar properties -  not 
least a putative common dependence on p38-mediated pathways. The study 
reveals a commonality of response to p38 inhibitors amongst normal and Gl 
primary cells and that following alleviation of stress from telomere attrition hTert- 
immortalised cells remain susceptible to SIPS. The thesis highlights successful 
approaches to testing the impact of p38 inhibitors by teasing out the nature of 
cellular heterogeneity arising from different sources, with implications for in vitro 
studies in carcinogenesis, senescence and physiological controls of cell 
proliferation.
The primary aim of this thesis was to identify any differences in fibroblast 
behaviour that may be indicative of SIPS in cells undergoing low levels of Gl, such 
as those derived from individuals with Gl syndromes. The findings (Chapter 3) 
indicate that a number of the Gl syndrome strains, including AG18375(RTS), 
GM07166(NBS), GM01774(DKC), GM18366(SS), all three HGPS strains and both 
LIG4 strains, have a truncated lifespan compared to normal cells, which may 
potentially reflect increased levels of SIPS in these cells. Reduced growth capacity 
compared to normal controls has been previously reported for BS, CSA and HGPS 
(Goldstein 1979; Thompson and Holliday 1983), but not for NBS, LIG4, RTS or SS, 
therefore this study provides novel information regarding the growth potential of 
these cells. Furthermore, these studies provide a coherent parallel comparison of 
growth potential in primary cell strains with different genetic backgrounds. 
Consistent with previous findings in the literature (Absher and Absher 1976; 
Absher et al. 1974; Cristofalo et al. 1998a; Martin and Sprague 1973; Passos and 
von Zglinicki 2007; Pious et al. 1964), the current study revealed marked
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heterogeneity in the growth potential of different normal cell strains as well as 
between strains from the same Gl syndrome. These findings suggest that there are 
inherent differences in the level of commitment to senescence (SIPS and/or 
replicative senescence) in primary cells that are not dependent on genetic 
background. Given that the assumption in this thesis is that the proportion of 
senescent cells in a population increases over time, the most likely explanation for 
the observed inter-strain differences are that they are due to differences in 
passage histories of the individual strains. These issues are discussed further 
below.
Studies using a range of p38 inhibitors with different modes of action suggest 
that whether p38 inhibition was achieved by induction of a conformational change 
in the active site of p38 (e.g. BIRB796) or by blocking p38 activation but not its 
phosphorylation (e.g. SB203580), the impact of inhibition consistently increased 
the growth potential. This reveals a commonality of p38 inhibitor responses in 
primary cell strains. Furthermore, the findings suggest that both normal and Gl 
syndrome cell strains in culture undergo some degree of p38-mediated proliferation 
restraint that can be relieved by p38 inhibition. Given the previous evidence that 
p38 inhibition does not prevent telomere-attrition driven replicative senescence and 
thus has a reduced effect on cells that are close to replicative senescence (Davis 
et al. 2005), the observation here that some cell strains show a truncated lifespan 
and yet have a relatively normal response to p38 inhibitors, suggests that these 
cells may simply be closer to replicative senescence due to strain history. In 
contrast, other strains, such as GM18366(SS) and to a greater extent 
GM07166(NBS), show a striking response to p38 inhibition, suggesting that the 
reduced replicative potential of these cells is derived from a greater commitment to 
SIPS.
An extensive screen of the cellular morphology of these cells was also 
undertaken to identify any morphological features that were indicative of cells 
undergoing SIPS, such as stress fibre presentation, and to assess the feasibility of 
such features as biomarkers of differences in the underlying commitment to
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senescence in these cells. The findings show that a complex relationship exists 
between growth arrest and the presentation of stress fibres, suggesting that stress 
fibre presentation accompanied enlargement as might be expected given the 
functional co-relationship. However, there were no clear trends relating stress fibre 
presentation with genetic background. These findings raise the need for a more 
quantitative assessment of cellular morphology, perhaps using cell size, rather 
than stress fibre presentation, as a marker of growth arrest. All cell strains tested 
showed a reduction in the proportion of enlarged cells following p38 inhibition. In 
general, these effects were minor, with the majority of cell stains showing a similar 
response as normal cells. However, some exceptions were observed, for example, 
both GM07166(NBS) and GM18366(SS) cell strains showed a higher proportion of 
enlarged cells, with cells estimated to be much larger than those observed in 
normal strains, and showed greater responses to p38 inhibitors. It is likely that the 
degree of enlargement relates simply to the time spent in arrest. Therefore the 
frequency of event detection and the degree of enlargement will be dependent 
upon the rate of proliferation of non-arrested cells and the effective dilution of 
arrested cells at subsequent passages. It is reasonable to suggest that Gl 
syndrome cells have an added layer of complexity due to the impact of the 
molecular defect on each of these features.
Overall, these studies provide valuable information regarding the heterogeneity 
in growth potential and cellular morphology of primary fibroblasts. Importantly, 
heterogeneity could not be ascribed primarily to differences in genetic background. 
Given the complications associated with the uncertain replicative histories of some 
of the cell strains used, this study underlines the difficulty of comparing Gl 
syndrome cell strains that may have different degrees of commitment to 
senescence due to telomere attrition. Thus the findings highlight the need to 
disassemble the complexity and history of these primary cell systems in order to 
study the impact of SIPS.
Given the restricted replicative potential of some Gl strains, and the lack of 
availability of early passage culture the project sought to establish an hTert
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immortalised panel of cell strains for more extensive studies in which lifespan is not 
limited (Chapter 5). The findings showed that ectopic expression of hTert is 
sufficient to extend the lifespan of all of the above cell strains beyond their normal 
senescence point. Importantly, the current study shows that RTS cells can be 
immortalised by ectopic expression of hTert, something that was not previously 
known. This provides a valuable measure for the study of RECQL4 helicase gene 
mutation. Thus, the work successfully established a bank of hTert-immortalised 
AG16409(N), AG18371 (RTS), GM02548(BS), GM07166(NBS), GM01856(CSA), 
AG11498(HGPS) and GM17523(LIG4) cell strains, providing a comparative 
resource. Pragmatically, the panel addresses the problems associated with 
working with primary fibroblasts that have a limited replicative lifespan, and 
provides a way of generating enough cells for further analysis. Importantly for this 
thesis, the implicit removal of stress signals associated with telomere attrition, that 
may obscure the impact of any endogenously generated stress signals, provides a 
unique opportunity to examine inherent differences in the cellular response to 
damage or p38 inhibitors in a panel with known molecular defects (addressed 
below).
The next aim of the thesis was to assess the activation status of p38 in 
primary cells undergoing low levels of Gl. Here, studies revealed that the level of 
p38 activation in Gl syndrome cells is similar to that observed for normal cells, 
although some inter-strain (and intra-GI syndrome) variation is observed. Given 
these findings, there are two possible explanations for the impact of p38 inhibitors 
on the growth potential and morphology of these cells. First, it is possible that 
relatively small changes in p38 activation are translatable into significant changes 
in the parameter of in vitro growth potential due to the exponential nature of growth 
changes over time and therefore the expansion of differences with time. Studies 
focusing on changes in p38 activation at a single cell level may provide a means of 
assessing the p38 activation status in informative cells when these are relatively 
infrequent in the population (see below). Secondly, it is possible that the small 
changes in replicative potential observed for most cultures are due to a 
combination of p38 inhibition and other off-target effects. The observation was
238
made that VX745, which is deemed to be highly specific for p38 (Lee and 
Dominguez 2005), consistently shows the smallest effects on cell growth. Thus 
action on off-targets may contribute to the observed impact of the p38 inhibitors. 
However, it was proposed that the use of multiple inhibitors, reducing the impact of 
specific off-target effects, confirm p38 involvement.
The finding that hTert-immortalisation reduced the level of detectable p38 
activation in normal cells, but not in Gl syndrome cells, suggests that the major 
stress signals giving rise to growth restraint in normal cells is due to telomere 
attrition, whereas Gl syndrome cells may have the added burden of SIPS. These 
findings suggest that the hTert panel provides an accessible model in which to 
study the differences in commitment to SIPS in Gl syndrome cells compared with 
normal cells.
The hTert panel was deployed in a range of studies aimed at investigating
whether hTert-immortalised Gl cells remain susceptible to SIPS following exposure
to DNA-damaging genotoxic agents (Chapter 6). The findings indicate that all cell
strains show hypersensitivity to DNA Table 9.1. Summary of drug sensitivities in
hTert-immortalised Gl syndrome fibroblasts
damage induced by at least one of the 
agents tested (see table). Specifically, all 
strains, with the exception of LIG4 cells, 
showed hypersensitivity to CPT. This may 
relate to the distinct S-phase (in cycle) 
selectivity of CPT. There is little 
consistent evidence in the literature for 
the sensitivity of Gl syndromes with 
known molecular defects to damage 
induced by genotoxic agents. Thus, the
present study provides a unique opportunity for coherent comparison of the 
sensitivity of Gl syndrome cell strains to general genotoxic damage using a 
standard technique. Although there is some evidence in the literature for the 
sensitivity of Gl syndrome cells, such as WS and BS, to genotoxic agents (Mao et
Syndrome Molecular
defect
Previous 
evidence of 
sensitivity to 
DNA damage
Evidence of 
sensitivity to 
DNA damage 
from current 
study
RTS RECQL4 YES 
(CPT. DOX, 
H20 2)
YES 
(CPT, CisPt)
CSA CSA YES 
(CPT, 4NQO)
YES 
(CPT, 4NQO)
BS BLM YES 
(CPT. CisPt)
YES 
(CPT, DOX)
NBS NBS1 YES
(CPT)
YES
(4NQO)
LIG4 LIG4 YES
(CisPt)
YES
(DOX)
HGPS Lamin A YES YES
(LMNA) (CPT) (CPT, DOX, 
CisPt)
WS W RN YES 
(CPT, 4NQO)
YES
(CPT)
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al. 2010) (Table 6.1), other syndromes, such as LIG4 and HGPS, have yet to be 
studied. Recently, two systematic studies of the sensitivity of RTS cells to a panel 
of genotoxic agents have been reported, both of which show conflicting results 
(Cabral et al. 2008; Jin et al. 2008). As a critique of such studies, here it is noted 
that Cabral et al evaluated cytotoxicity based on cell proliferation and MMT survival 
test after only 4 days, whereas Jin et al used a colony forming assay performed 
after 10-14 days. The MTT assay is a gross measure of residual metabolic activity 
in which arrested cells would provide a persistent signal. Jin et al did not consider 
the kinetic limitations of a colony forming assay. In addition, there were differences 
in the concentrations and exposure times to each of the drugs between the two 
studies. This raises the issues associated with comparing results from studies that 
have used different cell types (e.g. lymphocytes or fibroblasts that have different 
restraints on proliferation, such as contact inhibition) and the use of virally 
transformed cells in which checkpoint dysfunction may obscure the results.
Overall, the findings indicate that despite hTert-immortalisation cells remain 
susceptible to SIPS. The study also shows that recovery from CPT treatment in 
normal, CSA and BS cells was not affected by BIRB796, suggesting that p38 
inhibition alone is insufficient to relieve the restraint on cell cycle progression 
following CPT-induced DNA damage. Here it is suggested that arrest mediated by 
checkpoint activation in response to DNA damage supersedes p38 restraint. 
Whether or not p38 is functionally a minor component of a damage checkpoint 
response in human fibroblasts remains unclear.
A further investigation was undertaken to address whether the hTert panel 
members show any differences in cell cycle dynamics, in particular in cell cycle 
arrest, that may be indicative of differences in the level of commitment to SIPS. 
Here the working hypothesis was that differences in replicative potential reflect the 
degrees of commitment to long-term exit (senescence) from the cell cycle, 
reflecting the probability of transition between “out of cycle” and subsequent “re­
entry”. These studies clearly showed the capacity of BIRB796 to act acutely and 
consistently increase the proportion of cells that were designated as in cycle
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(G2 +S) within 24 hours. The findings suggest that BIRB796 can trigger cells to re­
enter the cell cycle within one cell cycle transit and thus provide information 
regarding the likely target population for BIRB796 action. This view supports the 
earlier finding that there is a common mechanism that limits retention in or re-entry 
into cycle in all cells that it is dependent, at least in part, on p38. Furthermore, 
these findings support and expand previous evidence in the literature that p38 is 
involved in growth arrest (Bulavin and Fornace 2004; Maruyama et al. 2009; Yee et 
al. 2004). It is reasonable to suggest that the p38 restraint acts primarily at the 
Gi/S transition in limiting re-entry into cycle in quiescent cells, since this is the 
primary physiological site for proliferation restraint.
Clonogenic analysis of the Gl syndrome panel revealed differences in the 
clonogenic potential between strains suggesting that some strains show a greater 
level of growth restraint. WS have been shown previously to have a reduced 
clonogenic potential but little information is available for the other syndromes. 
Therefore, this study provides novel information regarding the growth potential of 
these cells. The observation that BIRB796 increased the clonogenic potential of all 
cells supports the previous suggestion of a commonality of p38 restraint in these 
cells. Here it is noted that clonogenic potential, as determined by colony formation 
is a composite of absolute ability to form viable daughters upon cell division and 
the capacity for colony expansion. Further analysis of the impact of BIRB796 on 
the clonogenic potential of WS cells revealed that BIRB796 increases the 
proportion of cells that remain in cycle and therefore contribute to colony 
expansion, resulting in an increase in clonogenic potential. Together, these 
findings suggest that a subpopulation of cells that are BIRB796-responsive, are 
essentially “out of cycle”. Thus, different cell strains may simply differ from each 
other on the basis of the proportion of cells available for BIRB796 action. Overall, 
these studies indicate that stimulation of a non-clonogenic fraction of varying size 
underpins the increase in the clonogenic potential of these cells and explains the 
increase in population following BIRB796 treatment.
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The findings from the previous chapters revealed the presence of 
subpopulations of cells that are undergoing SIPS and suggest that the relative 
proportions of these subpopulations may impact upon the overall replicative 
potential of the strain. However, the findings also revealed that analysis at a whole 
population level did not have the resolution to fully examine the variation in the 
degree of commitment to cell cycle exit and the impact of p38 inhibition on this. 
This challenge was addressed in the last chapter by attempting to disassemble the 
complexity of cellular response to inhibition given the expectation of heterogeneity 
within the cellular systems. Here, the exemplars of RTS and WS cells were studied 
to determine the extent of the differences in commitment to cell cycle exit at a 
single cell level in these cells.
There were three fundamental aims of the final study. The first was to 
assess whether RTS and WS cells show a difference in the probability of entering 
mitosis compared to normal cells. The findings that both primary and hTert- 
immortalised RTS and WS cells show a significant increase in the proportion of 
non-dividing cells compared to their normal counterparts, suggest that the reduced 
replicative potential seen at both a whole population level and in the clonogenic 
analyses can be ascribed to an increase in SIPS in these cells. The findings 
support the original hypothesis that a small increase in the number of cells that exit 
the cell cycle due to SIPS can result in a dramatically reduced replicative potential 
(Figure 1.6). These findings support previous observations in the literature that WS 
cells show features of cells undergoing SIPS (Davis et al. 2005; Davis et al. 2006) 
and provide more definitive evidence of the differences in the proportions of cells 
that may be undergoing SIPS in WS. These studies also provide previously 
unreported evidence for an increased level of SIPS occurring in RTS cells. The 
observation that BIRB796 increases the proportion of cells that can enter cell 
division further supports the idea that all cells are undergoing some degree of SIPS 
and that the transition between in and out of cycle is mediated, at least in part, by 
p38 function.
242
The second aim was to assess whether RTS and WS cells traverse the cell 
cycle at the same rate as normal cells. The findings show that WS cells have an 
elongated cell cycle transit time as indicated by a longer average IMT compared to 
normal cells, whereas RTS cells have an IMT comparable to that of the normal 
reference. This is consistent with previous studies showing that WS cells have a 
prolonged S-phase (Poot et al. 1992) and suggests that the increased IMT in WS 
cells is due to slower progression through S-phase, most likely due to an increase 
in replication fork stalling (Rodriguez-Lopez et al. 2007). The observation here that 
BIRB796 reduces the cell cycle transit time of WS cells but not RTS or normal 
cells, suggests that WS cells have an added restraint on their progression through 
the cell cycle that is limited, at least in part, by p38.
The third aim of the final study was to determine the lineage characteristics 
of l/VS cells compared to normal cells. Initial studies suggest that once a cell has 
been identified as being capable of division, the number of progeny produced from 
a single progenitor cell is weighted towards the generation of fewer progeny in WS, 
with a reduction in the maximum number of progeny produced from a single 
progenitor cell in WS compared to normal cells. These findings suggest that the 
reduced replicative potential of WS cells may be due to the dual effects of a greater 
proportion of non-dividing cells and a reduced clonal potential of those that divide. 
However, it is important to note that the latter feature findings may be affected by 
the elongated IMT for WS and therefore further studies over a longer period of time 
may be required to fully assess the differences in lineage characteristics of WS and 
normal cells.
9.1 Conclusion and cell cycle model
In conclusion, the findings from this study suggest that p38 is involved in 
growth restraint in primary and hTert-immortalised cells. It is reasonable to suggest 
that this occurs primarily at Gi/S transition. The observation that all cell strains 
tested responded to p38 inhibitors suggests that all are undergoing some degree of 
p38-mediated growth restraint - most likely to be due to sub-optimal culture 
conditions. The current study provided a view of the heterogeneity in primary cell
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strains and raised the issue of differences in replicative histories as a means for 
generating heterogeneity observable at a given culture age. The generation of the 
hTert panel provided a unique opportunity to study the impact of endogenously (as 
a result of Gl) and exogenously (induced by DNA-damaging agents) generated 
stress signals in a system not limited by replicative lifespan. Differences in the 
clonogenic potential between members of the hTert panel are ascribed to inherent 
differences in growth restraint. Here it is proposed that growth restraint is a 
compound of differences in the commitment to (or probability of) cell cycle exit and 
subsequent likelihood of re-entry -  representing the observable differences in the 
commitment to SIPS in these cells.
The current study provides an in-depth analysis of the extent to which there 
are differences in the proportion of cells that show division capacity in cell strains
with known molecular 
b ir b 796 defects. Here, both RTS
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(Figure 9.1). p38 inhibition 
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non-dividing cells,
suggesting that p38 
stimulates cells to re-enter 
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the findings in this thesis, it
Figure 9.1. Population status of young unperturbed (no overt is reasonable to suggest 
checkpoint activation) fibroblast cultures governed by p38
restraint the cellular response
to Gl includes an increase in the level of commitment to cell cycle exit.
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According to the method of analysis there is a hierarchy of observable SIPS 
effects and the impact of p38 inhibition. When cultures are analysed over long 
periods (e.g. population doublings over multiple passages), the main effect is the 
exit rate with p38 inhibition permitting a larger cohort of cells to contribute to culture 
growth. When tracking over the medium term (e.g. population expansion capacity 
as in a clonogenic assay set at a given colony size to qualify for ‘clonogenicity’) the 
degree of lineage asymmetry plays a critical role in generation of progeny from a 
progenitor. Finally analysis over the short term (as in single cell tracking) reveals 
fundamental differences in IMT that may arise from genetically determined defects 
in cell cycle traverse overlaid by a stochastic probability of cell cycle re-entry 
following cell division. Given this complexity the degree of response to p38 
inhibition needs to be interpreted within the limits of a given assay.
In an attempt to explain the role of p38 in progression to SIPS based on the 
findings from this study, a mechanistic model is proposed (see figure). This model 
suggests that there are a number of restrains on growth potential, one of which can 
be ascribed to p38 function. The model suggests that p38 may be activated in 
response to low levels of stress, such as endogenously generated stress in Gl 
syndromes or compromised normal cells. Additional over-riding restraints (e.g. an 
activated DNA damage checkpoint), imposed as part of a response to higher levels 
of stress, predominate in the response to DNA damaging agents. In keeping with 
this model, in a system in which the level of stress is negligible, p38 inhibition 
would have no detectable effect on progression through the cell cycle given the 
difficulty of identifying informative cells. Similarly, in a system that was exposed to 
high levels of damage (e.g. exposure to CPT) an over-riding checkpoint would be 
activated and therefore p38 inhibition would have no effect. In contrast, in systems 
that were experiencing low levels of endogenous stress, such as Gl syndrome 
cells, the checkpoint would not be activated or sustained and therefore p38 plays a 
limiting (and therefore inhibitor responsive) role in growth restraint. In this model no 
distinction is made between p38 being a minor part of checkpoint response or a 
weak response pathway distal to checkpoint exit. Thus, p38 inhibition would have 
an effect on growth potential and it is reasonable to suggest that the impact of p38
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inhibition would differ depending on the level of stress. On the other hand, in a 
physiological system low levels of p38-mediated proliferative restraint may act to 
guide longer term tissue kinetics and dynamics and therefore become a critical 
factor in the generation of the multisystem disorder presented by Gl panel diseases 
(e.g. sub-optimal growth and altered tissues in WS).
9.2 Future direction
The suggestions for future study include:
1. Application of single-cell tracking. Successful application of single-cell 
analysis methods to identify inherent differences in the growth potential of RTS and 
WS cells compared to normal cells in Chapter 9 support the feasibility of this 
approach for studying heterogeneous fibroblast populations. These studies show 
that this approach provides a means of identifying differences in the commitment to 
division and allows lineage analysis to identify differences in the clonal expansion 
potential of these cells. This approach has the added advantage that relatively few 
cells are required for analysis compared to whole population analyses such as flow 
cytometry and is therefore ideal when working with limited resources such as 
primary Gl syndrome cells. This method could be improved by using an automated 
cell lineage tracker that encodes the microscopy images and deposits data in 
relational databases mining by bioinformatics tools. Software tools such as 
ProgeniTRAK along with the associated database -  ProgeniDB, have been shown 
to ease the burden of analysing large data sets associated with this type of study 
(Khan et al. 2007). This approach could be applied to other Gl syndrome cells to 
identify the quantitative differences in commitment to division in these strains. It my 
also be interesting to monitor the changes in cell size following BIRB796 treatment 
to investigate whether a change in morphology is indicative of an increased 
probability of division.
2. Improvement of techniques to assess p38 activation. Measurement of 
p38 activation status by Western blot in chapter 5 indicates that identifying 
phosphorylation patterns in informative cells may be problematic given that a 
relatively small change in phosphorylation levels may be sufficient to alter growth
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potential. Evidence in the literature suggests that p38 shuttles between the 
cytoplasm and the nucleus depending on the phosphorylation status (Crabtree and 
Olson 2002; Gomez del Arco et al. 2000; Porter et al. 2000; Wu et al. 2003), for 
example, p38 is localised in the cytoplasm in untreated HeLa cells but translocates 
to the nucleus following UV treatment. Similarly, a significant proportion of p38 is 
shown to translocate from the cytoplasm into the nucleus following treatment with 
the receptor activator of NF-kB ligand (RANKL), a known upstream activator of the 
p38 pathway (Matsumoto et al. 2004). It was therefore postulated that subcellular 
localisation rather than phosphorylation 
status perse could be used to determine the 
activation status of p38 on a cell-by-cell basis 
using immunofluorescence (IF). Preliminary 
studies show that it is possible to identify 
cells in which p38 has translocated to the 
nucleus (Figure 9.2); however, the effect is
more subtle than that previously seen for Figure 9.2. Subcellular localisation of p38
■I >i i  i . . . . as measured by IF. Arrow indicates a cell
cells that have been exposed to genotoxic with nuclear localisation of P38.
agents. Future studies should therefore include attempts to identify a threshold 
value for the biologically relevant ratio of nuclear versus cytoplasmic signals. 
Subcellular localisation of p38 could be used in future studies to determine the 
proportion of cells that have activated p38 in relation to critical cell cycle events 
(using additional protein/phosphorylation/location markers) such as stress 
signalling, checkpoint activation, mitotic entry and cell enlargement in arrest. Here 
methods for the abrogation of checkpoint responses (e.g. as realised in virally 
transformed or cancer cells) would be highly informative.
3. Identification of other syndromes that show an increased propensity 
for SIPS. The findings from the current study provide some evidence that defects 
in NBS1, ATR and WRN result in a reduced replicative potential and altered 
cellular morphology that may indicate increased SIPS in these cells. Thus, it is
2 4 7
possible that the probability of entering SIPS is dependent on the nature of the 
pathway that is defective.
NBS1
MRE1
ATR responds to a broad spectrum of DNA damage substrates and is 
crucial for maintaining genomic stability 
during S-phase (Cimprich and Cortez 
2008). The Mre11, Rad50 and Nbs1 
proteins form the MRN complex, which is 
involved in the cellular DNA damage 
response (Lavin 2007). Although MRN
complex function is widely accepted to Fl?ure,9;?IDMChA?Dtlc r®pJ®5®,[,tatlon the M role of WRN, ATR and MRN complex in
play a role in ATM activation in response resolution of stalled replication forks, 
to DSBs (Lee and Pauli 2007), its role in ATR activation and downstream signaling 
in response to different types of damage is less clear. Some evidence in the 
literature suggests that when replication forks are stalled (such as following UV 
exposure), MRN is required upstream of ATR to facilitate ATR activation, but is 
also a downstream substrate of ATR (NBS1 is phosphorylated by ATR) (Olson et 
al. 2007). WRN has been shown to associate with the MRN complex via binding to 
NBS1 in vitro and in vivo (Cheng et al. 2004). This provides support for a model in 
which NBS1 recruits WRN at stalled replication forks (Figure 9.3). Taken together, 
these findings suggest a functional link between the three syndromes, WS, NBS 
and SS, with partially overlapping phenotypes in a pathway that responds to DNA 
damage.
Further studies of SIPS using a more vigorous panel of markers in a larger 
panel of SS, WS and NBS cells would be warranted. Furthermore, examination of 
cells from other syndromes, such as AT like-disorder (ATLD), which have defects 
in MRE11 may also be of interest. However, any future studies should not be 
undertaken without full recognition of the heterogeneity between fibroblast strains 
and care should be taken to study cell strains with known replicative histories and 
fully characterised mutations.
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4. Improvements in the recognition of cell cycle exit in heterogeneous 
populations. The findings in chapter 4 raised the need for a more quantitative 
approach to analysis of cellular 
morphology and suggest that cell 
size may be a better indicator of 
differences in proliferation
potential than stress-fibre
presentation. Further support for 
this was provided by time-lapse 
microscopy studies in chapter 8, 
using image analysis software to 
identify the size of individual 
cells, which showed that 
enlarged cells correlated with a 
reduced probability of division.
These studies appear to have
sufficient resolution to identify Figure 9.4. (A) CyTRAK Orange staining of nucleus and
t h P  r p l a t i n n ^ h i n  h p f w p p n  t p I I  cytoPlasm- (B) Increase in CyTRAK Orange signal inthe relationship between cell resDonse to c p t  treatment
cycle exit and cell size but are labour-intensive. One approach is to use a reporter 
for arrest. It was postulated that an agent that stains both the nucleus and the 
cytoplasm could be used to distinguish between cell cycle exit and cell cycle 
position on the basis of increased cell size. Preliminary studies using the 
investigational agent CyTRAK Orange™ showed that this agent stains both the 
nucleus and the cytoplasm (Figure 9.4A) and that the CyTRAK Orange™ signal 
increases in cells in which cell cycle arrest is artificially induced using CPT (20 nM 
for 48 hours; figure 9.4B). Spectral differences allow CyTRAK Orange™ to be 
combined with other agents, for example, 5-dodecanoylaminofluorescein di-|3-D- 
galactopyranoside (C12FDG), a fluorogenic substrate for pgal activity that can be 
used to detect senescence cells in vitro (Debacq-Chainiaux et al. 2009; Noppe et 
al. 2009); therefore, CyTRAK Orange™ could potentially be used in future studies 
to distinguish between a cell that is long-term arrested and one that is senescent.
Control + CPT
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Appendix A Prevention of accelerated ageing in Werner
syndrome fibroblasts
A.1 Introduction
One of the hallmarks of WS is that primary dermal fibroblasts derived from 
WS individuals manifest a much-reduced replicative lifespan than normal 
fibroblasts (Faragher et al. 1993; Salk et al. 1981; Tollefsbol and Cohen 1984). 
This premature senescence of WS fibroblasts has been postulated as a major 
contributor to the accelerated ageing of mitotic tissues in vivo in this syndrome 
(Kipling et al. 2004). WS fibroblasts also divide more slowly than normal cells in 
part due to an increased S-phase of the cell cycle (Poot et al. 1992; Takeuchi et al. 
1982), and have an elevated level of replication fork stalling (Rodriguez-Lopez et 
al. 2002). Primary WS cells display genome instability, manifested by an elevated 
rate of chromosomal translocation and genomic deletions (Fukuchi et al. 1989), 
and are hypersensitive to a subset of DNA damaging agents (Comai and Li 2004), 
suggesting that the WRN protein plays a key role in the cellular response to 
specific types of DNA damage. In addition, WS is associated with an increased 
level of pro-oxidant stress (Pagano et al. 2005), and pro-oxidant stress is 
associated with increased genomic instability and premature cellular senescence, 
and has been linked to ageing, diabetes, cancer, atherosclerosis and osteoporosis, 
all features of WS (Pagano et al. 2005).
As with normal cells, senescent WS fibroblasts have an elevated production 
of pro-inflammatory cytokines and inflammatory markers such as ICAM-1 (Choi et 
al. 2001; Kumar et al. 1993). WS individuals have markedly elevated plasma levels 
of ICAM-1 (Murano et al. 1997) and TNFa (Yokote et al. 2004), both of which are 
associated with inflammatory diseases (Holtmann and Neurath 2004; Witkowska
2005). Moreover, WS fibroblasts, even at low population doublings, have an
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enlarged cellular morphology with extensive F-actin stress fibres and resemble 
senescent normal fibroblasts (Davis et al. 2005; Davis et al. 2006).
Overall, WS fibroblasts resemble normal cells that have undergone stress- 
induced premature senescence (SIPS). SIPS is known to result from activation of 
the p38 signalling pathway (Huot et al. 1997; Wang et al. 2002) and the genome 
instability seen in WS, increased pro-oxidant state, and the frequent replication fork 
stalling seen in WS cells, all provide a plausible trigger for intracellular stress in WS 
cells and a possible involvement for p38 signalling in inducing the shortened 
replicative life span. To test this WS fibroblasts were cultured in the presence of 
p38 inhibitors SB203580 and BIRB 796.
Please note that all data in this appendix have been provided courtesy of my 
supervisor Dr T. Davis and are shown here only as supporting data.
A.2 p38 inhibitors prevent the shortened lifespan of WS fibroblasts
WS fibroblast strain AG03141 was seeded into T25 culture vessels in 
EMEM supplemented with SB203580 at 2.5 pM and grown with daily re-feeding 
(with fresh inhibitor) until the cells reached replicative senescence. Control cells 
were grown in EMEM supplemented with the drug carrier DMSO (0.1 %). Cells 
were passaged either every five days or when they reached approximately 75 % 
confluency.
Control cells achieved 22.04 PDs at a maximal growth rate of 0.14 PD/day 
(Figure A1, graph a). In contrast AG03141(WS) cells grown in the presence of 
SB203580 achieved 40.84 PDs, well within the range seen for normal adult dermal 
fibroblasts, at a maximal growth rate of 0.32 PD/day (Davis et al. 2005). As these 
cultures were initiated when the cells had already achieved 9 PD this is equivalent 
to an increase in experimental lifespan of 144% (40.84-9)/(22.04-9) x 100%.
In a separate experiment a different batch of AG03141(WS) cells (initiated 
when they had reached 14 PDs) were cultured in the presence or absence of BIRB 
796 at 2.5 pM. In this case the control cells did 20.72 ± 0.09 PDs with a maximal
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growth rate of 0.21 PD/day (Figure A1, graph b). In both experiments the 
AG03141(WS) control cells reached a total of approximately 21 to 22 PDs, 
showing the shortened lifespan typical of WS cells. When cultured in the presence 
of BIRB796 the maximal growth rate increased to 0.37 PD/day and the lifespan to 
32.77 ± 0.34 PD (Figure A1, graph b). Whilst this lifespan is not as great in PD 
terms as seen with SB202580 it must be noted that the two experiments were 
initiated with cells of different replicative age. As measured as a percentage of 
experimental lifespan, however, the lifespan with BIRB796 is (32.77-14)/(20.72-14) 
x 100% = 279% of the control cells, an increase of 179%. As it has been shown 
that the lifespan extension of WS cells treated with p38 inhibitors is inversely 
proportional to the replicative age of the culture when drug treatment began (Davis 
et al. 2005), then if cultures with BIRB 796 were initiated at 9 PD and achieved an 
experimental lifespan increase of 279%, the BIRB 96 treated cells would have 
reached 41.7 PD. This inverse correlation has been seen many times (Davis et al. 
2007).
Thus, treatment using the p38 inhibitors SB203580 and BIRB796 essentially 
prevents the shortened lifespan and slow growth rates seen in AG03141(WS) 
dermal fibroblasts.
A.3 p38 inhibitors rescue the abnormal morphology of WS cells
A major characteristic of WS fibroblasts is that, even when young, they have 
an altered morphology with extensive F-actin stress fibres resembling that of 
senescent cells (Davis et al. 2005) [Figure A2, panels a and c show the AG03141 
cells used for the growth experiment in Figure A1 graph a at 10 PD]. Treatment 
with the p38 inhibitor SB203580 reverts this morphology to that more reminiscent 
of young normal dermal fibroblasts (Figure A2, panels b and d show the SB203580 
treated AG03141(WS) cells used for the growth experiment in Figure A1 graph a at 
12 PD). A similar effect is seen when the p38 inhibitor BIRB796 is used (Figure A2, 
panels e and f show the cells used for the growth experiment in Figure A1 graph 
b).
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Thus, treatment using the p38 inhibitors SB203580 and BIRB796 essentially 
reverts the abnormal senescent-like morphology seen in AG03141 WS dermal 
fibroblasts to that resembling normal dermal fibroblasts (Davis et al. 2005).
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Figure A1. Growth of AG 03141(W S) fibroblasts in the presence or absence of 
p38 inhibitors.
Panel a) SB203580: Open circles are control cells, closed circles are cells 
treated with SB203580; (b) BIRB796: closed squares and open diamonds are 
control cells, closed circles and open triangles are BIRB796 treated cells. Growth 
is measured as cumulative population doublings versus days.
253
Brightfield
phalloidin-
FITC
young control young SB203580 treated 
AG03141 cells AG03141 cells
Brightfield
young control young BIRB 796 treated 
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Figure A2. Morphology of AG03141(WS) cells.
Panels a, b, e and f bright field views of AG03141(WS) cells; c and d AG03141(WS) cells 
stained with phalloidin-FITC. Black bars are 100 ( im ,  white bars are 50 jaiti.
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Appendix B Determination of suitable p38 inhibitor
regimes for cellular growth experiments
B.1 Introduction
All p38 inhibitors show various degrees of cross-kinase specificity, including 
the inhibition of cell cycle kinases such as cdk2, growth related kinases such as c- 
Raf1, and other stress-related kinases such as c-Jun (Bain et al. 2007; Godl and 
Daub 2004). Thus, as these inhibitors are being used to prevent putative stress- 
induced cellular growth arrest, the ideal inhibitor concentration is the minimum that 
fully inhibits p38 and that leads to the maximal growth rate of the cells. Thus, a 
series of titrations were undertaken to determine these parameters for each drug of 
choice.
Please note that all data in this appendix have been provided courtesy of my 
supervisor Dr T. Davis and are shown here only as supporting data.
B.2 p38 inhibitor titrations
The cells used for the drug titrations were human HCA2 neonatal dermal 
foreskin fibroblasts immortalised by ectopic expression of the human telomerase 
reverse transcriptase protein subunit hTert (Wyllie et al. 2000). These cells were 
used simply as a model test bed for the efficacy of p38 inhibitors to inhibit 
anisomycin-induced p38 activity due to ease of use (Bagley et al. 2010). Cells were 
seeded onto 100 mm dishes in EMEM (composition described in Methods section) 
and allowed to settle for 24 hours at 37°C. The medium was replaced with EMEM 
containing a p38 inhibitor at various concentrations for 2 hours at 37°C after which 
the cells were exposed to anisomycin at 30 pM for 45 minutes. Controls were 
either DMSO alone or DMSO with anisomycin treatment. The cells were then 
collected and protein extracted as described (Bagley et al. 2006). The levels of 
HSP27 and p-HSP27 were determined by ELISA assay as described (Bagley et al. 
2007).
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Figure B1 shows that the IC50 for SB203580 inhibition of p38 (as measured 
by inhibition of HSP27 phosphorylation) is approximately 20 nM, and the maximal 
inhibition is at 1.0 pM. BIRB796 (Regan et al. 2002) was synthesised for the 
current studies in the Cardiff University School of Chemistry (Bagley et al. 2006) 
and has an IC50 less than 10 nM with maximal p38 inhibition achieved at 10 nM 
(Figure B2). VX745 (Natarajan and Doherty 2005) was synthesised for the current 
studies in the Cardiff University School of Chemistry (Bagley et al. 2007), and has 
an IC50 between 10 nM and 100 nM with maximal inhibition at 500 nM (Figure B3). 
All these values are in agreement with the published literature for in vivo cellular 
assays (Goldstein and Gabriel 2005; Regan et al. 2002).
B.3 Effects of p38 inhibitors on the growth rate of WS AG03141hTert cells
To determine the effects of these inhibitors on cellular growth hTert- 
immortalised AG03141(WS) cells were used (Wyllie et al. 2000). These cells retain 
several of the characteristics of primary WS cells in that they grow slowly and have 
an altered enlarged cellular morphology with extensive F-actin stress fibres, 
features which are corrected by growth in SB203580 (Davis et al. 2005; Davis et al.
2006). Cells were grown in EMEM containing inhibitors at various concentrations 
for a total of 42 days at 37°C to determine growth rate. The medium was changed 
daily with the addition of fresh inhibitor as it has been shown that this is required to 
attain maximal growth rate (Davis et al. 2005; Davis et al. 2006). Cells were 
passaged every three to five days (or when the cells reached approximately 75% 
confluency, whichever was the soonest) and the cells counted. Cumulative 
population doublings were measured as PD = log(NrN0)/log2, where Nt is number 
counted and N0 is number seeded.
Figure B4 shows the effects of increasing inhibitor concentration on the 
growth rate of the cells. For SB203580 the maximal growth rate (PDs/day) is 
achieved at 2.5 pM, for BIRB796 it is 2.5 pM, and for VX745 it is 500 nM. Thus 
these drug concentrations were chosen for the growth regimes of the progeroid 
cells. Note that for both SB203580 and BIRB796 the maximal growth rate is 
achieved at a concentration well above that required to maximally inhibit p38.
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B.4 Time courses for each p38 inhibitor in AG03141(WS)hTert cells
Finally, it was established that these drug concentrations remain fully active 
as p38 inhibitors over the 24-hour period between medium replacements (Figure 
B5). AG03141(WS)hTert cells were plated onto 100 mm dishes in EMEM and left for 
24 hours to settle. Then the medium was replaced with EMEM containing 
SB203580, BIRB796 or VX745 at the chosen concentration and the cells incubated 
at 37°C for between 2 and 24 hours, after which the cells were stimulated with 
anisomycin at 30 pM for 45 minutes. Controls were either DMSO alone or DMSO 
with anisomycin treatment. The cells were then collected and protein extracted as 
described (Bagley et al. 2006). The levels of HSP27 and p-HSP27 were 
determined by ELISA assay as described (Bagley et al. 2007). The data in Figure 
B5 shows that the p38 inhibitors remain fully capable of inhibiting the anisomycin 
induced p38 activity after 24 hours. Thus a re-feeding time of 24 hours was chosen 
for the growth experiments.
B.5 SB203580 and BIRB 796 inhibit JNK activity.
Many p38 inhibitors also inhibit the related stress-induced c-Jun kinases 
JNK1 and JNK2, at least in vitro (Godl and Daub 2004). Thus the ability of 
SB203580, BIRB796 and VX745 to inhibit total JNK activity in human cells was 
assessed in anisomycin treated HCA2hTert cells as described for p38 activity 
(Section B2). Cells were seeded onto 100 mm dishes in EMEM and allowed to 
settle for 24 hours at 37°C. The medium was replaced with EMEM containing a 
p38 inhibitor at various concentrations for 2 hours at 37°C after which the cells 
were exposed to anisomycin at 30 pM for 45 minutes. Controls were either DMSO 
alone or DMSO with anisomycin treatment. The cells were then collected and 
protein extracted as described. The levels of c-Jun and phospho(S63)c-Jun were 
determined by ELISA assay as described (Bagley et al. 2010). Figure B6 shows 
the ratio of p-c-Jun/c-Jun for each of the three p38 inhibitors. As can be seen, 
VX745 has no inhibitory activity for JNK1/2 as the ratio of p-c-Jun/c-Jun in 
anisomycin treated cells does not increase with increasing VX745 concentration. In 
contrast, BIRB796 significantly inhibits the JNKs above 10 pM but not significantly
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at 2.5 |jM, whilst SB203580 may inhibit cellular JNK1/2 at concentrations >25 pM 
(Bagley et al. 2010). As these ELISAs are measuring the JNK1/2 substrate c-Jun 
these data do not rule out the possibility that these inhibitors inhibit one of the 
JNKs but not the other.
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Figure B1. Titration of p38 inhibitor SB203580 in HCA2hTert cells.
The top panels are HSP27 and p-HSP27 protein levels, the bottom panels are the ratio of 
the phosphorylated protein to total protein. Controls were DMSO treated cells (DMSO), and 
anisomycin stimulated DMSO treated cells (An). 0.0010 to 50.000 are cells treated with 
SB203580 from 10 nM to 50 pM.
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Figure B2. Titration of p38 inhibitor BIRB796 in HCA2nTtKI cells. 
Panels are as in Figure B1.
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Figure B3. Titration of p38 inhibitor VX745 in HCA2nTERT cells. 
Panels are as in Figure B1.
2 6 1
140
120
c 100
.2
2 80
v
c 60
u
Ol3 40
TJ
2V 20M
0
I f
l ifo £ Si 8 2 ^
-o
, .  n  n  f i n n
L
§ o  in o  o  o  ct- cm m o  o  c
o  o  o  «- in c
o d d  b o o t-
[SB203580]
o  d  o
2 3 8
160
140
120
100
80
60
40
20
0
o  in Q o  o»- cm m o  oO O O r- 35
O O 
§ §
O -1- CM o  in o
t- cm m
[BIRB 796]
[VX-745]
Figure B4. Growth rates of AG3141nTERT(WS) cells treated with p38 inhibitors.
Growth rates are plotted as a percentage of the growth rate in the absence of 
p38 inhibitor. 0.000 are cells treated only with DMSO (0.1%), 0.010 to 50.000 are 
cells treated with p38 inhibitors from 10 nM to 50 jiM.
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Figure B5. Time courses for activity of p38 inhibitors in AG03141nTfcm(WS) 
cells.
The ratio of p-HSP27/HSP27 is plotted against time of incubation prior to 
anisomycin stimulation. Control is DMSO only and An = Anisomycin 
stimulation only. The drug concentration used is given above each panel 
and the times of incubation are given below the panels.
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Figure B6. Effects of p38 inhibitors on total JNK activity in HCA2nTERT cells.
Panels are the ratio of p-c-Jun/c-Jun. Controls were DMSO treated cells (DMSO), and 
anisomycin stimulated DMSO treated cells (An). 0.010 to 50.000 are cells treated with p38 
inhibitors from 10 nM to 50 nM.
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